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CB2 receptor plays an important role in inflammation and has been implicated in the 
pathologies of several diseases, including neurodegenerative disorders, cancer, and 
atherosclerosis. However, there is a lack of understanding of CB2 receptor expression 
and signalling, which significantly hinders the development of CB2 receptor-targeted 
therapies. The availability of a diverse range of advanced pharmacological tools for 
studying CB2 receptor would lead to improved understanding of CB2 receptor and thus 
aid drug development. Fluorescent ligands have been developed for other GPCRs and 
used to elucidate receptor expression and signalling roles. The aim of this PhD research 
was to develop a fluorescent ligand with high affinity and selectivity for CB2 receptor 
which would be suitable for use as a pharmacological tool. The alkylindole class of 
cannabinoids are well characterised regarding CB2 receptor affinity, selectivity and 
function, which was used to guide design of a series of fluorescent ligands. Compounds 
with linker and fluorophore substitution at the C5-, C6- or C7 indole positions were 
designed, synthesised and pharmacologically evaluated for CB2 receptor affinity and 
function (Chapters Two and Three). No high affinity fluorescent ligands resulted from 
these alkylindole series, but a very high affinity, selective CB2 receptor inverse agonist 
3.7b was identified amongst the non-fluorescent ligands. Alkylindole 3.7b showed very 
promising properties in relation to other small ligand inverse agonists for CB2 receptor. 
In addition, a lead pharmacophore-linker conjugate 3.13 was identified, which has 
potential for development into a fluorescent ligand. Fluorescent ligands were also 
developed from the 1,8-naphthyridin-2(1H)-one-3- carboxamide scaffold (Chapters 
Four and Five). A fluorescent ligand 5.9b with high affinity and selectivity for CB2 
receptor (Ki = 467 ± 20.0 nM at hCB2 receptor, Ki = >10 µM at hCB1 receptor) was 
identified amongst these compounds. This fluorescent ligand (5.9b) has potential as a 
pharmacological imaging tool with which to study CB2 receptor and could also be 
further derivatised and optimised in the development of other fluorescent ligands for 
CB2 receptor with a range of properties. CB2 receptor homology models were generated 
and used in ligand docking studies to aid ligand design and to rationalise biological 
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Chapter One: Introduction 
1.1 G protein-coupled receptors 
G protein-coupled receptors (GPCRs) comprise the largest family of membrane 
receptors in the human genome.1 GPCRs consist of an integral membrane protein 
composed of seven transmembrane helices (TMH), three extracellular loops (ECLs), 
three intracellular loops (ICLs) and an N- and a C-terminus (Figure 1).2 There are five 
classes of GPCR, of which Class A (the Rhodopsin family) is the largest and within 
Class A there are four groups (α, β, δ and λ) which are further classified into 
subfamilies (e.g. cannabinoid (CB) receptors) and then individual subtypes (e.g. 
cannabinoid type 1 (CB1) and type 2 (CB2) receptors).
3  
 
Figure 1: Basic structure of GPCRs 
GPCRs are associated with a broad range of physiological processes, can bind a diverse 
variety of ligands at both the orthosteric (endogenous ligand binding site) and allosteric 
sites (other binding sites distinct from the orthosteric site),4 and exhibit aberrant 
expression and signalling in a multitude of pathologies.5-7 For these reasons, GPCRs are 
highly druggable and are the target of around 33% of current drugs in use.8 However, a 
dearth of detailed knowledge surrounding the complexity of GPCR structure and 
function, as well as challenges in identifying new lead ligands, has thus far restricted 





1.1.1 GPCR signalling 
GPCRs mediate signals from both extracellular and intracellular stimuli to produce a 
broad range of cellular responses.10 The study of GPCR signalling pathways represents 
a large field of research and was the subject of the 2012 Nobel Prize in Chemistry.11 
The highly complex nature of GPCR signalling is reduced here to just a brief and 
simple overview.  
GPCRs couple with intracellular heterotrimeric G proteins, which are composed of 
three subunits (α, β and λ), of which the Gα subunit acts to catalyse hydrolysis of 
guanosine triphosphate (GTP) to guanosine diphosphate (GDP).12 Ligand binding 
induces conformational changes in GPCRs leading to exchange of GDP for GTP and 
disassociation of the GTP-bound Gα from Gβλ. GTP-bound Gα can then interact with 
effector molecules (e.g. adenylate cyclase or phospholipase C), initiating second-
messenger signalling. There are multiple subforms of Gα proteins, which can be 
divided into four families: Gαs, Gαi/Gαo, Gαq/Gα11 and Gα12/Gα13.
13 A single GPCR 
subtype is often able to activate multiple different G proteins and thus elicit diverse 
biological responses. GPCR kinases phosphorylate GPCRs, causing binding of β-
arrestin and subsequently receptor internalisation and recycling of receptor back to the 
cell surface.14 Some GPCRs are able to continue signalling whilst internalised and this 
mechanism enables ligand specific signalling by allowing cells to discriminate ligands 
which promote receptor endocytosis.15 The divergent nature of GPCR signalling means 
that on-target side effects can be a problem when developing therapies (i.e. undesirable 
effects mediated by the target receptor, as opposed to off-target side effects mediated 
by other targets). Functionally selective ligands which exhibit biased agonism and are 
able to elicit a specific set of signalling cascades are a potential means for targeting 
specific pathways without producing on-target adverse effects.16  
Endogenously expressed GPCRs in native cells have typically low levels of expression 
and preferentially localise to lipid raft microdomains in the cell membrane.17 This leads 
to highly concentrated receptor regions, promoting oligomerisation through formation 
of GPCR homodimers and heterodimers. GPCR oligomerisation allows for 
diversification of receptor signalling and function and is important in the modulation of 
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various physiological processes.18 GPCR oligomerisation is also an avenue for selective 
drug design by developing bivalent ligands which are able to target heterodimers.19  
1.1.2 GPCR crystal structures 
Crystallisation of GPCRs has furthered our understanding of GPCR structural biology, 
specifically ligand-receptor interactions and ligand-induced GPCR activation and has 
provided increased opportunity for rational, structure-based drug design.20 However, 
GPCRs are inherently difficult to crystallise due to poor solubility of lipophilic 
membrane-bound proteins, low native expressions levels, conformational flexibility and 
lack of stability.21 In 2000, the first GPCR crystal structure was solved for bovine 
rhodopsin22 and it was not until seven years later that the first crystal structure of a non-
rhodopsin GPCR was reported for β2 adrenoceptor.
23 Methodological innovations in 
protein expression, protein engineering, GPCR isolation and crystallography techniques 
has enabled improved opportunities for solving GPCR crystal structures over the last 
decade.24 There are now crystal structures available for 44 unique GPCRs (as of 
November 2017), 37 of which belong to the Class A family.25  
1.1.3 GPCR conformational states 
Protein crystallography and other biophysical techniques have enabled characterisation 
of conformationally distinct GPCR functional states and partial insight into 
mechanisms of receptor activation.26, 27 Traditional receptor theory states that GPCRs 
exist in an equilibrium between the inactive (R) state or active (R*) state, however 
GPCRs are in reality highly flexible and dynamic and exhibit multistate conformations. 
Crystallography has captured the conformation of GPCRs during active states (R*) and 
inactive states (R) as well as intermediate states between inactive and active, though 
GPCRs undoubtedly exhibit more conformational states beyond what have been 
characterised.28 When free from bound ligand, GPCRs can exist in varying equilibria of 
the different states, the distribution of which determines basal signalling levels (Figure 
2).2 Agonist binding pushes the equilibria towards the R* state, whilst inverse agonist-
receptor interactions direct it towards the R state, reducing basal activity levels. In 
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contrast, neutral antagonists do not affect the equilibrium of basal receptor. Ligand-
specific receptor conformations enable distinct and differentiated signalling pathways.29  
 
Figure 2: Illustration of the shift in helices associated with GPCR activation and the multiple equilibria in 
place between inactive (R), intermediate (R' and R'') active (R*) and active signalling (R*G) 
conformational states. Figure republished from Katritch et al, 2013.* 2  
Ligands can behave as inverse agonists, reducing basal signalling levels, but also as 
antagonists by blocking receptor access to agonists. Protean ligands can act as agonists, 
inverse agonists and antagonists at the same receptor according to the constitutive 
activity of the receptor population.30 For example, in a receptor population with high 
levels of constitutively active receptors, a low efficacy agonist may lower the activity 
of the basal population, therefore behaving as an inverse agonist.31 Whereas, in a 
receptor population with low levels of constitutively active receptor, the same ligand 
could raise the activity of the basal population, acting as an agonist.  
The diverse signalling pathways modulated by GPCRs provides a wealth of opportunity 
for drug development, yet produces distinct challenges in targeting specific downstream 
effects. A potential means for overcoming these challenges is by allosteric modulation, 
i.e. ligands that bind to allosteric sites and modulate the cellular responses produced by 
                                                 
* The journal was contacted for permission to republish this figure in a thesis and responded to state that 
no permission was required as long as the source was fully acknowledged. This also applies to Figure 12 
and Figure 16.  
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endogenous ligands,32, 33 or by developing ligands that exhibit signalling bias.34 
Allosteric ligands can also be a means of achieving greater receptor subtype selectivity, 
since allosteric sites are not as highly conserved across GPCRs compared to orthosteric 
sites.35 Allosterism and biased signalling are vast and complex topics within GPCR 
research and are not discussed in depth here, as it is beyond the scope of this thesis.   
6 
 
1.2 The endocannabinoid system 
The endocannabinoid system consists of the endocannabinoids, associated regulatory 
enzymes and the class A GPCR CB receptors. There are two known subtypes of CB 
receptors, CB1 and CB2 receptor. Two orphan receptors, GPR18 and GPR55, have been 
shown to be responsive to endocannabinoids and are suspected of being either further 
subtypes of CB receptor, or on the periphery of the endocannabinoid system.36-38 The 
major components of the endocannabinoid system were only elucidated relatively 
recently (within the last 30 years) and there are still considerable gaps in understanding 
of the complete system. The endocannabinoid system influences development and 
behaviour, reward processing, neural plasticity, lipid homeostasis and immune system 
processes.39 Consequently, dysfunction of the endocannabinoid system can contribute 
to neurodegenerative disorders,40 immune system disorders41 and cancer progression.42 
A major role of the endocannabinoid system is regulation of various neurotransmitter 
systems.43  
The endogenous ligands of CB receptors are the endocannabinoids of which the most 
well characterised are anandamide 1.1 (AEA; identified in 1992)44 and 2-
arachidonylglycerol 1.2 (2-AG; identified in 1995; Figure 3).45, 46 Endocannabinoids are 
lipids and can readily diffuse through cell membranes. They are synthesised on demand 
in response to elevations of intracellular calcium,47 in contrast to many other 
neurotransmitters which are stored in vesicles. A selective membrane transport process 
is thought to rapidly remove endocannabinoids from the synaptic space.48  
 
Figure 3: The endocannabinoids AEA 1.1 and 2-AG 1.2.  
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A complex assortment of regulatory enzymes are responsible for the synthesis and 
metabolism of AEA 1.1 and 2-AG 1.2. Monoacylglycerol lipase (MAGL) is considered 
to be the most important enzyme for 2-AG 1.2 metabolism,49 whereas fatty acid amide 
hydrolase (FAAH) is primarily responsible for AEA 1.1 breakdown.50  
1.2.1 CB1 receptor 
Evidence of a specific binding site for the cannabinoids in the brain was reported in 
198851 and CB1 receptor was cloned in 1990.
52 CB1 receptor is one of the most 
abundant GPCRs in the brain, and is present in particularly high levels in the sensory 
and motor regions, playing a significant role in motivation and cognition.53 
Cannabinoids can exert an affect through CB1 receptor activation on synaptic plasticity, 
cell migration and perhaps neuronal growth.54 CB1 receptor expression is 
predominantly in the central nervous system (CNS), primarily on the central and 
peripheral neurons in the presynapse, facilitating the endocannabinoid system’s role in 
inhibition of neurotransmitter release,55 but is also present in postsynaptic cells and 
astrocytes.56, 57 CB1 receptor has also been found in some peripheral organs, though at 
low levels.58 Like most GPCRs, CB1 receptor exhibits multiplicity of G protein 
coupling by activating Gi/o, Gs and/or Gq proteins thereby initiating diverse downstream 
signalling events, of which the most commonly studied are inhibition of adenylyl 
cyclase or reductions in cyclic adenosine monophosphate (cAMP).59 G protein coupling 
of CB1 receptor can be influenced by both receptor and G protein expression levels.
60 
CB1 receptor can also activate mitogen-activated protein kinases (MAPKs) and recruit 
β arrestin 1 and 2.61 CB1 receptor is a potential therapeutic target for neuropathic pain, 
neuroinflammation, cancer, gastrointestinal, cardiovascular, metabolic and psychiatric 
diseases.62 However, a key challenge in developing CB1 receptor targeted therapies is 
avoiding unwanted psychotropic side effects resulting from the high CB1 receptor 
expression levels in the CNS. For instance, the CB1 receptor inverse agonist rimonabant 
1.12 was licensed in the European Union as an obesity treatment, but was later 
withdrawn due to side effects of suicidal ideation and depression.63 Exploitation of 
biased signalling, whereby different ligands can differentially activate pathways, is a 




The crystal structure of CB1 receptor was recently determined by two research groups 
in 2016 and there are four high resolution crystal structures available, two in an active 
state65 and two in an inactive state.66, 67 This breakthrough represents a leap forward in 
the understanding of CB1 receptor structural biology as well as increased opportunities 
for structure based drug design.  
1.2.2 CB2 receptor 
CB2 receptor was cloned from spleen in 1993
68 and in contrast to CB1 receptor, is 
expressed mostly in peripheral tissue, particularly in immune cells and lymphoid 
tissues, such as spleen and tonsils.69 CB2 receptor was originally assumed to be present 
only in cells of the immune system, but it has now been identified throughout the CNS, 
particularly in microglial, but overall in much lower levels than CB1 receptor.
70, 71 
Functions of CB2 receptor in the immune system include regulation of immune 
responses and inflammatory pathways via modulation of cytokine release and immune 
cell migration.72, 73 Evidence shows that endocannabinoid signalling through CB2 
receptor may be part of immune protection.74 Altered CB2 receptor expression levels 
have been observed with many pathologies.75-78 Overall though, there is a lack of 
detailed knowledge of the role of peripheral CB2 receptor. The function of neuronal 
CB2 receptor has long been unknown and it is only recently that initial reports have 
suggested roles in basic neuronal transmission79 and the regulation of memory and 
anxiety.80 CB2 receptor appears to be less promiscuous than CB1 receptor, coupling 
with fewer G protein subforms, although this could be due to a lack of knowledge as 
CB2 receptor signalling is not as well understood. CB2 receptor has been shown to 
couple with Gi/o proteins through which it inhibits adenylyl cyclase and reduces cAMP 
levels, as well as activate MAPKs and engage in β-arrestin 2 recruitment.64 Little is 
understood about CB2 receptor trafficking, but receptor recycling has been shown to 
occur through alternating stimulation by agonists and inverse agonists.81 Differing 
chemical classes of CB2 receptor ligands have demonstrated functional selectivity over 
CB2 receptor internalisation, inhibition of adenylyl cyclase and arrestin recruitment, 
indicating potential for development of CB2 receptor ligands with on-target signalling 
selectivity and therefore less adverse effects.82, 83  
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1.2.2.1 CB2 receptor homology modelling and ligand binding 
A number of homology models for CB2 receptor have been reported in the literature, 
most of which were generated using the crystal structures of human β2-adrenoceptor,
84, 
85 bovine rhodopsin86 or sphingosine-1-phosphate receptor 1 (S1P1)
87 as templates. 
Homology modelling has been used in combination with mutational and ligand binding 
studies to elucidate structural details of CB2 receptor and assist rational design of CB2 
receptor selective ligands.86 There is currently no X-ray crystal structure reported for 
CB2 receptor, however the recently reported CB1 receptor crystal structures
65-67 are 
helpful in understanding the structure of CB2 receptor as there is a 44% shared 
sequence identity between CB1 and CB2 receptors.  
It is thought that ligand entry into CB receptors can be lipid-mediated. The 
endocannabinoids spend much of their life cycle at or in the lipid membrane where they 
are synthesised and metabolised and therefore it is not surprising that they would enter 
the receptor via the lipid bilayer.88 Molecular dynamics and nuclear magnetic resonance 
(NMR) studies on entry into CB receptors via lipid membrane have found this to be a 
plausible entry route for several cannabinoids, such as CP55,940 1.10 which was able 
to rapidly laterally diffuse through lipid membrane.89 Molecular dynamics with 2-AG 
1.2 suggested that 2-AG 1.2 approaches CB2 receptor at the interface between TMH6 
and 7, stimulating a movement in helices, allowing entrance of 2-AG 1.2 into the 
orthosteric binding pocket between TMH6 and TMH7.90 Molecular dynamics 
simulations with (-)-Δ9-tetrahydrocannabinol 1.5 ((-)-Δ9-THC) and AEA 1.1 found a 
probable CB1 receptor entry route between TMH7 and TMH1 from the lipid 
membrane.91 It is important to consider receptor entry route when designing ligands and 
it is possible that there are multiple entry routes into the orthosteric binding site of CB2 
receptor, as well as the allosteric sites.  
The endocannabinoids bind to the orthosteric site, which is a binding pocket located 
within the receptor as demonstrated experimentally by Janero et al with a covalent 
endocannabinoid based probe binding at CB1 receptor.
92 Cannabidiol 1.6 has been 
demonstrated to bind to an allosteric binding site of CB2 receptor
93 and act as a negative 




1.2.3 CB2 receptor as a therapeutic target 
The endocannabinoid system is associated with numerous physiological processes and 
disorders.95 However, the therapeutic potential of targeting CB1 and CB2 receptors has 
been largely unrealised due to the complex signalling pathways, poor physicochemical 
properties of typically lipophilic cannabinoids and psychotropic side effects. Due to 
their respective physiology, it is thought that the psychotropic side effects of 
cannabinoids are primarily mediated by CB1 receptor in the CNS,
96 and that by 
targeting CB2 receptor these can be minimised.
97 Although it is worth noting that there 
are current efforts to develop peripherally selective CB1 receptor ligands (i.e. with low 
blood-brain barrier penetration) in an attempt to circumvent psychotropic effects.98 CB2 
receptor is very important in mediating inflammatory processes and has been 
specifically shown to play a role in brain injury99 and neurodegenerative disorders such 
as Alzheimer’s disease,100 Parkinson’s disease,101 and Huntington’s disease,102 as well 
as atherosclerosis,103 myocardial infarction and restenosis,104 inflammatory bowel 
disease,105 osteoporosis,106 cancer, 42, 107 addiction,108 and inflammatory and chronic 
pain.109 In preclinical studies, both CB2 receptor agonists and inverse agonists have 
been shown to have analgesic and anti-inflammatory effects,109-112 which could be 
reflective of the complex role of CB2 receptor in these physiological processes. As yet, 
there are no CB2 receptor selective drugs available on the market, but a number of 
candidates have undergone clinical trials.113, 114 For example, the pyrimidine-based 
GW842166X 1.3 (Figure 4) completed phase II clinical trials for treatment of post-
operative pain, but was found to show low efficacy.115 Pyridine-based S-777469 1.4 
(Figure 4) completed phase II clinical trials evaluating safety and efficacy in treatment 
of atopic dermatitis.116 Some researchers have tried to synthesise cannabinoids with 
reduced lipophilicity in the pursuit of candidates with more favourable physicochemical 
properties.117, 118 In addition, the divergent nature of GPCR signalling creates 
challenges in achieving signalling selectivity. Teasing out the intricacies of CB2 
receptor signalling pathways and ligand binding interactions could enable development 




Figure 4: CB2 receptor agonists GW842166X 1.3 and S-777469 1.4. Ki values shown for human (h)CB 
receptors.† 112, 119  
Allosteric modulation is a potential strategy for developing CB2 receptor targeted drugs 
that produce a more nuanced fine-tuning of signalling pathways, reducing both off-
target and on-target effects. In addition, a recent study found that allosteric modulation 
of muscarinic receptors produced inhibition of dopamine release and antipsychotic 
effects which were mediated through CB2 receptor signalling.
120 This is perhaps not 
surprising considering the role of the endocannabinoid system in neurotransmitter 
inhibition, but does point to the subtle mechanisms by which CB2 receptor can be 
exploited to treat disease. 
CB2 receptor remains a promising pharmacological target for a multitude of disorders, 
but a more thorough understanding of the role CB2 receptor plays in disease is required 
before effective CB2 receptor targeted therapeutics can be developed. Greater 
appreciation of CB2 receptor function as well as the subtleties of regulation and 
variation in receptor expression levels, including variation between cell types and 
healthy and diseased tissue would improve opportunities for drug development.   
                                                 
† Where error values are not included for literature binding affinities, it is because they were not given in 




Cannabinoids are defined in this thesis as any ligands that bind to CB receptors and can 
include endocannabinoids (Figure 3), synthetic ligands and phytocannabinoids derived 
from plants. Cannabinoids can be agonists, inverse agonists or antagonists.  
1.3.1 Phytocannabinoids 
Discovery of the endocannabinoid system was as a result of research into the plant 
Cannabis sativa L., from which the endocannabinoid system and its constitutive 
receptors derive their names. Cannabis sativa L. has been used as a medicinal therapy 
since at least the second millennium BC.121 However, elucidation of the chemical 
components of cannabis extracts was not achieved until the second half of the twentieth 
century, largely due to the complex mixture of over 60 closely related, lipophilic 
compounds, resulting in challenging isolation and characterisation of key 
components.53 The structure of the major mood-altering constituent, (-)-Δ9-THC 1.5 
was elucidated in 1964122 and has since been found to act as a partial agonist with high 
affinity (Ki < 100 nM) at both CB receptors, mediating antinociceptive effects through 
CB1 receptor activation (Figure 5).
123 (-)-Δ9-THC 1.5 (dronabinol, Marinol®) is 
licensed for the treatment of nausea in chemotherapy patients.124 Cannabidiol 1.6 is a 
major non-psychoactive constituent, significant for its anti-inflammatory properties and 
acts as a non-competitive antagonist at CB1 receptor and an inverse agonist at CB2 
receptor, with micromolar affinity at both receptors (Figure 5).125 A 1:1 mixture of (-)-
Δ9-THC 1.5 and cannabidiol 1.6 (nabiximols, Sativex®) is licensed for the treatment of 
neuropathic pain and spasticity in multiple sclerosis (MS) patients.126 Despite over sixty 
years of pharmacological research into phytocannabinoids, most of the other 
phytocannabinoids present in Cannabis sativa L. have not been thoroughly evaluated, 
yet show promising pharmacological properties.127 Phytocannabinoids have also been 




Figure 5: Phytocannabinoids (-)-Δ9-THC 1.5 and (-)-Cannabidiol 1.6.129  
1.3.2 Synthetic cannabinoids 
The purported therapeutic effects of Cannabis sativa L. and subsequent appreciation for 
the physiological importance of CB receptors sparked intense interest in developing 
novel and diverse classes of synthetic cannabinoids. Numerous synthetic cannabinoids 
have been reported, but only a few of the most notable examples from each of the major 
chemical classes are described here, with particular focus on CB2 receptor selective 
cannabinoids. Unfortunately, several synthetic cannabinoids that were developed with 
the aim of understanding more about CB receptors have now been appropriated as 
drugs of abuse, leading to increased legislation in many countries regarding research 
into novel CB1 receptor ligands.
130, 131  
1.3.2.1 Endocannabinoid derivatives 
CB1 receptor selective agonists have been developed by introducing chlorine, fluorine, 
isopropyl or methyl substituents to the hydroxyl tail of AEA 1.1 as well as lengthening 
the alkyl chain and some of these ligands are stable to FAAH hydrolysis.132  
1.3.2.2 Classical cannabinoids 
Classical cannabinoids contain the same tricyclic dibenzopyran scaffold as the 
phytocannabinoid (-)-Δ9-THC 1.5. Stereoselectivity is a common feature amongst these 
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cannabinoids, for instance HU-210 1.7 (Figure 6) is a high affinity CB agonist, whereas 
the enantiomer HU-211 exhibits no significant affinity for CB receptors.133 Nabilone 
1.8 is a CB receptor agonist marketed as Cesamet® for treatment of chemotherapy 
induced nausea and for appetite stimulation in acquired immunodeficiency syndrome 
(AIDS)-related anorexia.134 Methylation of the phenolic hydroxyl in classical 
cannabinoids generally favours CB2 receptor selectivity, such as in the potent CB2 
receptor selective agonist L-759633 1.9.135  
 
Figure 6: Classical synthetic cannabinoids HU-210 1.7, Nabilone 1.8 and L-759633 1.9.129, 135, 136  
1.3.2.3 Non-classical cannabinoids 
Initial efforts at diversifying synthetic cannabinoid structures focused on derivatising 
and breaking the dibenzopyran ring of THC 1.5, giving rise to the non-classical 
cannabinoids (NCCs). Perhaps the most notable NCC is CP55,940 1.10, which is a high 
affinity agonist at both CB receptor subtypes (Figure 7). The tritiated analogue of 
CP55,940 1.10 is commonly used in radioligand binding assays at CB receptors (see 
1.4.2 and 1.6.1) and is used in this thesis (Chapters Two - Five). HU-308 1.11 is a CB2 





Figure 7: NCCs CP55,940 1.10 and HU-308 1.11.‡ 137, 138  
1.3.2.3.1 Diarylpyrazole cannabinoids 
Most reported diarylpyrazole-based cannabinoids are selective for CB1 receptor, e.g. 
Rimonabant 1.12 (SR141716A; see section 1.2.1; Figure 8).139 A notable exception is 
SR144528 1.13, which was the first highly potent, CB2 receptor selective antagonist 
reported (Figure 8).140 SR144528 1.13 also exhibits inverse agonism at CB2 receptor 
and has found widespread use as a pharmacological tool for characterising CB2 receptor 
function.141-143  
1.3.2.3.2 Aminoalkylindole cannabinoids 
The aminoalkylindoles (AAIs) represent a large chemical class of cannabinoids with 
extensive structure activity relationships (SAR) reported which will be discussed in 
more detail in Chapter Two. AM630 1.14135 (Figure 8) is a CB2 receptor selective AAI 
that has been characterised as an antagonist and inverse agonist at CB2 receptor, and it 
has also been proposed that 1.14 behaves as a protean ligand, behaving as an agonist in 
certain receptor populations.144  
                                                 
‡ Where species of receptor is not listed for literature binding affinities, it is because it was not specified 
in the original report. This applies to the whole thesis.  




Figure 8: Examples of diarylpyrazole, AAI, quinoline and 1,8-naphthyridin based cannabinoids.111, 135, 138, 
140, 145  
1.3.2.3.3 Quinoline and 1,8-naphthyridin cannabinoids 
Quinoline-based JTE-907 1.15 is a CB2 receptor selective inverse agonist with 
demonstrated anti-inflammatory and anti-pruritic effects in vivo (Figure 8).111, 146 1,8-
naphthyridin based cannabinoids (e.g. the antagonist 1.16; Figure 8) have emerged in 
recent years as providing a high degree of CB2 receptor selectivity and reduced 
lipophilicity in comparison to other scaffolds.145 1,8-naphthyridin-based cannabinoids 
will be reviewed in more detail in Chapter Four.  
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There are several other distinct cannabinoid scaffolds, such as imidazoles, 
benzimidazoles, pyridines and carbolines.113 Due to their therapeutic potential, there are 
many patent reports of novel CB2 receptor ligands, which were recently reviewed by 
Morales et al.147 However these are not discussed further here because this is outside of 




1.4 Tools for studying CB2 receptor 
There are a variety of pharmacological tools which have been invaluable in the 
discovery and characterisation of CB2 receptor thus far. However, each of these tools 
have their own distinct utilities and drawbacks. The further elucidation of complex CB2 
receptor processes requires a diverse set of tools with improved selectivity, 
pharmacokinetic profiles and utility in studying dynamic live cell receptor processes. A 
detailed review of radioligands, covalent ligands, antibodies and fluorescent ligands as 
tools for studying CB receptors and other lipid-binding Class A GPCRs can be found in 
the review article published during this PhD research (Anna Cooper, Sameek Singh, 
Sarah Hook, Joel D. A. Tyndall and Andrea J. Vernall, (2017) Chemical Tools for 
Studying Lipid-Binding Class A G Protein-Coupled Receptors, Pharmacol Rev 69:316-
353)148. Therefore, the use of radioligands, covalent ligands and antibodies are 
summarised very briefly in this thesis. However, fluorescent ligands are the main focus 
of this thesis and so will be covered in more depth in the subsequent section (1.5).  
1.4.1 Ligands 
High affinity CB2 receptor ligands are inherently useful for studying receptor function 
and have found substantial use in probing receptor signalling pathways and 
physiology.149 For instance, CP55,940 1.10 has been widely exploited in the study of 
CB receptor activation and physiology150, 151 and is used in this PhD research in cAMP 
assays to test for antagonists (see 1.6.2). The CB2 receptor selective inverse agonist 
SR144528 1.13 has been used to study CB2 receptor ligand binding, phosphorylation 
and physiological roles,142, 143, 152, 153 and in this PhD research was used as a reference 
ligand in both the radioligand binding assays and cAMP assays. CB2 receptor selective 
agonist HU-308 1.11 has been used to elucidate CB2 receptor trafficking mechanisms.
81 
In addition, high affinity ligands have been exploited as stabilising ligands in the 
crystallisation of CB1 receptor.




Radioligands can be used to investigate phenomena such as receptor distribution,154 
oligomerisation,155 signalling and allosteric modulation.156 Radioligands possessing 
radioisotopes such as 3H, 14C and 35S are frequently used in binding assays to identify 
or characterise CB2 receptor ligands
157 and determine ligand-receptor binding 
parameters, such as dissociation constant (Kd), inhibition constant (Ki; see section 1.6.1) 
or maximum specific binding (Bmax). The CB receptor radioligand [
3H]CP55,940 1.17 
(Figure 9) has proven a valuable tool in cannabinoid pharmacology, facilitating the 
discovery of CB1 receptor
51 and study of CB receptor expression in disease.158 
[3H]CP55,940 1.17 is used in this PhD research in competition radioligand binding 
assays (section 1.6.1). However, radioligands have significant drawbacks with their 
inherent safety hazards and disposal issues, expense and limited shelf life. Radioligands 
have been used to study the distribution of CB2 receptor with in vivo positron emission 
topography (PET) imaging, by incorporating radioisotopes such as 11C and 18F into CB2 
receptor ligands.148 PET imaging offers deep tissue penetration and high sensitivity, but 
poor spatial resolution.159, 160  
 
Figure 9: The CB receptor radioligand [3H]CP55,940 1.17 
1.4.3 Covalent ligands 
Covalent ligands possess electrophilic or photoactivatable functionality capable of 
forming a covalent bond with amino acid side chains.161 162 The primary utility of 
covalent ligands is in investigating receptor structure by identifying amino acid residues 
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key to ligand binding and receptor activation.148 Covalent ligands are often used in 
conjunction with site-directed mutagenesis studies and in silico modelling to 
characterise the topography of the ligand binding site(s). The electrophilic AM841 1.18 
(Figure 10) has been used in multiple structure studies to elucidate CB receptor 
structure, function, physiological roles and ligand entry pathways,163, 164 as well as a 
stabilising ligand in the crystallisation of CB1 receptor.
65 Many covalent ligands 
developed for CB2 receptor lack the required functionality for use as imaging tools, 
however covalent fluorescent probes can be developed, enabling utility as imaging 
tools to study dynamic receptor processes.165  
 
Figure 10: CB receptor electrophilic ligand AM841 1.18.65, 163  
1.4.4 Antibodies 
Antibodies are versatile and have been commonly used to study GPCRs166, 167 in 
conjunction with several techniques, such as western blotting, immunohistochemistry, 
immunocytochemistry, immunofluorescence and flow cytometry. Indeed, much of our 
current understanding of CB1 and CB2 receptor expression has been gleaned through 
antibodies.148  However, there have been notable reports of lack of reproducibility and 
poor specificity of CB receptor antibodies, resulting in false positives and false 
negatives.168, 169 Nanobodies are fragments of antibodies, derived from the variable 
domain and have been developed as diagnostics, therapeutics and as tools for studying 
GPCR structure and function.170 Allosteric nanobodies have been used to study 
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mechanisms of β2-adrenoceptor activation.
171 Nanobodies have also been used to 
stabilise GPCRs for obtaining X-ray crystal structures.172   
22 
 
1.5 Fluorescent ligands 
1.5.1 Principles of fluorescence 
Fluorescence occurs during vibrational relaxation of an excited state fluorophore.173 
The first stage is excitation, in which the fluorophore absorbs a photon, raising the 
energy level from a singlet ground state (S0) to an excited electronic singlet state (S1'; 
Figure 11).174 During the excited-state lifetime (typically 10-8 seconds) partial 
dissipation of energy occurs from the excited singlet state (S1') to yield a relaxed 
excited singlet state (S1). Subsequent emission of a photon produces a fluorescent 
signal and the fluorophore relaxes back to ground state (S0).  
 
Figure 11: Jablonski diagram175 representing the shift in energies between ground state (S0), excited 
electronic singlet state (S0') and relaxed excited singlet state (S1).  
A fluorophore emits light at a longer wavelength than it was excited at. This is due to 
the loss of energy between excitation and emission, during the excited-state lifetime, 
resulting in the emitted photon having lower energy than the absorbed photon.176 The 
Stokes shift describes the shift from high energy to low energy, i.e. the shift from the 
shorter absorption wavelength to the longer emission wavelength. The Stokes shift is 
important as it allows detection of emitted fluorophores to be distinguishable from 
absorbed photons. A fluorophore can repeatedly cycle through excitation (absorbance) 
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and relaxation (fluorescence) unless it is photobleached, whereby an over-excited 
fluorophore can react with oxygen to produce a nonfluorescent molecule.177  
Processes other than fluorescence can occur from the excited state, such as quenching 
leading to loss of photons. Quantum yield describes the efficiency of the fluorescence 
process and is equal to the number of emitted photons divided by the number of 
absorbed photons.178 Therefore, the maximum fluorescence quantum yield of a 
fluorophore is 1.0 and it can be as low as 0.05. The absorption efficiency of a 
fluorophore is described by the molar extinction coefficient, with typical values 
between 5000 – 200,000 cm-1M-1.174 The overall fluorescence output of a fluorophore is 
proportional to the product of the quantum yield and the molar extinction coefficient. 
Quenching can occur due to short-range interactions between the fluorophore and the 
local molecular environment, leading to loss of fluorescence signal.173, 179 For instance, 
when fluorophores are used in biological experiments, some fluorophores may be 
quenched in an aqueous environment, whereas others may be quenched in the 
membrane.  
1.5.2 Applications of fluorescence for studying GPCRs 
Fluorescence techniques, including fluorescent antibodies, autofluorescent proteins, 
tagged proteins and fluorescent ligands have found widespread use as non-invasive 
methods for visualising GPCR processes in real-time.180 This is a result of 
technological advances in fluorescence instrumentation as well as increased availability 
of diverse fluorophores. Fluorescent antibodies have been used to visualise membrane 
bound GPCRs in both living and fixed cells, or internalised GPCRs in fixed cells. 
Autofluorescent proteins, such as green fluorescent protein (GFP) and yellow 
fluorescent protein (YFP) are extensively used as reporter molecules for localising 
GCPRs and are utilised in fluorescence resonance energy transfer (FRET) and 
bioluminescence resonance energy transfer (BRET) techniques to uncover molecular 
mechanisms of dimerisation, signalling and receptor recycling.181  
Fluorescent ligands are powerful tools for studying receptor structure and function in 
whole live cells.182 The versatility of fluorescent ligands means that they can be used to 
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study receptor localisation, oligomerisation, allosterism and dynamic receptor processes 
such as activation and trafficking.183  
1.5.3 Fluorescent ligands for GPCRs 
Fluorescent ligands are adaptable to many different fluorescence-based assay and 
imaging systems, including high throughput screening (HTS),184, 185 FRET,186 confocal 
microscopy, scanning confocal microscopy (SCM), flow cytometry187 and fluorescence 
correlation spectroscopy (FCS).188 Fluorescent ligands can enable the analysis of single 
cells and single receptor-ligand interactions when utilised with SCM or FCS. 
Fluorescence is a highly sensitive spectroscopic method and is also a non-destructive 
process, so signal changes can be reliably measured as a function of time to determine 
receptor-ligand kinetics.180  
Near-infrared (NIR) fluorescent ligands have found in vivo applications, due to 
relatively deep tissue penetration and low autofluorescence in the near infrared region 
(650-900 nm).189 NIR fluorescent ligands offer high sensitivity and resolution and have 
found applications as tumour-specific probes for guided surgery,190 as well as in optical 
biopsies.191 Overexpression of GPCRs on the surface of tumour cells renders them a 
potential target for receptor specific in vivo tools.  
High affinity, specific fluorescent ligands have been successfully designed for other 
class A GPCRs and utilised in vitro in pharmacological studies.192 For instance, an α1L-
adrenoceptor fluorescent ligand was able to localise receptor in the muscle layer of 
human prostate.193 Fluorescent ligands for A3 adenosine receptor have been used to 
visualise receptor internalisation and arrestin recruitment,194 study single-cell ligand 
binding kinetics,195 as well as the effect of allosteric modulators in perfusion studies.196 
Quantification of ligand-receptor complexes was enabled using a fluorescent ligand for 
histamine-H1 receptor in conjugation with FCS.
197  
Fluorescent ligands require high affinity and specificity to be put to use as biological 
tools in native cells with mixed receptor populations. Non-specific membrane binding 
of fluorescent ligands is usually determined by confocal imaging studies of cells 
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overexpressing the target receptor, incubated with the fluorescent ligand and in the 
presence or absence of an excess of a non-fluorescent high affinity receptor selective 
ligand (‘blocking experiments’, e.g. Figure 12).198  
 
Figure 12: Example of a blocking experiment for determining non-specific binding of a GPCR 
fluorescent ligand. Confocal imaging of an A3 receptor fluorescent ligand (‘28’, A3 receptor selective 
pharmacophore-linker-BODIPY FL-X) in Chinese hamster ovary cells expressing human A3 receptor. 
The fluorescent labelling of A3 receptor by ‘28’ (top left panel) is blocked by a non-fluorescent high 
affinity, selective ligand for A3 receptor (MRS1220, top right panel), therefore demonstrating that ‘28’ 
has minimal non-specific membrane binding.§ 198  
1.5.3.1 Fluorescent ligands for CB2 receptor  
There have been several reported fluorescent ligands for CB2 receptor. However, many 
of these ligands have shown either poor affinity or selectivity for CB2 receptor, or high 
non-specific membrane binding, limiting their utility as imaging tools.184, 199-201 The 
challenge of developing a CB2 receptor fluorescent ligand with little non-specific 
membrane binding is exacerbated by the lipophilic nature of many cannabinoids and 
fluorescent dyes.  
                                                 
§ Figure republished from A. J. Vernall, L. A. Stoddart, S. J. Briddon, H. W. Ng, C. A. Laughton, S. W. 
Doughty, S. J. Hill and B. Kellam, Org. Biomol. Chem., 2013, 11, 5673 DOI: 10.1039/C3OB41221K - 
Published by The Royal Society of Chemistry. 
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The fluorescent ligand NMP6 1.19 was developed by replacing a portion of the 
pharmacophore with a nitrobenzoxadiazole (NBD) fluorophore (Figure 13).201 This 
approach is in contrast to most fluorescent ligand designs which append the fluorophore 
to the pharmacophore. NMP6 1.19 showed reasonable affinity and selectivity for CB2 
receptor (Table 1), although blocking experiments using NMP6 1.19 and a high 
concentration of non-fluorescent CB2 receptor agonist still showed a degree of non-
specific binding.  
 
Figure 13: Fluorescent CB2 receptor ligands NMP6 1.19 and Biotin-HU-210-1 1.20.  
The biotin-tagged HU210-1 1.20 showed high affinity for CB2 receptor but no subtype 
selectivity over CB1 receptor, limiting its utility in native cells (Table 1; Figure 13).
87 In 
situ conjugation of biotin-HU210-1 1.20 with a fluorophore streptavidin-Alexa488 was 




Table 1: Literature affinity data for CB receptor fluorescent ligands.  
Fluorescent ligand CB2 receptor affinity a CB1 receptor affinity a 
NMP6 1.19 201 Ki = 387 nM (h) < 40% at 10 µM (h) 
Biotin-HU210-1 1.20 87 Ki = 1.6 ± 0.4 nM (h) Ki = 2.4 ± 0.4 nM (h) 
NIR-mbc94 1.22 184 Ki = 260 nM (m) - 
NIR760-mbc94 1.23 200 Kd = 26.9 ± 3.7 nM (m) - 
ZW760-mbc94 1.24 199 Kd = 53.9 ± 13.0 nM (m) - 
IR700DX-mbc94 1.25 202 Kd = 42.0 ± 19.6 nM (m) - 
NIR760-Q 1.26 203 Kd = 75.5 ± 28.0 nM (h) - 
NIR760-XLP6 1.27 204 Kd = 169.1 ± 66.1 nM (m) Kd = >10000 nM (m) 
a Affinity reported as either Ki or Kd value and for mouse (m)CB or human (h)CB receptor. 
 
Most CB2 receptor fluorescent ligands for in vivo applications have utilised SR144528 
1.13 as the core pharmacophore. These studies illustrate the importance of selecting the 
appropriate position for linker conjugation, as linker attachment at the 4-chlorophenyl 
or pyrazole abolished CB2 receptor affinity, whereas attachment at the benzylic position 
was tolerated in the linker conjugate mbc94 1.21.184, 205 Conjugation of a NIR 
fluorophore, IRDye 800CWt (cyanine 7 (Cy7)) to mbc94 1.21, gave the fluorescent 
ligand NIR-mbc94 1.22, which demonstrated good affinity for mouse (m) CB2 receptor 
(Table 1; Figure 14), but high non-specific membrane binding.184 Changing the 
fluorophore to NIR760 (Cy7) resulted in a fluorescent ligand NIR760-mbc94 1.23 with 
high affinity for mCB2 receptor, but still showed significant non-specific binding.
200 
Conjugation of a zwitterionic NIR760 (Cy7) fluorophore to the same pharmacophore-
linker to give ZW760-mbc94 1.24 resulted in some improvement in non-specific 
binding compared to NIR760-mbc94 1.23, but there was still enough non-specific 
binding to limit utility.199 Fluorescent ligands have potential utility as photosensitiser 
therapies. For example, attaching the NIR fluorophore IR700DX to the pharmacophore-
linker mbc94 1.21 yielded the photosensitiser IR700DX-mbc94 1.25,202 which 
successfully inhibited CB2-positive tumours in mice following irradiation.
206 It is 
important to note that none of the mbc94 1.21 conjugated fluorescent dyes have 
reported affinities for CB1 receptor, so it is not yet demonstrated how selective they 




Figure 14: Fluorescent CB2 receptor ligands NIR-mbc94 1.22, NIR760-mbc94 1.23, ZW760-mbc94 1.24 
and IRD700DX-mbc94 1.25.  
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A quinolone-based ligand was used in the development of the fluorescent ligand 
NIR760-Q 1.26 (Table 1; Figure 15) possessing a Cy7 fluorophore, but it showed high 
non-specific binding in Jurkat cells.203 Conjugation of NIR760 to a pyrazolopyrimidine 
based pharmacophore yielded a fluorescent ligand NIR760-XLP6 1.27 with selectivity 
for CB2 over CB1 receptor, however non-specific binding was again observed.
204  
 
Figure 15: Fluorescent CB2 receptor ligands NIR760-Q 1.26 and NIR760-XLP 1.27. 
The availability of a high affinity, selective fluorescent ligand for CB2 receptor 
exhibiting little non-specific binding (meaning little non-specific membrane binding 
and little binding to other receptors) would enable a huge step forward in the in vitro 
study of CB2 receptor expression and function, thus enabling exploitation of CB2 
receptor as a therapeutic target.  
It is worth noting that there is also a lack of high affinity, selective fluorescent tools 




1.5.4 Fluorescent ligand design 
Fluorescent ligands are usually designed by first selecting an appropriate 
pharmacophore, such as a well characterised ligand with high affinity and selectivity 
for the target receptor. It is worth considering the desired functionality of the 
fluorescent ligand when selecting a pharmacophore. There is a need for fluorescent 
ligands for CB2 receptor with a range of functionality to expand the pharmacological 
toolbox and enable study of diverse receptor processes. Fluorescent antagonists for 
other GPCRs have proven utility in binding assays and studies of receptor expression 
and localisation.207 Whereas, fluorescent agonists have been used to probe receptor 
kinetics,195 internalisation,187 and allosteric modulation.196 It is therefore of interest to 
develop both fluorescent agonists and antagonists, as well as inverse agonists for CB2 
receptor.  
A linker is often employed to create physical distance between the pharmacophore and 
the fluorophore, with the intention of reducing any detrimental effect of the fluorophore 
on pharmacophore-receptor binding.208 Conjugation of a fluorescent dye and linker to a 
pharmacophore introduces a large amount of steric bulk to the ligand, which can 
significantly alter the pharmacology and physicochemical properties compared to the 
unconjugated pharmacophore. An appropriate region of the pharmacophore for linker 
conjugation needs to be identified that is amenable to change and the introduction of 
steric bulk/length. The linker and fluorophore are likely to engage in binding (either 
specific and/or non-specific) interactions with receptor and/or lipid membrane.  
Therefore varying the site of linker attachment, linker length and composition and 
fluorophore can have a significant effect on linker affinity and efficacy.209 In addition, 
linker and fluorophore choice can greatly affect the overall physicochemical properties 
of the ligand, impacting non-specific membrane binding and non-specific cell 
accumulation.  
There is a diverse selection of fluorophores commercially available that already contain 
a reactive group (e.g. sulfonyl chloride and activated esters), suitable for conjugation to 
amines. Important considerations when selecting a fluorescent dye include the 
excitation and emission wavelength, Stokes shift, molar extinction coefficient, quantum 
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yield, quenching environments, and susceptibility to photobleaching.210 The most 
commonly utilised fluorophores in GPCR fluorescent ligand design are boron-
dipyrromethene (BODIPY®),211 Alexa Fluor®,212 Rhodamines213 and Cyanines.214  
BODIPY® dyes are available across a range of wavelengths, which is determined by 
the substitutions on the core chromophore, with substitutions that extend the conjugated 
system producing longer wavelengths.215 As well as commercial sources, there are 
many published reports on the synthesis of novel BODIPY dyes.216-218  
Isothiocyanate containing fluorophores are not commonly commercially available due 
to long term instability. Sulfonyl chloride containing fluorophores are often unstable in 
water and therefore care has to be taken during conjugation reactions.219 Activated 
esters such as succinimidyl esters, tetrafluorophenyl esters and sulfodichlorophenol 
esters are generally stable and exhibit slow rates of hydrolysis220 and can react with 
primary amines to form highly stable amide bonds. Succinimidyl ester derivatives are 
the most widely available commercially.  
Identifying a high affinity, selective pharmacophore-linker conjugate opens up 
opportunities for the development of tools other than fluorescent linkers. As well as a 
range of type and wavelength of fluorophore, other moieties can be attached to the 
linker, such as biotin,87 covalent warheads, or a clickable handle for in vivo labelling,221 
or the pharmacophore-linker could be further developed into bitopic ligands for dual 
targeting of orthosteric and allosteric sites222 or bivalent ligands for targeting receptor 
oligomers.223   
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1.6 Pharmacological characterisation 
An array of assays have been reported for characterising ligand binding and function at 
CB2 receptor. The basic principles behind the assays utilised in this PhD research 
project will be briefly summarised here.  
1.6.1 Radioligand binding assays 
Competition radioligand binding assays measure the ability of a ligand to directly 
displace a known high affinity radioligand, such as [3H]CP55,940 1.17 from receptor. 
These assays are convenient for a 96-well plate format, meaning that multiple ligands 
can be tested in one plate.  Each well usually contains three components - a fixed 
concentration of radioligand and receptor and either test ligand, vehicle control, or a 
hetero- or homologous competitor (e.g. CP55,940 1.10). The vehicle control determines 
the maximum radioligand binding level, whilst the hetero- or homologous competitor 
determines maximum specific displacement and together these values determine the 
specific binding window. Determining the specific binding window is important as 
cannabinoids often exhibit high levels of non-specific membrane binding. When a 
concentration response assay is carried out, a Ki value of the test ligand can be 
determined using nonlinear regression to fit curves and then using the resultant half 
maximal inhibitory concentration (IC50) in the Cheng-Prusoff equation: 
𝐾𝑖 = 𝐼𝐶50/(1 +
[𝑟𝑎𝑑𝑖𝑜𝑙𝑖𝑔𝑎𝑛𝑑]
𝐾𝑑
).224 This equation requires the concentration and the Kd of 
the radioligand, the latter of which is predetermined in a saturation binding assay. A Kd 
value of a radioligand at a given receptor should theoretically be constant across cell 
lines and expression levels. However, there are sometimes minor differences in the 
reported values, possibly due to post-translational receptor modifications (e.g. 
phosphorylation or palmitoylation),225 assay conditions or the presence of native 
endocannabinoids in the serum used in binding buffers.226 Therefore it is important for 
a research group carrying out radioligand binding assays to determine the Kd value of 
the radioligand themselves, rather than use literature reported Kd values in Ki 
calculations. As the Kd value used effects the calculated Ki, it is also important to 
consider the Kd value when comparing Ki values across studies reported in the 
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literature. All pharmacological evaluation in this project was carried out in the 
laboratory of Professor Michelle Glass at the University of Auckland and therefore the 
Kd values determined by her laboratory group for the radioligand ([
3H]CP55,940) 1.17 
at human embryonic kidney (HEK)293 cell membranes overexpressing hCB1 and hCB2 
receptor were utilised. The Ki value determined in a radioligand binding assay is 
specific to the radioligand utilised and is therefore only a measure of the test ligand’s 
ability to displace that particular radioligand and assumes that the radioligand and the 
test ligand bind to the same or similar receptor site.  
1.6.2 cAMP bioluminescence resonance energy transfer assays 
BRET assays depend upon resonance energy transfer (RET) between a bioluminescent 
donor (Renilla luciferase (Rluc)) and a proximal fluorescent acceptor (e.g. YFP).227 
Rluc catalysed oxidation of coelenterazine causes Rluc to emit light which can lead to 
excitation of proximal YFP by RET. The inverse rate of RET is determined by dividing 
the Rluc signal by the YFP signal and essentially measures the proximity of YFP to 
Rluc. An EPAC (exchange protein directly activated by cAMP) sensor contains the 
donor and acceptor in the same protein and therefore the RET is intramolecular.228 
When EPAC comes into contact with cAMP, it changes conformation, forcing the 
donor and acceptor further apart, reducing BRET signal (Figure 16). This assay is 
useful for measuring the changing levels of cellular cAMP and therefore can determine 
whether a ligand is an agonist, antagonist or inverse agonist in the Gi coupled CB 




Figure 16: Rluc catalyses oxidation of the substrate (coelenterazine) causing simultaneous light emission, 
which can undergo RET to a proximal YFP. EPAC changes conformation on contact with cAMP, 
resulting in too great a distance between Rluc and YFP for RET to occur. Figure republished from 
Salahpour et al, 2012.228  
BRET assays are a popular technique for studying GPCRs and have found application 
in ligand binding assays,229 studying receptor-protein interactions (e.g. oligomerisation, 
G protein and β arrestin interactions) and receptor activation and signalling.230 BRET 
assays were carried out in this PhD research to characterise ligand function in cells 
overexpressing CB2 or CB1 receptor, monitoring cAMP signalling via the Gi/o coupled 
pathway (see Experimental 7.2.2).231   
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1.7 Aims of the Thesis 
The overall goal of this PhD research was to develop a high affinity, selective CB2 
receptor fluorescent ligand suitable for use as a pharmacological tool for studying CB2 
receptor in vitro or ex vivo. There were several objectives towards achieving this 
overall aim: 
- Identify positions of a suitable pharmacophore that are amenable for conjugation of 
a linker and fluorophore.  
- Synthesise a series of fluorescent ligands with varying linker positions, types and 
lengths.  
- Pharmacologically evaluate the fluorescent ligands, linker-pharmacophore 
conjugates and pharmacophores to determine affinity and selectivity for CB2 
receptor and function in a cAMP signalling assay.  
- Build a CB2 receptor homology model for use in ligand docking studies to 
rationalise pharmacological results and aid in refinement of ligand design.  
- Design a second generation of fluorescent ligands based on the first round results, 




 Chapter Two: Fluorescent ligands for CB2 
receptor based on 5 and 6 substituted alkyl-
indoles 
The first step in designing a fluorescent ligand is the selection of a suitable scaffold or 
ligand for derivatisation and conjugation with a fluorescent dye. Firstly, it is helpful for 
the scaffold to have well defined SAR patterns regarding high affinity and selectivity 
for CB2 receptor. It is also advantageous that the scaffold has well characterised SAR 
indicating where the chemical change and steric bulk of a fluorescent dye could be 
tolerated. To this end, high affinity, selective CB2 receptor ligand classes were 
examined and of these, AM630 1.14 of the AAI class of cannabinoids was selected as a 
promising candidate for development into a fluorescent ligand. The following section 
(2.1) outlines the literature SAR of the alkylindole (AI)** scaffold regarding affinity and 
selectivity for CB2 receptor, which informed the fluorescent ligand design.  
2.1 Indole-based cannabinoids 
The AAI WIN 48,098 (Pravadoline) 2.1 (Figure 17) was developed by Sterling 
Winthrop as a new nonsteroidal anti-inflammatory drug (NSAID),232 and shortly 
afterwards was discovered to have cannabimimetic activity.233 Further work led to the 
conformationally constrained, high affinity, CB receptor agonist WIN 55,212-2 2.2, in 
which the morpholino group is restrained by tethering to C7 of the indole core (Figure 
17).234 WIN 55,212 produces stereoselective cannabimimetic activity in vivo, with the 
R enantiomer (WIN 55,212-2 2.2) conferring higher potency than the S enantiomer 
(WIN 55,212-3).235 The binding distribution of radiolabelled WIN 55,212-2 2.2 to rat 
brain was shown to be very similar to the binding patterns of [3H]CP55,940 1.17, 
helping to validate cannabinoid receptors as the target of AAIs.236 A study exploring 
the effects of over 60 compounds from multiple neurotransmitter systems on AAI 
                                                 
** AAIs are classified as indoles which possess an amino alkyl group, e.g. the morpholino group in 
AM630 1.14, whereas AIs possess alkyl groups, e.g. the pentyl group of JWH-007 2.3.  
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binding showed that only cannabinoids (e.g. Δ1-THC, Δ6-THC, CP55,940 1.10) were 
able to inhibit binding of AAIs, demonstrating that AAIs bind to cannabinoid 
receptors.237  
 
Figure 17: Early AAI cannabinoids.129, 237  
2.1.1 SAR of the N1, C2 and C3 positions of indole 
A large number of AAIs and AIs have subsequently been synthesised, generating 
thorough SAR of the whole indole scaffold. In one of the earliest SAR studies, 
Huffman et al demonstrated that absence of an aromatic group at the C3 acyl resulted in 
loss of affinity at CB1 receptor.
238 The Winthrop group synthesised and studied over 
100 related compounds and showed that a bicyclic substituent at C3, ideally a 1-
naphthoyl or a substituted 1-naphthoyl, was preferred for CB1 receptor affinity.
239 The 
same study demonstrated that methyl was the largest group tolerated at C2 but that a 
C2-hydrogen atom was often preferable to a methyl. However, it is interesting to note 
that Shi et al recently reported that moving a C3-amidoadamantyl group to C2 resulted 
in high affinity and selective CB2 receptor ligands, so it appears that bulky groups can 
be tolerated at C2, but only in the absence of C3 substituents.240 The Winthrop group 
also found that for the N1 amino alkyl group, an amino ethyl was optimal and should be 
connected to a cyclic amino such as morpholino, piperidine or thiomorpholine,239 later 
showing that the ethyl can also be connected to the α carbon of the cyclic amino group 
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instead of the nitrogen.241 Exploration of N1 alkyl chain substituents have shown that 
the amino alkyl moiety is not necessary for CB1 or CB2 receptor affinity and in its 
place, an alkyl chain of three to six carbons is tolerated, generating AI compounds such 
as JWH-007 2.3 and JWH-015 2.4 (Figure 18).238, 242 Chains longer than hexyl were not 
tolerated, indicating limited opportunity for longer extension from this position. A 
propyl group at N1 appears to confer CB2 receptor selectivity, as demonstrated by the 
CB2 receptor selective agonists JWH-015 2.4 and JWH-046 2.5 (Figure 18),
243 whilst 
N1-pentyl generally produces unselective or moderately selective CB1 receptor 
ligands.136, 244 Many CB1 receptor agonists belonging to the AI class have been 
identified as constituents in synthetic cannabis drugs of abuse, such as ‘spice’.157  
 
Figure 18: Alkylindole compounds containing either an N1-pentyl or -propyl group and a substituted or 
unsubstituted C3-naphthoyl group.243, 245  
Two additional CB2 receptor selective N1-propyl containing agonists were identified by 
incorporating substitutions onto the C3-naphthoyl moiety, either 4-methyl-1-naphthoyl 
(JWH-120 2.6) or 6-methoxy-1-naphthoyl (JWH-151 2.7; Figure 18).245 In addition to 
the aforementioned weak to moderate electron releasing groups, incorporation of 
electron withdrawing halogen groups on the C3-naphthoyl moiety has also been utilised 
as a method to modulate selectivity and affinity for CB2 receptor.
246 It is important to 
note that many of the aforementioned compounds have been pharmacologically 
39 
 
characterised using rat (r)CB1 and human (h)CB2 receptor. McPartland et al have 
demonstrated that interspecies variations can lead to significant differences in ligand 
binding affinity at cannabinoid receptors.247 Therefore, the selectivity of these 
compounds between hCB1 and hCB2 may differ to that reported for rCB1 and hCB2 
receptor.  
A study exploring substitution of a variety of non-aromatic and aromatic heterocycles 
at N1 showed a degree of tolerance for varying chemical groups, but again with strict 
size limitations.248 For instance, propylmorpholino substitution led to a greater than 200 
fold loss in affinity at CB2 receptor when compared to the ethylmorpholino analogue. 
N1-methyl-tetrahydropyran (THP) and methyl-tetrahydrofuran (THF) were identified 
as privileged groups, conferring high CB2 receptor affinity (and extremely high 
selectivity in the case of methyl-THF; e.g. 2.8 versus 2.9, Figure 19). The same study 
also demonstrated that non-aromatic groups can be utilised at the C3-acyl position, with 
retained CB2 receptor affinity, with particular preference given to 
tetramethylcyclopropyl (e.g. 2.8, 2.9, Figure 19 and 2.13, Figure 21).  
 
Figure 19: High affinity, selective CB2 receptor ligands containing methyl-THP or methyl-THF at N1.248  
Two CB2 receptor selective ligands (L-768,242 2.10 and L-759,787 2.11; Figure 20)
249 
were identified by swapping the N1 cyclic amino groups with the C3 acyl groups, 
further showing that non-aromatic groups are tolerated at C3. Huffman et al found that 
substitution of the C3 carbonyl with a CH2 resulted in compounds with only slightly 
diminished CB1 receptor affinity, implying that AAIs may interact with CB1 receptor 
primarily by aromatic stacking, whilst the presence of a C3 carbonyl slightly enhances 
binding through hydrogen bonding.250 Variation of the C3 acyl to an amido group 
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demonstrated some sensitivity in this region to chemical change and led to 
identification of a high affinity, selective CB2 receptor agonist 2.12 (Figure 20).
251 
Modifying the C3 acyl to an acetyl, by synthesis of a series of 3-phenylacetylindoles, 
led to unselective, moderate CB2 receptor affinity compounds.
252 However, the 
identification of high affinity CB2 receptor selective ligands substituted at C3 with 
either an adamantylcarboxamide or adamantyloxalamide (e.g. 2.14; Figure 21), 
demonstrated that chemical change at the C3 position is somewhat tolerated.253  
 
Figure 20: CB2 receptor selective ligands with varying N1 and C3 groups. 249, 251 
Yates et al have already explored extension and fluorescent dye conjugation at the C3 
acyl position of the AI scaffold.254 Starting from the agonist JWH-015 2.4 (Figure 18), 
an amino group was substituted at the 3-position of the naphthoyl, to which glycine and 
then the fluorophore 7-NBD were conjugated. This approach was unsuccessful and 
resulted in a >250 fold loss in affinity for CB2 receptor compared to the parent 
pharmacophore and implied that there is a strict size limitation on the C3 acyl 
substituent critical for retaining affinity. 
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2.1.2 SAR of the C4-7 positions of indole 
Iodopravadoline (AM630) 1.14 (Figure 21) was initially investigated for its ability to 
antagonise CB receptor agonist induced twitch response in the mouse vas deferens 
(MVD).255 Significant differences in the ability of AM630 1.14 to antagonise different 
cannabinoids indicated the presence of multiple CB receptors in the MVD and that the 
primary receptor target of AM630 1.14 may not be CB1 receptor. AM630 1.14 was 
subsequently confirmed as being CB2 receptor selective and was found to act as an 
inverse agonist and antagonist at CB2 receptor and a weak partial agonist at CB1 
receptor.135  
 
Figure 21: CB2 receptor selective ligands with bulky substitutions at the C5-7 positions of indole.135, 253, 
256 
The presence of an iodine atom at C6 in AM630 1.14 is well tolerated with regards to 
CB2 receptor affinity when compared with the uniodinated analogue pravadoline 2.1. 
Substitution of bulky groups on the indole ring has been explored by Frost et al.256 
Indoles with tetramethylcyclopropyl at the C3 acyl and either ethylmorpholino or 
methyl-THP at N1, and with varying substitutions at C4-7 with either halogen atoms, 
CF3, SO2CH3, hydroxyl, methoxy, methanol, O-benzyl, NH2, alkylamines, O-butanol or 
O-butylbromine, nitrile, methoxymethane or phenyl groups were synthesised. In 
general, these substitutions were well tolerated, producing high CB2 receptor affinity, 
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especially in the N1-methylTHP derivatives, e.g. 2.13 (Figure 21). In the hydroxyl 
substituted derivatives, C5-hydroxyl substitution provided the highest CB2 receptor 
affinity (Table 2; entry 2), whilst C6 substitution gave the best selectivity (entry 3), 
whereas in the methoxy derivatives, 7 substitution provided the best CB2 receptor 
affinity and selectivity (entry 8). In the O-benzyl derivatives, C6 substitution provided 
the highest CB2 receptor affinity (entry 11), whereas C4 substitution was the most 
selective (entry 9). C5 substitutions appeared to impair CB1 receptor affinity, in every 
instance but one, resulting in a decrease in CB1 affinity when compared with the C6-
substituted analogues (entries 6, 10, 13, 15, 17 and 19 cf. to 7, 11, 14, 16, 18 and 20). 
Pasquini et al have also demonstrated that indole ring substitutions, such as furan in the 
high affinity CB2 receptor selective inverse agonist 2.14 (Figure 21), can be 
tolerated.253 Small substitutions of hydroxyl, methoxy or methyl ester groups at C4-7 of 
the indole ring have also been demonstrated in a number of other CB2 receptor 
ligands257, 258 as well as in compounds 2.10249 and 2.12 (Figure 20).251  
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Table 2: Literature reported radioligand binding data for C4-7 substituted indoles from Frost et al.256  
 
 Ki (nM) a 
Table Entry R1 hCB2 receptor hCB1 receptor SI b 
1 4-OH 3.9 388 99 
2 5-OH 1.9 204 107 
3 6-OH 8.5 >3000 >353 
4 7-OH 3.2 246 77 
5 4-OMe 3.3 1090 330 
6 5-OMe 4.6 282 61 
7 6-OMe 0.51 40 78 
8 7-OMe 0.12 45 375 
9 4-OBn 9.3 >10000 >1075 
10 5-OBn 1.3 238 183 
11 6-OBn 0.88 33 38 
12, 2.13 7-OBn 3.1 1095 353 
13 5-CN 30 3326 111 
14 6-CN 5.0 31 6.2 
15 5-COOCH3 238 >10000 >42 
16 6-COOCH3 1.4 25 18 
17 5-Cl 3.0 512 171 
18 6-Cl 2.5 14 5.6 
19 5-Br 6.6 1930 292 
20 6-Br 0.65 13 20 
a Data represent mean values from at least three experiments performed in duplicate. Ki values 
determined using HEK293-hCB2 or CHO-hCB1 membranes and [3H]CP55,940 (Kd values unreported). 
b SI = selectivity index for CB2 receptor, calculated by Ki(CB1)/ Ki(CB2).  
 
2.1.3 In vitro and in vivo effects of indole-based cannabinoids 
Indole-based cannabinoids with a range of functions have been developed, including 
agonists, inverse agonists, antagonists and neutral antagonists. Of these, the most 
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commonly identified have been agonists, which could be attributed to the increased 
interest in cannabinoid receptor agonists driven by drug discovery efforts.113 CB 
receptor agonist WIN 55,212-2 2.2 has been shown to increase intracellular calcium, 
through CB1 receptor coupling to Gq, independent of other G proteins.
259 The less 
potent S enantiomer, WIN 55,212-3 has been shown to act as a competitive neutral 
antagonist at CB2 receptor and an inverse agonist at CB1 receptor.
260 WIN 55,212-2 2.2, 
as well as some other AI cannabinoid agonists can elicit off-target effects through 
interaction with AI-sensitive GPCRs and microtubules, binding to which has been 
shown to enhance the anti-proliferative effects of AI cannabinoids.261 It is necessary to 
put any in vivo effects into context by examining the possibility of off-target effects. 
The most promising in vivo effect observed with AI-based CB2 receptor ligands is 
analgesia, for example AI CB2 receptor selective agonist AM1241 (Ki = 7.1 nM at 
mCB2 receptor, 580 nM at rCB1 receptor) inhibits pain through CB2 receptor binding, 
independent of CB1 receptors in the CNS.
262 The high affinity CB2 receptor selective 
agonist A-796260 has demonstrated efficacy in inflammatory, post-operative, 
neuropathic and osteoarthritic pain models.112  
2.1.4 Conclusions on literature SAR of the indole scaffold 
A fluorescent dye is very bulky and so it is important that the position of linker and dye 
attachment on the core ligand or pharmacophore is tolerant to chemical change. 
Existing SAR around N1 substituents of the indole scaffold shows quite clearly that 
there is a strict size and length limitation in this region (Figure 22).238, 248 In 
comparison, the chemistry and size of C3 groups may be slightly more amenable to 
change.248, 253 However, Yates et al have already explored extension and fluorescent 
dye conjugation at the C3 acyl position of the AI scaffold, which was unsuccessful.254 




Figure 22: Summary of existing CB2 receptor binding SAR of the indole scaffold 
Therefore, the only region of the indole scaffold left for possible extension and 
development into a fluorescent dye is C4-7. This portion of the indole ring is amenable 
to the substitution of some bulky groups253, 256 and this region is as yet unexplored with 
regards to development of longer linkers and fluorescent ligands. It is also worth noting 
that there are also numerous high affinity CB2 receptor ligands without substituents at 
C4-7,248, 263 demonstrating that C4-7 substituents are not necessary for binding and 
therefore extension at this region may avoid disturbing key binding regions.   
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2.2 Fluorescent ligand design 
2.2.1 Core ligand 
Various N1-alkyl or -aminoalkyl R1 and C3-acyl R2 groups were selected (Figure 23) 
based on previously reported optimal CB2 receptor affinity and selectivity as discussed 
in section 2.1.1. At the N1 (R1) position, the ethylmorpholino group was selected as a 
substituent due to its presence in multiple CB2 receptor ligands, such as AM630 1.14. 
In addition, methyl-THP and methyl-THF were selected due to the high CB2 receptor 
affinity and selectivity conferred by these groups (e.g. 2.8 and 2.9, Figure 19).248  
 
Figure 23: A library of fluorescent compounds were designed based on various combinations of R and X 
groups.  
For ease of synthesis methyl substitution was not used at C2, as the SAR shows this 
methyl to be non-essential for CB2 receptor affinity and selectivity with in some cases 
C2-H being preferred.239 A range of functional groups are tolerated at C3, including, 
acyl, aminoalkyl, amido, carboxamide and oxalamide.249, 251, 253 In this series an acyl 
group was utilised as it is present in AM630 1.14 and has well characterised SAR being 
the most pervasive C3 functionality amongst CB2 receptor ligands.  
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At the C3 acyl position (R2; Figure 23), the 4-methoxyphenyl moiety of AM630 1.14 
was selected as an R2 substituent, as well as the 1-naphthoyl utilised in ligands such as 
WIN 55,212-2 2.2 and JWH-015 2.4. In an attempt to sample non-aromatic groups at 
the C3 acyl, a cyclohexane was also selected as an R2 substituent, as it has been shown 
to offer reasonable CB2 receptor affinity
248 and the requisite starting materials are easily 
available. As tetramethylcyclopropyl substituents at the C3 acyl position (e.g. 2.8, 2.9, 
Figure 19 and 2.13, Figure 21) have shown high CB2 receptor affinity in combination 
with numerous different N1 groups,248, 256 utilising tetramethylcyclopropyl in this series 
was initially of interest. However, the synthetic route determined (discussed below in 
2.3.1) required the nitriles of substituents for C3 acylation. As the 
tetramethylcyclopropyl nitrile was not commercially available and synthesis of it would 
be time consuming, expensive and require unstable reagents,264 it was not considered as 
a substituent in this series.  
2.2.2 Linker 
In this series, substitution of linkers was explored at the C5 position, as well as an 
analogue at the C6 position. Existing SAR shows that substitution at these positions 
generally provides high CB2 receptor affinity, while substitution at C5 impairs CB1 
receptor affinity 256 and could therefore be anticipated to result in CB2 receptor 
selective ligands. A linker is usually employed in the design of a fluorescent ligand to 
create separation between the fluorescent dye and the core ligand, to help reduce 
fluorophore impact on ligand efficacy and affinity. In this series, a ‘mini-linker’ was 
first installed on the pharmacophore as a means to introduce a carboxylic acid handle 
for coupling with amine linkers (Figure 23).  
Three different linkers were included in the compound series: an alkyl chain (1,8-
diaminooctane), a polyethylene glycol (PEG) chain (1,8-diamino-3,6-dioxaoctane) and 
a short peptide (Ala-Ala-ethylamine; Figure 23). These linkers were chosen with the 
aim of generating tools with varied polarity for studying CB2 receptor with the 
diacetylated (i.e.AcNHXNHAc) alkyl chain, PEG chain and short peptide linkers 
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having calculated (c)LogP values of 0.54, -2 and -3, respectively.†† These cLogP values 
do not represent the linker-indole conjugates as a whole, but provide an indication of 
the rank lipophilicity of the linker components in isolation. Chain length was preserved 
at 10 atoms in each linker in order to allow evaluation of the effect of linker chemistry 
on CB2 receptor affinity and activity. It was expected that the alkyl chain would deliver 
ligands with higher affinity for CB2 receptor due to greater lipophilicity, as favoured in 
cannabinoids. It is possible that the lipophilicity of the linker could affect ligand entry 
into CB2 receptor as it is postulated that cannabinoids gain entry via the lipid 
membrane.90 This might potentially be more likely for the lipophilic alkyl linked 
conjugates than the PEG or peptide linked derivatives. In contrast, the hydrophilic short 
peptide was anticipated to produce a probe with improved physicochemical properties 
via decreased overall compound hydrophobicity, therefore reducing non-specific 
membrane binding which is typically problematic in GPCR fluorescent ligands.199 This 
approach of using peptide linkers has been successfully demonstrated with A3 
adenosine receptor fluorescent ligands.198 Di-alanine was chosen as the peptide linker, 
to be synthesised from the naturally occurring L-alanine, which has more affordable 
commercial availability than the D-isomer. The fluorescent ligands were designed as 
tools for in vitro use. However, in the event of identifying a good fluorescent ligand 
amongst the peptide-linked conjugates, it could potentially be resynthesised with the 
more metabolically stable D-alanine to facilitate in vivo use. The PEG linker was 
expected to provide a balance between the alkyl and peptide linkers, having moderate 
lipophilicity and therefore retaining affinity, but with diminished non-specific binding.  
2.2.3 Fluorescent dye 
The fluorophore selected can have a huge impact on the overall ligand properties and 
its use as an imaging tool. The fluorescent ligand design utilised here, where the dye is 
attached to a linker moiety, is highly versatile, as a promising linker-indole conjugate 
could be derivatised by attachment of different dyes, therefore varying physicochemical 
properties and excitation and emission wavelengths. This is in contrast to some 
published CB2 receptor fluorescent ligand designs,
201 where the fluorophore is 
                                                 




incorporated into the pharmacophore and so cannot be altered without a complete 
redesign of the compound. Fluorophore lipophilicity is an important consideration as 
this can affect non-specific membrane binding and cell accumulation. It is also 
advantageous in a GPCR probe that the fluorophore is quenched when the ligand is in 
an aqueous environment, but not when bound to the receptor or membrane.192  
 
Figure 24: Structure of BODIPY 630/650-X-OSu 2.15 
BODIPY 630/650-X-OSu 2.15 was chosen as the fluorescent dye (Figure 24). The 
commercially available succinimidyl ester can easily be reacted with a primary terminal 
amine of a linker to form a chemically stable peptide bond. This reaction is easier to 
control in comparison with reactions at some of the other dye groups such as 
isothiocyanates and sulfonyl chlorides.266 BODIPY 630/650-X-OSu 2.15 is a popular 
choice in fluorescent ligand design and has been successfully utilised in the design of 
other Class A GPCR fluorescent probes.194, 198, 207 BODIPY 630/650-X-OSu 2.15 also 
benefits from high photo and chemical stability, intense absorption and good 
fluorescence quantum yield while the red-emitting wavelength means minimal 




2.3.1 Synthesis of core ligand 
2.3.1.1 N1-alkylation with R1 groups 
All compounds were synthesised from the commercially available 5- or 6-
benzyloxyindole (2.18a-b; Scheme 1). N-alkylation of 2.18a-b required the mesylates 
(2.17a-c) of the requisite R1 groups, which were prepared from the commercially 
available alcohols (2.16a-c, Scheme 1, step i) and used without further purification. 
Initially, mesylation of 4-(2-hydroxyethyl)-morpholine 2.16a with methanesulfonyl 
chloride and triethylamine was attempted in dry THF.256 However, the reaction was not 
successful and 1H NMR confirmed that the starting material 4-(2-hydroxyethyl)-
morpholine 2.16a was still present and that the expected singlet peak of the methyl in 
product 2.17a was missing. It was thought that perhaps the THF had not been 
completely dry and that presence of water had either resulted in no reaction occurring 
or led to formation of mesic acid instead of the R1-mesylate 2.17a. Therefore, the 
mesylation reaction to form 2.17a was repeated using a slightly different procedure,267 
which utilised dry dichloromethane (DCM), a much less hygroscopic solvent than THF. 
Under these conditions, formation of 2.17a was successful and the same reaction 
conditions were repeated to form 2.17b and 2.17c (Scheme 1, step i). Triethylamine 
hydrochloride salt formed as a by-product of the mesylation reaction and was sparingly 
soluble in DCM (but not THF) so it was not completely filtered out before reaction of 
2.17a-c with the 5- or 6-benzyloxyindoles 2.18a-b. Therefore, a quantitative yield was 
assumed for R1-mesylates 2.17a-c and they were used the following day in the next step 
due to poor long term stability.268  
Indoles 2.18a-b were N-alkylated with R1-mesylates 2.17a-c using sodium hydride in 
dimethylformamide (DMF) to give 2.19a-d (Scheme 1, step ii). As the triethylamine 
hydrochloride salts were not soluble in DMF, a wide gauge needle (to prevent needle 
blockage) was used when adding the mesylates 2.17a-c to the benzyloxyindoles 2.18a-
b (whilst taking care to avoid excessive addition of salt). Alkyl-indoles 2.19a-d were 
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purified by flash silica chromatography and purification yields were correlated to the 
polarity of the product. The most non-polar 2.19c (retention factor (Rf) 0.71, 1:2 
petroleum ether (PE)/EA; 66%) eluted close to the non-polar fraction of unreacted 
starting material 5-benzyloxyindole 2.18a (Rf 0.81, 1:2 PE/EA), making separation 
more difficult, whereas 2.19d (Rf 0.63, 1:2 PE/EA; 70%) and the most polar 2.19a (Rf 
0.17, 1:2 PE/EA 76%), were more easily isolated in pure form. However, the 6-
benzyloxy analogue, 2.19b had the lowest purified yield (54%), possibly due to the 
large scale synthesis, making work up of the reaction more arduous.  
 
Scheme 1: Synthesis of core ligand. Reagents and conditions: (i) MsCl, Et3N, DCM, room temperature 
(rt), 2 h, quantitative; (ii) NaH, DMF, 45°C, 2 h, 54-76%; (iii) 1,10-phenanthroline, acetone, rt, 1 h, 57%; 




2.3.1.2 C3-acylation with R2 groups 
Friedel-Crafts acylation has commonly been used for C3 acylation of the indole class257 
however, this reaction typically uses hazardous reagents and generates large quantities 
of acidic and aluminium containing waste, as well as being prone to side reactions.269 
There have been several recently reported attempts at developing cleaner, safer 
methods for acylation of indoles, for example a solvent-free acid catalysed acylation 
method utilising 1,3-diones.270 Alternatively, another recently reported procedure271, 272 
utilises [(Phen)Pd(OAc)2] (2.21) to catalyse the addition of nitriles to indoles, providing 
3-acylindoles. This latter method was chosen to acylate N-alkylindoles 2.19a-d, due to 
the thorough validation of the reaction, which was reported with a range of nitrile 
substituents and varyingly substituted indoles.272 The palladium-ligand catalytic 
complex 2.21 was pre-formed273 (57% yield) from Pd(OAc)2 2.20 and 1,10-
phenanthroline (Scheme 1, step iii) rather than generated in situ as this was reported to 
give superior acylation yields.272  
In the mechanism put forward by Jiang and Wang (for indoles without N-
substituents),271 acetic acid protonates the carbon-carbon double bond at C3 of the 
starting indole, which then forms the iminium salt, before palladation by the catalyst 
(Scheme 2, steps i and ii). The nitrile coordinates to the cationic complex (step iii) and 
then forms a ketimine complex via carbopalladation of the nitrile (step iv). Protonation 
releases the free ketimine, regenerating [(Phen)Pd(OAc)2] 2.21 (step v). Finally, 




Scheme 2: The general reaction mechanism proposed by Jiang and Wang271 for the palladium-catalysed 
synthesis of 3-acylindoles (postulated for N-unsubstituted indoles), shown here for 2.22a-i.  
The reaction mechanism suggests acylation occurs at C3 as this is the favoured position 
for protonation of indoles. Proof that acylation occurred at C3 of 2.19a-d was 
determined using two dimensional (2D)-NMR experiments that were carried out on 
several of the series and is discussed here using the example of 5-(benzyloxy)-3-(4-
methoxybenzoyl)-1-[(oxolan-3-yl)methyl]-1H-indole 2.22h (Figure 25), which was 




Figure 25: 5-(Benzyloxy)-3-(4-methoxybenzoyl)-1-[(oxolan-3-yl) methyl]-1H-indole 2.22h, with HMBC 
or NOESY spectra correlations (red arrows).  
Homonuclear correlation spectroscopy (COSY) and heteronuclear single quantum 
coherence spectroscopy (HSQC) NMR experiments assisted in the partial assignment 
of the 1H NMR and 13C NMR spectra of 2.22h. The heteronuclear multiple bond 
correlation (HMBC) NMR spectrum corroborated these assignments and was used to 
identify the remaining unassigned peaks and along with the nuclear Overhauser effect 
spectroscopy (NOESY) spectrum was used to confirm acylation at indole-C3 (see 
appendix for spectra, section 8).  
The HMBC spectrum of 2.22h showed a strong cross peak across three bonds between 
the N-CH2 protons and C2 carbon and as it is the only protonated indole carbon coupled 
to the N-CH2 protons, it must indeed be C2 (Figure 25). A cross peak was also present 
between C2-H and the three closest quaternary carbons of the indole (C3, C3a and C7a) 
as well as long range cross peaks across four bonds to C4 and C7. Crucially, the C2 
proton is the only indole proton to correlate with the downfield carbonyl carbon at 
189.9 ppm. The carbonyl carbon also shows a cross peak with the proximal benzoyl 
aromatic protons (C2''-H and C6''-H). Therefore, the HMBC correlations for 2.22h, 
cement C2 as being located directly adjacent to the acyl group, confirming that C3 must 
have been acylated.  
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The NOESY spectrum of 2.22h showed that the C2-H and C4-H of the indole are in 
close proximity to benzoyl aromatic protons (C2''-H and C6''-H; Figure 25). There are 
also NOE correlations between C2-H and the N-CH2 protons as well as with C2'-H and 
C3'-H of the oxolane. This confirms that C2-H of indole is located between the N-alkyl 
and the acyl group and that acylation has occurred at C3.  
Indoles 2.19a-d were reacted in a pressure tube with the requisite R2-nitrile and 
catalytic [(Phen)Pd(OAc)2] 2.21 in glacial acetic acid, H2O and 1,4-dioxane to give 
2.22a-i (Scheme 1, step iv). Products were isolated with a generally robust yield (18-
83%). The reaction conditions used successfully converted the majority of starting 
material to product, for example, the crude 1H NMR spectra of 2.22a, showed a 5:1 
mixture of 2.22a and 2.19a. However, separating 2.22a, 2.22c and 2.22d from the small 
amount of unreacted 2.19a proved difficult due to similar Rf values and often required 
either multiple column purifications, or recrystallisation after column purification, 
leading to reduced isolated yield following purification of derivatives 2.22a (51%) and 
2.22c (18%). Compound 2.22d showed a high reaction yield in the crude 1H NMR 
spectra, but could not be isolated from the starting material and was taken forward as a 
4:1 mixture of desired product 2.22d and starting material 2.19a.  
2.3.1.3 Hydrogenolysis of O-benzyl 
The benzyl ether of 2.22a-f and 2.22h was cleaved using palladium on carbon and 
hydrogen (balloon) to reveal hydroxyindoles 2.23a-g (Scheme 1, step v). 
Hydrogenolysis of the benzyl ethers of 2.22g and 2.22i was not attempted and these 
two compounds were not progressed to pharmacological evaluation.  The option of 
resuming development was kept open if SAR results indicated that the combination of 
R groups in 2.22g and 2.22i might be favourable. Poor conversion rates of starting 
material to product led to generally disappointing isolated yields (2.23a-d, 2.23f and 
2.23g 12-39%). Strategies recognised to improve hydrogenolysis, such as a small 
amount of glacial acetic acid and fast stirring to improve mixing of phases, were trialled 
but had minimal effect. However, successful reaction optimisation was later achieved 
when larger quantities of 2.23e were required (for synthesis of compounds discussed in 
Chapter 3) and made multiple repeated syntheses necessary. Hydrogenation of 2.22e 
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using a 5:2 solvent mixture of CHCl3 and EtOH, instead of 2:1 EtOH and ethyl acetate 
(EA), as well as utilising a three-way tap for vacuum and hydrogen balloon 
connections, rather than a rubber bung and needle system, led to an increased yield of 
2.23e from 17 to 67%. It has been previously shown that the velocity of hydrogenation 
reactions is effected by solvent choice with the reaction rate being faster in chloroform 
than in ethanol, possibly due to the decreased viscosity of chloroform improving 
transport of dissolved hydrogen to catalyst.274 The three-way tap may have improved 
conversion of starting material to product by helping to maintain the hydrogen 
atmosphere better than that facilitated by a needle connection. Another option to 
increase reaction yields could be use of a Parr apparatus with higher hydrogen gas 
pressure or utilising a different catalyst, such as Pearlman’s catalyst (Pd(OH)2/C), 
rhodium or Raney nickel catalysts.275 Several of the hydroxyindoles were purified by 
precipitation, which also reduced the isolated yield obtained, but gave high purity and 
enough material for progression to the next step.  
Hydroxyindoles 2.23a-g were all evaluated for CB2 receptor binding (see section 2.4.1), 
however, not all of them were progressed further through the synthetic route. Three 
compounds (2.23a, 2.23c, 2.23e) were selected for progression, all of which possessed 
both well characterised N1 (R1) groups (ethylmorpholino and methyl-THP) and C3-
acyl (R2) groups (p-methoxyphenyl and 1-naphthalene).  
2.3.2 Linker and fluorophore conjugation 
Hydroxyindoles 2.23a, 2.23c and 2.23e were alkylated using tert-butylbromoacetate via 
a Williamson ether reaction, thereby installing a short spacer moiety (2.24a-c; 45-76%; 
Scheme 3, step i). Subsequent cleavage of the tert-butyl using trifluoroacetic acid 
(TFA) gave the 5-O-ethanoic acids 2.25a-c (Scheme 3, step ii), which all underwent 




Scheme 3: Attachment of linker and fluorophore to the core ligand. Reagents and Conditions: (i) tert-
butylbromoacetate, NaH, DMF, 60°C, 3 h, 45-76%; (ii) TFA, DCM, rt, 1 h, quantitative; (iii) 1. Fmoc-
Ala-Ala-trityl resin (2.26, see Scheme 4), piperidine, DMF, 2. HATU, DIPEA, DMF, 3. TFA, DCM, rt, 1 
h, 27-30%; (iv) Boc2O, dioxane or DCM, 0°C, 5–15 h, 69% ; (v) HATU, DIPEA, DMF, rt, 12 h, 50-
94%; (vi) TFA, DCM, rt, 1 h, 27-77%; (vii.) Ac2O, DCM, rt 1 h, 97%. (viii) BODIPY 630/650-X-OSu 
2.15, DIPEA, DMF, rt 12 h, 36-88%.  
58 
 
The 5-O-ethanoic acids 2.25a-c were coupled to three different linkers, either N-Boc-
1,8-diaminooctane (2.28a), N-Boc-1,8-diamino-3,6-dioxaoctane (PEG linker; 2.28b) or 
Ala-Ala-1,2-diaminoethane-resin-bound (9-fluorenylmethoxycarbonyl (Fmoc) 
deprotected 2.26). tert-Butoxycarbonyl (Boc)-protected linkers 2.28a and 2.28b were 
prepared at a 69% yield from either mono-Boc protection of 1,8-octanediamine 2.27a 
or 1,8-diamino-3,6-dioxaoctane 2.27b respectively (Scheme 3, step iv). Dilute addition 
of 0.2 equivalents (eq.) of di-tert-butyl dicarbonate (Boc2O) via a pressure equalised 
dropping funnel over a prolonged period with vigorous stirring minimised di-Boc 
protection.  
Solid-phase peptide synthesis (SPPS) was used to prepare the resin-bound dipeptide 
linker 2.26. Fmoc-Ala-OH was pre-activated with HBTU and N,N-
diisopropylethylamine (DIPEA), thereby preventing guanidine side products forming 
between HBTU and the resin-bound amine (Scheme 4; step 1). HBTU is a commonly 
used activating reagent in SPPS, providing reduced racemisation and good peptide 
coupling efficiency.276 Coupling of the activated ester of Fmoc-Ala with 1,2-
diaminoethane trityl resin was performed twice to maximise yield and was followed by 
capping of unreacted resin amines with acetic anhydride (Scheme 4; steps 2 & 3). An 
Fmoc loading test was performed to calculate the degree of resin substitution. Fmoc 
cleavage to reveal the amine was followed by a second coupling of activated Fmoc-Ala 
to give the Fmoc protected, resin-bound dipeptide 2.26 (Scheme 4; steps 4 & 5), after 




Scheme 4: SPPS of dipeptide linker 2.26. Reagents and conditions: (1) HBTU, DIPEA, DMF, added as a 
solution to (2); (3) Ac2O, DIPEA, DMF; (4) piperidine, DMF; (5) DIPEA, DMF.  
Fmoc cleavage of 2.26 and on-resin coupling to 2.25a-c using HATU and DIPEA was 
followed by resin cleavage with TFA to give primary amines 2.30e-g (Scheme 3, step 
iii). Time limitations resulted in only 2.25a and 2.25b being derivatised with linkers 
2.28a and 2.28b, which was achieved using HATU and DIPEA in DMF to give 2.29a-
d, which were purified by column chromatography to give typically good yields (50-
94%; Scheme 3; step v). Boc-deprotection of 2.29a-d using TFA yielded primary 
amines 2.30a-d (Scheme 3, step vi) Small quantities of the crude amines 2.30a-g were 
purified by semi-preparative RP-HPLC (reverse phase-high performance liquid 
chromatography) in order to ensure maximum purity before dye conjugation. 
Therefore, the percentages reported for the Boc-deprotection (2.30a-d: 27-77%) and 
synthesis of 2.30e-g (27-30%) are reflective of the small amount of product purified 
using semi-preparative RP-HPLC and not the overall reaction conversion.  
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Coupling with BODIPY 630/650-X-OSu 2.15 gave 2.32a-g which were also purified 
by semi-preparative RP-HPLC (36-88%; Scheme 3; step viii). The small quantities of 
2.30a-g purified meant that only small excesses of 2.30a-g (1.4 – 2.1 eq., av. 1.7 eq.) 
relative to mmol of dye could be used, which may have reduced the reaction yields. In 
addition, purification of 2.32g was very challenging due to the close elution of 2.32g to 
an unidentified peak (possibly hydrolysed BODIPY 630/650-X or an impurity present 
in the commercial dye) by semi-preparative RP-HPLC, resulting in a significantly 
reduced isolated yield (36%).  
The final fluorescent ligands 2.32a-g, as well as the pharmacophore-linker conjugates 
2.30a-g were pharmacologically evaluated (see section 2.4). Additionally, the amine 
2.30b was acetylated to give 2.31 (Scheme 3; step vii), which also underwent 
pharmacological testing to allow for evaluation of the effect of the primary amine on 
binding. All compounds pharmacologically tested had >95% purity as determined by 
analytical RP-HPLC.  
2.3.3 Synthetic summary 
The aim of this synthesis was to generate a small library of compounds exploring 
varying groups at N1 (R1) and C3 (R2), of which selected derivatives would have a 
linker and fluorophore appended. The starting indoles 2.18a-b possessed an O-benzyl 
group at C5 or C6 to allow for linker substitution at these positions. The synthetic route 
started with N-alkylation of the indole, followed by acylation at C3. Cleavage of the O-
benzyl group revealed an alcohol which was reacted with a brominated mini-linker. The 
tert-butyl group of the mini-linker was cleaved to reveal a carboxylic acid for coupling 
with a mono-Boc protected diamine linker or a peptide linker. Finally, BODIPY 
630/650-X-OSu 2.15 was coupled to the deprotected amine of the linker to give the 
final fluorescent ligand.   
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2.4 Pharmacological evaluation 
Seven derivatives of 5- or 6-hydroxyindoles (2.23a-g) representing the core 
pharmacophore, three 5-O-ethanoic acid substituted derivatives (2.25a-c), seven 
pharmacophore-linker conjugates (2.30a-g), one acetylated pharmacophore-linker 
derivative (2.31) and seven final fluorescent ligands (2.32a-g) were subjected to 
pharmacological evaluation. Radioligand binding assays were carried out to determine 
affinity at hCB2 and hCB1 receptor. Compounds with high affinity at CB2 receptor were 
then tested in cAMP assays to evaluate function (refer to section 1.6). All 
pharmacological assays were carried out by Anna Cooper, except where noted 
specifically. Refer to section 7.2 for a detailed list of experimental contributions by 
others, including membrane preparations.  
2.4.1 Radioligand binding assays 
2.4.1.1 Competition binding screens at 10 µM 
A competition binding screen was used to identify which compounds could displace 
more than 50% of bound [3H]CP55,940 1.17 at hCB2 and hCB1 receptors at a fixed 
concentration of 10 µM. In all binding assays (including concentration response assays 
in 2.4.1.2), there were fixed concentration controls of unlabelled CP55,940 1.10 (10 
µM) as a homologous competitor to determine maximum specific binding which, 
together with vehicle control, defined the specific binding window.  
Six of the seven hydroxyindole compounds (2.23a, 2.23c-g) showed close to or greater 
than 50% displacement of [3H]CP55,940 1.17 at CB2 receptor (Figure 26). The O-
ethanoic acid derivative 2.25c showed high displacement (80%) at CB2 receptor and 
two fluorescent ligands (2.32b and 2.32g) reached close to 50% displacement of 




Figure 26: Competition binding screen at CB2 receptor showing displacement of [3H]CP55,940 (2.5 nM) 
at HEK293 hCB2 (10 µg/point) membranes by a fixed concentration (10 µM) of test compound. Raw 
data was expressed in corrected counts per minute (ccpm) and normalised to unlabelled CP55,940 (10 
μM) (100%) and vehicle control (0%). Data shown is the mean value ± standard error of the mean (SEM) 
of three independent experiments conducted in triplicate. The dashed line indicates the 50% displacement 
criteria for progression to concentration response assays.  
6-Hydroxyindole 2.23b, 5-O-ethanoic acids 2.25a-b, pharmacophore-linker conjugates 
2.30a-g and 2.31 and fluorescent ligands 2.32a, 2.32c-f all had lower levels of 
displacement of [3H]CP55,940 1.17 at hCB2 receptor (Figure 26). This means that these 
compounds are unlikely to have high enough affinity to be able to accurately determine 
a Ki value. Therefore, statistical analysis was used to determine whether CB2 receptor 
binding occurred. The percentage displacement values (n = 3, in triplicate) of 2.23b, 
2.25a-b, 2.30a-d, 2.31, 2.32d-f at CB2 receptor all passed the D’Agostino & Pearson 
normality test and showed significant difference from the vehicle control (0%) in a one 
sample t-test and were thus determined to have a Ki value >10 μM at CB2 receptor 
(Table 3, Table 4). The percentage displacement values (n = 3, in triplicate) of 2.30e-g, 
2.32a and 2.32c all passed the D’Agostino & Pearson normality test, but did not show 
significant difference from the vehicle control (0%) in a one sample t-test and were 
therefore determined to not show significant binding to CB2 receptor (Table 3, Table 4).  
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Three 5-hydroxyindoles (2.23c, 2.23e and 2.23f) showed greater than 50% 
displacement of [3H]CP55,940 1.17 at CB1 receptor (61%, 74% and 78% respectively; 
Figure 26). The 5-hydroxyindoles 2.23a, 2.23d and 2.23g, 6-hydroxyindole 2.23b and 
5-O-ethanoic acids 2.25a-c all showed less than 50% displacement of [3H]CP55,940 
1.17 at CB1 receptor, so the D’Agostino & Pearson normality test and a one sample t-
test were used to determine whether significant CB1 receptor binding had occurred 
(Table 3). CB1 receptor binding of 2.30a-g, 2.31 and 2.32a-g could not be determined 
with statistical analysis, as n = 1 for these compounds. Repeat 10 µM binding screens 
were not carried out for 2.30a-g, 2.31 and 2.32a-g as they showed low displacement in 
the initial screen and were therefore a low priority for pharmacological testing.  
 
Figure 27: Competition binding screen at CB1 receptor, showing displacement of [3H]CP55,940 (2.5 nM) 
at HEK293 hCB1 (7.5 µg/point) membranes by a fixed concentration (10 µM) of test compound. Raw 
data was expressed in ccpm and normalised to unlabelled CP55,940 (10 μM) (100%) and vehicle control 
(0%). Data shown is the mean value ± SEM of three independent experiments conducted in triplicate, 





2.4.1.2 Concentration response assays 
Compounds that displaced approximately 50% or more of bound [3H]CP55,940 1.17 at 
hCB2 (2.23a, 2.23c-g, 2.25c, 2.32b and 2.32g) or hCB1 (2.23c, 2.23e-f) receptors were 
subjected to concentration response competition binding assays to determine Ki values 
(Table 3).  
 
Figure 28: Competition binding curve for SR144528 1.13 at hCB2 receptor, determined using 
[3H]CP55,940 (2.5 nM, Kd = 3 nM) and HEK293-hCB2 membranes (10 µg/point). Data is representative 
of one independent experiment conducted in triplicate and data shown are the mean ± SEM.  
The binding affinities of CB receptor inverse agonist SR144528 1.13 at CB2 and CB1 
receptors were also determined as a literature compound control. SR144528 1.13 
displayed a Ki = 51.0 ± 3.0 nM at CB2 and Ki = 5682 ± 2890 nM at CB1 receptor with a 
selectivity of 110-fold for CB2 receptor (Figure 28, Table 3). All the binding affinities 
reported here were calculated using the [3H]CP55,940 1.17 Kd values (3 nM at CB2 and 
2 nM at CB1 receptor) previously determined by the Glass laboratory, where 
pharmacological evaluation was carried out (refer to section 1.6.1). Varying Kd values 
for [3H]CP55,940 1.17 at hCB2 and hCB1 receptors have been reported in the literature 
and so it is important to note what the Kd value is when comparing results from 
different studies. The binding affinities determined in this study are comparable to the 
recently reported277 SR144528 1.13 pKi = 7.88 ± 0.06 at hCB2 (Ki = 13.2 nM) and pKi = 
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5.77 ± 0.09 at hCB1 receptor (Ki = 1698.2 nM), with a selectivity of 129-fold for CB2 
receptor. The literature study277 used [3H]CP55,940 1.17 Kd values of 0.33 nM at hCB2 
and 0.1 nM at hCB1 receptor. If these [
3H]CP55,940 1.17 Kd values are used with the 
raw data in this study, the recalculated CB2 receptor Ki value (10.9 nM) is very close to 
the literature reported value (13.2 nM). This validation of the binding assay gives 
confidence in the Ki values reported for the compounds tested.  
The 5-hydroxyindole 2.23g and the fluorescent ligands 2.32b and 2.32g showed low 
affinity at hCB2 receptor (Ki = 22.3 µM, 1.9 mM and 48.7 µM, respectively; all n = 1) 
and did not approach a plateau for maximum radioligand displacement at the highest 
concentration (126.4 µM; Figure 29). Thus, an accurate Ki value could not be 
calculated, so concentration response assays were not repeated for these compounds 
and 2.23g, 2.32b and 2.32g were all determined to have a Ki >10 µM at hCB2 receptor 
(Table 3, Table 4), using the D’Agostino & Pearson normality test and one sample t-
test as described for other low affinity compounds.  
 
Figure 29: Competition binding curves for 2.23g, 2.32b and 2.32g at hCB2 receptor, determined using 
[3H]CP55,940 (2.5 nM, Kd = 3 nM) and HEK293-hCB2 membranes (10 µg/point). Data is representative 
of one independent experiment conducted in triplicate and data shown are the mean ± SEM. CP55,940 
(10 µM) was a homologous competitor to determine specific binding.  
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Table 3: Affinity of 5- and 6-hydroxyindoles and 5-O-ethanoic acid derivatives for hCB2 and hCB1 
receptors. a 
 
 hCB2 receptor hCB1 receptor 
Comp-
ound 
R1 b R2 c 10 µM displ. 
[3H]CP 1.17 d 




10 µM displ. 
[3H]CP 1.17 d 





2.23a EtMorph MeOPh 85.1 ± 1.3 746.6 ± 140 25.7 ± 9.7 >10000 >13  
2.23b EtMorph MeOPh 33.7 ± 8.0 >10000 2.8 ± 5.2 no binding - 
2.23c EtMorph Naphth 92.6 ± 2.8 169.0 ± 16.7 60.8 ± 3.6 2838 ± 705 17  
2.23d EtMorph Cyclohex 79.9 ± 3.3 895.3 ± 332 16.3 ± 3.2 >10000 >11 
2.23e Me-THP MeOPh 91.2 ± 2.2 120.1 ± 23.4 74.0 ± 1.9 1406 ± 464 12 
2.23f Me-THP Naphth 93.0 ± 3.5 275.4 ± 82.7 77.6 ± 3.5 823.8 ± 215 3 
2.23g Me-THF MeOPh 49.7 ± 6.8 >10000 4.2 ± 5.3 no binding - 
2.25a EtMorph MeOPh 34.8 ± 8.3 >10000 13.4 ± 3.7 >10000 - 
2.25b EtMorph Naphth 31.0 ±10.0 >10000 18.7 ± 7.3 >10000 - 
2.25c Me-THP MeOPh 80.0 ± 5.6 1660 ± 114 37.8 ± 3.8 >10000 >6 
SR144528 
1.13 
- - - 51.0 ± 3.0 - 5628 ± 2890 110 
a Radioligand binding assays performed with [3H]CP55,940 (2.5 nM) and HEK293-hCB2 or -hCB1 
membranes. Data is the mean ± SEM of at least three individual experiments performed in triplicate.  
b EtMorph. is ethylmorpholino, c cyclohex. is cyclohexane, naphth. is 1-naphthoyl.  
d Percentage displacement of [3H]CP55,940 by test compound (10 µM). Raw data was normalised to 
the specific binding window (unlabelled CP55,940 (10 μM), 100%; vehicle control, 0%).  
e Ki calculated using [3H]CP55,940 Kd = 3 nM at hCB2 or 2 nM at hCB1 receptor. For compounds 
showing low displacement of [3H]CP55,940 in the 10 µM screens, the D’Agostino & Pearson 
normality test and a one sample t-test was used to determine if significant competition with 
[3H]CP55,940 occurred (Ki >10 µM) or not (no binding).  





The 5-hydroxyindole 2.23e had the highest CB2 receptor affinity (Ki = 120.1 nM ± 
23.4) of all the compounds and was followed by the 5-hydroxyindoles 2.23c, 2.23f, 
2.23a and 2.23d (Figure 30; Table 3). 6-Hydroxyl substitution resulted in a >13 fold 
loss in CB2 receptor affinity (2.23b) when compared with the 5-hydroxyl analogue 
(2.23a) (Table 3). Only one C6 substituted derivative (2.23b) was synthesised 
(possessing ethylmorpholino at R1 and methoxyphenyl at R2), so a general trend cannot 
be extrapolated from these results. It is possible that the 5-hydroxyl derivative 2.23a 
was able to form more favourable interactions with CB2 receptor. Frost et al found 6-
OMe substitution gave a >6 fold loss in CB2 receptor affinity in comparison to the 5-
OMe analogue in a series also possessing ethylmorpholino at R1, but with 
tetramethylcyclopropyl at R2, though this trend was not observed with the 5/6-O-benzyl 
and 5/6-OH analogues.256 The low CB2 receptor affinity observed for 2.23b was 
particularly surprising given that it is an analogue of AM630 1.14, which has very high 
affinity for CB2 receptor. These two compounds only differ by the C6-substituents 
(hydroxyl in 2.23b, iodine in AM630 1.14) and the C2-Me present in AM630 1.14. A 
key difference between the binding of 2.23b and AM630 1.14 to CB2 receptor, could be 
the ability of AM630 1.14 to participate in intermolecular halogen bonding with amino 
acid residues. Halogen bonding is orthogonal to hydrogen bonding and thus can form 
without interfering with the intramolecular hydrogen bonding of CB2 receptor and local 
residue conformation.278 Whilst halogen bonds are weak, they are highly specific and 
iodine substitutions in particular have been shown to have a large effect on affinity 
across a broad spectrum of targets.279  
The three derivatives with the 5-hydroxy and 4-methoxyphenyl R2 groups held 
constant, but with varying R1 groups, revealed that 4-methyl-THP (2.23e) had higher 
affinity for CB2 receptor compared to 4-ethylmorpholino (2.23a) and 3-methyl-THF 
(2.23g). Frost et al also found that for 5-hydroxyindole compounds 4-methyl-THP at R1 
provides a higher Ki at CB2 receptor than ethylmorpholino (when in combination with a 
tetramethylcyclopropyl group at R2).256 The 3-methyl-THF containing derivative 2.23g 
showed minimal binding to CB2 receptor and no significant binding to CB1 receptor. 
Whilst N1-methyl-THF is not a common substituent amongst AI CB2 receptor ligands, 
a previous report has resulted in very high CB2 receptor affinity and selectivity.
248 It is 
possible that in combination with other R2 groups, methyl-THF may be more 
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favourable, for instance in the 5-O-benzyl derivative 2.22i (containing R2 naphthoyl), 
which did not undergo hydrogenolysis and was not evaluated.  
By comparing 5-hydroxyl derivatives possessing the same R1 group it appeared that the 
optimal R2 group for CB2 receptor affinity was either 1-naphthoyl (compare 2.23c to 
2.23a and 2.23d; Figure 30a) or 4-methoxyphenyl (compare 2.23e to 2.23f; Figure 
30b), whilst cyclohexane (2.23d) showed the lowest affinity. It was perhaps to be 
expected that developing an AI-based CB2 ligand with a non-aromatic R
2 group, such 
as cyclohexane would be more challenging. Whilst there are some notable high affinity 
examples of CB2 receptor ligands possessing non-aromatic R
2 groups,248, 253 aromatic 
groups are much better characterised at this position and there is strong evidence that 
aromatic π-stacking is key to AI interactions with CB2 receptor.
250, 280, 281  
Extension of 5-hydroxyl 2.23e to the 5-O-ethanoic acid 2.25c led to a 14 fold loss in 
CB2 receptor affinity (Figure 30b; Table 3). This loss in affinity may be due to the 
increased size of the ethanoic acid substituent or to the carboxylic acid functionality 
itself. Larger groups than an ethanoic acid, such as O-benzyl or furan have been 
tolerated at C5 in published AI derivatives,253, 256 albeit with differing R1 and R2 groups 
to those used here. The carboxylic acid would be ionised at physiological pH, which 
could be detrimental to lipid-mediated entry to CB2 receptor (section 1.2.2.1) and may 
be the cause of the lower affinity observed. This could be investigated further by 
synthesising and testing the methylated ester analogue 5-O-CH2COOMe, however this 
was not carried out in this project. The weak binding of 5-O-ethanoic acid derivatives 
2.25a and 2.25b compared to 2.25c further indicated a preference for R1 group 4-




Figure 30: Competition binding curves at hCB2 receptor for (A) hydroxyindoles 2.23a, 2.23c and 2.23d 
which all contain ethylmorpholino at R1, but varying R2 groups, and (B) hydroxyindoles 2.23e, 2.23f and 
5-O-ethanoic acid 2.25c, which all contain methyl-THP at R1. Assays were carried out with 
[3H]CP55,940 (2.5 nM, Kd = 3 nM) and HEK293-hCB2 membranes (10 µg/point). [3H]CP55,940 bound 
(ccpm) raw values are normalised to the specific binding window (%). Data shown is representative of 
one independent experiment conducted in triplicate and data shown are the mean ± SEM. CP55,940 at 10 
µM was used as a homologous competitor to determine specific binding.  
The 5-hydroxyindoles 2.23c, 2.23e and 2.23f underwent concentration response assays 
at CB1 receptor to evaluate receptor subtype selectivity (Figure 31). The most CB2 
receptor selective compound of the three was 2.23c (KiCB1/KiCB2 = 17), followed by 
2.23e and 2.23f (KiCB1/KiCB2 = 12 and 3, respectively; Table 3), which suggests that 
ethylmorpholino at R1 confers better CB2 selectivity than methyl-THP. 5-
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Hydroxyindole 2.23f showed the highest affinity for CB1 receptor (Ki = 823.8 ± 215 
nM).  
 
Figure 31: Competition binding curves for 2.23c, 2.23e and 2.23f at hCB1 receptor, determined using 
[3H]CP55,940 (2.5 nM, Kd = 2 nM) and HEK293-hCB1 membranes (7.5 µg/point). Data is representative 
of one independent experiment conducted in triplicate and data shown are the mean ± SEM. CP55,940 
(10 µM) was used as a homologous competitor to determine specific binding.  
Unfortunately, conjugation of a linker and fluorescent dye to the C5 position of the 
indole scaffold failed to produce a high affinity CB2 receptor fluorescent ligand (Table 
4). The tolerability of bulky 5-substituents such as furan and O-benzyl in published 
indole SAR studies,253, 256 suggests that extension from C5 indole beyond the atom 
length that was achieved here (4 atoms, 2.25c) should be possible. All of the 
fluorophore-linker conjugates evaluated extended from the indole scaffold with the 
same functional group, an O-ethanamide. This strategy enabled divergence from one 
common derivative to give three different linker conjugates (e.g. synthesis of 2.30a, 
2.30b, and 2.30e from 2.25a). However, the ethanamide group is very polar and being 
located so close to the indole scaffold may well disrupt the binding of the core ligand to 
the lipid CB2 receptor. In particular, the ethanamide could possibly impede potential 
lipid-mediated entry of the indole core into CB2 receptor.  
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Table 4: Affinity of 5-substituted indole-based linker and fluorescent conjugates at hCB2 receptor. a 
 
Compound Linker R3 10 µM displ. [3H]CP 
1.17 at hCB2 
(% ± SEM) b 
Ki at hCB2 
(nM) c 
2.30a Alkyl H 32.0 ± 7.7 >10000 
2.30b PEG H 27.9 ± 7.0 >10000 
2.31 PEG Ac 24.5 ± 10.5 >10000 
2.30c Alkyl H 32.0 ± 7.5 >10000 
2.30d PEG H 36.5 ± 8.2 >10000 
2.30e Peptide H 14.3 ± 11.5 no binding 
2.30f Peptide H 24.7 ± 11.6 no binding 
2.30g Peptide H 22.7 ± 10.5 no binding 
2.32a Alkyl BODIPY 630/650-X 19.1 ± 11.0 no binding  
2.32c Alkyl BODIPY 630/650-X 16.2 ± 9.1 no binding 
2.32b PEG BODIPY 630/650-X 41.6 ± 9.5 >10000 
2.32d PEG BODIPY 630/650-X 22.3 ±7.2 >10000 
2.32e Peptide BODIPY 630/650-X 41.3 ± 7.8 >10000 
2.32f Peptide BODIPY 630/650-X 32.7 ± 7.5 >10000 
2.32g Peptide BODIPY 630/650-X 45.7 ± 5.5 >10000 
a Radioligand binding assays performed with [3H]CP55,940 (2.5 nM) and HEK293-hCB2 membranes. 
Data is the mean ± SEM of at least three individual experiments performed in triplicate.  
b Percentage displacement of [3H]CP55,940 by test compound (10 µM). Raw data was normalised to 
the specific binding window (unlabelled CP55,940 (10 μM), 100%; vehicle control, 0%).  
c D’Agostino & Pearson normality test and a one sample t-test was used to determine if significant 
competition with [3H]CP55,940 occurred (Ki >10 µM) or not (no binding).  
 
Linkers of identical atom length were chosen to allow direct comparison of the effect of 
linker chemistry on CB2 receptor binding. However, the limitation of this design was 
that varying the atom length of linkers was not explored and could have a large impact 
on receptor binding. For example, a lengthier linker may allow greater flexibility, 
enabling favourable positioning of the fluorophore and the indole core. A linker that is 
too short may prevent the indole core from favourable positioning within the ligand 
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binding pocket. Therefore, it would be interesting to explore variations in linker length 
as well as polarity at the 5 position of indole, in the pursuit of fluorescent ligands for 
CB2 receptor (although this was outside of the scope of this thesis).  
The primary amines (pKa = ~ 9-10) of the linker conjugates (2.30a-g) would all be 
predominantly ionised at physiological pH and so may impede ligand entry via the lipid 
bilayer. However, the shared low CB2 receptor affinity of acetylated analogue 2.31 and 
the corresponding primary amine 2.30b demonstrated that the primary amine is not 
solely responsible for the lack of affinity (Table 4). It would likely be more difficult for 
the linker conjugates and fluorescent ligands to gain receptor entry via the lipid 
membrane than for the smaller hydroxyindoles, due to the large size of the molecules. 
Therefore these larger compounds may possibly have to gain access to the receptor 
through the extracellular loops.  
The lack of detectable CB2 receptor binding observed for compounds containing a 
dipeptide linker (2.30e-g) may be due to a variety of reasons. As discussed in the linker 
design section (2.2.2), it was anticipated that the greater polarity of the peptide and 
PEG linkers (cLogP = -3 and -2, respectively)‡‡ may impede lipid membrane-mediated 
ligand entry when compared to the alkyl linker (cLogP = 0.54). It is also worth 
considering that perhaps the greater steric bulk of the alanine moieties (such as the 
methyl and amide) over the alkyl and PEG linkers may not be tolerated, especially if 
the linker resides in a narrow access point to the ligand binding pocket. It seems 
apparent that the ability of the di-alanine to engage in hydrogen bonding with receptor 
residues has not improved ligand binding in these derivatives. Conjugation of 
fluorophore to the peptide linked conjugates restored minimal CB2 receptor binding (Ki 
= >10 µM, 2.32e-g; Table 4), which may be due to the fluorophore acting as a lipid 
anchor, thereby improving affinity at receptor. Vernall et al reported that fluorophore 
conjugation increased the affinity of peptide-ligand conjugates for adenosine A3 
receptor, and that varying the amino acids of the peptide linker had a significant effect 
on receptor affinity.198 Altering the amino acid sequence and length of the peptide 
                                                 
‡‡ cLogP values calculated using Crippen's fragmentation,265 in ChemDraw Prime 15.1, PerkinElmer 
Informatics, Inc. Values were calculated for the diacetylated (i.e.AcNHXNHAc) linkers in isolation and 
are not representative of the linker-indole conjugates as a whole.  
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linkers utilised in this study may be worth exploring for improved ligand affinity at CB2 
receptor.  
The improved affinity of peptide linker containing fluorescent ligands was contrasted 
by the loss of discernible binding for the alkyl linker containing fluorescent ligands 
(2.32a, 2.32c; Table 4). This may be due to the very high lipophilicity of the overall 
fluorescent-alkyl linker conjugates (2.32a, 2.32c) which might result in high 
accumulation at the lipid membrane and only minimal ligand gaining entry to CB2 
receptor.  
2.4.2 Forskolin-stimulated cAMP assays 
Compounds that showed micromolar or nanomolar affinity for CB2 receptor were 
analysed for functional activity using a BRET sensor to measure modulation of 
forskolin-stimulated cAMP in whole HEK293 S4 low cells overexpressing hCB2 or 
hCB1 receptors (section 1.6.2). Potency (EC50) is determined in concentration response 
functional assays and is the concentration of compound required to produce a half 
maximal response, thus a highly potent compound can produce a significant response at 
a low concentration. Efficacy (maximum response, Emax) is a measure of the maximum 
response evoked by the compound and is determined at the 10 µM concentration in this 
study. Since both CB1 and CB2 receptor are Gi coupled, agonists cause a decrease in 
cellular cAMP in this assay. Emax values for agonists will therefore be <100% and the 
more efficacious an agonist, the closer Emax will be to 0%. In contrast, antagonists can 
prevent the inhibition produced by an EC90 concentration of a full agonist (i.e. 
CP55,940 1.10) and inverse agonists lead to an increase in cellular cAMP (Emax > 
100%). It is important to report both potency and efficacy as without one, the other can 
lack context. For instance whilst a compound may exhibit high potency, it could have 
low efficacy meaning that it will not invoke a large effect.  
The 5-hydroxyindoles 2.23a, 2.23c-f and 5-ethanoic acid 2.25c were initially tested in a 
10 μM screen under three conditions: in the absence of forskolin (to evaluate the effect 
on basal cAMP), in the presence of forskolin (to screen for agonism or inverse 
agonism), and in the presence of both forskolin and CP55,940 1.10 (to test for their 
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ability to antagonise CP55,940 1.10).§§ All compounds tested at 10 µM acted as 
agonists at both CB2 and CB1 receptors, producing a decrease in cAMP, whilst failing 
to antagonise an EC90 concentration (20 nM at CB2 and 4 nM at CB1 receptor) of 
CP55,940 1.10 (Figure 32).  
                                                 
§§ 10 µM BRET screen at hCB2 receptor in presence and absence of CP55,940 1.10 (n = 1) carried out by 





Figure 32: BRET assay screen measuring effect of compound (10 µM) on forskolin (Fsk)-stimulated (5 
µM) cellular cAMP levels in HEK293 cells overexpressing (A) hCB2 receptor (assay carried out by 
Christa Macdonald) or (B) hCB1 receptor. Compounds were checked for effect on basal cAMP 
(compound/vehicle (V)/V; light grey) and in the presence (compound/Fsk/CP; dark grey) and absence of 
CP55,940 (compound/Fsk/V; mid grey). Data is the mean ± SEM of (A) one or (B) three independent 
experiments conducted in duplicate. Data has been normalised to a percentage of forskolin only response 
(V/Fsk/V; 100%) and basal response (V/V/V; 0%).  
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All of the identified agonists (2.23a, 2.23c-f and 2.25c) were then subjected to a 
concentration response assay at CB2 receptor to determine potency (Figure 33; Table 
5). The potency of CP55,940 1.10 at CB2 receptor was also determined as a literature 
agonist for comparison. Only the lead compound (in terms of CB2 receptor affinity), 
2.23e was analysed for potency at CB1 receptor (Table 5).  
 
Figure 33: Forskolin-stimulated cAMP concentration response curves for CP55,940 1.10, 2.23e and 
2.25c at hCB2 receptor. Area under the curve (AUC) values are normalised so that forskolin only 
response = 100% and basal response = 0%. Data shown is representative of a single experiment, 
conducted in duplicate and data shown are the mean ± SEM.  
In contrast to the results observed, it was anticipated that these compounds would 
behave as inverse agonists or antagonists because of the structural similarities to 
AM630 1.14. However, there are several reported C5-substituted AI-based CB2 
receptor ligands which behave as agonists.31, 256 The highest affinity compound for CB2 
receptor (2.23e) also translated into the most potent agonist (CB2 EC50 = 4.4 ± 0.35 
nM). There appeared to be a trend for methoxyphenyl at R2 (2.23e, 2.23a) conferring 
higher potency than naphthoyl (2.23c, 2.23f), followed by cyclohexane. The aromatic 
R2 groups might engage in aromatic π-stacking interactions with CB2 receptor, resulting 
in a different degree of signalling to that caused by the non-aromatic cyclohexane 
group. It was curious that efficacy amongst the 5-hydroxyindoles seemed to be 
determined by the R1 group, with methyl-THP containing derivatives (2.23f, 2.23e), 
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producing the greatest maximal response, followed by ethylmorpholino derivatives 
(2.23a, 2.23d, 2.23c). The small sample size means that these trends lack rigour, 
especially in the absence of much literature SAR describing indole substituent effect on 
functional potency and efficacy at CB2 receptor. 5-Hydroxyindole 2.23e showed similar 
potency to the agonist CP55,940 1.10 at CB2 receptor, but it had significantly lower 
efficacy (Table 5; Figure 33). Whilst all of the compounds evaluated exhibited 
reasonable potencies, none of them demonstrated especially high efficacy when 
compared to CP55,940 1.10.  
Table 5: Potency (EC50) and efficacy (Emax) of 5-hydroxyindoles and a 5-O-ethanoic acid derivative at 
hCB2 and hCB1 receptors, determined using a forskolin-stimulated cAMP assay. a 
 hCB2 receptor hCB1 receptor 
Compound EC50  
(nM ± SEM) 
Emax b 
(% ± SEM) 
EC50  
(nM ± SEM) 
Emax b 
(% ± SEM) 
2.23a 5.4 ± 2.7 67.5 ± 2.9 n.d. 79.1 ± 6.3 
2.23c 8.7 ± 1.6 77.4 ± 6.1 n.d. 55.6 ± 4.1 
2.23d 18.6 ± 5.1 74.1 ± 1.2 n.d. 74.3 ± 4.2 
2.23e 4.4 ± 0.35 65.7 ± 3.7 62.9 ± 29.7 61.7 ± 2.9 
2.23f 14.7 ± 5.3 64.4 ± 1.5 n.d. 53.1 ± 1.3 
2.25c 70.2 ± 6.2 57.4 ± 3.2 n.d. 66.7 ± 4.4 
CP55,940 1.10 5.6 ± 2.3 41.0 ± 1.4 n.d. 56.5 ± 1.4 
a cAMP levels measured in a BRET assay using a CAMYEL sensor, performed in HEK293-hCB2 or 
hCB1 S4 low cells. Data is the mean ± SEM of three individual experiments performed in duplicate. 
b Emax is the response at 10 µM, normalised to basal (0%) and forskolin only (100%) levels of cAMP 
and the lower the value, the greater the efficacy of the agonist.   
 
Extension of the 5-hydroxyl position of 2.23e with an ethanoic acid moiety retained 
agonist activity (2.25c), but with reduced potency (Table 5; Figure 33). Despite the 14-
fold loss in CB2 receptor affinity of 2.25c compared to 2.23e, 2.25c is still able to elicit 
a signalling response at CB2 receptor. This may be because 2.25c is still able to make 
the necessary interactions with CB2 receptor to induce/stabilise an active receptor 
conformation. This illustrates how different lead compounds may be selected from the 
competition binding assay versus a forskolin-stimulated cAMP assay. The radioligand 
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binding assay measures the ability of the test compound to compete with [3H]CP55,940 
1.17, which is more complex than simply the affinity of the compound for receptor, as 
it is also affected by binding and competition kinetics. For instance, a larger compound 
may have a slower on rate, resulting in less competition with the radioligand. However, 
in the BRET cAMP assay, there is no competition and it is simply measuring the ability 
of the compound to produce a response, although the response would be effected by the 
on-rate of the compound.  
The lead compound 2.23e also showed agonist activity at CB1 receptor, but at a lower 
potency (EC50 = 62.9 ± 29.7 nM) than at CB2 receptor, demonstrating CB2 receptor 
selectivity. Two compounds (2.23c and 2.23f) showed similar efficacy to CP55,940 
1.10 at CB1 receptor and four out of the seven compounds evaluated (2.23c-f) showed 
similar or higher efficacy at CB1 receptor than at CB2 receptor, despite all showing low 
CB1 receptor affinity (Table 5). It is difficult to fully evaluate this trend without potency 
data, but it does further illustrate the very different parameters that are measured in a 
competition binding versus a signalling response assay.  
All of the compounds (2.23a, 2.23c-f and 2.25c) analysed for function were also 
screened in a cAMP BRET assay in wild type (WT) HEK293 cells, to verify that the 
observed effects at CB2 and CB1 receptors were receptor mediated (Table 6). WT 
HEK293 cells express some Class A GPCRs, such as chemokine, lysophospholipid and 
prostanoid receptors, but do not typically express cannabinoid receptors.282 The 
compound cAMP responses were normalised to basal (0%) and forskolin only (100%) 
responses and were then analysed in a one sample t-test to determine if the compound 
responses were significantly different from the forskolin only response. Compounds 
2.23a, 2.23d-f and 2.25c showed no significant response in the WT cells, verifying that 
the agonist activity observed for these compounds was indeed CB receptor mediated. 
Compound 2.23c invoked a small but significant response at 10 μM but not at 1 μM. As 
2.23c demonstrated a response in HEK293-hCB2 cells at 1 µM, it can be concluded that 
the WT HEK cell response is not large enough to have significantly affected the 
calculated CB2 receptor potency. However, as 2.23c was not tested at 1 µM in HEK293 
cells overexpressing hCB1 receptor, it cannot be definitively concluded that the agonist 
activity observed at CB1 receptor is receptor mediated. 
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Table 6: Forskolin stimulated cAMP response in WT HEK293 cells. a 
 % response in WT HEK293 cells 
Compound 10 µM (% ± SEM) 1 µM (% ± SEM) 
2.23a 105.2 ± 5.9 101.9 ± 1.8 
2.23c 118.7 ± 3.8 * 101.9 ± 3.2 
2.23d 105.1 ± 4.0 105.9 ± 2.6 
2.23e 109.6 ± 7.7 105.5 ± 3.5 
2.23f 108.1 ± 3.2 95.0 ± 5.0 
2.25c 100.1 ± 6.2 98.8 ± 3.7 
WIN 55,212-2 2.2 102.6 ± 2.1 96.1 ± 1.0 
CP55,940 1.10 98.0 ± 4.0 99.2 ± 2.7 
a Assay carried out in WT HEK293 cells measuring forskolin-stimulated (5 µM) cAMP. Data is 
normalised, so that forskolin only response is 100% and vehicle only response is 0%. Data is the mean 
± SEM of three individual experiments performed in duplicate. A one sample t-test was used to 
determine if values were significantly different from forskolin only response (100%), and where values 
are significantly different, they are marked with *.  
 
2.4.3 Off target activity 
Compounds 2.22e, 2.22f, 2.22g, 2.22h, 2.22i, 2.23e and 2.23f were accepted into the 
Eli Lilly and Company Open Innovation Drug Discovery Program and the Tres Cantos 
Open Lab Foundation and did not show significant proprotein convertase subtilisin 
kexin type 9 (PCSK9) inhibition, GPR120 agonism, disruption to IL-17 protein-protein 
interaction, Leishmania donovani growth inhibition, voltage-gated potassium channel 
KCNQ2/3 agonism or nicotinamide N-methyltransferase (NNMT) inhibition.   
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2.5 Conclusions and future directions 
A review of the published SAR informed the decision to explore the C5 and C6 
positions of the indole scaffold for tolerability of linker attachment, with the goal of 
developing a high affinity, selective CB2 receptor fluorescent ligand. A library of seven 
hydroxyindoles, three O-ethanoic acid derivatives, eight linker conjugates and seven 
linker-fluorophore conjugates were synthesised and underwent pharmacological 
evaluation. Varying R1 and R2 groups were trialled at the N1 and C3 acyl position of 
indole, with methyl-THP and p-methoxyphenyl (R1) or 1-naphthoyl (R2) identified as 
the preferred groups at N1 and C3 respectively (Table 3). Notably, 5-hydroxyl 
substitution was favoured over 6-hydroxyl. A high affinity CB2 receptor agonist 2.23e 
(Ki = 120.1 ± 23.4 nM at hCB2, KiCB1/KiCB2 = 12) was identified amongst the 5-
hydroxyl derivatives. However, extension of 2.23e to include a 5-O-ethanoic acid 
moiety (2.25c) led to a 14 fold loss in CB2 receptor affinity. It is not clear from these 
results whether this loss in affinity was due to intolerance to substituent size or 
carboxylic acid functionality, or both. All of the high affinity CB2 receptor compounds 
identified behaved as agonists at CB2 receptor. It remains to be seen if the low CB2 
receptor affinity of linker fluorophore conjugates was due to poor choice of linker 
length and functionality, or if the C5 position of indole is unsuitable for extension. In 
addition, the polarity of the O-ethanamide group so close to the core indole ligand may 
be unfavourable for entry and binding to the lipid CB2 receptor. Therefore, it would be 
interesting to explore varying the polarity of moieties adjacent to the indole scaffold, as 
well as linker length and position of linker appendage (as discussed in Chapter Three), 




 Chapter Three: Fluorescent ligands for CB2 
receptor based on 5 and 7 substituted alkyl-
indoles 
Chapter Two explored 5- and 6-substituted AIs, in the pursuit of CB2 receptor 
fluorescent ligands. A lead compound 2.23e was identified amongst the 5-substituted 
AIs, whereas, the 6-substituted AIs were not progressed further because of the poor 
CB2 receptor affinity attained. The findings of Chapter Two raised two key questions 
regarding the development of higher affinity 5-substituted AI fluorescent ligands. 
Firstly, was the polar O-ethanamide group adjacent to the indole ring responsible for 
the low CB2 receptor affinity of the linker-AI conjugates 2.30a-g and 2.31 or was the 
C5 position of the indole ring simply unsuitable for further extension? Secondly, would 
varying the linker length at the C5 position result in fluorescent ligands with improved 
affinity for CB2 receptor? The work described in sections 3.1, 3.2 and 3.3 of this 
chapter aimed to answer the first of these questions through synthesis and evaluation of 
linker-AI conjugates and subsequently opened up new avenues for development of AI-
based fluorescent ligands, which were explored further in the work described in 
sections 3.4, 3.5 and 3.6.  
3.1 AI and linker-AI conjugate design exploring varying polarity 
and substitution position of the indole ring 
The lead compound identified in Chapter Two was the 5-hydroxyindole agonist 2.23e, 
which showed the highest affinity for CB2 receptor out of the novel compounds 
evaluated (Ki = 120.1 ± 23.4 nM; Table 3). However, extension of the hydroxyl group 
of 2.23e to the more polar ethanoic acid (2.25c) considerably reduced CB2 receptor 
affinity, which was then reduced even further upon linker and dye conjugation (2.32g; 
Figure 34). It was not clear whether this loss of affinity from 2.23e to 2.25c was due to 
intolerance to extension at the C5 position, or whether the presence of the increasingly 
polar, ionised at physiological pH carboxylic acid of 2.25c and then amide of 2.32g in 
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such close proximity to the indole scaffold disrupted ligand binding (or whether both of 
these factors were detrimental). Substitution of large, bulky groups at the C5 position of 
indole has led to several high affinity CB2 receptor ligands reported in the literature,
253, 
256 therefore it would not be expected that the size of the O-ethanoic acid in 2.25c 
would be a hindrance to CB2 receptor binding. Therefore, a small library of compounds 
was designed, exploring reduction of the polarity of the linker moiety immediately 
adjacent to the indole ring.  
 
Figure 34: Extension of 2.23e to 2.25c and 2.32g led to a considerable reduction in hCB2 receptor 
affinity, which led to the suspicion that presence of the polar carboxylic acid and amide groups (circled) 
adjacent to the core indole scaffold could be detrimental to CB2 receptor binding.  
All derivatives of this small library were designed as analogues of the lead compound 
2.23e, possessing both the N1-methyl-THP and C3 acyl methoxyphenyl groups. An O-
propyl group with increased lipophilicity and no charge at physiological pH (3.7a) was 
designed as an equal atom-length replacement of the O-ethanoic acid of 2.25c.  
In addition, extension of 2.23e with a long PEG linker attached directly to the 5-
hydroxyl (3.12) was designed in order to explore replacement of the polar amide 
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immediately adjacent to the pharmacophore. The PEG linker was designed to possess 
the same length as the linker-AI conjugates (2.30a-g, 2.31) synthesised in Chapter Two, 
to allow meaningful comparison. It was decided that the amine terminus of 3.12 (and 
all subsequent amino linker-pharmacophore conjugates designed) should be acylated to 
produce ligands with no charge at physiological pH. Acylation was chosen over Boc-
protection due to lesser steric bulk and closer structural similarity to the amide bond 
that would be produced by conjugation with the fluorophore.  
There are several literature reports of 7-substituted indole derivatives with high affinity 
and selectivity for CB2 receptor.
251, 256, 257 Substitution at the C7 position of indole had 
not yet been explored in this study, so three 7-substituted analogues were designed to 
investigate whether linker extension from this position would be favoured over the C5 
position. The derivatives designed included a 7-hydroxyl analogue of 2.23e (3.4), a 7-
O-ethanoic acid analogue of 2.25c (3.6) and a 7-O-propyl analogue of 3.7a (3.7b). 
Ligand designs in this small series did not incorporate a fluorophore, as the primary aim 
was to investigate linker polarity and substitution position before further development 




Synthesis of the 7-hydroxyindole (3.4) and 7-O-ethanoic acid (3.6) derivatives followed 
the same pathway as that for the 5 substituted analogues (2.23e and 2.25c; Scheme 1 
and Scheme 3). Briefly, 7-benzyloxyindole 3.1 was N-alkylated using the mesylate of 
methyl-THP (2.17b; Scheme 1), to give 3.2 in high yield (87%; Scheme 5, step i), 
which was then acylated at C3 with methoxybenzonitrile via palladium catalysis with 
2.21, to give 3.3 (58%; step ii). The 7-O-benzyl 3.3 was benzyl deprotected by 
palladium catalysed hydrogenolysis to reveal 7-hydroxyindole 3.4 (55%; step iii). 
Reaction with tert-butylbromoacetate gave 3.5 in low yield (33%; step iv), probably 
due to the very small scale of the reaction (11 mg of 3.4), which meant any small loss 
of product during work-up and silica column purification had a significant impact on 
yield. Cleavage of the tert-butyl of 3.5 with TFA revealed 7-O-ethanoic acid 3.6 (53%; 
step v).  
 
Scheme 5: Synthesis of 7-hydroxyindole (3.4) and 7-O-ethanoic acid (3.6). Reagents and conditions: (i) 
NaH, DMF, 45°C, 2 h, 87%; (ii) methoxybenzonitrile, H2O, CH3CO2H, 1,4-dioxane, 140°C, 42 h, 58%; 
(iii) Pd/C, H2, EtOH, CHCl3, rt, 20 h, 55%; (iv) tert-butylbromoacetate, NaH, DMF, 60°C, 3 h, 33%; (v) 
TFA, DCM, rt, 1 h, 53%.  
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Hydroxyindoles 2.23e and 3.4 were reacted by Williamson ether procedure with 1-
bromopropane and NaH to give the O-propyl derivatives 3.7a and 3.7b respectively in 
moderate yield (57-83%; Scheme 6).  
 
Scheme 6: Synthesis of 5- and 7-O-propyl derivatives 3.7a and 3.7b. Reagents and conditions: (i) 1-
bromopropane, NaH, DMF, rt, 20 h, 57-83%.  
The first step in the synthesis of long PEG linker-AI conjugate 3.12 was Boc protection 
of the PEG-amine alcohol linker, 2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethanol 3.8 to 
give 3.9 (Scheme 7, step i). Reaction of the two alcohols 3.9 and 2.23e was initially 
attempted by Mitsunobu coupling, using triphenylphosphine and di-tert-butyl 
azodicarboxylate (DBAD) in THF, following a literature procedure for preparation of 
sulfamoylphenyl aminoalkyl ethers (Scheme 7, step ii).283 However, 2.23e was not 
soluble in THF, so a small amount of DMF (0.5 mL) was added to dissolve 2.23e. 
There is an inverse relationship between the polarity of the solvent used and the rate of 
a Mitsunobu reaction.284 Therefore it was expected that addition of polar DMF would 
result in a slower reaction than in just THF alone. However, after four days (and 
addition of extra triphenylphosphine), no product formation could be detected by thin 
layer chromatography (TLC), mass spectrometry or 1H NMR spectra. Mitsunobu 
reactions require the nucleophile to have a pKa <15, therefore the 5-hydroxy of 2.23e 
(pKa = 9.11***) should be suitable for coupling under these conditions. It was reasoned 
that the reagents were too dilute, as Mitsunobu reactions generally require a 
concentration of at least 0.1 M,285 so the reaction was repeated with all reagents at a 
concentration of >0.1 M in anhydrous DMF. Also, the order of addition of reagents can 
greatly effect Mitsunobu reactions.286 In the original attempt, triphenylphosphine was 
                                                 
*** pKa value calculated with MarvinSketch 17.2.27.0, ChemAxon Ltd.  
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added to the linker 3.9, followed by addition of the hydroxyindole 2.23e and the 
reaction mixture was then put on ice for dropwise addition of DBAD. This order of 
addition was used as it is reported to reduce by-product formation,287 but if it is 
unsuccessful, literature reports recommend altering the order of addition to pre-form 
the betaine between the azodicarboxylate and triphenylphoshine.288 Therefore, in the 
repeated reactions, DBAD was added to triphenylphosphine at 0°C and stirred for 15 
min, after which the linker (3.9) was added and after another 15 min stirring, the 
hydroxyindole 2.23e was added. The reaction mixture was sonicated for 30 min after 
addition of all reagents, as sonication has also been shown to improve Mitsunobu 
reaction yields.285 After three days an unsatisfactory amount of product (3.11) had 
formed, insufficient for progression to the next synthetic step. As the synthesis schedule 
was under strict time restrictions, it was decided that Mitsunobu coupling would not be 
an efficient method for coupling these two alcohols (2.23e and 3.9) with a satisfactory 
yield. If the schedule had not been so restrictive, it would have been interesting to 
pursue further variations to the order of addition, or increasing reagent concentration 
and sonication time or possibly changing the azodicarboxylate used e.g. to diethyl 




Scheme 7: Synthesis of linker-AI conjugate 3.12. Reagents and conditions: (i) Boc2O, dioxane, rt, 18 h, 
15%; (ii) Ph3P, DBAD, DMF, 70 h, no product isolated; (iii) Br2, Ph3P, Et3N, DCM, 0°C, 2 h, 26%; (iv) 
NaH, DMF, rt, 18 h, 31%, (v) 1. TFA, DCM, rt, 1 h, 2. Ac2O, DIPEA, DCM, rt, 1.5 h, 71%.  
Subsequently, synthesis of 3.11 was attempted using the Williamson ether reaction. The 
alcohol of the Boc-protected linker 3.9 was brominated to give 3.10, which was not 
easily visible on TLC by UV or permanganate staining, making purification by silica 
chromatography challenging and leading to a reduced isolated yield (Scheme 7, step 
iii). Brominated 3.10 was then reacted with 5-hydroxyindole 2.23e and NaH to give 
3.11 (step iv). Linker-pharmacophore 3.11 was Boc-deprotected and then acetylated to 
give 3.12 (step v).   
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3.3 Radioligand binding assays 
Concentration-response radioligand binding assays were carried out using HEK293-
hCB2 and hCB1 membranes in order to obtain Ki values for 3.4, 3.6, 3.7a, 3.7b and 3.12 
(Table 7).††† The binding affinities of these five compounds were analysed and 
compared to compounds reported in Chapter Two (Table 3) in the following section.  
The most striking pattern observed was the clear preference for substitution at the C7 
position over the C5 position of indole. 7-Hydroxyindole 3.4 had the highest hCB2 
receptor affinity and selectivity (Ki = 53.9 ± 7.6 nM, KiCB1/KiCB2 = 66; Table 7) of all 
the hydroxyindole compounds synthesised thus far and showed a two-fold increase in 
CB2 receptor affinity over the analogous 5-hydroxyl 2.23e and a five-fold increase in 
selectivity for CB2 over CB1 receptor. Similarly, 7-O-ethanoic acid 3.6 showed a three-
fold increase in CB2 receptor affinity over the analogous 5-O-ethanoic acid 2.25c. Most 
remarkably though, 7-O-propyl 3.7b showed around 230 fold higher affinity for CB2 
receptor than the analogous 5-O-propyl analogue 3.7a. This preference for 7-
substitution appears to be specific to the R1 and R2 groups utilised (i.e. 4-methyl-THP 
and methoxyphenyl), as Frost et al found a 5-hydroxyl derivative with 4-methyl-THP at 
R1 and tetramethylcyclopropyl at R2 to possess higher affinity than the analogous 7-
hydroxyl. Notably, 7-O-propyl 3.7b showed both the highest affinity (Ki = 5.7 ± 1.4 nM 
at CB2 receptor) and most pronounced selectivity (89 fold CB2 over CB1 receptor) of all 
the indole-based compounds tested (including those discussed in Chapter Two). It was 
also exciting to observe that 3.7b showed a 9-fold higher affinity for CB2 receptor than 
the inverse agonist SR144528 1.13.  
It is possible that 7-substituted indoles had a higher affinity for CB2 receptor because 
they form more favourable interactions with the ligand binding site than 5-substituents. 
Changing the position of substitution may also cause a subtle repositioning of the 
indole core and N1 and C3 groups of the molecule, altering the interactions of these 
moieties with the CB2 receptor orthosteric binding site. This surprising favourability of 
                                                 
††† Radioligand binding assays at hCB2 and hCB1 receptors on four (3.4, 3.7a, 3.7b and 3.12) out of the 
five compounds were carried out by Christa Macdonald.  
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7-substituted derivatives was explored further using homology modelling and ligand 
docking studies and is discussed in section 3.7.3.  
Table 7: Affinity of 5- and 7-substituted indole derivatives at hCB2 and hCB1 receptors. a 
 
Compound R 5 or 7 
Substitution 
Ki at hCB2 
(nM ± SEM) 
Ki at hCB1 
(nM ± SEM) 
SI b 
2.23e c H 5 120.1 ± 23.4 1406 ± 464 12 
3.4 H 7 53.9 ± 7.6 3583 ± 427 66 
2.25c c CH2CO2H 5 1660 ± 114 >10000 >6 
3.6 CH2CO2H 7 581.8 ± 70.8 >10000 >17 
3.7a n-propyl 5 1350 ± 399.3 4527 ± 676 3 
3.7b n-propyl 7 5.7 ± 1.4 504.6 ± 148.2 89 
3.12 (C2H4O)3C2H4NHAc 5 >10000 no binding - 
SR144528 1.13 - - 51.0 ± 3.0 5628 ± 2890 110 
a Radioligand binding assays performed with [3H]CP55,940 (1 nM or 2.5 nM) and HEK293-hCB2 or -
hCB1 membranes. Data are the mean ± SEM of at least three individual experiments performed in 
triplicate. Ki values calculated with a [3H]CP55,940 Kd = 3 nM for hCB2 receptor or Kd = 2 nM for 
hCB1 receptor. For compounds showing low displacement of [3H]CP55,940 in the 10 µM screens, the 
D’Agostino & Pearson normality test and a one-sample t-test were used to determine if significant 
competition with [3H]CP55,940 occurred (Ki >10 µM) or not (no binding). Binding assays (n = 4 or 5) 
of 3.4, 3.7a, 3.7b and 3.12 were performed by Christa Macdonald.  
b SI = KiCB1/KiCB2.  
c Binding affinities of 2.23e and 2.25c were reported in Chapter Two, but are repeated here to allow 
easy comparison of 5- and 7-substituted derivatives.  
 
Extension of the 7-hydroxyl 3.4 to the 7-O-propyl 3.7b led to a nine-fold increase in 
affinity for CB2 receptor, as well as a slight increase in selectivity (Table 7; Figure 35). 
Also, comparison of the 7-O-propyl 3.7b to the 7-O-ethanoic acid 3.6 showed that the 
non-polar alkyl was vastly preferred over the polar carboxylic acid at this position, with 
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over a hundred-fold difference in CB2 receptor affinity. The presence of the lipophilic 
propyl group may allow for favourable hydrophobic interactions with the ligand 
binding pocket, leading to the observed increase in CB2 receptor affinity. Increasing the 
overall lipophilicity of the molecule may also improve ligand entry into the receptor. 
The high affinity of 7-substituted derivatives 3.4 and 3.7b, as well as the apparent 
tolerance for extension at this position indicated that 7-substituted indoles are a 
promising lead for development of fluorescent ligands for CB2 receptor (as discussed in 
sections 3.4, 3.5 and 3.6).  
 
Figure 35: Competition binding curves for 3.4 and 3.7b at hCB2 receptor, determined using 
[3H]CP55,940 (1 nM, Kd = 3 nM). Data are representative of one independent experiment conducted in 
triplicate and data points shown are the mean ± SEM. CP55,940 (10 µM) was used as a homologous 
competitor to determine specific binding. Assay carried out by Christa Macdonald.  
The poor binding affinities observed for the 5-substituted compounds 3.7a and 3.12 did 
not support the hypothesis that the polar carboxylic acid and amide groups adjacent to 
the indole ring in the 5-substituted compounds from Chapter Two were detrimental to 
affinity for CB2 receptor. It was anticipated that replacing the 5-O-ethanoic acid of 
2.25c with a 5-O-propyl group would increase affinity for CB2 receptor. However, the 
5-O-propyl derivative 3.7a (Table 7) showed only a small improvement in CB2 receptor 
affinity over the 5-O-ethanoic acid derivative 2.25c (Ki = 1350 ± 399.3 nM versus 1660 
± 114.2 nM at CB2 receptor, respectively), which was shown to be non-significant by 
an unpaired t-test with Welch’s correction (p = 0.4934). Extension of 5-hydroxyindole 
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2.23e to the 5-O-propyl 3.7a led to an 11 fold loss in affinity for CB2 receptor. The 
intolerability of extension with a small, relatively benign group such as propyl, suggests 
that linker extension from the C5 position of 2.23e derivatives is likely not tolerated. It 
seems that the lack of success with the linker-AI conjugates in Chapter Two was not 
due to polarity alone, but intolerance to steric bulk, as demonstrated by the propyl 
group in 3.7a or ethanoic acid in 2.25c. However, the success of bulky group 
substitution at the C5 position of indoles in a number of publications253, 256 suggests that 
the findings observed here may be specific to the R groups utilised in the 2.23e 
derivatives (N1-methyl-THP and C3-acyl-methoxyphenyl). A key point of difference is 
that the bulky 5-substituted literature compounds possess non-aromatic groups at the 
C3 position, such as adamantyl and tetramethylcyclopropyl (Figure 21).253, 256 Indoles 
are thought to interact with CB2 receptor through aromatic stacking
152 and so these 
literature compounds 2.13 and 2.14 may have a considerably altered orientation in the 
ligand binding pocket, especially in the derivatives where aromatic groups are included 
at the C5 position of indole. The aromatic methoxyphenyl group employed in the 2.23e 
derivatives may ‘lock’ the ligands into an orientation whereby the methoxyphenyl 
forms aromatic interactions with the aromatic rich regions of the CB2 receptor between 
TMH3 and TMH6. Indeed, ligand docking studies with 2.23e, 2.25c and 3.7a (section 
3.7.3.1) did result in the methoxyphenyl group positioned in the aromatic regions 
between TMH3 and TMH6. This orientation may not allow for steric bulk at the C5 
position of the indole and might be key to the different findings of 5-extension 
tolerability observed for the 2.23e derivatives and literature compounds. In agreement 
with the results for 3.7a, conjugation of a long PEG linker to 2.23e was not well 
tolerated and resulted in a ligand (3.12) with only minimal affinity for CB2 receptor, 
showing no improvement on the Chapter Two linker-AI conjugates.  
At this stage 3.4, 3.6, 3.7a, 3.7b and 3.12 were evaluated only by radioligand binding 
assay and not analysed for function as the main criteria for a fluorescent ligand lead 
linker position was high CB2 receptor affinity. The primary aim of this small compound 
set was to elucidate the influence of the linker polarity and the position of attachment, 
in order to inform synthesis of a refined series of fluorescent ligands. Functional 
evaluation of 3.4, 3.6, 3.7a and 3.7b was carried out in conjunction with the next series 
and is discussed in section 3.6.2.   
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3.4 Ligand design of 7-substituted indole-based fluorescent 
ligands 
Extension from the C7 position of the indole scaffold with non-polar groups was 
identified as a promising lead for development of fluorescent ligands because of the 
high affinity of 7-O-propyl 3.7b. Thus, 3.7b, was used as the basis for the design of all 
subsequent indole-based fluorescent ligands. The intention was to maintain the 
lipophilic propyl moiety of 3.7b and keep any amide bond(s) or other polar groups of 
the linker at a distance from the indole scaffold. Varying the linker length was of 
interest, as it would determine where the fluorophore resides (at receptor, membrane or 
extracellular environment) and therefore has a large effect on CB2 receptor affinity as 
well as the utility of the fluorescent ligand.  
Two short linkers (methyl valerate and hexylamine) were selected to extend the indole 
scaffold 3.4. A diamine PEG linker (2.28b), rather than an alkyl linker, was chosen for 
further extension with the intention of reducing non-specific membrane binding. A di-
peptide linker was not utilised in this series, as the polarity may inhibit ligand entry and 
binding to the lipid CB2 receptor. In an attempt to sample dramatically varying linker 
length and polarity, a compound in which the fluorophore was directly attached to a 




Synthesis of fluorescent ligands 3.18 and 3.25 started from 7-hydroxyindole 3.4 (the 
synthesis of which is described in Scheme 5). Alkylation of 3.4 with methyl 5-
bromovalerate via Williamson ether synthesis gave 3.13 (Scheme 8, step i). Methyl 
ester hydrolysis of 3.13 using lithium hydroxide gave carboxylic acid 3.14 (step ii), 
which underwent an amide coupling with N-Boc-1,8-diamino-3,6-dioxaoctane 2.28b 
(Scheme 3) to yield 3.15 (step iii). Boc-deprotection of 3.15 revealed the amine 3.16 
(step iv), which was purified by semi-preparative RP-HPLC to ensure maximum purity. 
The purified amine 3.16 was then either acetylated to give 3.17 or used in four-fold 
excess for coupling to BODIPY 630/650-X-OSu 2.15, affording fluorescent ligand 3.18 
(steps v-vi). All reactions were achieved in high yield, apart from the first step (3.13, 
30%).  
 
Scheme 8: Reagents and conditions: (i) methyl 5-bromovalerate NaH, DMF, rt, 20 h, 30%; (ii) 0.2 M aq. 
LiOH.H2O, THF, 0°C, 12 h, 88%; (iii) N-Boc-1,8-diamino-3,6-dioxaoctane (2.28b), HATU, DIPEA, 
DMF, rt, 12 h, 88%; (iv) TFA, DCM, rt, 1 h, 95%; (v) Ac2O, DIPEA, DCM, rt, 1 h, 96%; (vi) BODIPY 
630/650-X-OSu 2.15, DIPEA, DMF, rt 12 h, 93%.  
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Synthesis of an alkyl chain-linked series began with Boc-protection of 6-amino-1-
hexanol 3.19 to give 3.20 (Scheme 9, step i), which was then brominated to give 3.21 
(step ii). Coupling of 7-hydroxyindole 3.4 with 3.21 via Williamson ether reaction 
afforded 3.22 (step iii). Subsequent Boc cleavage revealed the amine 3.23 (step iv), 
which was purified by semi-preparative RP-HPLC prior to conjugation as a five-fold 
excess with BODIPY 630/650-X-OSu 2.15 to give the fluorescent ligand 3.25 (step vi). 
The amine 3.23 was also acetylated to give 3.24 (step v).  
 
Scheme 9: Reagents and conditions: (i) Boc2O, dioxane, rt, 18 h, 79%; (ii) Br2, Ph3P, Et3N, DCM, 0°C, 2 
h, 57%; (iii) NaH, DMF, rt, 20 h, 79%; (iv) TFA, DCM, rt, 1 h, 92%; (v) Ac2O, DIPEA, DCM, rt, 1 h, 




3.6 Pharmacological evaluation 
3.6.1 Radioligand binding assays 
Radioligand binding assays were carried out on 3.13, 3.14, 3.17, 3.18, 3.24 and 3.25 at 
a fixed concentration of 10 µM, to evaluate the ability of the compounds to displace 
[3H]CP55,940 1.17 at hCB2 and hCB1 receptor (Figure 36).  
 
Figure 36: Combined results of competition binding screens showing displacement of [3H]CP55,940 (2.5 
nM) at HEK293 hCB2 (10 μg/point) (black) and HEK293 hCB1 (7.5 μg/point) (grey) membranes by a 
fixed concentration (10 μM) of test compound. Raw data were expressed in ccpm and normalised to 
unlabelled CP55,940 (10 μM) (100%) and vehicle control (0%). Data shown are the mean value ± SEM 
of three independent experiments conducted in triplicate, except for 3.13, 3.14 and 3.24 at hCB2 receptor 
where n = 2. The dashed line indicates the 50% displacement criteria for progression to concentration-
response assay.  
The long linker-AI conjugate 3.17 and the two fluorescent ligands 3.25 and 3.18 
showed less than 50% displacement of [3H]CP55,940 1.17 at both hCB2 and hCB1 
receptor (Figure 36), therefore affinity would be too low to accurately determine Ki 
values by concentration response assays. The 7-O-pentanoic acid 3.14 also showed less 
than 50% displacement of [3H]CP55,940 1.17 at hCB1 receptor. Subsequent statistical 
analysis with the D’Agostino and Pearson normality test and the one sample t-test was 
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carried out and showed that 3.17, 3.25 and 3.18 at hCB2 and hCB1 receptors and 3.14 at 
hCB1 receptor demonstrated statistically significant competition with [
3H]CP55,940 
1.17 (Table 8).  
The 7-O-methyl valerate conjugate 3.13, the 7-O-pentanoic acid 3.14, and the 
acetylated 7-O-hexylamine 3.24 all showed greater than 50% displacement of 
[3H]CP55,940 1.17 at hCB2 receptor and 3.13 and 3.24 also showed greater than 50% 
displacement at hCB1 receptor (Figure 36; Table 8). Therefore, these compounds were 
subjected to concentration-response assays at the respective receptors to ascertain Ki 
values.  
The highest affinity compound was the 7-O-methyl valerate conjugate 3.13, which 
demonstrated a Ki of 200.7 ± 4.9 nM at CB2 receptor (Table 8). Whilst this represents a 
35-fold reduction in CB2 receptor affinity compared to 3.7b (Table 7), 3.13 still 
retained reasonable CB2 receptor affinity and showed that extension of the 7-O-propyl-
chain of lead compound 3.7b was tolerated. The larger size of 3.13 perhaps reduced 
flexibility of the core ligand orientation, disrupting formation of favourable receptor 
interactions compared to the smaller 3.7b. The carboxylic acid 3.14 showed 
approximately a 6-fold loss in affinity for CB2 receptor compared to the methyl ester 
analogue 3.13. Carboxylic acid 3.14 and methyl ester 3.13 should be able to form very 
similar hydrogen bond interactions with CB2 receptor, therefore the loss of affinity 
demonstrated in 3.14 may be due to the ionised carboxylic acid which could impede 
lipid mediated ligand entry into the receptor. Prior to carrying out radioligand binding 
assays, it was considered a remote possibility that hydrolysis of the methyl ester might 
occur during the course of the assay. However, it is unlikely that this occurred as if it 
had, the binding affinities found for 3.14 and 3.13 would likely have been very similar.  
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Table 8: Affinity of 7-substituted indole linker-AI conjugates and fluorescent ligands at hCB2 and hCB1 
receptors. a 
 
  hCB2 receptor hCB1 receptor  
Comp-
ound 
R 10 µM 
displ. 
[3H]CP 1.17  
(% ± SEM) b 
Ki 
(nM ± SEM) c 
10 µM 
displ. 
[3H]CP 1.17  
(% ± SEM) b 
Ki 
(nM ± SEM) c 
SI d 
3.13 COOMe 97.2 ± 1.5 200.7 ± 4.9 77.1 ± 2.0 1583 ± 242.7 8 
3.14 CO2H 85.1 ± 1.6 1307 ± 302.5 29.8 ± 3.2 >10000 >7  
3.24 C2H4NHAc 74.6 ± 1.8 1969 ± 351.9 65.0 ± 3.7 3918 ± 800.4 2 
3.17 CONH(C2H4O)2 
C2H4NHAc 
14.8 ± 1.5 >10000 13.4 ± 5.4 >10000 - 
3.25 C2H4NHAc 
BODIPY630/650-X 




27.3 ± 1.4 >10000 11.1 ± 4.8 >10000 - 
SR144528 
1.13 
- - 51.0 ± 3.0 - 5628 ± 2890 110 
a Radioligand binding assays performed with [3H]CP55,940 (2.5 nM) and HEK293-hCB2 or -hCB1 
membranes. Data are the mean ± SEM of at least three individual experiments performed in triplicate.  
b Percentage displacement of [3H]CP55,940 by test compound (10 µM). Raw data were normalised to 
the specific binding window (unlabelled CP55,940 (10 μM), 100%; vehicle control, 0%).  
c Ki calculated using [3H]CP55,940 Kd = 3 nM at hCB2 receptor or 2 nM at hCB1 receptor. For 
compounds showing low displacement of [3H]CP55,940 in the 10 µM screens, the D’Agostino & 
Pearson normality test and a one sample t-test were used to determine if significant competition with 
[3H]CP55,940 occurred (Ki >10 µM) or not (no binding).  
d SI = KiCB1/KiCB2.  
 
Extension of the 7-O-ethanoic acid 3.6 (Table 7) to the 7-O-pentanoic acid 3.14 led to a 
two-fold loss in affinity for CB2 receptor (Table 8). It had already been demonstrated 
that a substituent length of eight atoms at the C7 position of indole is tolerated in 3.13, 
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therefore, the physical size of the pentanoic acid should not prohibit CB2 receptor 
binding. It is therefore possible that unfavourable placement of the carboxylic acid 
moiety in 3.14 contributed to the loss in CB2 receptor affinity. On the contrary, the 
carboxylic acid of 3.6 may form favourable hydrogen bonds with residues within the 
ligand binding site and therefore movement of the carboxylic acid moiety three atoms 
further along from the indole core (as in 3.14) may be disruptive. In addition, the larger 
size of 3.14 compared to 3.6 might reduce ligand entry via the lipid membrane.  
The linker-indole conjugate 3.24 was the longest linker to show appreciable binding to 
CB2 receptor (Ki = 1969 ± 351.9 nM; Table 8) of all the indole compounds synthesised 
thus far (Chapters Two and Three). Whilst 3.13 and 3.24 had the highest affinity for 
CB2 receptor of all the linker-indole conjugates, they both showed only minimal 
selectivity (KiCB2/KiCB1 = 8 and 2, respectively). This was disappointing as one of the 
key criteria for developing a successful fluorescent ligand was good subtype selectivity 
for CB2 receptor. The considerable binding affinities of 3.13 and 3.24 for CB2 receptor 
show that polar groups such as an ester and an amide are tolerated in the linker when at 
a distance of six to eight atoms away from the indole scaffold.  
PEG-linked 3.17, which is an extension of 3.14, showed minimal affinity for CB2 
receptor (Ki = >10 µM). Similarly, fluorescent ligands 3.18 and 3.25, which are 
extended from 3.17 and 3.24, also showed low affinity for CB2 receptor (Ki >10 µM). 
This disappointing affinity may be due to unfavourable linker length or positioning of 
the amide bonds and fluorophore. In addition, the polarity of the PEG linker in 3.17 
may disrupt binding. Whilst two considerably different linker lengths were trialled in 
3.18 and 3.25, these are only two derivatives on a large spectrum of possible linker 
lengths. As previously discussed, linker length dictates where the fluorophore resides 
upon ligand binding and can have a significant impact on positioning of the core ligand. 
The considerable difference in affinity between 7-O-ethanoic acid 3.6 and 7-O-
pentanoic acid 3.14 indicates that polar groups such as amide may be better tolerated 
closer to the indole core. However, in order to retain the high affinity of the lead 
compound 7-O-propyl 3.7b, it may be the case that an amide linker has to be located 
somewhere in between the two positions of the carboxylic acids in 3.6 and 3.14, say at 
four or five atoms away from the indole core. Using a different fluorophore other than 
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BODIPY 630/650-X is another potential strategy for improving CB2 receptor affinity. It 
is also possible that extension from the C7 position of indole beyond the eight and ten 
atoms (3.13 and 3.24) achieved here is not tolerated. Indeed, a literature search of 7-
substituted indole ligands for CB2 receptor failed to find any compounds with groups as 
long as those described here. The closest found in length, though bulkier in size, was O-
benzyl substitution.256  
3.6.2 Forskolin-stimulated cAMP assays 
Compounds 3.13, 3.14, and 3.24, as well as 3.4, 3.6, 3.7a and 3.7b from the series 
discussed in sections 3.1-3.3 were all able to displace CP55,940 1.10 at CB2 receptor by 
more than 50% in the 10 µM binding screen and so were also analysed for functional 
activity in the cAMP BRET assay. Compounds were subjected to a concentration-
response assay at CB2 receptor to determine potency and efficacy and the two 
compounds, 3.4 and 3.7b, with the highest affinity for CB2 receptor were also analysed 
for potency at CB1 receptor (Table 9). In contrast to agonists, the Emax of inverse 
agonists will be >100% and higher percentages represent greater efficacy for inverse 
agonists.  
Previously, all of the compounds evaluated by cAMP assay that were 5-substituted (for 
example 2.23e) showed agonist activity (Table 5). However, 5-O-propyl 3.7a showed 
no functional response at CB2 or CB1 receptors under the assay conditions (Table 9), in 
contrast to the analogous 5-O-ethanoic acid 2.25c (Table 5). It is curious that 
substituting the ethanoic acid for a propyl group would result in such a loss of function 
as these substituents are the same length, and it is suggestive that hydrogen bonding 
(which could be formed by the carboxylic acid and hydroxyl groups, but not the alkyl 
chain), may be responsible for the agonist activity of 5-O-ethanoic acid 2.25c and 5-
hydroxyls 2.23a and 2.23c-f.  
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Table 9: Potency (EC50) and efficacy (Emax) of 5-and 7-substituted indoles at hCB2 and hCB1 receptors, 
determined using a forskolin-stimulated cAMP assay. a 
 
  hCB2 receptor hCB1 receptor 
Comp-
ound 
R EC50  
or IC50 b, c 
(nM ± SEM) 
Emax f 




(nM ± SEM) 
Emax f 
(% ± SEM) 
Func. 
g 
3.7a - - - NR - - NR 
3.4 H 271.7 ± 131 c 189.8 ± 13.8 IA 632.5 ± 315 64.3 ± 8.1 A 
3.7b C3H7 30.6 ± 13.9 c 263.3 ± 14.4 IA - - NR 
3.6 CH2CO2H >10000 b 84.9 ± 3.3 A n.d. 80.5 ± 5.5 A 
3.13 C4H8CO2Me >10000 c, d 165.8 ± 7.1 IA n.d. 77.8 ± 3.6 A 
3.14 C4H8CO2H >10000 c, d 123.6 ± 7.7 IA n.d. 82.5 ± 1.6 A 
3.24 C6H12NHAc >10000 c, d 150.9 ± 10.7 IA n.d. 74.3 ± 4.9 A 
SR144528 
1.13 
- 760 ± 61.7 d , e 212.2 ± 2.5 IA - - NR 
CP55,940 
1.10 
- 5.6 ± 2.3 b 41.0 ± 1.4 A n.d. 56.5 ± 1.4 A 
a cAMP levels measured in a BRET assay using a CAMYEL sensor, performed in HEK293-hCB2 or 
hCB1 S4 low cells. Data are the mean ± SEM of three individual experiments performed in duplicate, 
except e which is two individual experiments performed in duplicate.  
b EC50 for compounds showing agonist activity. c IC50 for compounds showing inverse agonist activity. 
d compounds did not reach a plateau for maximum efficacy.  
f Emax is the response at 10 µM, normalised to basal (0%) and forskolin only (100%) levels of cAMP 
and or agonists, the lower the value, the greater the efficacy, whereas for inverse agonists, the higher 
the value, the greater the efficacy.  
g Compounds were characterised as either agonists (A) or inverse agonists (IA). t-Tests were used to 
determine if the Emax observed was significantly different from the forskolin only response and if no 
significant difference was found, the compounds were deemed to show no response (NR).  




In contrast to the 5-substituted agonists, derivatisation of the AI core in the C7 position 
led to inverse agonist activity at CB2 receptor in five out of six compounds (3.4, 3.7b, 
3.13, 3.14, 3.24) analysed (Table 9). Of note is the dramatic difference in function 
between the regioisomers 5-hydroxy-2.23e (Table 5) and 7-hydroxy-3.4 (Figure 37; 
Table 9), which showed agonism or inverse agonism at CB2 receptor respectively. 
However, bucking this trend, 7-O-ethanoic acid derivative, 3.6, showed weak agonist 
activity at CB2 receptor.  
 
Figure 37: Forskolin-stimulated cAMP concentration response curves for 2.23e and 3.4 at hCB2 receptor. 
Area under the curve values are normalised so that forskolin only response = 100% and basal response = 
0%. Data shown is representative of a single experiment, conducted in duplicate and data points shown 
are the mean ± SEM. 
It remains to be determined if this regioisomer functional switch between 5- and 7-
substituted indoles is a more general trend since there is no additional SAR available in 
the literature directly comparing the function of 5- and 7-substituted analogues with 
regards to cAMP signalling. Pasquini et al identified 5-aryl-substituted indoles that 
displayed inverse agonism with cAMP signalling,253 however with very different N1 
and C3 indole substituents than those utilised in this study. In an interesting study by 
Frost et al256 using 4-, 5-, 6- and 7-hydroxyl, O-benzyl and methoxy substituted indoles, 
the 7-substituted analogues failed to show agonism in a fluorescence imaging plate 
reader (FLIPR) calcium flux assay (but were not tested for antagonism or inverse 
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agonism), whilst two out of three 5-substituted analogues did display agonism through 
Gαq/o5 coupling. It is important to note that this study only analysed the Gi pathway via 
cAMP production and not any other CB signalling pathways such as β-arrestin 
recruitment, Gq coupling (intracellular calcium release), or Gs coupling (adenyl cyclase 
stimulation). GPCR ligands are well known to exhibit signalling bias,64, 290 and 
therefore the new ligands reported here could possess varying functions via signalling 
pathways other than cAMP. If a more comprehensive trend for a functional switch 
between 5- and 7-substituted indoles does indeed exist, this might be due to the 5- or 7-
substituents inducing different interactions with receptor residues which might cause a 
conformational switch in the receptor to either the inactive R or active R* state. Such a 
trend has been reported in the literature with another scaffold, the 1,8-naphthyridin 
class of cannabinoids (see Chapters Four and Five), in which a functional switch has 
been shown between analogues with or without C6 substituents.145  
The compound with the highest hCB2 receptor potency of the inverse agonists, 3.7b 
(IC50 = 30.6 ± 13.9 nM), was also the compound with the highest affinity for CB2 
receptor. In fact, 3.7b represents a uniquely high affinity CB2 receptor inverse agonist 
amongst the AI scaffold. In comparison to previously reported AI inverse agonists, 3.7b 
showed improved hCB2 receptor affinity over AM630 1.14 (hCB2 Ki = 32.1 nM, 
KihCB1/ KihCB2 = 165)
135 but with less subtype selectivity. There are only very few 
higher affinity AIs that have been reported as inverse agonists, one example being the 
inverse agonist 2.14 (Ki = 0.37 nM at hCB2, Ki = 344.9 nM at hCB1 receptor, calculated 
using [3H]CP55,940 1.17 hCB2 Kd = 0.31 nM, hCB1 Kd = 0.18 nM) reported by 
Pasquini et al.253 However there are many higher affinity CB2 receptor AI-based 
agonists reported, which could be attributed to the increased interest in CB receptor 
agonists driven by drug discovery efforts.113 It was very exciting to see that 3.7b also 
showed a higher affinity for CB2 receptor than diarylpyrazole inverse agonist 
SR144528 1.13 (Ki = 51.0 ± 3.0 nM at hCB2) in both this study and when considering 
literature reported binding affinities for SR144528 1.13.277 3.7b also showed higher 
potency and efficacy than SR144528 1.13 (Figure 38; Table 9), which is often used as a 
tool in pharmacological research on CB2 receptor.
142, 143 These promising results 




Figure 38: Forskolin-stimulated cAMP concentration response curves for 3.7b and SR144528 1.13 at 
hCB2 receptor. Area under the curve values are normalised so that forskolin only response = 100% and 
basal response = 0%. Data shown is representative of a single experiment, conducted in duplicate and 
data points shown are the mean ± SEM. 
The 7-O-ethanoic acid 3.6 showed significantly reduced potency and efficacy as an 
agonist compared to the 5-O-ethanoic acid analogue (2.25c; Table 5), despite the nearly 
three-fold higher affinity of 3.6 compared to 2.25c for CB2 receptor. This reiterates the 
differing requirements for a ligand to show high displacement of [3H]CP55,940 1.17 
versus producing a signalling response in the absence of competition.  
Compound 3.13 was the highest affinity pharmacophore-linker conjugate, and 3.24 was 
the longest linked derivative to show appreciable hCB2 receptor binding (Table 8). 
However, despite both 3.13 and 3.24, as well as 3.14 behaving as inverse agonists at 
hCB2 receptor, an IC50 could not be estimated as a maximal response plateau was not 
reached (Figure 39). An IC50 of >10 µM for 3.13, 3.14 and 3.24 was determined by use 
of a one-sample t-test (Table 9). Whilst inverse agonists induce the inactive R state of 
the receptor, they behave differently to neutral antagonists, in that they are able to 
reduce basal receptor signalling levels (section 1.1.3). The large loss of potency and 
efficacy in 3.13, 3.14 and 3.24 compared to 3.7b may be due to the long 7-substituents 





Figure 39: Forskolin-stimulated cAMP concentration response curves for 3.13, 3.14 and 3.24 at hCB2 
receptor. cAMP values are the AUC. Data shown is representative of a single experiment, conducted in 
duplicate and data points shown are the mean ± SEM.  
7-Hydroxyindole 3.4 and 7-O-propyl 3.7b were also analysed for CB1 receptor potency 
and showed either agonism or no response respectively (Table 9). Compounds 3.6, 
3.13, 3.14 and 3.24 were analysed at CB1 receptor only at 10 µM and all showed 
agonist activity. These results continue the trend observed in Chapter Two, in which all 
compounds demonstrated either agonism or no response at CB1 receptor. The CB2 
receptor inverse agonist AM630 1.14 also behaves as a partial agonist at CB1 
receptor,135 demonstrating that the structural requirements for an inverse 
agonist/agonist at CB2 or CB1 receptor can be quite distinct.  
All the compounds analysed for function in the cAMP BRET assay were also tested at 
10 µM and 1 µM in WT HEK293 cells to verify that the observed effects at hCB2 and 
hCB1 receptors were receptor-mediated (Table 10). 7-O-Ethanoic acid 3.6 showed no 
significant response in the WT cells, verifying that the agonist activity observed for this 
compound was indeed CB receptor mediated.  3.4, 3.7a, 3.7b, and 3.14 all invoked a 
small but significant response at 10 μM but not at 1 μM. As 3.4, 3.7b and 3.14 all 
demonstrated a response in HEK293-hCB2 cells at 1 µM, it can be concluded that the 
WT HEK cell response is not large enough to have significantly affected the calculated 
CB2 receptor potencies. 5-O-Propyl 3.7a showed no response in either receptor 
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subtype, so a WT response at 10 µM is surprising, but not concerning. It could be 
possible that the WT response observed for 3.7a (where cAMP is increased) masks an 
agonist effect (where cAMP would be decreased) in the CB2 receptor assay by 
cancelling each other out, resulting in an appearance of no response at CB2 receptor. 
However, the minimal effect of 3.7a at 1 µM in the CB2 receptor cAMP assay, 
combined with no significant response at 1 µM in the WT cells suggests that any 
masked agonist activity of 3.7a would be of very low efficacy. 7-Hydroxyindole 3.4 
demonstrated a response in HEK293-hCB1 cells at 1 µM, so it can be concluded that 
the WT HEK cell response is not large enough to have significantly affected the 
calculated CB1 receptor potency of 3.4. 7-O-Propyl 3.7b demonstrated no response at 
CB1 receptor, whilst 3.14 showed agonism at CB1 receptor but was not tested at 1 µM, 
so it cannot be definitively concluded that the agonist activity observed for 3.14 at CB1 
is receptor mediated. Linker-pharmacophores 3.13 and 3.24 showed a significant 
response in WT HEK cells at both 10 μM and 1 μM, but as both compounds 
demonstrated very weak potency at CB2 receptor (IC50 >10 µM) the potential effect of 




Table 10: Forskolin stimulated cAMP response in wild-type HEK293 cells. a  
 % response in WT HEK293 cells 
Compound 10 µM (% ± SEM) 1 µM (% ± SEM) 
3.4 135.3 ± 4.0 * 104.3 ± 2.5 
3.6 102.8 ± 1.8 104.5 ± 3.3 
3.7a 127.6 ± 4.9 * 95.0 ± 3.7 
3.7b 133.9 ± 4.7 * 105.4 ± 2.5 
3.13 160.6 ± 2.6 * 124.3 ± 2.4 * 
3.14 129.1 ± 3.5 * 105.6 ± 3.6 
3.24 128.0 ± 2.7 * 114.8 ± 7.1 * 
WIN 55,212-2 2.2 102.6 ± 2.1 96.1 ± 1.0 
CP55,940 1.10 98.0 ± 4.0 99.2 ± 2.7 
SR144528 1.13 94.5 ± 1.6 99.8 ± 2.2 
a Assay carried out in wild-type HEK293 cells measuring forskolin-stimulated (5 µM) cAMP. Data is 
normalised so that forskolin only response is 100% and vehicle only response is 0%. Data are the mean 
± SEM of three individual experiments performed in duplicate. A one-sample t-test was used to 
determine if values were significantly different from forskolin only response (100%), and where values 
are significantly different, they are marked with *.  
 
3.6.3 Off target activity 
Compounds 3.3, 3.4 and 3.7a were accepted into the Eli Lilly and Company Open 
Innovation Drug Discovery Program and the Tres Cantos Open Lab Foundation and did 
not show significant proprotein convertase subtilisin kexin type 9 (PCSK9) inhibition, 
GPR120 agonism, disruption to IL-17 protein-protein interaction, Leishmania donovani 
growth inhibition, voltage-gated potassium channel KCNQ2/3 agonism or nicotinamide 
N-methyltransferase (NNMT) inhibition.   
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3.7 Homology modelling of AIs at CB2 receptor 
Whilst modelling of AIs binding to CB receptors has only been reported in a handful of 
studies,240, 245 molecular modelling combined with mutational and ligand binding 
studies has contributed significantly to rational design of CB2 receptor selective ligands 
across a range of scaffolds.86 Homology modelling offers a useful method for 
rationalising the pharmacological results observed in this study. However, there are 
limitations to homology modelling when attempting to design ligands or rationalise 
SAR. Generation of a homology model requires the crystal structure of a closely related 
protein and small differences in sequence homology can lead to significant differences 
in secondary structure, reducing how true-to-life the homology model is. Also, a 
homology model is generated based on a static structure and so is itself static, failing to 
account for the flexible and dynamic nature of GPCRs.  
3.7.1 Generation of hCB2 receptor homology models 
3.7.1.1 hCB2 receptor homology model based on β2-adrenoceptor crystal 
structure 
The first step in generating a homology model is making a sequence alignment between 
the template receptor and CB2 receptor. At the time this PhD project commenced, no 
crystal structure was available for CB1 receptor and so there were no template receptors 
available with a high degree of sequence homology to CB2 receptor. Therefore, to 
generate a more reliable alignment, a consensus sequence alignment was made between 
CB2 receptor and four of the most closely related crystallised GPCRs (bovine 
rhodopsin, β1-adrenoceptor, β2-adrenoceptor, and D3 receptor). The alignment was 
generated using T-Coffee291 and then optimised manually to account for known 
structural features (Figure 40). For instance, unlike most other GPCRs (84%), CB2 
receptor lacks the highly conserved proline (P5.50) in TMH5 and in its place there is a 
leucine (L5.50) which has been shown to be critical to the function of CB2 receptor.
292 
The conserved cysteine in TMH3, which is required in most other GPCRs for the 
highly conserved disulphide bridge connecting THM3 to phenylalanine in ECL2, is 
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also not present. However, there is a disulphide bridge present in ECL2 between two 
cysteine residues (C174 & C179 in CB2 and C257 & C264 in CB1 receptor), which is 
highly conserved in CB receptors and key to ligand binding.293, 294 Across the GPCRs 
there is a huge variation in sequence, length and structure between extracellular loops, 
making them difficult to model. This is especially true of ECL2 as it is key to ligand 
binding and so has specific structural features to suit the endogenous ligands of its 
receptor subfamily.295 The N- and C-termini were deleted in the sequence alignment 
due to the lack of sequence homology and a template structure in these regions.  
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                                                 /           TMH1              
P34972|CNR2_   ----MEECWVTEIANGSKDGLDSNPMKDYMILSGPQKTAVAVLCTLLGLLSALENVAVLYLIL 
P02699|OPSD_   MNGTEGPNFYVPFSNKTGVVRSPFEAPQYYLAEPWQFSMLAAYMFLLIMLGFPINFLTLYVTV 
P07550|ADRB2   --------------------------------DEVWVVGMGIVMSLIVLAIVFGNVLVITAIA 
P35462-3|DRD   ---------------------------------------YALSYCALILAIVFGNGLVCMAVL 
P08588|ADRB1   -------------------------------LSQQWEAGMSLLMALVVLLIVAGNVLVIAAIG 
 
               \  ICL1  /          TMH2           \  ECL1   /            TMH3 
P34972|CNR2_   SSHQLRRKPSYLFIGSLAGADFLASVVFACSFVNFHVFHGVDS--KAVFLLKIGSVTMTFTAS 
P02699|OPSD_   QHKKLRTPLNY-ILLNLAVADLFMVFGGFTTTLYTSLHG-YFVFGPTGCNLEGFFATLGGEIA 
P07550|ADRB2   KFERLQTVTNY-FITSLACADLVMGLAVVPFGAAHILMK-MWTFGNFWCEFWTSIDVLCVTAS 
P35462-3|DRD   KERALQTTTNY-LVVSLAVADLLVATLVMPWVVYLEVTGGVWNFSRICCDVFVTLDVMMCTAS 
P08588|ADRB1   STQRLQTLTNL-FITSLACADLVVGLLVVPFGATLVVRG-TWLWGSFLCELWTSLDVLCVTAS 
 
                              \    ICL2     /         TMH4         \     
P34972|CNR2_   VGSLLLTAIDRYLCLRYPPSYKA--LLT-RGRALVTLGIMWVLSALVSYLPLMGWT------- 
P02699|OPSD_   LWSLVVLAIERYVVVCKPMSNF---RFG-ENHAIMGVAFTWVMALACAAPPLVGWSRYIPEGM 
P07550|ADRB2   IETLCVIAVDRYFAITSPFKYQS--LLT-KNKARVIILMVWIVSGLTSFLPIQMHWYRATHQE 
P35462-3|DRD   IWNLCAISIDRYTAVVMPVHYQHGTGQSSCRRVALMITAVWVLAFAVSCPLLFGFNTT---GD 
P08588|ADRB1   VETLCVIAIDRYLAITSPFRYQS--LMT-RARAKVIICTVWAISALVSFLPIMMHWWRDEDPQ 
 
                    ECL2               /          TMH5             \ ICL3  /.. 
P34972|CNR2_   ---CCPRP--CSELFPL-----IPNDYLLSWLLFIAFLFSGIIYTYGHVLWKAHQHV/……ARM 
P02699|OPSD_   QCSCGIDYYTPHEETN------NESFVIYMFVVHFIIPLIVIFFCYGQLVFTVKEAA/……TTQ 
P07550|ADRB2   AINCYAE-ETCCDFFT------NQAYAIASSIVSFYVPLVIMVFVYSRVFQEAKRQL/……KFC 
P35462-3|DRD   PTVCSIS---------------NPDFVIYSSVVSFYLPFGVTVLVYARIYVVLKQRR/……--P 
P08588|ADRB1   ALKCY-QDPGCCDFVT------NRAYAIASSIISFYIPLLIMIFVALRVYREAKEQI/……VML 
 
                     TMH6                     \  ECL3  /         TMH7  
P34972|CNR2_   RLDVRLAKTLGLVLAVLLICWFPVLALMAHSL-ATTLSD-QVKKAFAFCSMLCLINSMVNPVI 
P02699|OPSD_   KAEKEVTRMVIIMVIAFLICWLPYAGVAFYI--FTHQGSDFGPIFMTIPAFFAKTSAVYNPVI 
P07550|ADRB2   LKEHKALKTLGIIMGTFTLCWLPFFIVNIVH--VIQDN-LIRKEVYILLNWIGYVNSGFNPLI 
P35462-3|DRD   LREKKATQMVAIVLGAFIVCWLPFFLTHVLN--THCQTCHVSPELYSATTWLGYVNSALNPVI 
P08588|ADRB1   MREHKALKTLGIIMGVFTLCWLPFFLVNIVN--VFNRD-LVPKWLFVAFNWLGYANSAMNPII 
 
                  \   
P34972|CNR2_   YALRSGEIRSSAHHCL--------------------------- 
P02699|OPSD_   YIMMNKQFRNCMVTTLCCGKNPLGDDEASTTVSKTETSQVAPA 
P07550|ADRB2   YC-RSPDFRIAFQELLCL------------------------- 
P35462-3|DRD   YTTFNIEFRKAFLKILSC------------------------- 
P08588|ADRB1   LC-RSPDFRKAFKRLLA-------------------------- 
 
Figure 40: Consensus sequence alignment between hCB2 receptor (CNR2) bovine rhodopsin (OPSD), 
human β2-adrenoceptor (ADRB2), human D3 receptor (DRD) and human β1-adrenoceptor (ADRB1), 
generated by the T-coffee server and then manually optimised. Conserved residues are highlighted red. 
Highly conserved residues across GPCRs that are not present in CB2 are highlighted cyan. T-coffee 
highlights highly conserved regions pink, moderately conserved yellow and poorly conserved green. The 
‘/’ symbol in the ICL3 sequence region indicates where there is a break in the chain, due to deleted 
sequence where stabilising moieties, such as antibodies, are present in the crystal structures. P34972, 
P02699, P07550, P35462-3 and P08588 are the Universal Protein Resource (UniProt) sequences used for 
hCB2, bovine rhodopsin, human β2-adrenoceptor, human D3 receptor, and human β1 adrenoceptor, 
respectively.  
Using this consensus alignment (Figure 40), a series of 25 models was generated based 
on just one template to minimise errors. The human β2-adrenoceptor (protein database 
(PDB) ID: 2RH1) was selected as the template as it had the highest sequence homology 
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(18% identity, 35% similarity‡‡‡) to CB2 receptor of all the available high resolution 
class A GPCR crystal structures. Models were evaluated by the DOPE (discrete 
optimised protein energy) method which is the most reliable method for detecting 
native-like models.296 The model with the best energy profile (most negative DOPE 
score; model A; Figure 41) was then chosen from the 25 models generated.  
 
Figure 41: Homology model of CB2 receptor (model A), based on the crystal structure of inverse agonist 
bound β2-adrenoceptor (PDB ID: 2RH1).  
3.7.1.2 CB2 receptor homology models based on CB1 receptor crystal 
structures 
Homology model A was intended to be employed for ligand docking studies, to aid in 
the rationalisation of pharmacological results. However, after biological evaluation of 
the indole series was completed, two crystal structures of inactive state CB1 receptor 
were reported (one inverse agonist-bound, one antagonist-bound),66, 67 which were 
followed by two agonist-bound CB1 crystal structures.
65 This was an exciting 
development as a CB1 receptor template provided a much closer related structure and 
                                                 
‡‡‡ Sequence identity and similarity calculated by a similarity search on GPCRdb,25 comparing the TMH 
and loop regions (not including the N-and C-terminals).  
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sequence to CB2 receptor (44% sequence identity, 61% similarity
§§§), enabling 
generation of a more accurate homology model. Therefore, new homology models of 
CB2 receptor were generated based on these CB1 crystal structures.  
P34972|CNR2   -------------------------------------------------------------------- 
P21554|CNR1   MKSILDGLADTTFRTITTDLLYVGSNDIQYEDIKGDMASKLGYFPQKFPLTSFRGSPFQEKMTAGDNP 
cons                                                                               
 
                                                           /          TMH1 
P34972|CNR2   ---------------MEECWVTEIANGSKDGLDSNPMKDYMILSGPQKTAVAVLCTLLGLLSALENVA 
P21554|CNR1   QLVPADQVNITEFYNKSLSSFKENEENIQCGENFMDIECFMVLNPSQQLAIAVLSLTLGTFTVLENLL 
cons               ::  :**: * * ..:..*            :: :*:*. .*: *:***.  ** ::.***:  
 
                    \  ICL1  /          TMH2           \ ECL1  /          THH3 
P34972|CNR2   VLYLILSSHQLRRKPSYLFIGSLAGADFLASVVFACSFVNFHVFHGVDSKAVFLLKIGSVTMTFTASV 
P21554|CNR1   VLCVILHSRSLRCRPSYHFIGSLAVADLLGSVIFVYSFIDFHVFHRKDSRNVFLFKLGGVTASFTASV 
cons          ** :** *:.** :*** ****** **:*.**:*. **::*****  **: ***:*:*.** :***** 
 
                            \   ICL2   /         TMH4         \        ECL2        
P34972|CNR2   GSLLLTAIDRYLCLRYPPSYKALLTRGRALVTLGIMWVLSALVSYLPLMGWTCCP--RPCSELFPLIP 
P21554|CNR1   GSLFLTAIDRYISIHRPLAYKRIVTRPKAVVAFCLMWTIAIVIAVLPLLGWNCEKLQSVCSDIFPHID 
cons          ***:*******:.:: * :** ::** :*:*:: :**.:: ::: ***:**.*      **::** *  
 
              /           TMH5            \              ICL3             /        
P34972|CNR2   NDYLLSWLLFIAFLFSGIIYTYGHVLWKAHQHV-ASLS-G-----------HQDRQVPGMARMRLDVR 
P21554|CNR1   ETYLMFWIGVTSVLLLFIVYAYMYILWKAHSHAVRMIQRGTQKSIIIHTSEDGKVQVTRPDQARMDIR 
cons          : **: *: . :.*:  *:*:* ::*****.*.   :. *           . . **.   : *:*:* 
 
                   TMH6                 \ ECL3 /          TMH7           \ 
P34972|CNR2   LAKTLGLVLAVLLICWFPVLALMAHSLATTLSDQVKKAFAFCSMLCLINSMVNPVIYALRSGEIRSSA 
P21554|CNR1   LAKTLVLILVVLIICWGPLLAIMVYDVFGKMNKLIKTVFAFCSMLCLLNSTVNPIIYALRSKDLRHAF 
cons          ***** *:*.**:*** *:**:*.:.:  .:.. :*..*********:** ***:****** ::* :  
 
 
P34972|CNR2   HHCLAHWKKCVRGLGSEAKEEAPRSSVTETEADGKITPWPDSRDLDLSDC-------------- 
P21554|CNR1   RSMFPSCEGTAQPLDNSMGDSDCLHKHANNAASVHRAAESCIKSTVKIAKVTMSVSTDTSAEAL 
cons          :  :.  :  .: *...  :.            . *:: :  ::  **:    . * * . .   
 
Figure 42: Sequence alignment between hCB2 (CNR2) and hCB1 (CNR1) receptors, generated with the 
T-coffee server291 and then manually optimised. Highly conserved regions are highlighted pink, 
moderately conserved are yellow and poorly conserved are green. Conserved residues are designated by a 
*. P34972 and P21554 are the UniProt sequences used for hCB2 and hCB1 receptor, respectively.  
A sequence alignment between hCB2 and hCB1 receptors was generated using T-
coffee291 and manually optimised (Figure 42). CB1 receptor, similarly to CB2 receptor, 
does not possess the highly conserved cysteine residue in TMH3, has L5.50 in place of 
the highly conserved P5.50 and contains the cysteine disulphide bridge in ECL2.294, 297 
The sequence of hCB1 receptor is much longer than hCB2 receptor (472 versus 360 
                                                 
§§§ Sequence identity and similarity calculated by a similarity search on GPCRdb,25 comparing the TMH 
and loop regions (not including the N-and C-terminals).  
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amino acids), and contains much longer N- and C-terminals, as well as a longer ECL2 
and ICL3. A key residue difference between CB2 and CB1 receptors is in the flexible 
hinge of TMH6 with the sequence CWFP, in which the phenylalanine of CB2 receptor 
is replaced with a glycine in CB1 receptor.  
Using the CB2-CB1 sequence alignment (Figure 42), three sets of 25 models were 
generated using three of the CB1 crystal structures (PDB ID: 5U09; 5TGZ; 5XRA) as 
templates and then assessed by DOPE score. From each of the three sets, the model 
with the best energy profile was selected (Figure 44). These models will hereafter be 
referred to as model B, model C and model D, generated using the 5U09, 5TGZ and 
5XRA CB1 crystal structures respectively. Models B and C have been used to model 
the inactive R state of CB2 receptor (as they are based on the inverse agonist- and 
antagonist-bound CB1 structures, respectively) and model D has been used to model the 
active R* state of CB2 receptor (as it is based on the agonist-bound CB1 structure). The 
conformation of residues within the ligand binding site of each of the models closely 
matched those of the respective crystal structures and the highly conserved disulphide 
bridge of ECL2 was present in all three models. Models B, C and D were used for 
docking studies of the indole series, as well as the naphthyridin-based series discussed 
in Chapters Four and Five.  
3.7.2 Comparison of homology models A, B, C and D 
Comparison of R state model A (generated based on β2-adrenoceptor) with R state 
models B and C (generated based on CB1 receptor) illustrates the considerable 
influence of the template on the secondary and tertiary structure of the homology model 
(Figure 43). Model A shows significant differences in the secondary structure of TMH2 
as well as more subtle differences in the orientation of all other TMHs. Key residues, 
such as S285 show a significant shift in positioning and the ECLs (which are difficult to 
model accurately anyway due to inherent flexibility) are considerably different, in 
particular ECL2 and the disulphide bridge. It would be expected that these significant 
variations in structure would have a considerable impact on the results of ligand 
docking studies. Model A was not utilised in ligand docking studies and so it will not 




Figure 43: Overlay of CB2 R state homology models A (grey; based on β2-adrenoceptor, PDB ID: 
2RH1), B (green; based on CB1 receptor, PDB ID: 5U09) and C (red; also based on CB1 receptor, PDB 
ID: 5TGZ), all viewed from the extracellular space.  
The two R state models B and C show close overlap of residue conformation and 
secondary structure (Figure 44). One key point of difference is in the conformation of 
S285, however, they both match the S285 conformation of their respective CB1 crystal 
structure templates. Comparison of the R* state model D with the R state models B and 
C shows some movement of TMHs between active and inactive states. For instance, in 
the active state (model D) the tops of TMH1 and TMH2 have moved in, whilst the 
bottom of TMH6 has splayed out at the point of the flexible CWFP hinge. This change 
in receptor conformation reflects the effect of agonist binding to the template CB1 
receptor and homology modelling relies on the assumption that a similar movement of 
TMHs will be observed upon agonist binding to CB2 receptor. It is interesting to note 
that all three ECLs show very similar conformations (ECL2 in particular) between the 
three homology models. This is surprising as the ECLs are very flexible.298 The 
presence of the disulphide bridge in ECL2 may induce a fairly consistent conformation 
in this region. In addition, the overall similarity in the ECLs could be reflective of a 
favourable conformation of CB1 receptor ECLs for crystallisation, rather than a 




Figure 44: hCB2 receptor homology models generated using a sequence alignment between hCB2 and 
hCB1 receptors and the crystal structures of hCB1 receptor. Models B (green; based on PDB ID: 5U09) 
and C (red; based on PDB ID: 5TGZ) represent the inactive R state of CB2 receptor, whereas model D 
(blue; based on PDB ID: 5XRA) represents the active R* state. (A) Viewed from the lipid membrane. (B) 
Viewed from the extracellular space.  
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There are two notable differences in residue orientation in the ligand binding pocket 
between the R* and R state models. In the R* state model, F117 has shifted 
considerably, whilst W258 of the flexible hinge has also moved (Figure 45). This shift 
in residue F117 is reflected in subtle differences in the conformation of TMH3. In the R 
state models B and C there are offset stacked π-interactions between residues F117 and 
W258, which may stabilise the receptor conformation. It is possible that bulky 
antagonist or inverse agonist binding causes F117 to be pushed down, locking its 
movement and ability to rotate up into the conformation seen in the R* model D. The 
flexible hinge region CWXP in TMH6 is largely accepted to act as a conformational 
switch in GPCRs299 and it is therefore not surprising to see considerable movement of 
the flexible hinge residues W258 and F259 between the R and R* state models. This 
variation in positioning of residues within the flexible hinge is likely responsible for 
TMH6 in R* state model D being splayed out below the flexible hinge (Figure 44).  
 
Figure 45: Key ligand binding residues in CB2 receptor model B (green), C (red) and D (blue). Some 
extracellular loops are hidden for clarity. There is a clear shift in the orientation of residues F117 and 
W258 between the inactive and active states.  
The shift in TMHs is also reflected in the surface of models of B, C and D, showing a 
change in openings between TMHs for potential ligand entrance into the receptor 
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orthosteric binding site (Figure 46). In the R state models B and C there are openings 
between TMH1 and 2 and between TMH1 and 7. However, in the R* model D the 
openings have shifted to between TMH2 and 3 and between TMH3 and 4, indicating 
that ligand entry into CB2 receptor would have to be achieved through a different 
region in the active state. Openings between the ECLs into the extracellular space have 
also moved between the R state and R* state models, however the flexibility of the 
ECLs makes it difficult to extrapolate meaningful observations in this change.  
 
Figure 46: Surface of hCB2 receptor homology models B (green), C (red) and D (blue), all viewed from 
the same angle, showing the entrance to the ligand binding pocket between TMH1 and 7 in models B and 
C, which is closed in model D.  
A detailed comparison of these homology models with literature models has not been 
included here, as CB2 receptor homology models reported prior to the determination of 
CB1 crystal structures have utilised other, less closely related crystal structures and 
therefore will differ slightly to the models generated here.  
3.7.3 Ligand docking studies 
Ligand docking studies were carried out with the aim of rationalising the differences in 
CB2 receptor affinity observed between ligands. Specifically, of interest was the affinity 
difference between 5-hydroxyl 2.23a and 6-hydroxyl 2.23b, as well as between the N1-
methyl-THP derivatives 2.23e, 2.25c, 3.6 and 3.7a. In addition, the favourability of 7-
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substitution over 5-substitution was of interest. Docking of longer linker-AI conjugates 
3.13 and 3.24 was carried out with the aim of rationalising whether it was a promising 
lead for further development of fluorescent ligands.  
3.7.3.1 Agonist docking studies 
The agonists 2.23a, 2.23e, 2.25c and 3.6, as well as 3.7a (which showed no response in 
the cAMP assay) and 2.23b (which showed minimal CB2 receptor affinity) were 
docked into the R* state model D. In order to validate the docking results, the CB2 
receptor-docked 5-hydroxyl 2.23e was compared to the orientation of agonist 
AM11542 which was bound in the CB1 crystal structure (Figure 47A). The ligands 
overlapped, indicating the appropriate region of the binding site had been identified. 
The indole ring overlapped with the cyclohexane ring of AM11542 and the carbonyl 
overlapped with the oxygen atom of the middle ring of AM11542. The overlap fulfilled 
the expectation that the aromatic methoxyphenyl would be orientated towards the 
aromatic region of the ligand binding pocket between TMH3 and TMH6. As a control, 
the CB receptor agonist CP55,940 1.10 was also docked into model D and when 
overlaid with AM11542, it showed a close overlap of structural features, such as the 
cyclohexanol rings, aliphatic alkyl chains and cyclohexane rings, thereby validating the 
homology model and ligand docking protocol (Figure 47B).  
 
Figure 47: Overlay of CB1 receptor-bound AM11542 (pink) with the most consistent, lowest energy 




The docking poses of 5-hydroxyl indole 2.23e, 5-O-ethanoic acid 2.25c, 5-O-propyl 
3.7a and 7-O-ethanoic acid 3.6 were compared to try to rationalise the differences in 
CB2 receptor affinity. The most consistent docking poses of 2.23e and 2.25c (three out 
of four and seven out of ten poses, respectively) showed the methoxyphenyl group 
orientated towards the aromatic TMH3-TMH6 region of the ligand binding pocket, the 
methyl-THP group pointing upwards, and the 5-O-substituent pointing between TMH2 
and TMH3 (Figure 48A & B). The most consistent pose (three out of four) of 3.7a was 
similarly orientated (Figure 48C) to 2.23e and 2.25c, whereas the most consistent pose 
of 7-substituted 3.6 (three out of four) was shifted considerably (Figure 48D).  
   
Figure 48: Consensus poses of (A) 2.23e, (B) 2.25c, (C) 3.7a and (D) 3.6 in R* state CB2 receptor model 
D. Side chains of residues within 4 Å of the ligands are shown as sticks (pale yellow). Red atoms 
represent oxygen, blue atoms represent nitrogen and dark yellow atoms represent sulphur. Some ECLs 
are hidden for clarity.  
The ligand docking studies did not produce an obvious explanation for the difference in 
CB2 receptor affinity between the high affinity 5-hydroxyl 2.23e and the analogous, 
moderate affinity 5-O-ethanoic acid 2.25c and 5-O-propyl 3.7a, as the docking poses of 
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these ligands are very similar (Figure 49A). 5-O-propyl 3.7a and 5-O-ethanoic acid 
2.25c show similar affinity, so it does not appear to be principally related to the ionised 
carboxylic acid of 2.25c. The 5-hydroxyl of 2.23e may be engaged in favourable 
hydrogen bonding not demonstrated in the docking results, which could be disrupted by 
extension with a propyl or ethanoic acid. Comparing the docking poses of 2.25c and 
3.6, there is a clear downward shift in the positioning of the indole ring of 3.6, allowing 
the methoxyphenyl group to extend a bit further into the aromatic region of the ligand 
binding pocket than 2.25c. This may allow greater aromatic interactions and van der 
Waals interactions with the hydrophobic pocket, improving the affinity of 3.6 for CB2 
receptor. In addition, the different positioning of hydrogen bond acceptors such as the 
carbonyl or ether moieties may allow for formation of more favourable hydrogen bond 
interactions between 3.6 and CB2 receptor.  
 
Figure 49: Overlay of the most consistent, lowest energy docking poses of (A) 5-hydroxyl 2.23e (cyan), 
5-O-ethanoic acid 2.25c (green) and 5-O-propyl 3.7a (magenta) and (B) 5-O-ethanoic acid 2.25c (green) 
and the analogous 7-O-ethanoic acid 3.6 (orange) docked into R* state CB2 receptor model D. Side 
chains of residues within 4 Å of the ligands are shown as sticks (pale yellow). Some ECLs are hidden for 
clarity. 
Docking studies with 5-hydroxyl 2.23a and 6-hydroxyl 2.23b into R* state model D 
failed to identify a reason for the poor affinity of 2.23b, as they both docked in almost 
identical positions.  
120 
 
3.7.3.2 Inverse agonist docking studies 
Docking of inverse agonists 3.4, 3.7b, 3.13 and 3.24 was initially attempted in both 
model B and C, however docking with model C produced more consistent docking 
poses and so was used for all AI inverse agonists. The aim of the docking studies was 
to rationalise the high affinity of 3.7b and investigate why 7-hydroxyl 3.4 and 7-O-
propyl 3.7b had higher CB2 receptor affinity than the analogous 5-hydroxyl 2.23e and 
5-O-propyl 3.7a. The binding position of the linker-AI conjugates 3.13 and 3.24 was 
also of interest, as the lead compounds for further development of AI-based fluorescent 
ligands for CB2 receptor.  
The docked poses of 7-O-propyl 3.7b and 7-hydroxyl 3.4 show overlap in the 
methoxyphenyl and ethylmorpholino moieties, but the indole ring of 3.7b is positioned 
at an angle of about 40° along the C3 and C8 edge of the 3.4 indole ring (Figure 50). 
This shift in positioning of the core indole, as well as the lipophilic O-propyl being able 
to engage in van der Waals interactions with hydrophobic side chains, may be 




Figure 50: Overlay of the most consistent, lowest energy docking poses of 7-hydroxyl 3.4 (yellow) with 
7-O-propyl 3.7b (orange) docked into R state CB2 receptor model C. Side chains of residues within 4 Å 
of the ligands are shown as sticks (pale green). Some ECLs are hidden for clarity.  
The most evident SAR identified in this chapter was the higher CB2 receptor affinity 
conferred by 7-substituents compared to 5-substituents. Comparing the poses of 7-
hydroxyl 3.4 and 7-O-propyl 3.7b docked into R state model C, with the analogous 5-
hydroxyl 2.23e or 5-O-propyl 3.7a docked into R* state model D, there is a clear 
difference in the ligand orientation. Overall, 7-hydroxyl 3.4 is positioned deeper into 
the ligand binding pocket than 5-hydroxyl 2.23e and the methoxyphenyl of 3.4 
protrudes deeper into the hydrophobic pocket between TMH3-6 (Figure 51A). 
Similarly, 7-O-propyl 3.7b is also buried further into the ligand binding pocket, with 
the methoxyphenyl deeper into the hydrophobic pocket, than the analogous 5-O-propyl 
3.7a (Figure 51B). This pattern is similar to that shown between the docking of 7-O-
ethanoic acid 3.6 and 5-O-ethanoic acid 2.25c in the active R* model D (Figure 49). 
The ability to engage in greater aromatic interactions, which are key to CB2 receptor 






Figure 51: Overlay of the most consistent, lowest energy docking poses of (A) 5-hydroxyl 2.23e (cyan) 
and 7-hydroxyl 3.4 (yellow) and (B) 5-O-propyl 3.7a (magenta) and 7-O-propyl 3.7b (orange). 7-
Hydroxyindole 3.4 and 7-O-propyl 3.7b are docked into R state CB2 receptor model C (shown), whereas 
2.23e and 3.7a are docked into R* state model D (not shown). Side chains of residues within 4 Å of the 
ligands are shown as sticks (pale green). Some ECLs are hidden for clarity.  
The inverse agonist linker-AI conjugates 3.13 and 3.24 were also docked into R state 
model C to gain further understanding of how these two ligands were able to retain 
affinity for CB2 receptor and how they might be successfully developed into fluorescent 
ligands. The docking poses of 3.13 were clustered into two groups, with the most 
consistent pose showing the linker oriented out of the binding pocket, into the lipid 
bilayer (Figure 52A). In this pose, the 7-ether demonstrates hydrogen bonding with 
S285, whilst THP hydroxyl and the ester carbonyl form hydrogen bonds with residue 
N20 of the amino terminal. The other, smaller cluster of poses (three out of ten) of 3.13 
showed the linker exiting through the extracellular loops, however the flexibility of 
extracellular loops makes docking in this region difficult. The most consistent docking 
pose of acetylated 7-O-hexylamine 3.24 showed close overlap to the most consistent 
pose of 3.13, with the 7-ether and THP hydroxyl engaging in hydrogen bonding with 
the same residues as 3.13 (Figure 52A). The phenyl groups of 3.13 and 3.24 are 
positioned in a hydrophobic pocket between TMH3-TMH6 and the indole core and 
phenyl are able to engage in van der Waals interactions with multiple nearby aromatic 
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residues (F183, W194, W258 and F281). The linker terminals of the docked ligands 
3.13 and 3.24 protrude slightly out of the ligand binding pocket, orientating towards the 
gaps between TMH1 and TMH7 and between TMH1 and TMH2 (Figure 52B). 
Molecular dynamics simulations conducted by Jakowiecki et al have revealed a likely 
entry route between TMH1 and TMH7 for (-)-Δ9THC 1.5 and AEA 1.1 binding to CB1 
receptor.91 Similarly, an exit pathway from the orthosteric binding site of CB2 receptor 
between TMH1 and TMH7 has been proposed for the biotin-containing CB2 receptor 
probe 1.20.87 In addition, the taranabant-bound CB1 receptor crystal structure indicated 
a ligand entry channel between TMH1 and TMH7.67 The linker poses of 3.13 and 3.24 
reinforce that the indole C7 position holds promise for linker and fluorescent dye 
conjugation.  
 
Figure 52: The most consistent, lowest energy docking pose of inverse agonists 3.13 (cyan) and 3.24 
(orange) docked into R state hCB2 receptor homology model C. (A) Hydrogen bonding (yellow dashed 
line) is shown between the 7-ether and S285 as well as the THP hydroxyl and the ester carbonyl (of 3.13) 
with N20 of the N-terminal. Side chains of residues within 4 Å of the ligands are shown as sticks (pale 
green). (B) Model C shown with surface, indicating potential entry points between TMH1 and 7 or 
TMH1 and 2 for 3.13 and 3.24 into CB2 receptor.  
Examining how far the linker terminals of 3.13 and 3.24 reach out of the ligand binding 
pocket, may help to determine why further extension of these ligands was not 
ultimately successful. Linker-pharmacophore conjugate 3.24 was conjugated directly to 
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the fluorophore to give 3.25, however the docking pose of 3.24 (Figure 52B) suggests 
that the linker would not have been long enough to allow favourable positioning of both 
the fluorophore and pharmacophore of 3.25. Conversely, 3.13 was extended by 10 
atoms with a PEG linker prior to conjugation of the fluorophore and it is possible that 
the linker in the resulting fluorescent ligand was too long. This hypothesis is reinforced 
by examining the docking results of the more successful CB2 receptor fluorescent 
ligands identified in Chapter Five (section 5.5) which suggest that a favourable linker 




The work discussed in this chapter was initiated by a desire to explore whether the CB2 
receptor affinity of the 5-substituted linker-AI conjugates evaluated in Chapter Two 
could be improved by reducing the polarity of the region of the linker immediately 
adjacent to the indole core. However, contrary to expectations, it was demonstrated that 
replacement of the ethanoic acid moiety of 2.25c with the same length propyl group 
(3.7a) led to no significant improvement in affinity. The finding that substitution with a 
simple, small propyl group did not retain CB2 receptor affinity indicated that extension 
of the lead compound from Chapter Two, 5-hydroxyl 2.23e, would likely lead to only 
low affinity compounds.  
Simultaneously to the exploration of varying polarity at the C5 position, 7-substituted 
indoles were also investigated as CB2 receptor ligands. A clear preference for 7- over 5-
substitituted indoles was demonstrated and a new, high affinity CB2 receptor selective 
inverse agonist 3.7b was identified (Ki = 5.7 ± 1.4 nM at hCB2, KihCB1/KihCB2 = 88). 
7-O-Propyl 3.7b is an especially high affinity CB2 receptor inverse agonist with high 
potency and efficacy both within the AI scaffold and other classes of CB2 receptor 
inverse agonists. A general trend of agonism for 5-substituted indoles and inverse 
agonism for 7-substituted indoles was observed in the cAMP assays.  
Extension of the new lead compound 3.7b resulted in the pharmacophore-linker 
conjugate 3.13 which retained CB2 receptor affinity and demonstrated that a linker at 
the C7 position of indole is tolerated. Modelling suggests that 3.13 would be amenable 
to further extension and fluorophore conjugation. Unfortunately, further linker 
extension and conjugation of a fluorescent dye to the linker-indole derivatives 3.13 and 
3.24 failed to produce a high affinity CB2 receptor fluorescent ligand.  
3.8.1 Future directions 
3.13 remains a promising pharmacophore-linker lead and future studies could explore 
extension of 3.13 to identify more appropriate linker lengths and types in addition to 
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conjugation with different fluorescent dyes. Ligand docking studies with 3.13 and 3.24 
suggest that the linker lengths of the final fluorescent compounds 3.18 and 3.25 were 
unfavourable. In light of the results from Chapter Five, it may be worthwhile exploring 
conjugation of a short linker, between three to eight atoms (rather than the longer 10 
atom linker 2.28b), onto 3.13, before conjugation of BODIPY 630/650-X OSu 2.15. In 
addition, conjugation of a linker possessing multiple groups capable of hydrogen 
bonding with the polar residues located around the exit of the orthosteric site may help 
improve affinity for CB2 receptor.  
In the context of the C5-C7 indole work presented in this chapter and Chapter Two and 
in light of previous efforts of linker conjugation via the C3 acyl group 254 or extension 
of the N1 substituent,243 the search for an AI-based fluorescent ligand for CB2 receptor 
remains elusive.   
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 Chapter Four: Fluorescent ligands for CB2 
receptor based on N-substituted 1,8-
naphthyridin 
4.1 Scaffold selection 
Biological evaluation of the indole-based compounds (Chapters Two and Three) 
indicated very few positions on the indole scaffold tolerated a linker and then 
attachment of fluorescent dye. Therefore, a literature review of cannabinoid structural 
classes was undertaken to select a second scaffold for development into CB2 selective 
fluorescent ligands. The criteria for selecting this scaffold was similar to the indole 
scaffold, in that it should have high affinity and selectivity for CB2 receptor, have 
existing SAR indicating positions amenable to change and demonstrate antagonist or 
inverse agonist activity. In addition, a relatively polar cannabinoid was sought in order 
to reduce the overall hydrophobicity of the final fluorescent compound, thereby in 
theory reducing non-specific membrane binding. It was with this criteria in mind that 
the 1,8-naphthyridin-2(1H)-one-3-carboxamide scaffold145 was chosen for development 
of a series of fluorescent CB2 receptor ligands. The following section (4.1.1) outlines 
the literature SAR of this scaffold as a CB receptor ligand, which then informed the 
decision of linker placement (as discussed in section 4.2).  
4.1.1 1,8-Naphthyridin-3-carboxamide-based cannabinoids 
1,8-Naphthyridin-4(1H)-one-3-carboxamide (Figure 53) based cannabinoids were 
initially designed by including key structural motifs of other classes of cannabinoids,300 
such as the N1-alkyl or aryl alkyl substituents of AAIs (e.g. WIN 55,212-2 2.2) and the 
C3-aliphatic or aromatic carboxamide substituents of quinolines (e.g. JTE-907 1.15). 
This strategy led to identification of several nanomolar affinity (e.g. 4.1 and 4.2, Figure 




Figure 53: Examples of the first 1,8-naphthyridin-4(1H)-one-3-carboxamide based cannabinoids,  
(A) 4.1 and 4.2300 and (B) 4.3 and 4.4.301  
Refinement of the series shown in Figure 53A guided by molecular modelling and 
ligand docking of nonaromatic substituents at the C3 carboxamide group (R2) and 
different N1 (R1) lipophilic substituents, resulted in ligands with moderately improved 
affinity and selectivity for CB2 receptor (e.g. 4.3 and 4.4, Figure 53B).
301, 302 Varying 
the C7 (R3) substituent with methyl, chloro, methoxy or hydrogen had only a minimal 
impact on affinity and selectivity, indicating that C7 (R3) substituents were not essential 
(unsubstituted C7-H derivatives are detailed in Table 11). In addition, it was 
demonstrated that the presence of a carbonyl group on the naphthyridin ring (which was 
hypothesised to induce planarity with the carboxamide via intramolecular bonding with 
the amidic NH) was necessary for CB2 receptor affinity.  
Exploration of how to further improve the CB2 receptor affinity and selectivity of this 
scaffold, led to considering the position of the carbonyl group. Superimposition of a 1,8 
naphthyridin-4(1H)-one-3-carboxamide derivative with the corresponding 1,8-
naphthyridin-2(1H)-one-3-carboxamide derivative showed adequate overlap of the key 
substituents.303 Therefore, a series of 1,8-naphthyridin-2(1H)-one-3-carboxamide 




Figure 54: General structure of 1,8-naphthyridin-2(1H)-one-3-carboxamide based cannabinoids. Refer to 
Table 12 for example R groups. The grey dashed line between the C2 carbonyl and NH indicate the 
position of a potential intramolecular hydrogen bond.  
Manera et al concluded that the 2-one (Figure 54) derivatives303 showed a significant 
improvement in CB2 receptor affinity (and in selectivity for the R
1 ethylmorpholino 
containing derivative), when compared with the 4-one (Figure 53) derivatives301 (see 
Table 11 for comparison). Therefore, 2-one derivatives were pursued exclusively in the 
development of this scaffold. However, it is important to note that the two studies used 
different species of CB receptor to determine Ki values: mouse brain membranes (CB1) 
and mouse spleen homogenate (CB2) for the 4-one derivatives
301 versus HEK293 hCB1 
and hCB2 membranes for the 2-one derivatives.
303 The Ki value for a reference 
compound, JWH-133 (a classical cannabinoid) was determined in both studies, with 
significantly different selectivity found. At mouse receptors, JWH-133 showed a Ki of 
65 nM at CB2 and 458 nM at CB1 receptor (seven fold selectivity for CB2 receptor),
301 
whereas at human receptors JWH-133 showed a Ki of 3 nM at CB2 and 677 nM at CB1 
receptor (226 fold selectivity for CB2 receptor; Table 11).
303 This difference in affinity 
and selectivity broadly echoes the differences found between the 4-one and 2-one series 
and therefore, without repeating binding assays of the 4-one derivatives at human CB 
receptor, it is questionable how significant the difference in affinity and selectivity 
really is between these two series. Any real improvement in affinity and selectivity may 
be due to the 3-carboxamide group not having to rotate to form an intramolecular 
hydrogen bond between the amidic NH and the 2-one, therefore altering the spatial 
arrangement of the carboxamide R2 substituent (Figure 54).  
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Table 11: A comparison of literature301, 303 reported radioligand binding data for 1,8-napthyridin-4(1H)-
one-3-carboxamide and 1,8-napthyridin-2(1H)-one-3-carboxamide derivatives. a 
 
  
 4-one derivatives b 2-one derivatives c 
 Ki (nM)  Ki (nM)  
Table 
Entry 
R1 R2 mCB2 mCB1 SI d hCB2 hCB1 SI d 
1 ethylmorpholino cyclohexyl 67.2 >1000 >15 7.9 560 71 
2 benzyl cyclohexyl 48.6 >1000 >21 31 560 18 
3 p-fluorobenzyl cyclohexyl 13 384.1 29 2.2 56 25 
4 ethylmorpholino 4-methylcyclohexyl - - - 1.9 1000 526 
5, 4.5 
CB74 
benzyl 4-methylcyclohexyl - - - 7.8 1600 205 
6 benzyl trans-4-
methylcyclohexyl 
- - - 39.8 5255 132 
7 benzyl cis-4-
methylcyclohexyl 
- - - 5.8 1519 262 
8, CB91 p-fluorobenzyl 4-methylcyclohexyl - - - 0.9 200 222 
9 p-fluorobenzyl trans-4-
methylcyclohexyl 
- - - 9.0 300 33 
10 p-fluorobenzyl cis-4-
methylcyclohexyl 
- - - 0.7 200 286 
JWH-
133 
- - 65 458 7 3 677 226 
a Data represent mean values of Ki (nM) from experiments performed at least three times in duplicate.  
b Data from Manera et al, 2006.301 A dash indicates that a direct comparison compound to the 2-one 
derivative is not available, as the 4-one derivatives with matching R1 and R2 groups contained either 
chloro or methyl substituents at C7. Affinity of compounds determined using mouse spleen for CB2, 
mouse brain membranes for CB1 receptor and [3H]CP55,940.  
c Data from Manera et al, 2009.303 Affinity of compounds determined using membranes from HEK293 
cells transfected with either hCB2 or hCB1 receptor and [3H]CP55,940 (Kd = 0.18 nM at CB1 or Kd = 
0.31 nM at CB2). 





Several high affinity, selective ligands were identified amongst the 1,8-naphthyridin-
2(1H)-one-carboxamide series, with two derivatives possessing subnanomolar affinity 
for CB2 receptor and >200 fold selectivity over CB1 receptor (Table 11, entry 8 and 
10).303 In addition, this series revealed some interesting SAR, including that 4-
methylcyclohexyl substitution at the carboxamide (R2) confers better affinity and 
selectivity for CB2 receptor than with a cyclohexyl (Table 11, cf. entry 4 with 1, 5 with 
2, or 8 with 3). Some derivatives were tested with the 4-methylcyclohexyl substituent 
(R2) as a mixture of both the cis and trans stereoisomers (i.e. the orientation of the 
methyl para to the carboxamide; Table 11, entries 4, 5 and 8). The SAR shows that it is 
the cis stereoisomer that is responsible for the high CB2 receptor affinity and selectivity 
of these compounds, as the isolated trans isomers show significantly worse affinity and 
selectivity (Table 11, cf. entry 6 with 7, or 9 with 10). Other substituents trialled at the 
carboxamide (R2) included cycloheptyl, which led to improved CB1 receptor affinity 
and therefore worse CB2 receptor selectivity, and 4-fluorophenethyl which resulted in a 
decrease in affinity at both receptors. At the N1 position, the highest CB2 receptor 
affinity R1 substituent was p-fluorobenzyl, followed by ethylmorpholino, then benzyl 
(Table 11, cf. entries 8, 4 and 5, or (2-one) 3, 1 and 2). In contrast, the substituent 
conferring the highest CB2 receptor selectivity was ethylmorpholino, followed by p-
fluorobenzyl then benzyl (cf. entries 5, 8 and 6 or (2-one) 1, 3 and 2).  
Functional characterisation of N-(4-methylcyclohexyl)-1-benzyl-1,8-naphthyridin-
2(1H)-one-3-carboxamide (CB74) 4.5 (Table 11, entry 5; Figure 55) indicated this 
compound acts as an agonist, exerting a CB2 receptor-mediated inhibition of human 
basophil activation.303 Additionally, in a cytotoxicity assay 4.5 elicited a concentration 
dependent decrease in the viability of the Jurkat human T cell leukaemia line. The 
potential immunomodulatory activity of 4.5 was further investigated in a study on 
activated lymphocytes isolated from MS patients.304 CB74 (4.5) was shown to inhibit 
cell activation markers linked to MS progression and to block cell proliferation. In 
particular, 4.5 reduced cyclooxygenase-2 (a key enzyme in inflammatory reaction) 
levels in MS lymphocytes, but not in healthy control lymphocytes. The promising 
activity of this 1,8-naphthyridin-2(1H)-one-3-carboxamide derivative in autoimmune 
pathologies has increased interest in this class of cannabinoids. Intermediates 
synthesised in the course of fluorescent ligand development in this chapter may 
132 
 
therefore also be of interest themselves as novel analogues of this class of 
cannabinoids.  
The 1,8-naphthyridin-2(1H)-one-3-carboxamide scaffold has already shown promise as 
a scaffold for the development of chemical tools. Radiofluorination of derivative N-(4-
methylcyclohexyl)-1-(p-fluorobenzyl)-1,8-naphthyridin-2(1H)-one-3-carboxamide 
(CB91, Table 11, entry 8) yielded [18F]CB91 4.6 (Figure 55), which was evaluated as a 
tool for PET imaging CB2 receptor.
305 Whilst uptake of [18F]CB91 4.6 was 
demonstrated in CB2 receptor rich spleen, it showed widespread distribution. The 
authors cite ongoing studies to demonstrate specific CB2 receptor binding.  
Substitution of a hydroxyl group at C4 of the 1,8-napthyridin-2(1H)-one-3-
carboxamide core has been explored, with mixed SAR in terms of CB2 receptor affinity 
and selectivity.306, 307 However, one compound of note was the agonist N-cycloheptyl-
4-hydroxy-1-(2-morpholin-4-ylethyl-2-oxo-1,2-dihydro-1,8-naphthyridine-3-
carboxamide (VL15) 4.7 (Figure 55), which showed high affinity (Ki = 1.8 nM at 
hCB2) and selectivity (Ki(CB1)/Ki(CB2) = 130). Compound 4.7 was investigated for 
immunomodulatory properties and found to reduce peripheral blood mononuclear cell 
proliferation, block cell cycle progression and downregulate T cell activation markers 
usually enhanced in autoimmune disease.308 Additionally, 4.7 was found to have 
promising physicochemical properties for MS treatment, with high intestinal absorption 
and blood-brain barrier penetration.  
 
Figure 55: CB2 receptor agonist CB74 (4.5), radioligand [18F]CB91 (4.6) and agonist VL15 (4.7). 
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Variation of the N1 and C6 substituents (R1 and R3 respectively in Figure 56) of this 
scaffold have been explored while keeping the C3 carboxamide 4-methylcyclohexyl 
constant.145 Differing lengths of alkyls, alcohols, esters, carboxylic acids and alkyl 
fluorides were substituted at N1 (R1), which demonstrated a tolerance for chain length 
variation at this position (Table 12, entries 11-23). Exploration of the C6 position with 
R3 = bromine, 2-thienyl, 2-furyl, p-methoxyphenyl or p-fluorophenyl while holding N1 
(R1) as p-fluorobenzyl or ethylmorpholino resulted in all high affinity CB2 receptor 
compounds (entries 25-35 and 37-41). The combination of R1 = ethylmorpholino and 
R2 = p-methoxyphenyl (as a mixture of cis and trans isomers) offered the best CB2 
receptor selectivity, with a SI of >6802 (entry 38). The cis isomers again had higher 
CB2 receptor affinity and selectivity than the corresponding trans isomers (cf. entries 
27, 32 and 35 with 26, 31 and 34).  
 




Table 12: Literature reported radioligand binding data for 4-methylcyclohexyl-1,8-naphthyridin-2(1H)-
one-3-carboxamide derivatives (as shown in Figure 56) from Lucchesi et al.145, a 





N1 (R1) C6 (R3) hCB2 hCB1  SI d 
11 50:50 CH2CH2OH H 2096 >10000 >5 
12 50:50 CH2(CH2)2OH H 129 >10000 >77 
13 50:50 CH2(CH2)3OH H 53.3 >10000 >187 
14 50:50 CH2(CH2)4OH H 3.60 >10000 >2778 
15 50:50 CH2(CH2)5OH H 18.0 >10000 >554 
16 50:50 CH2(CH2)2CH3 H 3.90 2314 593 
17 50:50 CH2(CH2)3CH3 H 2.82 908 322 
18 50:50 CH2CH2COOEt H 176 >10000 >57 
19 50:50 CH2(CH2)2COOEt H 62.6 >10000 >160 
20 50:50 CH2(CH2)3COOMe H 27.1 >10000 >369 
21 50:50 CH2(CH2)3F H 1.36 1011 743 
22 50:50 CH2(CH2)4F H 0.56 22.59 40 
23 50:50 CH2(CH2)5F H 1.46 35.67 24 
24 50:50 p-fluorobenzyl H 0.9 200 222 
25 50:50 p-fluorobenzyl Br 0.18 96.1 534 
26 Trans p-fluorobenzyl Br 1.12 166 148 
27 Cis p-fluorobenzyl Br 0.12 121 1010 
28 50:50 p-fluorobenzyl p-methoxyphenyl 3.83 3262 851 
29 50:50 p-fluorobenzyl p-fluorophenyl 2.17 >10000 >4608 
30 50:50 p-fluorobenzyl 2-thienyl 1.85 3280 1773 
31 Trans p-fluorobenzyl 2-thienyl 65.6 430 6.5 
32 Cis p-fluorobenzyl 2-thienyl 0.96 472 491 
33 50:50 p-fluorobenzyl 2-furyl 0.67 3444 5140 
34 Trans p-fluorobenzyl 2-furyl 94.2 >10000 >106 
35 Cis p-fluorobenzyl 2-furyl 0.27 4056 15022 
36 50:50 Ethylmorpholino H 1.90 1000 526 
37, 4.8 50:50 Ethylmorpholino Br 1.26 750 595 
38, 1.16 50:50 Ethylmorpholino p-methoxyphenyl 1.47 >10000 >6802 
39 50:50 Ethylmorpholino p-fluorophenyl 0.68 66.7 98 
40 50:50 Ethylmorpholino 2-thienyl 0.17 32.7 192 
41 50:50 Ethylmorpholino 2-furyl 0.35 52.9 151 
a Data represent mean values of Ki (nM) from experiments performed at least three times in duplicate.  
b Affinity of compounds determined using HEK293-hCB1 or -hCB2 membranes and [3H]CP55,940 (Kd 
= 0.18 nM at hCB1 or Kd = 0.31 nM at hCB2). 
c cis- or trans-4-methylcycylohexylcarboxamide.  
d SI = Ki(CB1)/Ki(CB2).  
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Lucchesi et al also carried out functional assays on three 6-substituted derivatives 
(Table 12: R1 = p-fluorobenzyl, R3 = bromine, entry 25; R1 = ethylmorpholino, R3 = 
bromine, entry 37; and R1 = ethylmorpholino, R3 = p-methoxyphenyl, entry 38) and 4 
unsubstituted derivatives (R1 = p-fluorobenzyl, entry 24; R1 = ethylmorpholino, entry 
36; R1 = butan-1-ol, entry 13; and R1 = 4-fluorobutane, entry 21). β-Arrestin 2 
recruitment and forskolin-stimulated cAMP assays revealed that derivatives with a C6-
substituent (R3) behaved as an antagonist and inverse agonist at CB2 receptor, whereas 
derivatives with only hydrogen at C6 behaved as CB2 receptor agonists.
145 The authors 
used molecular modelling and docking studies to hypothesise that this change in 
functionality was due to a ‘molecular toggle switch’, whereby C6 (R3) substituents 
could penetrate deep into the ligand binding pocket and block movement of residue 
W6.48 (258), part of the CB2 receptor TMH6 flexible hinge (CWXP).  
Several 1,8-naphthyridin-2(1H)-one-3-carboxamide ligands with high affinity for CB2 
receptor possess relatively low cLogP values when compared with the typically 
lipophilic cannabinoids. For example, 6-bromo-N-(4-methylcyclohexyl)-1-(2-
morpholinoethyl)-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide (Table 12; entry 
37) has a cLogP of 2.07, compared with 7.77 for SR144528 1.13, 6.16 for CP55,940 
1.10 and 4.19 for AM630 1.14.**** Conjugation of a fluorescent dye such as BODIPY 
630/650-X to a pharmacophore will make the overall ligand more lipophilic and 
therefore prone to high non-specific membrane binding. Selection of a less lipophilic 
pharmacophore such as the 1,8-napthyridin-2(1H)-one-3-carboxamides should help to 
reduce this non-specific membrane binding in the final fluorescent compounds.  
Within the broad category of 1,8-napthyridin derivatives, biological activities reported 
include anti-viral, anti-microbial, anti-tuberculosis, anti-cancer and anti-
inflammatory.309 A structure search of the 1,8-napthyridin-2(1H)-one-3-carboxamide 
scaffold revealed that the number of biological targets other than CB receptors was 
limited and included hypoxia inducible factor prolyl hydroxylases,310 
cytomegalovirus311 and human immunodeficiency virus (HIV)-1 integrase strand 
transfer.312 The 1,8-naphthyridin-4(1H)-one-3-carboxamide scaffold has been used in 
                                                 
**** cLogP values calculated using Crippen's fragmentation,265 in ChemDraw Prime 15.1, PerkinElmer 
Informatics, Inc.  
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development of ligands for another GPCR, adenosine A2A receptor.
313 However, the 
reported adenosine A2A receptor ligands differ quite significantly from CB2 receptor 
1,8-naphthyridin ligands, lacking N1 substituents and with very different carboxamide 
substituents. The only report of CB1 receptor selective 1,8-naphthyridinones presents 
structures with quite different N1 and C3 substituents and simultaneous substitution of 
p-chlorophenyl at C6 and o,p-dichlorophenyl at C7.314  
4.1.2 Conclusions on literature SAR of the 1,8-naphthyridin-2(1H)-one-
3-carboxamide scaffold 
In conclusion, the 1,8-napthyridin-2(1H)-one-3-carboxamide scaffold possesses many 
of the desirable characteristics for development into fluorescent ligands. There are 
many high affinity CB2 receptor ligands identified within this class, several with 
subnanomolar affinity. Compounds are generally CB2 receptor selective, with many 
exhibiting very high selectivity (KiCB1/KiCB2 >500) and SAR is well characterised as 
to which groups confer this high selectivity. The presence of a C6 substituent appears to 
influence ligand function for CB2 receptor in a predictable way therefore, either agonist 
or antagonist fluorescent ligands may be intentionally developed. There are areas of the 
scaffold that are tolerant to change and steric bulk, providing guidance as to where 
conjugation of a linker and fluorescent dye might be tolerated, and the scaffold itself 
possesses desirable physicochemical properties.   
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4.2 Fluorescent ligand design 
4.2.1 Linker position and ‘R’ group choice  
The first goal was to develop a fluorescent antagonist and therefore inclusion of bulky 
substituents at C6 of naphthyridin was planned (R3, Figure 57). Docking studies by 
Lucchesi et al suggested that C6 substituents are positioned deep into the orthosteric 
CB2 receptor-binding pocket.
145 Therefore C6 is an unsuitable location for conjugation 
of a fluorescent dye. Variation of substituents at the C3 carboxamide appears to have a 
significant impact on CB2 receptor affinity and selectivity, as demonstrated by the cis 
trans isomers of 4-methylcyclohexyl derivatives (Table 12, entries 26-27, 31-32, 34-
35). In contrast, variation in length of substituents at the N1 position appears to be well 
tolerated (Table 12, entries 11-23).145 Therefore, it is possible that conjugation of a 
linker and fluorescent dye will be tolerated at the N1 (R1) position of the naphthyridin 
scaffold.  
The 4-methylcyclohexyl substituent at the C3 carboxamide has well characterised SAR 
and offers high affinity and selectivity for CB2 receptor, therefore this group was 
preserved in the ligand design (Figure 57). The significant difference in affinity and 
selectivity between the cis and trans isomers made pursuing the cis isomers preferable, 
however the expense of sourcing the starting material, 4-methylcyclohexylamine, as the 
single cis isomer made this prohibitive. Therefore, the compounds were synthesised and 
pharmacologically evaluated as a mixture of cis and trans isomers, with the intention of 
re-synthesising or isolating the cis isomers of any promising candidates.  
From amongst the existing SAR for C6 (R3) substituents, p-methoxyphenyl, 2-furyl and 
bromine were considered in the ligand design. p-Methoxyphenyl stood out as 
consistently providing a good combination of high CB2 receptor affinity and selectivity 
in conjunction with varying N1 substituents (Table 12, entries 28 and 38). However, 
bromine-containing derivatives also possess high CB2 receptor affinity and selectivity 
(entries 25 and 37) and require one less synthetic step. Derivatising C6 with (R3) 2-
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furyl would result in a ligand with reduced lipophilicity,†††† however high selectivity is 
not as consistently conserved with N1 variation, when compared with p-methoxyphenyl 
(entries 33 and 41). Due to time constraints, it was not possible to synthesise large 
numbers of derivatives, so it was determined that a bromine atom at C6 (R3) would be 
conserved throughout the series (Figure 57). However, to inform a later, refined series, 
one example with p-methoxyphenyl at R3 was planned for comparison.   
 
Figure 57: Core ligand design of 1,8-napthyridin-2(1H)-one-3-carboxamide based fluorescent ligands.  
4.2.2 Linker 
Literature C6-substituted antagonists145 contain N1 (R1) substituents unsuitable for 
direct conjugation of a fluorescent dye (e.g. ethylmorpholino, p-fluorobenzyl). 
However, there are a number of literature agonists, which are unsubstituted at C6, that 
contain varying lengths of alkyls, alcohols and esters at N1 (Table 12, entries 11-23). 
Attachment of an ester R1 group at N1 could be followed by ester hydrolysis, revealing 
a carboxylic acid suitable for amide coupling to a linker. Therefore, methyl valerate 
was selected as an R1 group (Figure 57). As aromatic substituents are well tolerated at 
N1 (Table 11, entries 5-10; Table 12, entries 24-35),145, 303 linker extension from an 
                                                 
†††† cLogP values calculated for bromo (2.99), p-methoxyphenyl (3.71) and 2-furyl (2.45) C6-derivatives 
with methyl valerate substitution at N1. Calculated using Crippen's fragmentation,265 in ChemDraw 
Prime 15.1, PerkinElmer Informatics, Inc.  
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aromatic group was explored. Alkylation at N1 with methyl-4-methylbenzoate would 
provide an intermediate that could be extended in parallel with the methyl valerate 
derivatives (Figure 57). In addition, a literature derivative containing ethylmorpholino 
was planned for use as a reference in pharmacological testing (Table 12; entry 37).  
As previously stated in section 1.5.4, including a linker between the pharmacophore 
and fluorophore creates space, hopefully reducing the impact of the large fluorophore 
on the binding properties of the pharmacophore. For this series, two of the diamine 
linkers previously synthesised for the indole series, N-Boc-1,8-octanediamine 2.28a 
and N-Boc-2,2’-(ethylenedioxy)diethylamine 2.28b (‘PEG’ linker; Scheme 3) were 
used. It was hypothesised that the polar dipeptide linkers used in the indole scaffold 
may be too hydrophilic and attenuate binding to the lipid CB receptor, therefore they 
were not utilised. Ligand entry into CB receptors is thought to occur via the lipophilic 




Synthesis up to the intermediate 4.15 followed procedures reported by Lucchesi et al 
(Scheme 10).145 Bromination of the commercially available 2-amino-3-
pyridinecarboxaldehyde 4.12 yielded 4.13 (step i), introducing a bromine group and a 
handle for derivatisation at what would become the C6 position of the pharmacophore. 
An aldol condensation between 4.13 and diethyl malonate using piperidine formed the 
1,8-naphthyridin-2-one core 4.14 in high yield (step ii). Preparation of 4.15, ready for 
derivatisation at N1 and C6, was achieved by reacting 4.14 with 4-
methylcyclohexylamine (50:50 mixture of cis and trans isomers) at high temperature, 
forming a mixture of the cis and trans isomers of the carboxamide 4.15 (step iii). 
Analysis of the 1H NMR spectra of 4.15 showed splitting of the carboxamide NH into 
two doublets (9.51 & 9.96 ppm) and the adjacent tertiary CH into two multiplets (3.90 
& 4.25) as a result of the isomeric mix. Subsequently, all compounds in this chapter 
were synthesised/carried through as a mixture of cis and trans isomers, giving rise to 
the same proton splitting at the carboxamide NH and adjacent CH as well as carbon 
splitting throughout the scaffold in 13C NMR spectra.  
Alkylation of 4.15 at N1 was achieved using the corresponding chloro or bromo alkyl 
halide to yield 4.8, 4.9 and 4.10 in typically low yields (22-37%; Scheme 10; step iv). 
This was due to incomplete conversion of 4.15 and challenging separation of product 
from unreacted starting material (4.15), which was achieved by either flash silica gel 
chromatography or recrystallisation. The difficulty in purifying sufficient quantities of 
4.10, along with a strict synthesis schedule, meant that further development of the 
methyl-4-methylbenzoate derivative into a fluorescent ligand was abandoned. 
However, pharmacological evaluation of the intermediate 4.10 would inform whether it 
was worth a repeated attempt at this route in later synthesis. Literature compound 4.8 
was not developed further beyond this point, as it was only being synthesised as a 
reference compound for pharmacological testing. Lucchesi et al reported a microwave 
assisted Suzuki coupling to derivatise the bromo at C6 of 1,8-naphthyridin compounds 
(yields: 41-94%).145 In the absence of a microwave reactor, Suzuki coupling of 4.9 with 
4-methoxyphenylboronic acid was achieved under modified conditions, at 110°C and 
using a mixture of water and DMF as solvent, to give 4.11, with moderate and 
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comparable yield (55%). Purification of all compounds shown in Scheme 10 was 
achieved by either recrystallisation or silica column chromatography.  
 
Scheme 10: Reagents and conditions: (i) Br2, glacial AcOH, rt, 24 h, 61%; (ii) diethyl malonate, 
piperidine, EtOH, reflux, 18 h, 94%; (iii) 4-methylcyclohexylamine (50:50 cis/trans), 150°C, 24 h, 72%; 
(iv) R-bromo or R-chloro, Cs2CO3, DMF, 50°C, 12 h, 22-37%; (v) 4-methoxyphenylboronic acid, 
Pd(OAc)2, Na2CO3, H2O & DMF (1:4), 110°C, 3 h, 55%.  
Saponification of 4.9 with 10% NaOH gave the carboxylic acid 4.16, with an 
unexpectedly low yield (43%), likely due to loss of product during the work up 
(Scheme 11, step i). HATU-mediated amide coupling of 4.16 with either N-Boc-1,8-
octanediamine 2.28a or N-Boc-2,2’-(ethylenedioxy)diethylamine 2.28b (Scheme 3) 
yielded the Boc-protected pharmacophore-linker conjugates 4.17a and 4.17b, which 
were purified by silica column chromatography (step ii). Boc deprotection with TFA 
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gave the amines 4.18a and 4.18b (step iii) which were purified by semi-preparative RP-
HPLC prior to fluorescent dye conjugation to ensure optimal purity. The amines 4.18a 
and 4.18b were then either acylated to give 4.19a and 4.19b or used in 3-fold excess for 
conjugation to BODIPY 630/650-X-OSu 2.15, yielding the final fluorescent 
compounds 4.20a and 4.20b, all of which were purified by semi-preparative RP-HPLC 
for pharmacological testing. As expected, the mixtures of cis trans isomers eluted as 
two very close peaks in RP-HPLC, which were collected together and 
pharmacologically evaluated as a mixture. All compounds that underwent 
pharmacological testing (4.8-4.11, 4.19a-b and 4.20a-b) had >95% purity (as the 
mixture of cis trans isomers) as determined by analytical RP-HPLC.  
 
Scheme 11: Reagents and conditions: (i) 10% NaOH, EtOH, 110°C, 5 h, 43%; (ii) N-Boc-1,8-
octanediamine 2.28a or N-Boc-2,2’-(ethylenedioxy)diethylamine 2.28b, DIPEA, HATU, DMF, rt, 14 h, 
71–77%; (iii) TFA, DCM, rt, 1 h, 86-91%; (iv) Ac2O, DIPEA, DCM, rt, 1 h, 95-96%; (v) BODIPY 
630/650-X-OSu 2.15, DIPEA, DMF, rt, 15 h, 88-92%.   
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4.4 Pharmacological evaluation 
Four pharmacophore intermediates, 4.8, 4.9, 4.10 and 4.11, two pharmacophore-linker 
conjugates, 4.19a and 4.19b, and two final fluorescent compounds, 4.20a and 4.20b 
were subjected to pharmacological evaluation. Radioligand binding assays were carried 
out to determine affinity at hCB2 and hCB1 receptors and compounds with high affinity 
at CB2 receptor were tested in cAMP assays to determine function (refer to section 1.6).  
4.4.1 Radioligand binding assays 
A 10 µM competition binding screen was used to identify which compounds could 
displace more than 50% of bound [3H]CP55,940 1.17 at hCB2 and hCB1 receptors 
(Figure 58). As expected, literature compound 4.8 displayed high displacement (95%) 
at hCB2 receptor, along with compounds 4.9 and 4.11 (73% and 87%, respectively). 
Only compounds 4.8 and 4.11 reached close to 50% displacement of [3H]CP55,940 
1.17 at hCB1 receptor (50% and 43%, respectively).  
 
Figure 58: Combined results of competition binding screens showing displacement of [3H]CP55,940 (2.5 
nM) at HEK293 hCB2 (10 μg/point) (black) and HEK293 hCB1 (7.5 μg/point) (grey) membranes by a 
fixed concentration (10 μM) of test compound. Raw data was expressed in ccpm and normalised to 
unlabelled CP55,940 (10 μM) (100%) and vehicle control (0%). Data shown is the mean value ± SEM of 
three independent experiments conducted in triplicate, except for 4.8, 4.9 and 4.11 at hCB2, where n = 2. 
Dashed line indicates 50% displacement criteria for progression to concentration response assay.  
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Compounds 4.10, 4.19a, 4.19b, 4.20a and 4.20b displaced less than 50% of bound 
[3H]CP55,940 1.17 at hCB2 receptor (Figure 58) and so were unlikely to have affinity 
high enough to be able to accurately determine a Ki value. Therefore, statistical analysis 
was used to determine whether binding occurred. The percentage displacement values 
(n = 3, in triplicate) of 4.10, 4.19a, 4.19b, 4.20a and 4.20b at hCB2 receptor all passed 
the D’Agostino & Pearson normality test, showed significant difference from the 
vehicle control (0%) in a one sample t-test and were thus determined to have a Ki value 
>10 μM at hCB2 receptor (Table 13). Similarly, 4.9, 4.10, 4.19a, 4.19b, 4.20a and 
4.20b were also determined to have a Ki value >10 μM at hCB1 receptor.  
Compounds that displaced 50% or more of bound [3H]CP55,940 1.17 at hCB2 or hCB1 
receptor were subjected to a concentration response binding assay to generate Ki values 
(Figure 59, Table 13).‡‡‡‡ A concentration response assay was also carried out for 4.11 
at hCB1 receptor, as the SEM of radioligand displacement reached the 50% target.  
 
Figure 59: Competition binding curves for 4.8, 4.9 and 4.11 at hCB2 receptor, determined using 
[3H]CP55,940 (2.5 nM) and HEK293-hCB2 membranes. Data points are the mean ± SEM of one 
independent experiment conducted in triplicate points. Assay performed by Jamie Manning.  
                                                 
‡‡‡‡ Concentration response assays (n = 4) at hCB2 receptor for 4.8, 4.9 and 4.11 were carried out by 
Jamie Manning.  
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The highest affinity compound at hCB2 receptor was the literature compound 4.8 which 
showed a Ki of 45.2 nM (Figure 59), compared to the literature reported value of 1.26 
nM.145 This difference in values is augmented due to the different [3H]CP55,940 1.17 
Kd values used to determine Ki (refer to section 1.6.1 for equation explanation). In this 
study a Kd of 3 nM at hCB2 receptor was used, versus a Kd of 0.31 nM in the literature 
study. Utilising the literature [3H]CP55,940 1.17 Kd value (0.31 nM) with the raw data 
in this study brings the Ki value (9.1 nM) of 4.8 at CB2 receptor into an acceptable 
range of the literature Ki value (1.26 nM). In this study, compound 4.8 showed an 
average Ki of 16.7 µM at hCB1 (calculated using a [
3H]CP55,940 1.17 Kd value of 2 
nM) and was therefore designated as >10 µM due to the inaccuracy of determining Ki 
in this low affinity range. Utilising the literature [3H]CP55,940 1.17 Kd value (0.18 nM) 
at CB1 receptor, with the raw data in this study, 4.8 shows a Ki of 2.52 µM, closer to the 
literature value of 750 nM. The selectivity of 4.8 in this study (KiCB1/KiCB2 = 369, 
using Ki = 16.7 μM at CB1) was found to be quite similar to the literature selectivity 
difference (KiCB1/KiCB2 = 595).  
Amongst the C6-bromine derivatives, ethylmorpholino at N1 conferred the highest 
affinity at CB2 receptor (4.8), followed by methyl valerate (4.9; Figure 59; Table 13). 
The N1-methyl-4-methylbenzoate derivative 4.10 showed minimal binding (Ki >10 
µM; Figure 58) and is therefore unsuitable for further development into a fluorescent 
compound. This latter result was quite surprising, as aromatic groups such as benzyl (in 
C6-H derivatives) and p-fluorobenzyl (in both C6-H and C6-substituted derivatives) 
have been shown to be tolerable at the N1 position (Table 11, entries 5 and 8; Table 12, 
entries 25-35).145, 303 Additionally, the hydrophilic terminal methyl ester is tolerated in 
the methyl valerate derivative (4.9; Table 13) as well as the corresponding C6-
unsubstituted literature analogue (Table 12; entry 20). It is possible that the unique 
combination of the aromatic benzyl and the methyl ester in the N1 group of 4.10 
significantly alters the ligand orientation, hindering CB2 receptor binding.  
Substituting the C6-bromine for p-methoxyphenyl in the N1-methyl valerate derivatives 
led to a three-fold improvement in hCB2 receptor affinity from Ki = 906 nM (4.9) to Ki 
= 265 nM (4.11; Figure 59; Table 13) and therefore represents a potential means for 
refinement in a subsequent fluorescent compound series. This increase in affinity could 
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be due to the hydrophobicity of the p-methoxyphenyl group. The larger p-
methoxyphenyl group may also be able to form more favourable interactions with the 
ligand binding pocket than the smaller bromine.  
The cLogP values of the four pharmacophore intermediates were calculated to explore 
whether there was any correlation between overall compound lipophilicity and CB2 
receptor binding affinity. The rank order of lipophilicity (by cLogP value) in 
descending order was: 4.10 (4.03), 4.11 (3.71), 4.9 (2.99), and 4.8 (2.07).§§§§ This 
contrasts to the order of CB2 receptor affinity (high to low: 4.8, 4.11, 4.9 and 4.10; 
Table 13), which indicates that the varying, but similarly sized N1 substituents are 
likely having subtle effects on binding interactions, perhaps by altering the ring core 
orientation, rather than lipophilicity being the determining factor.  
Comparing the binding affinities of the C6-substituted, N1-methyl valerate derivatives 
4.9 and 4.11 with the published data of the literature C6-unsubstituted analogue (Table 
12, entry 20, Ki = 27.1 nM at hCB2 receptor
145), it initially appears as if C6-substitution 
leads to a significant decrease in CB2 receptor affinity. However, recalculating the 
binding affinities of 4.9 and 4.11 using the literature Kd value (0.31 nM at hCB2 
receptor), generates much lower Ki values of 183 nM and 53.5 nM at CB2 receptor, 
respectively which, for 4.11 in particular, shows a much less dramatic effect of C6-
substitution on affinity.  
                                                 
§§§§ cLogP values calculated using Crippen's fragmentation,265 in ChemDraw Prime 15.1, PerkinElmer 
Informatics, Inc.  
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Table 13: Affinity of N-substituted 1,8-naphthyridin based compounds for hCB2 and hCB1 receptors. a 
 









(% ± SEM)b 





(% ± SEM)b 
Ki (nM ± 
SEM) d 
SI e 
4.8 § Br Ethylmorpholino 94.7 ± 2.4 c 45.2 ± 10.8 50.0 ± 23 >10000 >221 
4.10 † Br Me-4-MeOBz 19.2 ± 3.4 >10000 16.7 ± 4.8 >10000 - 
4.9 † Br (CH2)4CO2Me 73.1 ± 1.0 c 906 ± 223 27.4 ± 3.1 >10000 >11 
4.11 † MeOPh (CH2)4CO2Me 87.2 ± 1.3 c 265 ± 31.9 43.4 ± 6.1 8708 ± 
617 
33 
4.19a § Br 
(CH2)4CONH 
(CH2)8NHAc 
28.0 ± 2.9 
>10000 
25.2 ± 5.0 
>10000 - 
4.19b † Br 
(CH2)4CONH 
(C2H4O)2NHAc 









22.5 ± 3.2 
>10000 
18.6 ± 5.3 
>10000 - 





34.6 ± 1.3 
>10000 




- - - 51.0 ± 3.0 - 5628 ± 
2890 
110 
a Radioligand binding assays performed with [3H]CP55,940 (2.5 nM) and HEK293-hCB2 or -hCB1 
membranes. Data is the mean of at least three or c two individual experiments performed in triplicate.  
b Percentage displacement of [3H]CP55,940 by test compound (10 µM). Raw data was normalised to 
the specific binding window (unlabelled CP55,940 (10 μM), 100%; vehicle control, 0%).  
d Ki calculated using [3H]CP55,940 Kd = 3 nM at hCB2 or 2 nM at hCB1 receptor. For compounds 
showing <50% displacement of [3H]CP55,940 at 10µM, the D’Agostino & Pearson normality test and 
a one sample t-test was used to determine if significant competition with [3H]CP55,940 had occurred 
(Ki >10 µM).  
e SI = KiCB1/KiCB2. 
† Compounds were tested as approximately a 50:50 mixture of cis and trans isomers 
§ Compounds were tested as a 57:43 or 40:60 mixture of cis and trans isomers, which are unassigned. 
See experimental Chapter 7.  
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Unfortunately, none of the longer pharmacophore linkers (4.19a and 4.19b) or final 
fluorescent compounds (4.20a and 4.20b) showed good affinity for hCB2 receptor. The 
two linkers of compounds 4.19a and 4.19b were of identical length and it is possible 
that this linker length was either too long or too short to allow favourable positioning of 
the fluorescent dye whilst still allowing the pharmacophore to bind to the receptor. It is 
also possible, in light of these results, that the N1 position is in fact a poor choice for 
linker and fluorophore conjugation regardless of linker length or type. It was pleasing 
to see that all compounds tested in this series showed minimal affinity at hCB1 receptor, 
in agreement with literature results for 4.8 and other similar scaffolds.  
4.4.2 Forskolin-stimulated cAMP assays 
High affinity hCB2 receptor compounds (4.8, 4.9 and 4.11) were evaluated in a 
concentration response BRET assay measuring forskolin-stimulated cAMP (section 
1.6.2) to determine potency (IC50; Table 14). The response evoked at the highest 
concentration (10 µM) was used to determine efficacy (Emax).  
The HEK293 hCB2 S4 low cell line has high receptor expression and is therefore ideal 
for producing membranes for radioligand binding assays and was also used for the 
cAMP assays carried out on the indole derivatives (sections 2.4.2 and 3.6.2). However, 
due to the high receptor expression levels, often only a small window between vehicle 
and forskolin-stimulated cAMP levels was observed. Therefore, it was decided that the 
lower expressing HEK293-Flp cell line overexpressing hCB2 receptor would be better 
suited for cAMP assays. Pharmacological evaluation of 4.8, 4.9 and 4.11 was carried 
out in both cell lines (Table 14). There are significant differences in the IC50 values 
calculated for the two hCB2 receptor cell lines. However, they both generate the same 
pattern in terms of potency, with the most potent being 4.8, followed by 4.11, then 
SR144528 1.13, and least potent 4.9. There appeared to be only a small variation in 
Emax values between compounds, therefore a one way ANOVA (analysis of variance; 
Tukey’s multiple comparisons test) was performed on the Emax values at hCB2 receptor 
in each cell line to determine if there was any significance to the different efficacy 
values observed. There was a significant difference between the Emax of 4.8 and 4.11 in 
the HEK-Flp hCB2 cell line (p = 0.0277), therefore it can be concluded that the efficacy 
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of 4.8 is greater than 4.11 in the HEK-Flp hCB2 cells. In the hCB2 S4 low cell line, both 
4.9 (p = 0.0064) and 4.11 (p = 0.0008) were found to have significantly higher efficacy 
than SR144528 1.13. There is no significant difference between any of the other 
compound Emax values in either cell line.  
Table 14: Potency (IC50) and efficacy (Emax) of N-substituted 1,8-naphthyridin based compounds 
determined using a forskolin-stimulated cAMP assay.a 
 hCB2, S4 low line b hCB2, Flp line c hCB1 d 
Compound 
IC50 nM ± 
SEM 
Emax % ± 
SEM e 
IC50 nM ± 
SEM 
Emax % ± 
SEM e 
IC50 nM ± 
SEM 
Emax % ± 
SEM e 
4.8 114 ± 12.2 f 237 ± 6.0 f 46.5 ± 20.2 164.8 ± 8.2 no response 89 ± 5.6 g 
4.9 1764 ± 491 f 257 ± 12.9 f 584 ± 62.9 f 161 ± 5.0 f 2085 ± 729 134 ± 4.4 
4.11 463 ± 41.3 f 269 ± 11.3 f 91.8 ± 49.0 139 ± 4.2 1235 ± 486 126 ± 3.2 
SR144528 
1.13 
760 ± 61.7 f 227 ± 2.2 132 ± 24.1 153 ± 3.8 no response 108 ± 3.6 g 
a cAMP levels measured in a BRET assay using a CAMYEL sensor, performed in either b HEK293-
hCB2 S4 low cells, c HEK-Flp hCB2 cells or d HEK293 hCB1 pEF4A cells.  
e Emax is the response at 10 µM, normalised to basal (0%) and forskolin only (100%) levels of cAMP.  
All values represent the mean ± SEM of at least three independent experiments conducted in duplicate, 
except f are two independent experiments performed in duplicate.  
A one sample t-test was used to determine if Emax values were significantly different from forskolin 
only values (100%) and for g no significant difference was found, therefore the compounds were 
determined to show no response under the assay conditions.  
 
All three compounds evaluated were found to be inverse agonists for hCB2 receptor, in 
agreement with the literature for 4.8 and as speculated for the C6-substituted 
compounds 4.9 and 4.11. The literature compound, 4.8 showed the highest potency of 
the series. However, the lead compound for further development of this series, 4.11, 
showed potential in the functional assay, demonstrating greater potency at hCB2 




Figure 60: IC50 curves for forskolin-stimulated cAMP at hCB2 receptor (S4 low line). Values shown are 
mean ± SEM from one independent experiment conducted in duplicate. Values have been normalised to 
basal (0%) and foskolin only response (100%).  
Comparing 4.9 and 4.11, it is interesting to note that the substitution of bromine for p-
methoxyphenyl at C6, leads to a large increase in potency (Table 14). At hCB1 receptor, 
4.9 and 4.11 were found to have low potency, whilst 4.8 and SR144528 1.13 showed 
Emax values close to the forskolin only response (100%) and using a one sample t-test, 
were determined as showing no response.  
The hCB2 receptor IC50 of 4.8 in the HEK-Flp cell line compares well with the 
literature value of 59.6 nM.145 However, it is worth noting that the literature study uses 
a different cell line (U2OS cell line), and therefore a comparison is of limited 
significance, due to variables in expression of both CB2 and endogenously expressed 
receptors.  
All compounds were screened in a BRET forskolin-stimulated cAMP assay in WT 
HEK293 cells to verify that the response observed at hCB2 and hCB1 receptor was 
receptor mediated (Table 15). The compound cAMP responses were normalised to 
basal (0%) and forskolin only (100%) response, and then analysed in a one sample t-
test to determine if the compound responses were significantly different from the 
forskolin only response. Compounds 4.8 and 4.11 showed no significant response in 
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both the WT S4 low line and WT HEK-Flp line, verifying that the inverse agonist 
activity observed for these compounds is indeed receptor mediated. However, 4.9 
showed a significant response in the S4 low line at 10 µM, but when screened at 1 µM, 
showed no significant response. As 4.9 shows a significant response at 1 µM in the S4 
low hCB2 line, it can be concluded that the inverse agonist activity observed is hCB2 
receptor mediated. However, as 4.9 was not tested at 1 µM in HEK293 cells 
overexpressing hCB1 receptor, it cannot be concluded whether the inverse agonist 
activity observed at hCB1 is receptor mediated. SR144528 1.13, CP55,940 1.10 and 
WIN 55,212-2 2.2 were also screened for activity in WT cells. SR144528 1.13 and 
CP55,940 1.10 demonstrated no significant response in either cell line. WIN 55,212-2 
2.2 showed a response at 10 μM in the HEK-Flp line but not the S4 low line. It is 
interesting to note that the response of WIN 55,212-2 2.2 is observed in a different cell 
line to that of 4.9, indicating that the responses are likely to be mediated by different 
pathways in the WT cells.  
Table 15: Forskolin stimulated cAMP response in WT HEK293 cells. a  
 % response ± SEM, S4 low line % response ± SEM, Flp line 
Compound 10 µM 1 µM 10 µM 1 µM 
4.8 114.9 ± 8.2 103.0 ± 2.0 109.5 ± 3.9 95.8 ± 4.7 
4.9 121.5 ± 3.5 * 95.7 ± 3.6 100.6 ± 3.0 94.3 ± 2.2 
4.11 107.2 ± 2.8 97.9 ± 2.6 97.4 ± 3.3 96.4 ± 1.9 
CP55,940 1.10 98.0 ± 4.0 99.2 ± 2.7 90.1 ± 5.5 91.4 ± 3.1 
SR144528 1.13 94.5 ± 1.6 99.8 ± 2.2 97.4 ± 5.9 98.5 ± 3.8 
WIN 55,212-2 2.2 102.6 ± 2.1 96.1 ± 1.0 87.2 ± 2.9 * 90.1 ± 4.6 
a cAMP levels measured in a BRET assay using a CAMYEL sensor. Data represent mean values ± 
SEM for at least three independent experiments conducted in duplicate. Values are normalised to basal 
(0%) and forskolin (100%) response. Data was analysed for normality in a D’Agostino & Pearson 
normality test and then analysed using a one sample t-test for significant difference to forskolin only 





4.5 Molecular modelling 
Ligand docking studies were carried out using the CB2 receptor homology model B, 
based on the crystal structure of inverse agonist-bound CB1 receptor (PDB ID: 5U09),
67 
generated as previously described in Chapter 3 (section 3.7.1.2). Ligands 4.8, 4.9, 4.10 
and 4.11 were all docked into the CB2 receptor homology model B in an attempt to 
understand the differences in CB2 receptor affinity observed during pharmacological 
testing.  
The orientation of the docked cis-4.8 was compared with that of the antagonist and 
inverse agonist present in the two published inactive CB1 receptor crystal structures.
66, 
67 The naphthyridin core rings of cis-4.8 partially overlaps with aromatic rings in both 
taranabant and AM6538, whilst the C6-bromine overlaps with the chlorine atom in 
taranabant and the C3-carboxamide also overlaps with the carboxamide in taranabant 
(Figure 61).  
 
Figure 61: Orientation of docked cis-4.8 (pink) in CB2 receptor homology model B overlapped with the 
inverse agonist taranabant (orange) and antagonist AM6538 (purple) from CB1 receptor crystal 
structures. Image viewed from above the receptor, down from the extracellular space. Receptors have 
been hidden for clarity.  
The arrangement of the residues F87, K109, F117, W194, W258 and S285 in the CB2 
receptor homology model generated by Lucchesi et al (built using an inactive 
Rhodopsin crystal structure)145 matches up well with the arrangement of these residues 
in the CB1 receptor-based homology model generated in this study. Docking poses of 
153 
 
cis-4.8 and cis-4.9 were clustered into two groups, with the most consistent poses (three 
out of five and six out of ten, respectively; Figure 62) showing the C6-bromine buried 
deep in the ligand binding pocket, orientated close to residue W258, which is in 
agreement with the findings of Lucchesi et al for the 1,8-naphthryridin scaffold.145  
 
Figure 62: Clusters of the most consistent docking poses for (A) cis-4.8 and (B) cis-4.9 in hCB2 receptor 
homology model B. The C6-bromine of both atoms comes into close proximity with residue W258. Side 
chains of residues within 4 Å of cis-4.8 and cis-4.9 are shown as sticks (pale blue). The N-terminal is 
hidden for clarity. 
Docking poses of trans-4.8 were also clustered into two groups and the most consistent 
pose (four out of five) showed significant shift in orientation from the cis isomer 
(Figure 63), which could explain the significant difference in affinity typically 
observed303 between the cis and trans isomers of the N-(4-methylcyclohexyl)-1,8-




Figure 63: Overlap of the most consistent, lowest energy docking poses for cis-4.8 (raspberry) and trans-
4.8 (pale pink), showing significant shift in the positioning of the core naphthyridin rings and C6-
bromine substituent. Side chains of residues within 4 Å of cis- or trans-4.8 are shown as sticks (pale 
blue). The N-terminal is hidden for clarity.  
The docking poses of cis-4.8 and cis-4.9 showed almost an exact overlap with each 
other (Figure 64). However, all four clusters of docking poses for cis-4.10, showed a 
significant alteration in the orientation of the core rings when compared to cis-4.8 and 
cis-4.9. In the most consistent pose (seven out of ten), the 4-methylcyclohexyl group of 
cis-4.10 still points in the same direction, but the C6 and N1 groups have effectively 
swapped positions, with the N1-methylbenzoate pointing towards residue W258 
(Figure 65). The presence of the bulky methylbenzoate group at N1 may force a less 
favourable orientation of the core rings, resulting in the loss of CB2 receptor affinity 




Figure 64: Overlap of the most consistent, lowest energy docking poses of cis-4.8 (raspberry) and cis-4.9 
(green). Side chains of residues within 4 Å of cis-4.8 or cis-4.9 are shown as sticks (pale blue). The N-
terminal is hidden for clarity. 
 
Figure 65: The most consistent docking poses of cis-4.10, showing a significant shift in orientation from 
other derivatives. Side chains of residues within 4 Å of cis-4.10 are shown as sticks (pale blue). The N-
terminal is hidden for clarity. 
It was not possible to achieve consistent docking poses with cis-4.11, which produced 
nine different poses. However, the highest ranked solution showed the p-MeOPh group 
at C6 pushed down into the receptor pocket, but pointing in a significantly different 
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position to the C6-bromine of cis-4.9 (Figure 66). It is somewhat expected that such a 
large group as p-MeOPh would lead to a significant shift in ligand orientation, 
however, it is difficult to draw conclusions from the docking of cis-4.11 due to the 
inconsistency in poses. Docking of cis-4.11 was also attempted in CB2 receptor 
homology model C, built from the other CB1 receptor crystal structure (PDB ID: 
5TGZ;66 see section 3.7.1.2 for description of model), however, docking poses were 
just as inconsistent.  
 
Figure 66: The lowest energy docking poses of cis-4.9 (green) and cis-4.11 (brown). Side chains of 
residues within 4 Å of cis-4.9 and are shown as sticks (pale blue). The N-terminal is hidden for clarity. 
Consistently, across the ligand docking studies of 4.8, 4.9 and 4.11, the N1-alkyl group 
has protruded sideways towards TMH2 and TMH3, whereas in docking studies 
conducted by Lucchesi et al,145 N1 substituents of analogues appeared to point 
upwards. If the N1 substituents in 4.8, 4.9 and 4.11 do indeed point sideways in the 
ligand binding site, that might explain why linker and dye conjugation was not tolerated 
at the N1 position. Interestingly, in the docking studies described here, the 4-
methylcyclohexyl substituent appears to slightly protrude through a gap between 




1,8-Naphthyridin-2(1H)-one-3-carboxamide was chosen as a scaffold for development 
of fluorescent ligands because of the many high affinity, CB2 receptor selective 
compounds already identified within this compound class, as well as the well-defined 
functional switch with C6 substitution. The relatively low lipophilicity of this scaffold 
also made it an attractive target for development into a fluorescent ligand with 
potentially reduced hydrophobicity and therefore reduced non-specific membrane 
binding. A series of 1,8-naphthyridin-2(1H)-one-3-carboxamide based compounds were 
synthesised, exploring variation of the N1 and C6 groups, as well as linker and 
fluorescent dye conjugation via an N1-alkyl group. Aliphatic methyl valerate was 
identified as a promising N1 substituent for extension, whilst the aromatic methyl-4-
methylbenzoate substituent (4.10) had poor CB2 receptor affinity. Substitution of a p-
methoxyphenyl group at C6 (4.11) showed improved CB2 receptor affinity over the 
bromine substituted analogue (4.9). However, extension of the methyl valerate by 
conjugation of a linker and fluorophore only produced ligands with CB2 receptor Ki 
>10 μM. Docking studies of the pharmacophore intermediates suggested that the poor 
affinity of the fluorescent ligands could be due to the N1-alkyl group orientating into 
the ligand binding pocket, rather than extending out as initially thought based on 
literature biological activity. Considering both the biological results and modelling 
results, it was decided to abandon linker extension at the N1 position of the scaffold 




 Chapter Five: Fluorescent ligands for CB2 
receptor based on C3-carboxamide cyclohexyl-
substituted 1,8-naphthyridin 
Evaluation of the N-substituted 1,8-naphthyridin based compounds synthesised in 
Chapter Four indicated that N1 was not an appropriate position for linker and 
fluorophore substitution (Figure 67). However, subsequent ligand docking studies on 
these compounds suggested that the 4-methylcyclohexyl substituent may protrude out 
of the orthosteric binding pocket though a gap between TMH1 and TMH7 and therefore 
may be a suitable alternative position for conjugation of a fluorescent dye. This chapter 
explores that hypothesis in the design, synthesis and pharmacological evaluation of 
fluorescent C3-carboxamide cyclohexyl-substituted fluorescent ligands.  
 




5.1 Ligand docking studies 
Ligand docking studies using R state CB2 receptor homology model B (section 3.7.1.2) 
were carried out to explore how linker extension from the 4-methylcyclohexyl group 
would affect the docked ligand orientation. Ligands were built in Avogadro315 with an 
ethylmorpholino at N1 and a p-methoxyphenyl group at C6. Whilst these two groups 
were not used in combination in any of the Chapter Four ligands, they were the 
favoured groups at their relative positions and they have been used in combination in 4-
methylcyclohexyl literature derivatives (e.g. Table 12, entry 38, 1.16).145 Replacement 
of the 4-methylcyclohexyl with a 4-cyclohexanol was explored along with linker 
extension from the hydroxyl (Figure 68-71).  
Cis- and trans-cyclohexanol derivatives 5.1a and 5.1b (Figure 68A) were docked into 
the CB2 receptor homology model (Figure 68B & C) and the most consistent poses 
were in a similar orientation to the 4-methylcyclohexyl and C6-methoxyphenyl 
derivative 4.11 in Chapter Four (Figure 66). The presence of a hydroxyl group at the 
cyclohexyl instead of a methyl did not appear to significantly alter the preferred 
docking position of the core naphthyridin rings, indicating that this chemical change 
may be tolerated. The cyclohexyl hydroxyl groups of 5.1a and 5.1b appeared to 
protrude through a gap in the surface of the homology model between TMH1 and 2 
(Figure 68C), whereas the methylcyclohexyl derivatives in Chapter Four, protruded 
through the gap between TMH1 and TMH7. It is unclear whether this change is due to 
the replacement of the methyl with a hydroxyl, or the presence of N1-ethylmorpholino 
and C6-methoxyphenyl in combination. The trans-hydroxyl of 5.1a appeared to point 
directly out of the opening between the TMHs, whereas the cis-hydroxyl pointed 
towards receptor residues, suggesting that trans derivatives may be more amenable to 




Figure 68: The most consistent, lowest energy poses of cis-(blue) and trans-(gold) cyclohexanol 
containing derivatives 5.1a and 5.1b into inactive state CB2 receptor homology model B. Side chains of 
residues within 4 Å of the ligands are shown as sticks (pale blue).  
Docking of ligands with linkers (such as an ethanoic acid 5.2, a methyl valerate 5.3 or a 
hexylamide 5.4) extended from the trans-cyclohexanol groups resulted in the same 
orientation as the smaller trans-5.1a, with the linker moiety still protruding out of the 
orthosteric binding pocket between TMH1 and TMH7 (Figure 69). Extension of the 
trans-ethanoic acid 5.2 by conjugation of a PEG (NH(C2H4O)2C2H4NHAc) linker (5.5) 
was also tolerated, with the ligand docking into the same orientation, with just the 
ethylmorpholino group slightly rotated (Figure 69). However, extension of the trans-
ethanoic acid by conjugation of an alkyl (NHC8H16NH) linker disrupted the docked 
orientation of the ligand, with the methoxyphenyl group pointing up towards the ECLs, 
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whilst the alkyl linker exited the orthosteric binding pocket between TMH1 and TMH2 
further down into the lipid bilayer. It would be expected that the hydrophobic alkyl 
linker would be strongly favoured to bind in the lipid bilayer (and the hydrophobic 
portion of the lipid-buried receptor surface) and this presumably caused the disruption 
to docking orientation of the core ligand.  
 
Figure 69: Ligand docking exploring linker extension of trans derivatives with an ethanoic acid 5.2 
(cyan), a methyl valerate 5.3 (salmon), a hexylamide 5.4 (white) or an acylated PEG linker conjugated to 
the ethanamide (5.5, yellow), using CB2 receptor homology model B. Docking poses shown are 
representative of the lowest energy, most consistent poses generated. Side chains of residues within 4 Å 
of the ligands are shown as sticks (pale blue).  
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It was promising to see the linkers protrude into the lipid bilayer, as this may allow for 
favourable lipid-mediated ligand entry (Figure 70).  
 
Figure 70: Top view of CB2 receptor homology model B with trans derivatives 5.2-5.5 docked, showing 
the linkers protruding into the lipid bilayer (viewed from the extracellular space).  
Unexpectedly, docking of the analogous ethanoic acid 5.6, methyl valerate 5.7 or 
hexylamide 5.8 cis-linked derivatives resulted in significantly different positioning of 
the naphthyridin core, with the linkers buried in the orthosteric binding pocket, whilst 
the C6 methoxyphenyl and N1-ethylmorpholino both protruded out of the orthosteric 
binding pocket (Figure 71). Docking of cis derivatives with an acylated PEG or alkyl 
chain conjugated to the ethanamide moiety consistently produced poses in which the 
linkers were within the orthosteric binding pocket, whilst the core ligand and N1 and 
C6 groups were almost entirely in the extracellular space or lipid bilayer. Docking of 
these ligands in CB2 receptor homology model C did not show any improvement in the 




Figure 71: Ligand docking exploring linker extension of cis derivatives with an ethanoic acid 5.6 (cyan), 
a methyl valerate 5.7 (salmon) or a hexylamide 5.8 (green), using CB2 receptor homology model B. 
Docking poses shown are representative of the lowest energy, most consistent poses generated. Side 




5.2 Ligand design 
It was fortunate that between the large body of published SAR and the work carried out 
in Chapter Four, a favourable design of the core ligand had already been elucidated. 
Therefore the fluorescent ligand design focused on exploring linker type and length.  
5.2.1 Core ligand 
The most favourable N1 group amongst the compounds synthesised in Chapter Four 
was the ethylmorpholino (4.8), which conferred high affinity and selectivity and has 
also been successfully utilised in published CB2 receptor ligands.
145 At C6, 
methoxyphenyl was favoured over bromine (in N1-methylvalerate derivatives 4.9 and 
4.11). Therefore, the core ligand was designed to possess N1-ethylmorpholino and C6-
methoxyphenyl (Figure 72).  
 
Figure 72: Fluorescent ligand design for cyclohexylcarboxamide substituted series. Ligands were 
designed to possess various combinations of cis- or trans-cyclohexyl moieties with either ethanamide or 
pentanamide and alkyl or PEG chains.  
5.2.2 Linker attachment 
The significant differences observed between docking poses of cis and trans linker 
derivatives raised an interesting design question regarding which isomers should be 
synthesised. The cis isomers of methylcyclohexyl N-substituted 1,8-naphthyridin 
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derivatives are consistently favoured in the literature over the analogous trans 
isomer,145, 303 but the docking studies (Figure 68 - 71) appeared to indicate that trans 
derivatives may be favoured for linker extension. Whilst published studies provide 
indisputable evidence in favour of cis-methylcyclohexyl isomers, there is no biological 
data reported for compounds possessing any groups other than methyl at the 4-
cyclohexyl position. It is reasonable to expect that extension and substitutions of the 
methyl would have a significant effect on CB2 receptor binding. However, it is also 
important to consider the limitations of the docking studies, which uses a CB2 receptor 
homology model based on CB1 receptor, which has considerable differences in 
sequence identity and presumable secondary structure. In addition, the type of docking 
studies carried out here, whether with a crystal structure or homology model, utilise a 
static structure, whereas in reality GPCRs are highly flexible and dynamic. Therefore, it 
seemed prudent to design a ligand library containing both cis and trans isomers.  
Modification of the 4-methylcyclohexyl substituent was necessary to allow for linker 
conjugation and was guided by the commercial availability of 4-substituted 
cyclohexylamino based reagents and the ligand docking studies carried out in section 
5.1. The methyl of methylcyclohexyl was replaced with an oxygen because this was 
tolerated in ligand docking studies, the requisite reagents (cis- or trans-4-
aminocyclohexanol) were commercially available and the oxygen would allow for 
conjugation of linkers (Figure 72).  
5.2.2.1 Planned linkers 
As a way of exploring varying linker length, an ethanamide and a pentanamide moiety 
were planned for attachment at the 4-cyclohexanol, which would utilise reagents 
already available in the lab and was tolerated in ligand docking studies on trans 
derivatives (section 5.1). The ethanamide and pentanamide could be easily extended 
with linkers of varying polarity such as an alkyl (2.28a) or PEG (2.28b) linkers (Figure 
72). However, a problematic synthesis meant that this intended design was not achieved 
(see section 5.3.2).  
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5.2.2.2 Linkers prepared 
An alternative design was proposed whereby a glycine or an aminoheptyl moiety was 
attached, followed by conjugation of the fluorophore (Figure 73). At the time of this 
redesign there was only a short period remaining in which synthesis could be 
completed. This strict schedule along with the availability of reagents in the lab were 
the primary influences on the designs selected, which is discussed further in section 
5.3.2.  
 





5.3.1 Core ligand 
The N1 and C6 substituents were kept constant in this series and the first point at which 
the compounds diverged was in attachment of a cis- or trans-cyclohexanol group. 
Therefore, the synthetic route for the core ligand was reordered from that carried out in 
Chapter Four (where the cyclohexyl group was attached first, followed by N1 and C6 
substituents), so that divergence was delayed until the last possible step, to reduce the 
number of reactions carried out.  
Synthesis proceeded from 4.14 (Scheme 10), which was N-alkylated on a small scale 
(20 mg of 4.14) with 4-(2-chloroethyl)morpholinhydrochloride and recrystallised in 
acetonitrile (ACN) to give the ethylformate 5.10a (41%). However, when this reaction 
was repeated at a larger scale (6.08 g of 4.14) the reaction mixture got wet, which 
combined with the basic conditions led to partial ester hydrolysis of the ethylformate 
5.10a. The crude residue precipitated in ACN therefore yielding 5.10a and 5.10b as a 
1:3 mixture (Scheme 12, step i). It was anticipated that Suzuki coupling of 5.10a with 
4-methoxyphenylboronic acid would lead to complete hydrolysis of the ester anyway 
due to the use of aqueous basic conditions therefore the mixture of 5.10a and 5.10b was 
not purified. The 1:3 mixture of 5.10a/5.10b carried into the Suzuki coupling reaction, 
however afforded a 1:15 mixture of the ethylformate (5.11a) and the carboxylic acid 
(5.11b) (Scheme 12, step ii). The 5.11a/5.11b 1:15 mixture was subjected to hydrolysis 
conditions using 0.2 M aq. lithium hydroxide monohydrate to give the carboxylic acid 
5.11b in pure form (Scheme 12, step iii). Coupling of the carboxylic acid 5.11b with 
either trans- or cis-4-aminocyclohexanol gave the carboxamides 5.1a or 5.1b 
respectively, which were purified by precipitation in ACN in good yield (79-82%; 




Scheme 12: Synthesis of 5.1a and 5.1b. Reagents and conditions: (i) 4-(2-
chloroethyl)morpholinhydrochloride, Cs2CO3, DMF, 50°C, 12 h, 41% (for ethylformate 5.10a only 
formation); (ii) 4-methoxyphenylboronic acid, Na2CO3, Pd(OAc)2, H2O, DMF, 110°C, 3 h; (iii) 0.2 M 
aq. LiOH.H2O, THF, 0°C, 1 h; (iv) trans- or cis-4-aminocyclohexanol, DIPEA, HATU, DMF, rt, 14 h, 
79-82%.*****  
                                                 




5.3.2 Linker and fluorophore 
The next step was attempted installation of a mini-linker, via reaction with tert-
butylbromoacetate or methyl-5-bromovalerate. Alkylation of the cyclohexanol of 5.1a 
and 5.1b with tert-butylbromoacetate was attempted using Williamson ether conditions 
using 2 eq. of NaH in DMF at 60°C, however this yielded only minimal product 5.12a 
or 5.12b (Scheme 13, reaction i.). Most of the starting material (5.1a, 5.1b) appeared to 
have broken down, possibly as a result of the harsh NaH base. The same reaction on 
5.1a was attempted again using 3 eq. of CsCO3 as the base, however, this also yielded 
insufficient product 5.12a (reaction ii.). The high pKa of the cyclohexanol likely 
required a very strong base for deprotonation, so the reaction was attempted with NaH 
again, but with batch wise addition of the NaH (1 eq., then 1 eq. again) to try to reduce 
breakdown of starting material (reaction iii.), however, this attempt was no more 
successful than the first attempt with NaH. Changing the solvent was not considered as 
the polar, aprotic DMF should have favoured the alkoxide nucleophile over the 
hydroxyl. Bulky alkoxides such as the deprotonated cyclohexanol can sometimes 
favour E2 elimination over SN2 reactions.316 Therefore, the reaction of 5.1a and 5.1b 
with methyl-5-bromovalerate using batch wise addition of NaH (1 eq., then 1 eq. again) 
was carried out at room temperature to favour the SN2 reaction (reaction iv.). 
Monitoring of the reaction by MS showed a high conversion rate of starting material to 
a product with the desired molecular mass. However, NMR spectra of the isolated 
product indicated that the methyl valerate had added to the aromatic ring at the C4 
position yielding products (suspected to be 5.13a and 5.13b) with the exact same mass 
as the intended product 5.3 and 5.7. If other potential linker positions were explored in 




Scheme 13: Attempted alkylation of cyclohexanol. Reagents and conditions: (i) tert-butylbromoacetate, 
NaH, DMF, 60°C, 3 h; (ii) CsCO3, DMF, 60°C, 14 h; (iii) tert-butylbromoacetate, batch wise addition of 
NaH, DMF, 60°C, 14 h; (iv) tert-butylbromoacetate, batch wise addition of NaH, DMF, rt, 14 h.  
It seems that the pKa (calculated to be 15.43)
††††† of the hydroxyl of 5.1a and 5.1b was 
perhaps too high for deprotonation and the conditions utilised were too harsh for the 
rest of the molecule. An alternative synthetic route to install small linkers onto the 
cyclohexanol could be to first alkylate the cis- or trans-4-aminocyclohexanol and then 
couple to the carboxylic acid 5.11b to form 5.12a-b, 5.3 and 5.7. This proposed route is 
illustrated for the synthesis of 5.12a (Scheme 14). Harsh conditions would still have to 
be used for the alkylation of the hydroxyl as the pKa (15.26)
‡‡‡‡‡ of the trans-4-
aminocyclohexanol 5.14 hydroxyl is not so dissimilar to that of the hydroxyl of 5.1a. 
Therefore, it is probable that the amino group of 5.14 would first need to be protected. 
                                                 
††††† pKa values for the hydroxyl of 5.1a and 5.1b and  
‡‡‡‡‡ 4-aminocyclohexanol 5.14 were calculated in Marvin Sketch 17.2.27, ChemAxon Ltd.  
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The amino protecting group would need to be non-labile under the strong basic 
conditions needed for alkylation and it also could not be deprotected using acidic 
conditions, as that would cleave the tert-butyl group of the tert-butylacetate mini-linker. 
Therefore, a potential protecting agent could be benzylchlorofomate, to form the 
carboxylbenzyl (Cbz) protected 5.15. Alkylation of 5.15 with tert-butylbromoacetate to 
form 5.16 could be followed by hydrogenation to cleave the Cbz group, revealing the 
amine 5.17, ready for coupling with the carboxylic acid 5.11b to form 5.12a. The major 
drawback to this route is the number of synthetic steps required and the early 
divergence of the cis and trans isomers, meaning that synthesis of 5.12a-b, 5.3 and 5.7 
from 5.11b would require 14 reactions versus the six reactions required in the original 
attempted route. This synthetic route was considered, however time constraints and the 
length of the synthetic route, combined with insufficient supplies of 5.11b, meant that it 
was not feasible to attempt this synthesis. It would be interesting to attempt this 
proposed synthetic route to 5.12a-b, 5.3 and 5.7 in future work.  
 
Scheme 14: Proposed alternative route for alkylation of trans-4-aminocyclohexanol to form 5.12a.  
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As synthesis of the original ligand design (5.12a-b, 5.3 and 5.7) was not possible, an 
alternative design was sought that would enable evaluation of the cyclohexanol as a 
position for linker and fluorophore conjugation. Derivatising of the cyclohexanol 
required a reaction where it did not matter that the hydroxyl was a poor nucleophile. 
Converting the hydroxyl to either a bromine or a mesylate was considered, as these 
groups could then be reacted with a hydroxyl functionalised linker. However, this 
reaction would then be relying upon the likely poor nucleophilic character of the linker 
hydroxyl.  
Conjugating an activated carboxylic acid to the hydroxyl of 5.1a and 5.1b to form an 
ester would be a relatively straightforward reaction, which could be carried out quickly. 
The major drawback of this approach is that an ester would not usually be desirable in a 
fluorescent ligand due to the potential for hydrolysis. However, methyl esters had been 
demonstrated to be stable under the assay conditions (section 3.6.1, page 96) and this 
design would at least enable evaluation of some compounds with linkers and dyes 
conjugated to the cyclohexyl group as a proof of concept. Boc-glycine and 7-
aminoheptanoic acid 5.18 were readily available in-house and coupling of these as 
linkers to the cyclohexanol would allow for sampling of varying lengths of linker. 7-
Aminoheptanoic acid 5.18 was Boc protected to yield 5.19 (60%; Scheme 15, step i). 
Carbodiimides such as N-ethyl-N’-(3-dimethylaminopropyl)carbodiimide (EDC) are 
commonly used in ester coupling reactions, but can lead to formation of N-acylurea 
side products, reducing product yield, which is especially likely when the alcohol is a 
very poor nucleophile, such as 5.1a or 5.1b.317 Therefore, 
tetramethylfluoroformamidinium hexafluorophosphate (TFFH) was chosen to activate 
the carboxylic acid, as it would be less likely to form side products. Boc-glycine or 
Boc-protected 7-aminoheptanoic acid 5.19 were reacted with TFFH and triethylamine 
to form the activated acyl fluoride prior to 4-dimethylaminopyridine (DMAP) catalysed 
coupling to 5.1a or 5.1b, yielding 5.20a-5.20d (Scheme 15, step ii). The isolated yield 
of 5.20b was particularly low (9%) due to poor conversion of 5.1b to 5.20b. The MS-
ESI of the crude 5.20b showed a large M+H+ peak corresponding to unreacted starting 
material 5.1b. It is interesting to note that the longer, linear, less bulky (at the point of 
reaction) linker (5.19) gave higher yields in the formation of 5.20c and 5.20d (66-80%) 




Scheme 15: Synthesis of linker conjugates and fluorescent ligands. Reagents and conditions: (i) Boc2O, 
dioxane, NaOH, H2O, rt, 14 h, 60%; (ii) Boc-glycine or 5.19, TFFH, Et3N, DMAP, DCM, rt, 14 h, 9-
80%; (iii) TFA, DCM, rt, 1 h, 45-55%; (iv) Ac2O, DIPEA, DCM, rt, 1 h, 96-98%; (v) BODIPY 630/650-
X-OSu 2.15, DIPEA, DMF, rt, 14 h, 72-97%.  
Boc deprotection of 5.20a-d using TFA revealed the amines 5.21a-d (Scheme 15, step 
iii) which were purified by semi-preparative RP-HPLC to obtain maximum purity 
before further reaction. The amines 5.21a-d were then either acetylated (Scheme 15, 
step iv) to yield 5.22a-d or conjugated to BODIPY 630/650-X-OSu 2.15 to yield 
fluorescent ligands 5.9a-d (step v). The acetylated 5.22a-d and fluorescent ligands 
5.9a-d were purified by semi-preparative RP-HPLC.   
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5.4 Pharmacological evaluation 
Two pharmacophores (5.1a, 5.1b) four pharmacophore-linker conjugates (5.22a-d) and 
four final fluorescent compounds (5.9a-d) were subjected to pharmacological 
evaluation. Radioligand binding assays were carried out to determine affinity at hCB2 
and hCB1 receptors and compounds with high affinity at CB2 receptor were tested in 
cAMP assays to determine function (refer to section 1.6).  
5.4.1 Radioligand binding assays 
A competition binding screen was used to identify which compounds at a fixed 
concentration of 10 µM could displace more than 50% of bound [3H]CP55,940 1.17 at 
hCB2 and hCB1 receptors (Figure 74). All compounds, apart from 5.22a and 5.9c 
displaced more than 50% of radioligand at hCB2 receptor. It was gratifying to observe 
that all compounds showed low displacement of [3H]CP55,940 1.17 at hCB1 receptor, 
indicating CB2 receptor subtype selectivity. Statistical analysis using the D’Agostino 
and Pearson normality test and a one sample t-test was carried out to determine whether 
compounds which displaced less than 50% of the radioligand showed significant 
binding at CB1 and CB2 receptors. All compounds demonstrated significant binding at 
CB1 receptor (Ki = >10 µM), apart from 5.1a and 5.22a which both failed the normality 
test (Table 16). Linker-pharmacophore 5.22a showed significant binding at CB2 




Figure 74: Combined results of competition binding screens showing displacement of [3H]CP55,940 (1 
nM) at HEK293-hCB2 (7.5 µg/point; black) and -hCB1 (5 μg/point; grey) membranes by a fixed 
concentration (10 µM) of test compound. Raw data was expressed in ccpm and normalised to unlabelled 
CP55,940 (10 μM) (100%) and vehicle control (0%). Data shown is the mean value ± SEM of three 
independent experiments conducted in triplicate, except for 5.1a, 5.22c, 5.9a and 5.9d at hCB2, where n 
= 2 and 5.1b, 5.22b, 5.22d and 5.9b at hCB2, where n = 1. The dashed line indicates the 50% 
displacement criteria for progression to concentration response assays.  
All of the compounds that showed greater than 50% displacement of radioligand at CB2 
receptor were subjected to concentration response assays to determine Ki values (Table 
16). Amongst these compounds were three fluorescent ligands 5.9a, 5.9b and 5.9d, of 
which the fluorescent glycine conjugate 5.9b showed particularly high displacement 
(90.2 ± 0.7%) of [3H]CP55,940 1.17. Concentration response assays determined the 
highest affinity compound amongst the series was fluorescent ligand 5.9b which had a 
Ki = 467 ± 20.0 nM at hCB2 receptor and >21-fold selectivity over CB1 receptor (Table 
16). Fluorescent ligand 5.9b represents a high affinity, selective fluorescent ligand for 
CB2 receptor and fulfils the central aim of this thesis and the significance of this result 
will be discussed in more depth on page 179.  
Cis isomers of the pharmacophore, pharmacophore-linkers and fluorescent ligands 
consistently showed higher affinity for CB2 receptor than the analogous trans isomers, 
sometimes as much as ten-fold (5.22b vs 5.22a and 5.9b vs 5.9a). This pattern was 
contrary to what was predicted by ligand docking studies, which showed trans linkers 
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positioned more favourably for fluorescent dye conjugation. However, cis-4-
methylcyclohexyl derivatives have been shown to be favoured in literature reports.145, 
303 It was interesting that substitution of the cis-4-methylcyclohexyl for a cis-4-
cyclohexanol or even an extended cis-4-cyclohexyl ester linker still resulted in cis 
derivatives being favoured (section 4.1.1, pg 131). The identification of linker 
conjugates and fluorescent ligands with affinity for CB2 receptor showed that the ligand 
docking carried out with a CB2 receptor homology model was a reliable method for 
selecting an appropriate position for linker extension. However, the favoured cis 
isomers demonstrate that the ligand docking studies were perhaps not accurate at 
predicting precise ligand orientations, but nevertheless were a very useful exercise for 
ligand design in this instance.  
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Table 16: Affinity of C3-carboxamide cyclohexyl-substituted 1,8-naphthyridin based compounds for 
hCB2 and hCB1 receptors. a 
 






R 10 µM 
displ. 
[3H]CP 1.17 
(% ± SEM)b 










5.1a Trans H 55.7 ± 1.7 3685 ± 906 12.2 ± 4.2 no 
binding 
- 
5.1b Cis H 70.0 ± 2.8 2249 ± 385 24.8 ± 4.8 >10000 >4 
5.22a Trans C(O)CH2NHAc 45.6 ± 1.9 >10000 20.1 ± 4.3 no 
binding 
- 
5.22b Cis C(O)CH2NHAc 87.8 ± 1.2 1027 ± 68.1 18.2 ± 4.8 >10000 >9 
5.22c Trans C(O)C6H12NHAc 66.2 ± 0.8 3748 ± 478 24.8 ± 2.2 >10000 >2 




56.4 ± 1.5 
5955 ± 840 





90.2 ± 0.7 
467 ± 20.0 






32.4 ± 1.3 
no binding 






57.4 ± 2.8 
7945 ± 668 




- - - 51.0 ± 3.0 - 5628 ± 
2890 
110 
a Radioligand binding assays performed with [3H]CP55,940 (1 nM) and HEK293-hCB2 or -hCB1 
membranes. Data is the mean of at least three experiments performed in triplicate.  
b Percentage displacement of [3H]CP55,940 by test compound (10 µM). Raw data was normalised to 
the specific binding window (unlabelled CP55,940 (10 μM), 100%; vehicle control, 0%).  
c Ki calculated using [3H]CP55,940 Kd = 3 nM at hCB2 or 2 nM at hCB1 receptor. For compounds 
showing <50% displacement of [3H]CP55,940 at 10 µM, the D’Agostino & Pearson normality test and 
a one sample t-test were used to determine if significant competition with [3H]CP55,940 had occurred.  
d SI = Ki(CB1)/Ki(CB2). 
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The glycine linker was clearly favoured for CB2 receptor affinity over the 
aminoheptanoate linker in both the linker conjugates and fluorescent ligands (Table 
16). For instance, the cis-glycine conjugate 5.22b showed a three-fold improvement in 
CB2 receptor affinity over the analogous cis-aminoheptanoate conjugate 5.22d and the 
cis-glycine fluorescent ligand 5.9b showed a 17-fold improvement over the analogous 
cis-aminoheptanoate fluorescent ligand 5.9d. It was somewhat surprising that the 
glycine linker was long enough to allow favourable positioning of both the ligand and 
the fluorescent dye, however the pentyl chain of BODIPY 630/650-X does increase 
linker length between fluorophore and core ligand. The ligand docking studies with the 
original ligand designs (section 5.1) suggested that cyclohexanol substituted linkers 
may exit into the lipid membrane and therefore a linker as short as glycine may allow 
for favourable positioning of the lipophilic pentyl chain and fluorophore in the lipid 
membrane. In addition, the glycine linker conjugates 5.22b and 5.9b possess an ester 
and an amide in close proximity to each other which may both be able to form 
hydrogen bonds with residues located around the ligand binding pocket exit between 
TMH1 and TMH7 and this was explored in later ligand docking studies (see section 
5.5). In contrast the amide of the aminoheptanoate conjugates 5.22d and 5.9d would 
likely be positioned in the membrane or extracellular space and thus may not be able to 
form hydrogen bonds with receptor residues.  
A trend of increasing molecular weight correlating to increased CB2 receptor affinity 
was observed - conjugation of a glycine linker (5.22b) to the cis isomer of the 
pharmacophore (5.1b) improved affinity for CB2 receptor by two-fold, whilst 
conjugation of a fluorophore (5.9b) improved affinity even further (by almost five fold 
cf. to 5.1b; Table 16; Figure 75). Similar observations that a fluorescent ligand has a 
higher affinity for the receptor than the parent pharmacophore have been reported in the 
literature.198, 207, 318 This pattern indicates that the linker and fluorophore are making 
favourable interactions with receptor residues and the membrane and are not latent 




Figure 75: Competition binding curves for 5.1b, 5.22b and 5.9b at hCB2 receptor, determined using 
[3H]CP55,940 (1 nM) and HEK293-hCB2 membranes. Data points are the mean ± SEM of one 
independent experiment conducted in triplicate.  
Identification of the high affinity fluorescent ligand 5.9b (Ki = 467 ± 20.0 nM at hCB2, 
Ki = >10 µM at hCB1 receptor) was an exciting development in this project and 
validated the ligand design of conjugating fluorophores and linkers to the cyclohexyl 
moiety. It is difficult to compare the affinity of 5.9b to existing CB2 fluorescent ligands 
(section 1.5.3.1), as many of these only have affinities reported for mCB2 receptor,
184, 
199, 200, 202, 204 and ligand receptor affinities are known to show dramatic variation 
between species,247 making comparison meaningless. Whilst NIR760-Q 1.26 has an 
affinity reported for hCB2 receptor (Ki = 75.5 ± 28.0 nM),
203 it was determined using a 
fluorescence saturation binding assay, so cannot be reliably compared to the Ki value of 
5.9b determined using a [3H]CP55,940 1.17 competition binding assay. NMP6 1.19 has 
a reported affinity for hCB2 receptor (Ki = 387 nM) which was determined using a 
radioligand binding assay, but in CHO-K1 cells (versus HEK293 cells used here) and 
does not report the Kd value used for [
3H]CP55,940 1.17,201 also prohibiting 
comparison. Several fluorescent ligands for CB2 receptor do not have an affinity value 
reported for CB1 receptor and therefore have undetermined selectivity. The selectivity 
of 5.9b compares favourably to fluorescent ligands which have reported selectivity. For 
example, 5.9b (Ki = 467 ± 20.0 nM at hCB2; 22.5% displacement at 10 µM at hCB1 
receptor) has equal (or higher) selectivity for CB2 receptor than NMP6 1.19 (Ki = 387 
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nM at hCB2, <40% displacement at 10 µM at hCB1 receptor)
201. The biotin tagged HU-
210 1.20 showed high affinity for CB2 receptor, but no selectivity (Ki = 1.6 ± 0.4 nM at 
hCB2, Ki = 2.4 ± 0.4 nM at hCB1 receptor; determined for biotin-HU-210 1.20, not the 
final fluorescent ligand conjugate).87 A fluorescent ligand needs high CB2 receptor 
selectivity for use in mixed receptor population, native cell types. Therefore the good 
selectivity of 5.9b for CB2 receptor over CB1 receptor is a promising indicator for its 
potential as a pharmacological tool.  
5.4.2 Forskolin-stimulated cAMP 
Compounds that showed greater than 50% displacement of [3H]CP55,940 1.17 at CB2 
receptor were analysed for functional activity using a BRET sensor to measure 
modulation of forskolin-stimulated cAMP in whole HEK293 Flp cells overexpressing 
hCB2 or hCB1 receptors (refer to section 1.6.2). Compounds were initially analysed at 
10 µM in the absence of forskolin to assess effect on basal cAMP, and in the presence 
and absence of an EC90 concentration of CP55,940 1.10 to test for antagonism, inverse 
agonism and agonism (Figure 76). All compounds behaved as inverse agonists at hCB2 
receptor, reducing basal signalling levels, whilst 5.1b, 5.22b, 5.22d and 5.9b also 
blocked receptor access of the agonist CP55,940 1.10. Compounds all behaved as 




Figure 76: BRET assay screen measuring effect of compound (10 µM) on forskolin-stimulated (5 µM) 
cellular cAMP levels in HEK293 cells overexpressing (A) hCB2 receptor or (B) hCB1 receptor. 
Compounds were checked for effect on basal cAMP (compound/V/V; light grey) and in the presence 
(compound/Fsk/CP; dark grey) and absence of CP55,940 (compound/Fsk/V; mid grey). Data is the mean 
± SEM of at least three independent experiments conducted in duplicate, except for those marked by * 
are two independent experiments conducted in duplicate or # are one experiment conducted in duplicate. 
Data has been normalised to a percentage of forskolin only response (V/Fsk/V; 100%) and basal response 
(V/V/V; 0%).  
The four compounds with the highest affinity for CB2 receptor (5.1b, 5.22b, 5.22d and 
5.9b) were then subjected to functional concentration response assays at CB2 receptor 
to determine potency as inverse agonists and 5.9b was also tested at CB1 receptor 
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(Table 17). Compounds 5.1b, 5.22b, 5.9b and the literature control SR144528 1.13 all 
showed similar IC50 values at CB2 receptor and statistical analysis by a one way 
ANOVA (Tukey’s multiple comparisons test) showed no significant difference between 
them. In contrast, 5.22d showed a much lower potency (in the micromolar range), 
which is interesting considering it is the only compound with the aminoheptanoate 
linker. It is possible that the aminoheptanoate linker has much less favourable 
interactions with receptor residues for cAMP signalling than the glycine linker. 
Fluorescent ligand 5.9b showed a significantly reduced potency at CB1 receptor (IC50 = 
4252 ± 530 nM) and all compounds showed reduced efficacy at CB1 receptor, 
demonstrating CB2 receptor selectivity. 
Table 17: Potency (IC50) and efficacy (Emax) of C3-carboxamide cyclohexyl-substituted 1,8-naphthyridin 
based compounds determined using a forskolin-stimulated cAMP assay. a 
 hCB2 receptor b hCB1 receptor c 
Compound 
IC50  
nM ± SEM 
Emax  
% ± SEM d 
IC50  
nM ± SEM 
Emax  
% ± SEM d 
5.1a - 160 ± 4.6 - - 
5.1b 211 ± 83.4 156 ± 5.5 - 117 ± 2.4 e 
5.22b 109 ± 28.4 154 ± 5.4 no response 115 ± 6.5 e, f 
5.22c - 165 ± 10.1 - 116 ± 4.4 e 
5.22d 1738 ± 489 179 ± 12.1 - 130 ± 2.6 e 
5.9a - 172 ± 11.1 no response 123 ± 9.9 e, f 
5.9b 221 ± 75.1 210 ± 15.7 4252 ± 530 157 ± 2.1 
5.9d - 201 ± 3.6 - 134 ± 5.8 e 
SR144528 1.13 132 ± 24.1 153 ± 3.8 no response 108 ± 3.6 f 
a cAMP levels measured in a BRET assay using a CAMYEL sensor, performed in either b HEK293-
hCB2 Flp cells or c HEK293 hCB1 S4 low cells.  
d Emax is the response at 10 µM, normalised to basal (0%) and forskolin only (100%) levels of cAMP.  
All values represent the mean ± SEM of at least three independent experiments conducted in duplicate, 
except e which are two independent experiments performed in duplicate.  
A one sample t-test was used to determine if Emax values were significantly different from forskolin 
only values (100%) and for f no significant difference was found, therefore the compounds were 




Comparison of the efficacy (Emax) of compounds at CB2 receptor (Table 17) by a one 
way ANOVA (Tukey’s multiple comparisons test) showed few significant differences 
between them. However, 5.9b showed statistically significant higher efficacy than 5.1a 
(p = 0.0196), 5.1b (p = 0.0021), 5.22b (p = 0.0013) while SR144528 1.13 (p = 0.0020) 
and 5.9d also showed statistically significant higher efficacy than 5.1b (p = 0.0293), 
5.22b (p = 0.0195) and SR144528 1.13 (p = 0.0176). It is interesting that the 
fluorescent ligand 5.9b should show higher efficacy than the analogous linker-
pharmacophore 5.22b and pharmacophore 5.1b, as this demonstrates that the steric bulk 
of the fluorescent dye and linker is not having a negative impact on the efficacy of the 
ligand. It appears that ligand entry into receptor is not impeded by this bulk either.  
The observation that lead fluorescent ligand 5.9b showed a similar IC50 value (221 ± 
75.1 nM) and a higher efficacy at hCB2 receptor than SR144528 1.13 was an excellent 
indicator for its potential use as a pharmacological tool. Published fluorescent ligands 
for CB2 receptor have not reported characterisation of the ligand function through 
signalling assays. However, a selection of fluorescent ligands with varying functions 
would allow for a diversity of applications. An inverse agonist fluorescent ligand such 
as 5.9b could potentially be used in studies of CB2 receptor expression and localisation 
and binding assays.  
The inverse agonist function observed for compounds 5.1a, 5.1b, 5.22b-d, 5.9a, 5.9b 
and 5.9d is in line with literature reports for C6-substituted 1,8-naphthyridin-2(1H)-
one-3-carboxamide derivatives,145 as well as the results observed in Chapter Four.  
All of the compounds (5.1a, 5.1b, 5.22b-d, 5.9a, 5.9b and 5.9d) analysed for function 
were also screened in a cAMP BRET assay in WT HEK293 Flp and WT HEK293 S4 
low cells to verify that the observed effects at CB2 and CB1 receptors were receptor 
mediated (Table 18). The compound cAMP responses were normalised to basal (0%) 
and forskolin only (100%) response, and then analysed in a one sample t-test to 
determine if the compound responses were significantly different from the forskolin 
only response. Compounds 5.1b, 5.22b and 5.22c showed no significant response in the 
WT Flp cells, verifying that the inverse agonist activity observed for these compounds 
at CB2 receptor was indeed CB2 receptor mediated. Compounds 5.1a, 5.22d and 5.9b 
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invoked a small but significant response at 10 μM but not at 1 μM. As 5.22d and 5.9b 
demonstrated a response in HEK293-hCB2 cells at 1 µM, it can be concluded that the 
WT HEK293 Flp cell response is not large enough to have significantly affected the 
calculated CB2 receptor potency. However, as 5.1a was not tested at 1 µM in HEK293-
hCB2 cells, it cannot be definitively concluded that the inverse agonist efficacy 
observed at CB2 is receptor mediated. Fluorescent ligands 5.9a and 5.9d also invoked a 
small but significant response at 10 μM, but were not tested at 1 µM in either WT 
HEK293 Flp or HEK293-hCB2 Flp cells, so it similarly cannot be concluded whether 
the inverse agonist efficacy observed at CB2 is receptor mediated. Fluorescent ligand 
5.9b showed a significant response at 10 µM in the WT HEK293 S4 low cells, but not 
at 1 µM and as 5.9b invoked a response at 1 µM in HEK293-hCB1 S4 low cells, it can 
be concluded that the response observed is CB1 receptor mediated. Linker-
pharmacophore conjugates 5.22b and 5.22d, and fluorescent ligands 5.9a and 5.9d also 
showed significant responses at WT HEK293 S4 low cells. However, as 5.22b and 5.9a 
did not show significant responses at HEK293-hCB1 cells, their response in WT cells is 
of limited concern. Whilst 5.22d and 5.9d did not show a significant response at 1 µM 
in WT S4 low cells, neither compound was tested at 1 µM in HEK293-CB1 S4 low 
cells, so it cannot be absolutely demonstrated that the inverse agonist responses 




Table 18: Forskolin stimulated cAMP response in WT HEK293 cells. a  
 % response ± SEM, Flp line % response ± SEM, S4 low line 
Compound 10 µM 1 µM 10 µM 1 µM 
SR144528 1.13 97.4 ± 5.9 98.5 ± 3.8 94.5 ± 1.6 99.8 ± 2.2 
WIN 55,212-2 2.2 87.2 ± 2.9 * 90.1 ± 4.6 102.6 ± 2.2 96.1 ± 1.0 
CP55,940 1.10 90.1 ± 5.5 91.4 ± 3.1 98.0 ± 4.0 99.2 ± 2.7 
5.1a 118.0 ± 5.1 * 96.5 ± 6.4 c - - 
5.1b 111.9 ± 5.4 95.3 ± 1.4 107.7 ± 4.9 103.0 ± 2.5 b 
5.22b 109.8 ± 5.2 92.2 ± 1.1 121.7 ± 5.0 * 103.8 ± 3.3 b 
5.22c 110.1 ± 5.2 - 127.7 ± 6.2 c - 
5.22d 122.9 ± 6.2 * 98.3 ± 2.5 144.3 ± 10.8 * 107.4 ± 2.7 b 
5.9a 120.9 ± 7.6 * - 142.0 ± 0.4 * c - 
5.9b 139.5 ±10.0 * 100.5 ± 2.5 166.6 ± 11.1 * 105.4 ± 2.9 
5.9d 127.3 ± 4.4 * - 137.8 ± 6.7 * 101.2 ±1.7 b 
a cAMP levels measured in a BRET assay using a CAMYEL sensor. Data represent mean values ± 
SEM for at least three independent experiments conducted in duplicate, except which b are two 
independent experiments conducted in duplicate, or c which is one experiment conducted in duplicate. 
Values are normalised to basal (0%) and forskolin (100%) response. Data was analysed using a one 
sample t-test for significant difference to forskolin only (100%) response and values marked with * 





5.5 Molecular modelling 
The cis-glycine linked 5.22b was docked into homology model C of CB2 receptor, to 
investigate its receptor binding interactions. The docking poses generated were 
clustered into two groups, with the most consistent pose (six out of ten) showing the 
methoxyphenyl group positioned down in the aromatic region between TMH3 and 6 
and the glycine linker pointing out of the orthosteric binding pocket (Figure 77). The 
core naphthyridin rings and the C6 and N1 substituents appear to fill a large portion of 
the orthosteric binding site (Figure 78C). A fluorophore conjugated to 5.22b, such as in 
the lead fluorescent ligand 5.9b, may potentially exit between either TMH1 and 7 or 
TMH1 and 2 (Figure 78B). The methoxyphenyl is able to form a hydrogen bond with 
S292, whilst the phenyl is within 3.0 Å of W258 with which is can engage in aromatic 
stacking or van der Waals interactions (Figure 78A). The glycine linker is able to form 
multiple hydrogen bonds with Q32 of TMH1 and D24 of the amino terminus (Figure 
77). This supports the hypothesis previously postulated - that glycine linkers may be 
favourable over the heptylamide linkers due to the close proximity of the ester and the 
amide groups in glycine, which are both capable of forming hydrogen bonds with 
residues around the exit of the orthosteric binding pocket. In contrast, the amide of the 
heptylamide linked derivatives may be too distant to position favourably for hydrogen 




Figure 77: The lowest energy, most consistent docking pose of the glycine linker-pharmacophore 5.22b 
(cyan) docked into CB2 receptor homology model C. The glycine linker is able to form hydrogen bonds 
(yellow dashed lines) with two amino acid residues (D24 and Q32) located by the exit from the 




Figure 78: The lowest energy, most consistent docking pose of the glycine linker-pharmacophore 5.22b 
(cyan) docked into CB2 receptor homology model C. (A) The ether of the methoxyphenyl is able to 
hydrogen bond (yellow dashed line) with S292 on TMH7, whilst the phenyl is in close range (3.0 Å) of 
W258 on TMH6 for potential π stacking or van der Waals interactions. Side chains of residues within 4 
Å of 5.22b are shown as sticks (pale green). (B) Fluorophore conjugated to the glycine linker (as in 5.9b) 
may exit between TMH1 and TMH7 or TMH1 and TMH2. (C) Glycine linker-pharmacophore 5.22b fills 
the orthosteric pocket of CB2 receptor.   
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5.6 Design and synthesis of a non-ester analogue of 5.9b 
A major concern for the use of 5.9b as a pharmacological imaging tool is the potential 
for hydrolysis of the ester bond between the cyclohexyl group and the glycine. Whilst 
the stability of methyl esters have been demonstrated under the radioligand assay 
conditions, it remains to be seen whether the ester present in 5.9b would be stable 
across the range of temperatures and experiment lengths it could be subjected to during 
CB2 receptor studies.  
5.6.1 Design 
Since 5.9b showed such good biological activity it is now of interest to try to refine the 
design of 5.9b by replacing the ester with a more stable group. An amide was selected 
as a promising substitution for the ester, as it would maintain the carbonyl group in the 
same position, retain similar molecular geometry and the ability to engage in hydrogen 
bonding with receptor residues. However, the reduced flexibility of the amide bond 
compared to the ester, as well as the slight increase in hydrophilicity may affect CB2 
receptor binding.  
5.6.2 Synthesis 
Coupling of the commercially available mono-Boc protected cis-1,4-cyclohexyldiamine 
with 5.11b yielded 5.23 (Scheme 16, step i). Subsequent TFA cleavage of the Boc 
group of 5.23 (step ii) revealed the amine 5.24 which was coupled to Boc-glycine to 
give 5.25 (step iii). Cleavage of the Boc of 5.25 gave the amine 5.26 (step iv) which 
was purified by semi-preparative RP-HPLC to ensure maximum purity. Conjugation of 
BODIPY 630/650-X-OSu 2.15 to 5.26 yielded the fluorescent ligand 5.27 (step v), 




Scheme 16: Synthesis of fluorescent ligand 5.27. Reagents and conditions: (i) 1-N-Boc-cis-1,4-
cyclohexyldiamine, HATU, DIPEA, DMF, rt, 14 h, 71%; (ii) TFA, DCM, rt, 1 h, quantitative; (iii) Boc-
glycine, HATU, DIPEA, DMF, rt, 14 h, 31%; (iv) TFA, DCM, rt, 1 h, 57%; (v) BODIPY 630/650-X-
OSu 2.15, DIPEA, DMF, rt, 14 h, quantitative yield.§§§§§  
  
                                                 




In this chapter, a series of fluorescent ligands was synthesised by substitution of the C3-
carboxamide cyclohexyl group with linkers and fluorophore. Pharmacological 
evaluation of this series identified a high affinity, CB2 receptor selective fluorescent 
ligand 5.9b (Ki = 467 ± 20.0 nM at hCB2 receptor, Ki(CB1)/Ki(CB2) = >21; Figure 79) 
with inverse agonist activity at CB2 receptor.  
 
Figure 79: The lead fluorescent ligand 5.9b. 
The identification of 5.9b fulfils the major aim of this PhD project. As well as being a 
promising potential imaging tool, it has validated the linker and fluorophore 
substitution position selected in this chapter. Two additional fluorescent ligands (5.9a 
and 5.9d) were also identified with micromolar affinity for CB2 receptor. Furthermore, 
pharmacological evaluation of the precursor linker-ligand conjugates 5.22a-d and 
ligands 5.1a and 5.1b revealed a clear preference for the cis over trans isomers.  
5.7.1 Future directions 
Confocal imaging studies of 5.9b with whole live cells expressing CB2 receptor will be 
carried out by collaborators at the University of Auckland. Non-specific membrane 
binding is a typical stumbling block in the pursuit of fluorescent ligands for GPCRs,199 
so it is important to properly validate a fluorescent ligand as a practical tool for imaging 
studies. Experiments are planned in which HEK293 cells overexpressing hCB2 receptor 
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will be incubated with 5.9b in the presence or absence of a high concentration of pre-
incubated high affinity, CB2 receptor selective non-fluorescent ligand SR144528 1.13. 
This will enable receptor-specific binding versus membrane binding of 5.9b to be 
examined. If successful and 5.9b demonstrates selective CB2 receptor binding with low 
level of non-specific binding, it can then begin rigorous evaluation using, for example, 
cells overexpressing CB1 receptor (in the hope of there being little binding) and in other 
cell types and native cells with mixed receptor populations.  
The ester bond present in 5.9b could potentially be hydrolysed, therefore, a key priority 
is to carry out stability studies on 5.9b. In addition, 5.9b will be functionally 
characterised at other signalling pathways, such as β arrestin recruitment, [35S]-GTPλS 
binding and membrane potential assays.  
Pharmacological evaluation of the fluorescent ligand 5.27 (which contains an amide 
bond in place of the ester bond of 5.9b) will be undertaken in future studies by 
collaborators to evaluate its affinity, selectivity and function at CB2 receptor. It will be 
interesting to see if 5.27 retains the affinity of the analogous 5.9b, or whether 
substitution of the ester for an amide leads to a loss (or gain) in affinity for CB2 
receptor. These pharmacological results will inform further efforts to refine the design 
of 5.9b. For instance, it is possible that presence of an amide might induce too much 
rigidity for favourable CB2 receptor binding, especially in the narrow region between 
TMH1 and 7 or TMH1 and 2, where ligand docking studies suggest the amide bond 
may be positioned. If this proves to be the case, it would be interesting to replace the 
ester of 5.9b with a flexible ethyl ether, maintaining the same linker length as 5.9b, as 




Figure 80: Fluorescent ligand design replacing the ester of 5.9b with an ether (5.28). 
It was extremely gratifying to identify a high affinity fluorescent ligand for CB2 
receptor in this study. The validation of C3-carboxamide cyclohexyl as an appropriate 
position for linker and fluorophore conjugation has opened up new opportunities for 
design and synthesis of further fluorescent ligands for CB2 receptor. Future studies 
could explore variations on this design to improve upon the affinity for CB2 receptor.  
It could be worthwhile exploring replacement of the BODIPY 630/650-X fluorophore 
used in the lead fluorescent ligand 5.9b with other fluorophores, such as BODIPY FL-
X, BODIPY TMR-X, BODIPY TR-X, or a cyanine or Alexa Fluor dye. Replacing the 
fluorophore could have a significant effect on ligand affinity and physicochemical 
properties, such as non-specific membrane binding. In addition, generating a range of 
fluorescent ligands with different wavelengths would enable application in varying 
techniques, such as FRET or BRET assays.319  
This study has clearly demonstrated that linker length can have a huge impact on CB2 
receptor affinity. Therefore, synthesis of derivatives with varying linker length, perhaps 
exploring the range between the three and eight atoms already trialled might be a 
potential avenue to improving CB2 receptor affinity. In addition, published studies have 
shown that the individual amino acid residues present in a peptide linker hugely impact 
GPCR affinity of fluorescent ligands.198 Substitution of the glycine in 5.9b (or non-
ester analogues) with other single amino acid residues is likely to significantly affect 
CB2 receptor affinity.  
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A pattern of inverse agonism and/or antagonism for C6-substituted and agonism for 
C6-unsubstituted 1,8-napthyridin-2(1H)-one-3-carboxamide derivatives was identified 
by Lucchesi et al.145 In accordance with this pattern, the inverse agonist derivatives 
identified in this chapter all contained methoxyphenyl substitutions at C6. It would be 
interesting to synthesise analogues of 5.9b (or any other fluorescent ligands later 
identified in this series) without C6 substituents, to explore whether agonism in C6-
unsubstituted ligands is preserved upon extension with a fluorophore. A fluorescent 
agonist would have substantially different applications to an inverse agonist or 
antagonist in pharmacological studies (section 1.5.3) and so expanding the available 
toolbox in this way would be a highly worthwhile endeavour.   
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 Chapter Six: Executive Conclusions 
The aim of this PhD research was to develop a high affinity, selective fluorescent 
ligand for CB2 receptor. Libraries of pharmacophores, linker-pharmacophore 
conjugates and fluorescent ligands were developed from two classes of cannabinoids: 
indole and 1,8-naphthyridin.  
Literature SAR of the indole cannabinoids was utilised to guide selection of the C5-7 
positions for linker and fluorophore substitution (Chapters Two and Three). The C7 
position was found to be strongly favoured for linker substitution over the C5 and C6 
positions. A very high affinity, selective inverse agonist ligand 3.7b (Figure 81) for 
CB2 receptor was identified, which showed higher affinity, potency and efficacy for 
CB2 receptor than the inverse agonist SR144528 1.13, which is commonly used in 
pharmacological research. The indole-based fluorescent ligands did not have high 
affinity for CB2 receptor, however, a linker-pharmacophore lead 3.13 (Figure 81) could 
potentially be optimised in future work to develop fluorescent ligands for CB2 receptor.  
 
Figure 81: Indole based CB2 ligands: high affinity, selective inverse agonist 3.7b and lead linker-
pharmacophore 3.13.  
A library of 1,8-naphthyridin-2(1H)-one-3-carboxamide based compounds with linker 
and fluorophore substitution at the N1 position was designed based on literature SAR 
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for this scaffold (Chapter Four). However, pharmacological evaluation of this series 
indicated that the N1 position was unsuitable for extension. Ligand docking studies 
aided design of a series of C3-carboxamide cyclohexyl substituted fluorescent ligands, 
which resulted in a high affinity, selective inverse agonist fluorescent ligand 5.9b 
(Figure 82) for CB2 receptor. These results demonstrated that the cyclohexyl group is a 
suitable position for linker and fluorophore conjugation and provides opportunities for 
developing a range of fluorescent ligands with varied functionality at CB2 receptor, 
expanding the variety of tools available for studying CB2 receptor. Future studies will 
evaluate 5.9b as an imaging tool for CB2 receptor.  
 




 Chapter Seven: Experimental 
7.1 Chemistry 
Chemicals and solvents were purchased from Sigma Aldrich, Merck or AK Scientific 
and were used without further purification. BODIPY 630/650-X-OSu 2.15 was 
purchased from Life Technologies. Anhydrous grade solvents were used when a dry 
atmosphere was required. Unless stated, all reactions were carried out at room 
temperature (rt) and under atmospheric pressure.  
TLC was carried out on 0.2 mm aluminium-backed silica gel plates 60 F254 and 
visualised under UV light at λ = 254 nm and 365 nm and then with potassium 
permanganate dip. Flash column chromatography was carried out using 40-63 µm 
silica. All columns were performed by a gradient method and the starting conditions are 
given in each instance. RP-HPLC was carried out on an Agilent 1260 Infinity system, 
using an YMC C8 5 µm (150 × 10 mm) column for semi-preparative RP-HPLC and an 
YMC C8 5 µm (150 × 4.6 mm) column for analytical RP-HPLC. The mobile phases 
used were A: H2O (0.05% TFA) and B: 9:1 ACN/H2O (0.05% TFA). Analytical RP-
HPLC retention times quoted below were determined with a standard method - 5% A 
for 1 min, then a linear gradient of 5-95% B from 1-27 min (followed by 1 min at 95% 
B, 2 min linear gradient 95-5% B and then 4 min re-equilibration at 5% A). All 
compounds analysed for biological activity were >95% purity by UV detection at 254 
and 380 nm (and 550 nm for fluorescent compounds) by analytical RP-HPLC. All 
compounds HPLC purified as the TFA salt were neutralised using an Amberlyst A21 
ion exchange resin before biological testing.  
High resolution electrospray ionisation mass spectra (HRMS-ESI) were obtained on a 
microTOFQ mass spectrometer. Proton and carbon NMR spectra were obtained on 
either a 400 MHz or a 500 MHz Varian NMR spectrometer. Two-dimensional NMR 
experiments, including COSY, HSQC, HMBC and NOESY were used to assign 
spectra. Chemical shifts are listed on the δ scale in part(s) per million (ppm), referenced 
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to CDCl3, MeOD-d4 or DMSO-d6 with residual solvent as the internal standard and 
coupling constants (J) recorded in hertz (Hz). Signal multiplicities are assigned as: s, 
singlet; d, doublet; t, triplet; q, quartet; quint, quintet; dd, doublet of doublets; dt, 
doublet of triplets; td, triplet of doublets; br, broad; or m, multiplet.  
1H and/or 13C NMR spectra are not reported for some compounds near the end of 
multistep syntheses. This is because these compounds were synthesised and/or purified 
on a small scale and had poor solubility, so NMR characterisation would require a large 
fraction of the product to be dissolved in deuterated dimethyl sulfoxide (DMSO), which 
would be difficult to recover. However, HRMS-ESI was obtained for all compounds 
and >95% purity demonstrated by analytical RP-HPLC. In addition, NMR 
characterisation was carried out for the precursors of products without NMR spectra. 
For instance, Boc-protected linker-indole conjugates were characterised by NMR and 
as Boc-cleavage is a straightforward procedure, it is extremely unlikely any other 
changes would occur to these molecules. Therefore, there can be confidence in the 
structures of the resulting deprotected amines, especially when considering the 
matching HRMS-ESI data. Similarly, the dye coupling reactions are straightforward 
and the HRMS-ESI corroborates the correct product was obtained.   
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2-(Morpholin-4-yl)ethyl methanesulfonate (2.17a) 
A stirred solution of 4-(2-hydroxyethyl)-morpholine 2.16a (2.5 mL, 
20.7 mmol) and Et3N (8.6 mL, 62.0 mmol) in anhydrous DCM (48 
mL) under N2 was cooled to 0°C and then methanesulfonyl chloride 
(2.4 mL, 31.0 mmol) was added dropwise. The mixture was stirred at rt for 2 h, filtered, 
the solid washed with minimal DCM and this filtrate combined with the original filtrate 
was evaporated under reduced pressure to give a yellow oil (10.24 g) as a mixture of 
the desired product 2.17a and a salt (Et3NH
+Cl-). This material was used without 
further purification.  
(Oxan‐4‐yl)methyl methanesulfonate (2.17b) 
4-(Hydroxymethyl) tetrahydropyran 2.16b (2.9 mL, 25.0 mmol), Et3N 
(10.4 mL, 74.9 mmol) and methanesulfonyl chloride (2.9 mL, 37.5 
mmol) in DCM (50 mL) were reacted as described in the procedure for 
2.17a to give an orange oil (7.77 g) as a mixture of the desired 2.17b 
and a salt. This material was used without further purification.  
(Oxolan‐3‐yl)methyl methanesulfonate (2.17c) 
Tetrahydro-3-furanmethanol 2.16c (0.86 mL, 9.0 mmol), Et3N (3.7 mL, 
26.9 mmol) and methanesulfonyl chloride (1.0 mL, 13.4 mmol) in DCM 
(21 mL) were reacted as described in the procedure for 2.17a to give a 
yellow oil (3.29 g) as a mixture of the desired 2.17c and a salt. This material was used 




A stirred solution of 5-benzyloxyindole 2.18a (600 mg, 2.7 
mmol) in anhydrous DMF (11 mL) under N2 was cooled to 
0°C, and then NaH (60% by mass dispersion in mineral oil; 
358 mg, 9.0 mmol) was added. The mixture was stirred at 
0°C for 10 min and then warmed to rt and stirred for 30 
min. The reaction mixture was cooled to 0°C and a solution of 2.17a (1.13 g, 5.4 mmol) 
in anhydrous DMF (5 mL) was added. The mixture was warmed to 45°C and stirred for 
2 h, cooled to rt, diluted with EA (20 mL) and quenched with sat. aq. NH4Cl (20 mL) 
and H2O (10 mL). The layers were separated and the aqueous layer extracted with EA 
(3 × 20 mL). The combined organics were washed with H2O (4 × 70 mL), dried over 
MgSO4, filtered and evaporated under reduced pressure. The crude product was 
purified using flash silica column chromatography (1:2 PE/EA) to yield the desired 
2.19a (690 mg, 2.1 mmol, 76%) as a light brown wax (Rf 0.17, 1:2 PE/EA).  
1H NMR (400 MHz, CDCl3): δ 7.52 – 7.46 (m, 2H, aromatic(Ar)H Bn), 7.43 – 7.37 (m, 
2H, ArH Bn), 7.37 – 7.30 (m, 1H, ArH Bn), 7.26 (d, J = 8.8 Hz, 1H, ArH indole), 7.18 
(d, J = 2.3 Hz, 1H, ArH indole), 7.13 (d, J = 3.1 Hz, 1H, ArH indole), 6.98 (dd, J = 8.9, 
2.2 Hz, 1H ArH indole), 6.41 (dd, J = 3.2, 1.1 Hz, 1H, ArH indole), 5.12 (s, 2H, CH2 
Bn), 4.22 (t, J = 6.9 Hz, 2H, N1-CH2), 3.72 (t, J = 4.6 Hz, 4H, O-CH2 morpholino), 
2.75 (t, J = 6.9 Hz, 2H, N1-CH2CH2), 2.49 (t, J = 4.6 Hz, 4H, N-CH2 morpholino).  
13C NMR (101 MHz, CDCl3) δ 153.33, 137.86, 131.56, 128.98, 128.69, 128.61, 127.85, 
127.64, 112.69, 110.03, 104.38, 101.03, 71.01, 67.03, 58.36, 53.99, 44.29.  
HRMS-ESI calculated for C21H25N2O2 [M+H]
+ 337.1911, found m/z 337.1884.  
6-(Benzyloxy)-1-[2-(morpholin-4-yl) ethyl]-1H indole (2.19b) 
6-Benzyloxyindole 2.18b (1.34 g, 6.0 mmol), NaH (732 
mg, 18.3 mmol), and 2.17a (2.51 g, 12.0 mmol) in DMF 
(48 mL) were reacted as described in the procedure for 
2.19a. The crude product was purified using flash silica 
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column chromatography (1:2 hexane/EA) to yield the desired 2.19b (1.10 g, 3.3 mmol, 
54%) as a brown solid (Rf 0.13, 2:1 PE/EA).  
1H NMR (400 MHz, CDCl3) δ 7.55 – 7.44 (m, 3H, ArH Bn & ArH indole), 7.44 – 7.36 
(m, 2H, ArH Bn), 7.36 – 7.29 (m, 1H, ArH Bn), 7.04 (d, J = 3.2 Hz, 1H, ArH indole), 
6.95 – 6.83 (m, 2H, ArH indole), 6.42 (dd, J = 3.2, 0.7 Hz, 1H, ArH indole), 5.14 (s, 
2H, CH2 Bn), 4.32 – 4.04 (br m, 2H, N1-CH2), 3.82 – 3.57 (br m, 4H, O-CH2 
morpholino), 2.83 – 2.62 (br m, 2H, N1-CH2CH2), 2.60 – 2.29 (br m, 4H, N-CH2 
morpholino).  
13C NMR (101 MHz, CDCl3) δ 155.44, 137.60, 136.67, 128.67, 127.97, 127.63, 127.26, 
123.27, 121.68, 109.95, 101.38, 94.83, 70.94, 67.02, 58.08, 53.99, 44.10.  
HRMS-ESI calculated for C21H25N2O2 [M+H]
+ 337.1911, found m/z 337.1880.  
5-(Benzyloxy)-1-[(oxan-4-yl) methyl]-1H-indole (2.19c) 
5-Benzyloxyindole 2.18a (600 mg, 2.7 mmol), NaH (481 
mg, 12.0 mmol) and 2.17b (1.04 g, 5.4 mmol) in DMF 
(17 mL) were reacted as described in the procedure for 
2.19a. The crude product was purified using flash silica 
column chromatography (2:1 PE/EA) to yield the desired 
2.19c (570 mg, 1.8 mmol, 66%) as a light brown oil (Rf 0.44, 2:1 PE/EA).  
1H NMR (400 MHz, CDCl3) δ 7.52 – 7.44 (m, 2H, ArH Bn), 7.43 – 7.36 (m, 2H, ArH 
Bn), 7.35 – 7.29 (m, 1H, ArH Bn), 7.23 (d, J = 8.9 Hz, 1H, ArH indole), 7.17 (d, J = 
2.4 Hz, 1H, ArH indole), 7.03 (d, J = 2.4 Hz, 1H, ArH indole), 6.96 (dd, J = 8.9, 2.4 
Hz, 1H, ArH indole), 6.40 (d, J = 3.0 Hz, 1H, ArH indole), 5.11 (s, 2H, CH2 Bn), 3.99 
– 3.91 (m, 4H, N-CH2 & O-CH2 tetrahydropyran (THP)), 3.31 (td, J = 11.7, 2.3 Hz, 2H, 
O-CH2 THP), 2.16 – 2.02 (m, 1H, CH THP), 1.53 – 1.32 (m, 4H, O-CH2CH2 THP).  
13C NMR (101 MHz, CDCl3) δ 153.29, 137.85, 131.77, 129.02, 128.96, 128.61, 127.85, 
127.64, 112.68, 110.25, 104.24, 100.72, 70.97, 67.58, 52.65, 36.40, 30.98.  
HRMS-ESI calculated for C21H24NO2 [M+H]
+ 322.1802, found m/z 322.1778.  
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5-(Benzyloxy)-1-[(oxolan-3-yl) methyl]-1H-indole (2.19d) 
5-Benzyloxyindole 2.18a (600 mg, 2.7 mmol), NaH (322 
mg, 8.1 mmol) and 2.17c (969 mg, 5.4 mmol) in DMF (16 
mL) were reacted as described in the procedure for 2.19a. 
The crude product was purified using flash silica column 
chromatography (2:1 PE/EA) to yield the desired 2.19d 
(582 mg, 1.9 mmol, 70%), as a red-orange oil (Rf 0.63, 2:1 EA/PE).  
1H NMR (400 MHz, CDCl3) δ 7.55 – 7.46 (m, 2H, ArH Bn), 7.44 – 7.37 (m, 2H, ArH 
Bn), 7.37 – 7.30 (m, 1H, ArH Bn), 7.27 (d, J = 8.9 Hz, 1H, ArH indole), 7.19 (d, J = 
2.5 Hz, 1H, ArH indole), 7.08 (d, J = 3.1 Hz, 1H, ArH indole), 6.98 (dd, J = 8.9, 2.4 
Hz, 1H, ArH indole), 6.43 (dd, J = 3.1, 0.8 Hz, 1H, ArH indole), 5.12 (s, 2H, CH2 Bn), 
4.06 (d, J = 7.8 Hz, 2H, N-CH2), 3.97 (td, J = 8.3, 5.5 Hz, 1H, O-CH2 tetrahydrofuran 
(THF)), 3.82 – 3.67 (m, 2H, O-CH2 THF), 3.61 (dd, J = 8.9, 4.7 Hz, 1H, O-CH2 THF), 
2.90 – 2.75 (m, 1H, CH THF), 2.10 – 1.94 (m, 1H, CH2 THF), 1.73 – 1.57 (m, 1H, CH2 
THF).  
13C NMR (101 MHz, CDCl3) δ 153.39, 137.84, 131.69, 129.02, 128.63, 128.43, 127.87, 
127.65, 112.84, 110.11, 104.36, 101.14, 71.13, 71.01, 67.68, 49.22, 40.16, 29.97.  
HRMS-ESI calculated for C20H21NNaO2 [M+Na]
+ 330.1464, found m/z 330.1441.  
Formation of [(Phen)Pd(OAc)2] complex (2.21) 
Palladium (II) acetate 2.20 (324 mg, 1.5 mmol) was dissolved in 
acetone (28 mL) and left unstirred for 30 min at rt, after which, 
undissolved solid Pd(OAc)2 was removed by filtration with fine filter 
paper. 1,10-Phenanthroline (313 mg, 1.7 mmol) was added to the reddish-brown 
filtrate, the solution swirled for 1 min in which time a precipitate started to form. The 
solution was left to sit unstirred for 30 min, the precipitate was filtered, washed with 
cold acetone and vacuum dried, yielding 2.21 (336 mg, 0.83 mmol, 57%) as a canary 
yellow solid, as described in the literature.273  
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5-(Benzyloxy)-3-(4-methoxybenzoyl)-1-[2-(morpholin-4-yl)ethyl]-1H-indole (2.22a)  
A stirred solution of 2.19a (104 mg, 0.31 mmol), 4-
methoxybenzonitrile (119 mg, 0.89 mmol) and 2.21 
(13 mg, 31.0 μmol) dissolved in H2O (0.12 mL), 
glacial AcOH (0.18 mL) and 1,4-dioxane (0.6 mL) 
was heated to 140°C in a sealed pressure tube for 42 h. 
The reaction mixture was cooled to rt, diluted with 
DCM (18 mL), filtered through a celite pad and the celite washed with DCM (6 mL). 
The filtrate was evaporated under reduced pressure. The crude residue was purified by 
flash silica column chromatography (99:1 DCM/MeOH with 0.3% Et3N to load silica), 
and recrystallised using MeOH to yield 2.22a (74 mg, 0.16 mmol, 51%) as dark brown 
crystals (Rf 0.53, 95:5 DCM/MeOH).  
1H NMR (400 MHz, CDCl3) δ 8.06 (d, J = 2.4 Hz, 1H, ArH indole), 7.90 – 7.81 (m, 
2H, ArH MeOPh), 7.65 (s, 1H, ArH indole), 7.53 – 7.47 (m, 2H, ArH Bn), 7.43 – 7.36 
(m, 2H, ArH Bn), 7.35 – 7.31 (m, 1H, ArH Bn), 7.29 (dd, J = 8.9, 0.5 Hz, 1H, ArH, 
indole), 7.05 (dd, J = 8.9, 2.5 Hz, 1H, ArH indole), 7.02 – 6.96 (m, 2H, ArH MeOPh), 
5.17 (s, 2H, CH2 Bn), 4.22 (t, J = 6.3 Hz, 2H, N1-CH2), 3.90 (s, 3H, O-CH3), 3.70 (t, J 
= 4.6 Hz, 4H, O-CH2 morpholino), 2.77 (t, J = 6.4 Hz, 2H, N1-CH2CH2), 2.48 (t, J = 
4.7 Hz, 4H, N-CH2 morpholino).  
13C NMR (101 MHz, CDCl3) δ 189.85, 162.30, 155.70, 137.49, 137.18, 133.59, 131.90, 
130.98, 128.64, 128.31, 127.95, 127.81, 115.46, 114.71, 113.63, 110.48, 105.36, 70.69, 
67.02, 57.84, 55.58, 53.82, 44.45.  
HRMS-ESI calculated for C29H31N2O4 [M+H]
+ 471.2278, found m/z 471.2239. 
6-(Benzyloxy)-3-(4-methoxybenzoyl)-1-[2-(morpholin-4-yl)ethyl]-1H-indole (2.22b) 
A solution of 2.19b (123 mg, 0.37 mmol), 4-
methoxybenzonitrile (144 mg, 1.1 mmol) and 2.21 (14 
mg, 37.0 μmol) in H2O (0.14 mL), glacial AcOH (0.21 
mL) and 1,4-dioxane (0.7 mL) was reacted as 
described in the procedure for 2.22a. The crude 
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residue was purified by flash silica column chromatography (99:1 DCM/MeOH, with 
0.3% of 25% aq. ammonia solution to load silica) to yield 2.22b (129 mg, 0.27 mmol, 
75%) as a brown solid (Rf 0.47, 95:5 DCM/MeOH).  
1H NMR (500 MHz, CDCl3) δ 8.29 (d, J = 8.7 Hz, 1H, ArH indole), 7.87 – 7.80 (m, 
2H, ArH MeOPh), 7.56 (s, 1H, ArH indole), 7.50 – 7.44 (m, 2H, ArH Bn), 7.42 – 7.36 
(m, 2H, ArH Bn), 7.36 – 7.30 (m, 1H, ArH Bn), 7.05 (dd, J = 8.7, 2.2 Hz, 1H, ArH 
indole), 7.00 – 6.93 (m, 2H, ArH MeOPh), 6.90 (d, J = 2.2 Hz, 1H, ArH indole), 5.14 
(s, 2H, CH2 Bn), 4.15 (t, J = 6.4 Hz, 2H, N1-CH2), 3.87 (s, 3H, O-CH3), 3.68 (t, J = 4.6 
Hz, 4H, O-CH2 morpholino), 2.72 (t, J = 6.4 Hz, 2H, N1-CH2CH2), 2.46 (t, J = 4.7 Hz, 
4H, N-CH2 morpholino).  
13C NMR (126 MHz, CDCl3) δ 189.64, 162.25, 156.39, 137.55, 137.15, 136.38, 133.43, 
130.93, 128.65, 128.02, 127.57, 123.54, 121.79, 115.74, 113.53, 112.23, 95.19, 70.75, 
66.94, 57.51, 55.50, 53.74, 44.12.  
HRMS-ESI calculated for C29H31N2O4 [M+H]
+ 471.2276, found m/z 471.2278.  
5-(Benzyloxy)-1-[2-(morpholin-4-yl)ethyl]-3-(naphthalene-1-carbonyl)-1H-indole 
(2.22c) 
A solution of 2.19a (525 mg, 1.6 mmol), 1-naphthonitrile 
(717 mg, 4.7 mmol) and 2.21 (76 mg, 0.19 mmol) in H2O 
(0.63 mL), glacial AcOH (0.93 mL) and 1,4-dioxane (3.1 
mL) was reacted as described in the procedure for 2.22a. 
The crude residue was purified by flash silica column 
chromatography twice (1st 99:1 DCM/MeOH, with 0.3% 
Et3N to load silica, 2
nd 10:1 EA/hexane with 0.5% of 25% 
aq. ammonia solution to load silica) to yield 2.22c (138 
mg, 0.28 mmol, 18%) as a brown solid (Rf 0.34, 4:1 EA/hexane).  
1H NMR (400 MHz, CDCl3) δ 8.22 – 8.15 (m, 2H, ArH indole & naphthalene), 8.00 – 
7.89 (m, 2H, ArH naphthalene), 7.65 (dd, J = 7.0, 1.2 Hz, 1H, ArH naphthalene), 7.57 – 
7.45 (m, 5H, ArH Bn & naphthalene), 7.45 – 7.37 (m, 3H, ArH Bn & indole), 7.37 – 
7.27 (m, 2H, ArH Bn & indole), 7.08 (dd, J = 8.9, 2.5 Hz, 1H, ArH indole), 5.20 (s, 2H, 
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CH2 Bn), 4.29 – 3.97 (br m, 2H, N1-CH2), 3.76 – 3.36 (br m, 4H, O-CH2 morpholino), 
2.85 – 2.58 (br m, 2H, N1-CH2CH2), 2.57 – 2.19 (br m, 4H, N-CH2 morpholino).  
13C NMR (101 MHz, CDCl3) δ 192.18, 156.04, 139.21, 138.98, 137.42, 133.83, 132.12, 
130.87, 130.04, 128.66, 128.32, 128.00, 127.86, 127.76, 126.89, 126.43, 126.05, 
125.80, 124.60, 117.54, 114.86, 110.71, 105.55, 70.72, 66.87, 57.57, 53.65, 44.40.  
HRMS-ESI calculated for C32H31N2O3 [M+H]
+ 491.2329, found m/z 491.2303.  
5-(Benzyloxy)-3-cyclohexanecarbonyl-1-[2-(morpholin-4-yl)ethyl]-1H-indol (2.22d) 
A solution of 2.19a (100 mg, 0.3 mmol), 
cyclohexanecarbonitrile (106 µL, 0.89 mmol) and 2.21 
(12 mg, 30.0 μmol) in H2O (0.12 mL), glacial AcOH (0.18 
mL) and 1,4-dioxane (0.6 mL) was reacted as described in 
the procedure for 2.22a. The crude residue was purified by 
flash silica column chromatography (99:1 DCM/MeOH, 
with 0.3% Et3N to load silica) to yield a red oil as a 4:1 mixture of 2.22d and 2.19a 
(100 mg) (Rf 2.22d 0.17, 99:1 DCM/MeOH). This mixture could not be separated 
further and was therefore used without further purification in subsequent reactions.  
HRMS-ESI calculated for 2.22d C28H35N2O3 [M+H]
+ 447.2642, found m/z 447.2605 
(from HRMS-ESI of the 4:1 mixture).  
5-(Benzyloxy)-3-(4-methoxybenzoyl)-1-[(oxan-4-yl)methyl]-1H-indole (2.22e) 
A solution of 2.19c (103 mg, 0.32 mmol), 4-
methoxybenzonitrile (127 mg, 0.95 mmol) and 2.21 
(14 mg, 32.0 μmol) in H2O (0.12 mL), glacial AcOH 
(0.18 mL) and 1,4-dioxane (0.6 mL) was reacted as 
described in the procedure for 2.22a. The crude 
residue was purified by flash silica column chromatography (2:1 PE/EA) to yield 2.22e 
(118 mg, 0.26 mmol, 81%) as a brown oil (Rf 0.32, 1:1 PE/EA).  
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1H NMR (400 MHz, CDCl3) δ 8.04 (d, J = 2.5 Hz, 1H, ArH indole), 7.87 – 7.80 (m, 
2H, ArH MeOPh), 7.53 – 7.47 (m, 3H, ArH Bn & ArH indole), 7.43 – 7.36 (m, 2H, 
ArH Bn), 7.36 – 7.30 (m, 1H, ArH Bn), 7.28 (dd, J = 8.9, 0.5 Hz, 1H, ArH indole), 7.06 
(dd, J = 8.9, 2.5 Hz, 1H, ArH indole), 7.03 – 6.97 (m, 2H, ArH MeOPh), 5.17 (s, 2H, 
CH2 Bn), 4.01 (d, J = 7.3 Hz, 2H, N-CH2), 3.99 – 3.93 (m, 2H, O-CH2 THP), 3.90 (s, 
3H, O-CH3), 3.31 (td, J = 11.8, 2.2 Hz, 2H, O-CH2 THP), 2.21 – 2.05 (m, 1H, CH 
THP), 1.56 – 1.28 (m, 4H, O-CH2CH2 THP).  
13C NMR (101 MHz, CDCl3) δ 189.89, 162.34, 155.71, 137.47, 136.76, 133.54, 132.11, 
130.96, 128.65, 128.39, 127.97, 127.82, 115.43, 114.88, 113.71, 110.83, 105.31, 70.69, 
67.42, 55.58, 53.33, 36.06, 30.86.  
HRMS-ESI calculated for C29H30NO4 [M+H]
+ 456.2169, found m/z 456.2128.  
5-(Benzyloxy)-3-(naphthalene-1-carbonyl)-1-[(oxan-4-yl)methyl]-1H-indole (2.22f) 
A solution of 2.19c (103 mg, 0.32 mmol), 1-
naphthonitrile (147 mg, 0.96 mmol) and 2.21 (14 mg, 
32.0 μmol) in H2O (0.12 mL), glacial AcOH (0.18 mL) 
and 1,4-dioxane (0.6 mL) was reacted as described in the 
procedure for 2.22a. The crude residue was purified by 
flash silica column chromatography (2:1 PE/EA) to yield 
2.22f (87 mg, 0.18 mmol, 59%) as a brown oil (Rf 0.5, 1:1 
PE/EA).  
1H NMR (400 MHz, CDCl3) δ 8.19 (dd, J = 8.5, 1.2 Hz, 1H, ArH naphthalene), 8.13 (d, 
J = 2.5 Hz, 1H, ArH indole), 7.98 (dd, J = 8.3, 1.1 Hz, 1H, ArH naphthalene), 7.95 – 
7.89 (m, 1H, ArH naphthalene), 7.66 (dd, J = 7.0, 1.3 Hz, 1H, ArH naphthalene), 7.60 – 
7.44 (m, 5H, ArH Bn & naphthalene), 7.44 – 7.37 (m, 2H, ArH Bn), 7.37 – 7.31 (m, 
1H, ArH indole), 7.28 (d, J = 8.9 Hz, 1H, ArH Bn), 7.27 (s, 1H, ArH indole), 7.08 (dd, 
J = 8.9, 2.5 Hz, 1H, ArH indole), 5.18 (s, 2H, CH2 Bn), 4.00 – 3.85 (m, 4H, N-CH2 & 
O-CH2 THP), 3.28 (td, J = 11.8, 2.1 Hz, 2H, O-CH2 THP), 2.13 – 1.96 (m, 1H, CH 
THP), 1.48 – 1.24 (m, 4H, O-CH2CH2 THP).  
13C NMR (101 MHz, CDCl3) δ 192.14, 156.02, 139.12, 138.36, 137.40, 133.88, 132.31, 
130.90, 130.16, 128.67, 128.33, 128.01, 127.88, 126.86, 126.45, 126.11, 125.97, 
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124.71,117.40, 114.99, 111.03, 105.44, 70.70, 67.36, 53.28, 35.93, 30.75.  
HRMS-ESI calculated for C32H29NNaO3 [M+Na]
+ 498.2040, found m/z 498.1996.  
5-(Benzyloxy)-3-cyclohexanecarbonyl-1-[(oxan-4-yl)methyl]-1H-indole (2.22g) 
A solution of 2.19c (100 mg, 0.31 mmol), 
cyclohexanecarbonitrile (0.11 mL, 0.93 mmol) and 2.21 
(13 mg, 28.0 μmol) in H2O (0.12 mL), glacial AcOH 
(0.18 mL) and 1,4-dioxane (0.6 mL) was reacted as 
described in the procedure for 2.22a. The crude residue 
was purified by flash silica column chromatography (2:1 
PE/EA) to yield 2.22g (112 mg, 0.26 mmol, 83%) (Rf 
0.36 2:1 PE/EA) as a red brown oil.  
1H NMR (400 MHz, CDCl3) δ 8.07 (d, J = 2.5 Hz, 1H, ArH indole), 7.68 (s, 1H, ArH 
indole), 7.49 (d, J = 7.2 Hz, 2H, ArH Bn), 7.43 – 7.36 (m, 2H, ArH Bn), 7.35 – 7.29 
(m, 1H, ArH Bn), 7.24 (d, J = 8.9 Hz, 1H, ArH indole), 7.02 (dd, J = 8.9, 2.5 Hz, 1H, 
ArH indole), 5.15 (s, 2H, CH2 Bn), 4.11 – 3.84 (m, 4H, N-CH2 & O-CH2 THP), 3.33 
(td, J = 11.7, 2.3 Hz, 2H, O-CH2 THP), 2.99 (tt, J = 11.8, 3.3 Hz, 1H, CH 
cyclohexane), 2.23 – 2.05 (m, 1H, CH THP), 1.96 – 1.82 (m, 4H, CH2 cyclohexane), 
1.79 – 1.33 (m, 10H, CH2 cyclohexane & O-CH2CH2 THP).  
13C NMR (101 MHz, CDCl3) δ 199.77, 155.74, 137.49, 134.45, 132.22, 128.64, 127.96, 
127.81, 127.72, 115.27, 114.70, 110.78, 105.33, 70.62, 67.45, 53.36, 47.89, 36.10, 
30.89, 30.08, 26.21, 26.14.  
HRMS-ESI calculated for C28H34NO3 [M+H]
+ 432.2533, found m/z 432.2506. 
5-(Benzyloxy)-3-(4-methoxybenzoyl)-1-[(oxolan-3-yl)methyl]-1H-indole (2.22h) 
A solution of 2.19d (87 mg, 0.28 mmol), 4-
methoxybenzonitrile (130 mg, 0.98 mmol) and 2.21 
(13 mg, 28.0 μmol) in H2O (0.12 mL), glacial AcOH 
(0.18 mL) and 1,4-dioxane (0.6 mL) was reacted as 
described in the procedure for 2.22a. The crude residue was purified by flash silica 
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column chromatography (2:1 PE/EA) to yield 2.22h (84 mg, 0.19 mmol, 67%) as a 
light brown oil (Rf 0.12, 2:1 PE/EA).  
1H NMR (400 MHz, CDCl3) δ 8.05 (d, J = 2.5 Hz, 1H, ArH indole), 7.83 (dt, J = 8.7, 
2.8, 2.6 Hz, 2H, ArH MeOPh), 7.54 (s, 1H, ArH indole), 7.50 (d, J = 6.9 Hz, 2H, ArH 
Bn), 7.40 (t, J = 7.2 Hz, 2H, ArH Bn), 7.32 (dd, J = 9.4, 8.1 Hz, 2H, ArH Bn, ArH 
indole), 7.07 (dd, J = 8.9, 2.5 Hz, 1H, ArH indole), 7.00 (dt, J = 8.7, 2.8, 2.6 Hz, 2H, 
ArH MeOPh), 5.17 (s, 2H, CH2 Bn), 4.11 (d, J = 7.8 Hz, 2H, N-CH2), 3.97 (td, J = 8.3, 
5.4 Hz, 1H, O-CH2 THF), 3.90 (s, 3H, O-CH3), 3.77 (t, J = 8.3, 6.9 Hz, 1H, O-CH2 
THF), 3.71 (dd, J = 9.1, 6.4 Hz, 1H, O-CH2 THF), 3.61 (dd, J = 9.1, 4.4 Hz, 1H, O-CH2 
THF), 2.92 – 2.79 (m, 1H, CH THF), 2.12 – 1.99 (m, 1H, CH2 THF), 1.73 – 1.60 (m, 
1H, CH2 THF).  
13C NMR (101 MHz, CDCl3) δ 189.91, 162.36, 155.77, 137.45, 136.23, 133.48, 132.00, 
130.96, 128.65, 128.41, 127.97, 127.82, 115.71, 114.99, 113.73, 110.68, 105.34, 70.85, 
70.69, 67.62, 55.58, 49.90, 39.74, 29.86.  
HRMS-ESI calculated for C28H28NO4 [M+H]
+ 442.2013, found m/z 442.1985.  
5-(Benzyloxy)-3-(naphthalene-1-carbonyl)-1-[(oxolan-3-yl)methyl]-1H-indole 
(2.22i) 
A solution of 2.19d (92 mg, 0.3 mmol), 1-naphthonitirile 
(159 mg, 1.0 mmol) and 2.21 (13 mg, 28.0 μmol) in H2O 
(0.12 mL), glacial AcOH (0.18 mL) and 1,4-dioxane (0.6 
mL) was reacted as described in the procedure for 2.22a. 
The crude residue was purified by flash silica column 
chromatography (2:1 PE/EA) to yield 2.22i (86 mg, 0.19 
mmol, 62%) as a red-orange oil (Rf 0.2, 2:1 PE/EA).  
1H NMR (400 MHz, CDCl3) δ 8.19 (ddt, J = 8.2, 1.6, 0.8 Hz, 1H, ArH naphthalene), 
8.14 (d, J = 2.5 Hz, 1H, ArH indole), 7.98 (dt, J = 8.3, 1.1 Hz, 1H, ArH naphthalene), 
7.92 (dt, J = 8.1, 0.9 Hz, 1H, ArH naphthalene), 7.65 (dd, J = 7.0, 1.3 Hz, 1H, ArH 
naphthalene), 7.56 – 7.45 (m, 5H, ArH Bn, ArH naphthalene), 7.41 (tt, J = 6.6, 0.9 Hz, 
2H, ArH Bn), 7.37 – 7.28 (m, 3H, ArH Bn, ArH indole), 7.09 (dd, J = 8.9, 2.5 Hz, 1H, 
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ArH indole), 5.19 (s, 2H, CH2 Bn), 4.01 (d, J = 7.8 Hz, 2H, N-CH2), 3.90 (td, J = 8.3, 
5.4 Hz, 1H, O-CH2 THF), 3.75 – 3.62 (m, 2H, O-CH2 THF), 3.52 (dd, J = 9.1, 4.4 Hz, 
1H, O-CH2 THF), 2.88 – 2.67 (m, 1H, CH THF), 2.08 – 1.92 (m, 1H, CH2 THF), 1.64 – 
1.54 (m, 1H, CH2 THF).  
13C NMR (101 MHz, CDCl3) δ 192.16, 156.10, 139.07, 137.81, 137.40, 133.89, 132.22, 
130.89, 130.19, 128.67, 128.34, 128.01, 127.92, 127.87, 126.90, 126.46, 126.06, 
125.94, 124.70, 117.71, 115.12, 110.88, 105.53, 70.76, 70.72, 67.55, 49.89, 39.66, 
29.81.  
HRMS-ESI calculated for C31H28NO3 [M+H]
+ 462.2064, found m/z 462.2023.  
3-(4-Methoxybenzoyl)-1-[2-(morpholin-4-yl)ethyl]-1H-indol-5-ol (2.23a) 
A flask containing a stirred solution of 2.22a (497 mg, 1.1 
mmol), EtOH (12 mL), MeOH (12 mL) and AcOH (1 mL) 
was evacuated and purged with N2, followed by addition of 
Pd/C (10% by weight loading (dry basis), matrix carbon 
powder, wet support) (50 mg). The solution evacuated and 
then placed under an atmosphere of hydrogen (balloon) 
(evacuated and purged with H2 three times) and stirred for 20 h at rt. The solution was 
then filtered through celite, the celite washed with 1:1 EtOH:MeOH and then MeOH, 
and the filtrate evaporated under reduced pressure. The crude residue was purified by 
precipitation in EA to yield the desired product 2.23a (54 mg, 0.14 mmol, 13%) as a 
pale fawn solid (Rf 0.29, 95:5 DCM/MeOH).  
1H NMR (400 MHz, DMSO-d6) δ 9.08 (s, 1H, OH), 7.93 (s, 1H, ArH indole), 7.77 (d, J 
= 8.3 Hz, 2H, ArH MeOPh), 7.66 (s, 1H, ArH indole), 7.41 (d, J = 8.8 Hz, 1H, ArH 
indole), 7.06 (d, J = 8.3 Hz, 2H, ArH MeOPh), 6.76 (d, J = 8.7 Hz, 1H, ArH indole), 
4.30 (t, J = 6.2 Hz, 2H, N1-CH2), 3.85 (s, 3H, O-CH3), 3.54 (t, J = 4.6 Hz, 4H, O-CH2 
morpholino), 2.67 (t, J = 6.3 Hz, 2H, N1-CH2CH2), 2.47 – 2.35 (br m, 4H, N-CH2 
morpholino).  
13C NMR (101 MHz, DMSO-d6) δ 188.12, 161.52, 153.35, 138.50, 133.22, 130.81, 




HRMS-ESI calculated for C22H25N2O4 [M+H]
+ 381.1809, found m/z 381.1779.  
Analytical RP-HPLC Rt = 12.89 min.  
3-(4-Methoxybenzoyl)-1-[2-(mopholin-4-yl)ethyl]-1H-indol-6-ol (2.23b) 
A mixture of 2.22b (75 mg, 0.16 mmol), EtOH (2.6 mL), EA 
(1.3 mL) and Pd/C (7.5 mg) was reacted as described in the 
procedure for 2.23a. The reaction mixture was filtered 
through celite, the celite washed with 2:1 EtOH:EA and then 
MeOH, and the filtrate evaporated under reduced pressure. 
The crude residue was purified by precipitation in EA to 
yield the desired product 2.23b (9.4 mg, 24.7 µmol, 16%), as a pale brown solid (Rf 
0.21, 95:5 DCM/MeOH). Less than 95% purity necessitated semi-preparative RP-
HPLC on a small amount of this material (6 mg) to yield a sample of 2.23b (4.8 mg) as 
a pale brown solid.  
1H NMR (400 MHz, DMSO-d6) δ 9.38 (s, 1H, ArOH), 8.00 (d, J = 8.6 Hz, 1H, ArH 
indole), 7.84 (s, 1H, ArH indole), 7.81 – 7.75 (m, 2H, ArH MeOPh), 7.09 – 7.03 (m, 
2H, ArH MeOPh), 6.88 (d, J = 2.1 Hz, 1H, ArH indole), 6.76 (dd, J = 8.5, 2.1 Hz, 1H, 
ArH indole), 4.25 (t, J = 6.3 Hz, 2H, N1-CH2), 3.85 (s, 3H, O-CH3), 3.55 (t, J = 4.6 Hz, 
4H, O-CH2 morpholino), 2.66 (t, J = 6.3 Hz, 2H, N1-CH2CH2), 2.44 (t, J = 4.6 Hz, 4H, 
N-CH2 morpholino).  
13C NMR (126 MHz, DMSO-d6) δ 188.10, 161.59, 154.39, 137.76, 137.37, 133.07, 
130.45, 122.27, 119.71, 114.01, 113.54, 112.04, 95.81, 66.25, 57.07, 55.41, 53.18, 
42.91.  
HRMS-ESI calculated for C22H25N2O4 [M+H]
+ 381.1809, found m/z 381.1804.  




A mixture of 2.22c (299 mg, 0.61 mmol), EtOH (11 mL), EA 
(5.5 mL) and Pd/C (30 mg) was reacted as described in the 
procedure for 2.23a. The reaction mixture was filtered through 
celite, the celite washed with 2:1 EtOH:EA and then MeOH, and 
the filtrate evaporated under reduced pressure. The crude residue 
was purified by precipitation in EA to yield the desired product 
2.23c (95 mg, 0.24 mmol, 39%) as a white solid (Rf 0.35, 95:5 
DCM/MeOH).  
1H NMR (400 MHz, MeOD-d4) δ 8.03 (dd, J = 8.2, 4.6 Hz, 2H, ArH naphthalene), 7.99 
– 7.94 (m, 1H, ArH naphthalene), 7.82 (d, J = 2.4 Hz, 1H, ArH indole), 7.65 (dd, J = 
7.0, 1.4 Hz, 1H, ArH naphthalene), 7.62 – 7.57 (m, 1H, ArH naphthalene), 7.55 (s, 1H, 
ArH indole), 7.55 – 7.46 (m, 2H, ArH naphthalene), 7.39 (d, J = 8.8 Hz, 1H, ArH 
indole), 6.88 (dd, J = 8.8, 2.5 Hz, 1H, ArH indole), 4.21 (t, J = 6.1 Hz, 2H, N1-CH2), 
3.53 – 3.40 (m, 4H, O-CH2 morpholino), 2.67 (t, J = 6.1 Hz, 2H, N1-CH2CH2), 2.37 (t, 
J = 4.6 Hz, 4H, N-CH2 morpholino).  
13C NMR (126 MHz, CDCl3) δ 194.66, 155.60, 141.78, 141.08, 135.85, 134.00, 132.88, 
132.13, 130.36, 129.98, 128.93, 128.49, 128.07, 127.79, 126.68, 119.17, 115.54, 
112.71, 109.78, 68.95, 59.58, 55.73, 46.54.  
HRMS-ESI calculated for C25H25N2O3 [M+H]
+ 401.1860, found m/z 401.1850.  
Analytical RP-HPLC Rt = 14.70 min.  
3-Cyclohexanecarbonyl-1-[2-(morpholin-4-yl)ethyl]-1H-indol-5-ol (2.23d) 
A mixture of 2.22d (85 mg, 0.19 mmol), EtOH (3 mL), EA (1.5 
mL) and Pd/C (8.5 mg) was reacted as described in the procedure 
for 2.23a. The reaction mixture was filtered through celite, the 
celite washed with 2:1 EtOH:EA and then MeOH, and the filtrate 
evaporated under reduced pressure. The crude residue was 
purified by flash silica gel column chromatography (1:1 PE/EA) 
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and precipitation in EA to yield the desired product 2.23d (11 mg, 30.9 µmol, 16%) as 
a pale pink solid (Rf 0.54, 95:5 DCM/MeOH).  
1H NMR (400 MHz, DMSO-d6) δ 9.01 (s, 1H, ArOH), 8.26 (s, 1H, ArH indole), 7.60 
(d, J = 2.4 Hz, 1H, ArH indole), 7.35 (d, J = 8.8 Hz, 1H, ArH indole), 6.71 (dd, J = 8.8, 
2.4 Hz, 1H, ArH indole), 4.27 (t, J = 6.4 Hz, 2H, N1-CH2), 3.53 (t, J = 4.6 Hz, 4H, O-
CH2 morpholino), 3.12 – 2.99 (m, 1H, CH cyclohexane), 2.66 (t, J = 6.4 Hz, 2H, N1-
CH2CH2), 2.43 (t, J = 4.7 Hz, 4H, N-CH2 morpholino), 1.84 – 1.65 (m, 5H, CH2 
cyclohexane), 1.49 – 1.31 (m, 4H, CH2 cyclohexane), 1.27 – 1.13 (m, 1H, CH2 
cyclohexane).  
13C NMR (126 MHz, DMSO-d6) δ 197.90, 153.24, 136.82, 130.92, 127.23, 113.26, 
112.37, 110.97, 106.11, 66.23, 57.20, 53.14, 46.27, 43.26, 29.73, 25.67, 25.49.  
HRMS-ESI calculated for C21H29N2O3 [M+H]
+ 357.2173, found m/z 357.2154.  
Analytical RP-HPLC Rt = 13.77 min.  
3-(4-Methoxybenzoyl)-1-[(oxan-4-yl)methyl]-1H-indol-5-ol (2.23e) 
A mixture of 2.22e (1.10 g, 2.4 mmol), EtOH (15 mL), 
CHCl3 (40 mL), AcOH (1 mL) and Pd/C (110 mg) was 
reacted as described in the procedure for 2.23a. The reaction 
mixture was filtered through celite, the celite washed with 
3:1 CHCl3:EtOH and then MeOH, and the filtrate evaporated 
under reduced pressure. The crude residue was purified by precipitation in 1:1 
EtOH:MeOH to yield the desired product 2.23e (588 mg, 1.6 mmol, 67%) as a creamy 
pearl solid (Rf 0.37, 95:5 DCM/MeOH).  
1H NMR (400 MHz, DMSO-d6) δ 9.11 (s, 1H, OH), 7.89 (s, 1H, ArH indole), 7.82 – 
7.73 (m, 2H, ArH MeOPh), 7.68 (d, J = 2.4 Hz, 1H, ArH indole), 7.45 (d, J = 8.8 Hz, 
1H, ArH indole), 7.12 – 7.03 (m, 2H, ArH MeOPh), 6.78 (dd, J = 8.8, 2.4 Hz, 1H, ArH 
indole), 4.11 (d, J = 7.2 Hz, 2H, N-CH2), 3.85 (s, 3H, O-CH3), 3.84 – 3.76 (m, 2H, O-
CH2 THP), 3.19 (td, J = 11.5, 2.3 Hz, 2H, O-CH2 THP), 2.15 – 1.98 (m, 1H, CH THP), 
1.41 – 1.19 (m, 4H O-CH2CH2 THP).  
13C NMR (101 MHz, DMSO-d6) δ 188.18, 161.54, 153.40, 138.08, 133.15, 131.11, 
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130.46, 128.00, 113.62, 113.26, 112.86, 111.46, 106.07, 66.48, 55.38, 51.59, 35.29, 
30.00.  
HRMS-ESI calculated for C22H23NNaO4 [M+Na]
+ 388.1519, found m/z 388.1489.  
Analytical RP-HPLC Rt = 18.02 min.  
3-(Naphthalene-1-carbonyl)-1-[(oxan-4-yl)methyl]-1H-indol-5-ol (2.23f) 
A mixture of 2.22f (54 mg, 0.11 mmol), EtOH (2.5 mL), EA 
(1.25 mL) and Pd/C (6 mg) was reacted as described in the 
procedure for 2.23a. The reaction mixture was filtered through 
celite, the celite washed with 2:1 EtOH:EA and then MeOH, and 
the filtrate evaporated under reduced pressure. The crude residue 
was purified by flash silica gel column chromatography (10:1 EA/hexane), 
recrystallisation in MeOH and semi-preparative RP-HPLC to yield the desired product 
2.23f (14.7 mg, 38.1 µmol, 33%) as a brown solid (Rf 0.65, 95:5 DCM/MeOH).  
1H NMR (400 MHz, MeOD-d4) δ 8.06 – 7.99 (m, 2H, ArH naphthalene), 7.98 – 7.92 
(m, 1H, ArH naphthalene), 7.82 (d, J = 2.7 Hz, 1H, ArH indole), 7.65 – 7.60 (m, 1H, 
ArH naphthalene), 7.60 – 7.49 (m, 2H, ArH naphthalene), 7.48 – 7.42 (m, 2H, ArH 
indole & naphthalene), 7.40 – 7.36 (m, 1H, ArH indole), 6.88 (dd, J = 8.8, 2.5 Hz, 1H, 
ArH indole), 4.06 – 3.94 (m, 2H, N-CH2), 3.92 – 3.80 (m, 2H, O-CH2 THP), 3.26 (dd, J 
= 11.7, 2.1 Hz, 2H, O-CH2 THP), 2.12 – 1.98 (m, 1H, CH THP), 1.41 – 1.21 (m, 4H, 
O-CH2CH2 THP).  
HRMS-ESI calculated for C25H23NNaO3 [M+Na]
+ 408.1570, found m/z 408.1535.  
Analytical RP-HPLC Rt = 19.69 min.  
3-(4-Methoxybenzoyl)-1-[(oxolan-3-yl)methyl]-1H-indol-5-ol (2.23g) 
A mixture of 2.22h (72 mg, 0.16 mmol), EtOH (2.5 mL), EA 
(1.4 mL) and Pd/C (7 mg) was reacted as described in the 
procedure for 2.23a. The reaction mixture was filtered 
through celite, the celite washed with 2:1 EtOH:EA and then 
MeOH, and the filtrate evaporated under reduced pressure. The crude residue was 
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purified by flash silica gel column chromatography (1:1 hexane/EA) to give 2.23g (6.8 
mg, 19.4 μmol, 12%) as a brown oil (Rf 0.27, 1:1 hexane/EA; shown to be pure by 
NMR spectra). Significant degradation upon long term storage (56% purity according 
to analytical RP-HPLC) necessitated further purification immediately prior to 
biological testing, therefore a small amount of this material (4 mg) was purified using 
semi-preparative RP-HPLC to yield a sample of 2.23g (1.58 mg) as a pale fawn solid.  
1H NMR (400 MHz, CDCl3) δ 8.41 (d, J = 2.4 Hz, 1H, ArH indole), 7.83 (d, J = 8.5 
Hz, 2H, ArH MeOPh), 7.52 (s, 1H, ArH indole), 7.28 (d, J = 6.1 Hz, 1H, ArH indole), 
7.02 (d, J = 8.6 Hz, 2H, ArH MeOPh), 6.98 (dd, J = 8.8, 2.4 Hz, 1H, ArH indole), 4.10 
(d, J = 7.8 Hz, 2H, N-CH2), 3.96 (td, J = 8.3, 5.4 Hz, 1H, O-CH2 THF), 3.90 (s, 3H, O-
CH3), 3.81 – 3.66 (m, 2H, O-CH2 THF), 3.61 (dd, J = 9.1, 4.3 Hz, 1H, O-CH2 THF), 
2.86 (td, J = 12.8, 6.2 Hz, 1H, CH THF), 2.05 (m, 1H, CH2 THF), 1.66 (m, 1H, CH2 
THF).  
13C NMR (101 MHz, CDCl3) δ 191.02, 162.49, 154.10, 137.38, 133.26, 131.70, 131.01, 
128.69, 115.23, 113.97, 113.95, 110.69, 107.61, 70.89, 67.65, 55.62, 50.05, 39.66, 
29.90.  
HRMS-ESI calculated for C21H21NNaO4 [M+Na]
+ 374.1363, found m/z 374.1345.  
Analytical RP-HPLC Rt = 17.16 min.  
tert-Butyl 2-{[3-(4-methoxybenzoyl)-1-[2-(morpholin-4-yl)ethyl]-1H-indol-5-
yl]oxy}acetate (2.24a) 
A stirred solution of 2.23a (87 mg, 0.23 mmol) in 
anhydrous DMF (2.5 mL) was added dropwise to a 
mixture of NaH (60% by mass dispersion in 
mineral oil) (13 mg, 0.54 mmol) in anhydrous 
DMF (1 mL). The mixture was heated to 60°C for 
1 h, then cooled to rt and a solution of tert-
butylbromoacetate (44 µL, 0.30 mmol) in anhydrous DMF (1 mL) was added. The 
reaction was stirred at 60°C for 3 h, then quenched with sat. aq. NH4CL (4 mL) and 
H2O (4 mL) and extracted with EA (4 × 4 mL). The combined organics were washed 
with H2O (3 × 7 mL), dried over MgSO4 and evaporated under reduced pressure. The 
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crude product was purified by flash silica gel column chromatography (99:1 
DCM/MeOH with 0.3% of 25% aq. ammonia solution to load silica) to yield 2.24a (51 
mg, 0.10 mmol, 45%) as a pale yellow oil, (Rf 0.39, 95:5 DCM/MeOH).  
1H NMR (400 MHz, CDCl3) δ 7.89 (d, J = 2.6 Hz, 1H, ArH indole), 7.87 – 7.80 (m, 
2H, ArH MeOPh), 7.65 (s, 1H, ArH indole), 7.29 (d, J = 8.9 Hz, 1H, ArH indole), 7.07 
(dd, J = 8.9, 2.6 Hz, 1H, ArH indole), 7.02 – 6.95 (m, 2H, ArH MeOPh), 4.62 (s, 2H, 
O-CH2), 4.36 – 4.08 (br m, 2H, N1-CH2), 3.89 (s, 3H, O-CH3), 3.78 – 3.62 (br m, 4H, 
O-CH2 morpholino), 2.91 – 2.65 (br m, 2H, N1-CH2CH2), 2.63 – 2.36 (br m, 4H, N-
CH2 morpholino), 1.51 (s, 9H, CH3 t Bu).  
13C NMR (126 MHz, CDCl3) δ 189.67, 168.39, 162.25, 154.71, 137.26, 133.53, 132.16, 
130.89, 128.10, 115.42, 114.60, 113.60, 110.59, 105.12, 82.27, 66.91, 66.33, 57.73, 
55.54, 53.73, 44.28, 28.19.  
HRMS-ESI calculated for C28H35N2O6 [M+H]
+ 495.2490, found m/z 495.2457.  
tert-Butyl 2-({1-[2-(morpholin-4-yl)ethyl]-3-(naphthalene-1-carbonyl)-1H-indol-5-
yl}oxy)acetate (2.24b) 
A solution of 2.23c (71 mg, 0.18 mmol), NaH (14 mg, 
0.36 mmol) and tert-butylbromoacetate (34 µL, 0.23 
mmol) in DMF (3 mL) was reacted as described in the 
procedure for 2.24a. The crude product was purified by 
flash silica gel column chromatography (99:1 
DCM/MeOH with 0.3% of 25% aq. ammonia solution 
to load silica) to yield 2.24b (56 mg, 0.11 mmol, 61%) 
as a brown oil (Rf 0.6, 95:5 DCM/MeOH).  
1H NMR (400 MHz, CDCl3) δ 8.14 (d, J = 8.3 Hz, 1H, ArH naphthalene), 8.02 (d, J = 
2.5 Hz, 1H, ArH indole), 7.96 (d, J = 8.2 Hz, 1H, ArH naphthalene), 7.90 (d, J = 8.0 
Hz, 1H, ArH naphthalene), 7.63 (d, J = 6.9 Hz, 1H, ArH naphthalene), 7.56 – 7.42 (m, 
3H, ArH naphthalene), 7.38 (s, 1H, ArH indole), 7.29 (d, J = 8.9 Hz, 1H, ArH indole), 
7.10 (dd, J = 9.0, 2.6 Hz, 1H, ArH indole), 4.67 (s, 2H, O-CH2), 4.25 – 4.00 (br m, 2H, 
N1-CH2), 3.70 – 3.43 (br m, 4H, O-CH2 morpholino), 2.80 – 2.57 (br m, 2H, N1-
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CH2CH2), 2.54 – 2.24 (br m, 4H, N-CH2 morpholino), 1.54 (s, 9H, CH3 t Bu).  
13C NMR (101 MHz, CDCl3) δ 192.09, 168.44, 155.09, 139.13, 139.05, 133.85, 132.38, 
130.85, 130.04, 128.33, 127.60, 126.88, 126.43, 125.99, 125.72, 124.61, 117.58, 
114.92, 110.86, 105.20, 82.45, 66.79, 66.32, 57.49, 53.59, 44.28, 28.25.  
HRMS-ESI calculated for C31H35N2O5 [M+H]
+ 515.2540, found m/z 515.2497.  
tert‐Butyl 2‐{[3‐(4‐methoxybenzoyl)‐1‐[(oxan‐4‐yl)methyl]‐1H‐indol‐5‐
yl]oxy}acetate (2.24c) 
A solution of 2.23e (50 mg, 0.14 mmol), NaH (11 
mg, 0.27 mmol) and tert-butylbromoacetate (26 µL, 
0.18 mmol) in DMF (3 mL) was reacted as 
described in the procedure for 2.24a. The crude 
product was purified by flash silica gel column 
chromatography (1:1 hexane/EA) to yield 2.24c (50 mg, 0.10 mmol, 76%) as a 
colourless oil (Rf 0.41, 1:1 hexane/EA).  
1H NMR (400 MHz, CDCl3) δ 7.87 (d, J = 2.5 Hz, 1H, ArH indole), 7.83 – 7.78 (m, 
2H, ArH MeOPh), 7.48 (s, 1H, ArH indole), 7.27 (d, J = 7.8 Hz, 1H, ArH indole), 7.07 
(dd, J = 8.9, 2.6 Hz, 1H, ArH indole), 7.02 – 6.95 (m, 2H, ArH MeOPh), 4.62 (s, 2H, 
O-CH2), 4.03 – 3.91 (m, 4H, N-CH2, O-CH2 THP), 3.88 (s, 3H, O-CH3), 3.30 (td, J = 
11.8, 2.1 Hz, 2H, O-CH2 THP), 2.16 – 2.04 (m, 1H, CH THP), 1.53 – 1.31 (m, 13H, O-
CH2CH2 THP & CH3 t-Bu).  
13C NMR (101 MHz, CDCl3) δ 189.71, 168.38, 162.28, 154.73, 136.82, 133.53, 132.39, 
130.87, 128.20, 115.41, 114.82, 113.69, 110.93, 105.05, 82.30, 67.39, 66.32, 55.55, 
53.31, 36.00, 30.83, 28.21.  
HRMS -ESI calculated for C28H33NNaO6 [M+Na]





To a stirred solution of 2.24a (25 mg, 51.5 µmol) in 
anhydrous DCM (1.8 mL) at 0°C, was added TFA 
(0.9 mL). The reaction mixture was stirred at rt for 3h, 
then evaporated under N2 stream, followed by reduced 
pressure. The TFA salt of the crude product 2.25a (34 
mg), was used in the next reaction without further 
purification. Some crude TFA salt 2.25a (approx. 3 mg) was purified for biological 
testing by semi-preparative RP-HPLC, yielding 2.25a (1.38 mg) as a white solid.  
HRMS-ESI calculated for C24H27N2O6 [M+H]
+ 439.1864, found m/z 439.1826.  
Analytical RP-HPLC Rt = 13.20 min.  
2-({1-[2-(Morpholin-4-yl)ethyl]-3-(naphthalene-1-carbonyl)-1H-indol-5-
yl}oxy)acetic acid (2.25b) 
A solution of 2.24b (18 mg, 35.9 µmol) and TFA (0.75 
mL) in anhydrous DCM (1.5 mL) was reacted as described 
in the procedure for 2.25a. The TFA salt of the crude 
product 2.25b (24 mg) was used in the next reaction 
without further purification. Some crude TFA salt 2.25b 
(approx. 3 mg) was purified for biological testing by semi-
preparative RP-HPLC, yielding 2.25b (1.1 mg) as a white 
solid.  
HRMS-ESI calculated for C27H27N2O5 [M+H]
+ 459.1914, found m/z 459.1889.  





A solution of 2.24c (17 mg, 0.04 mmol) and TFA 
(0.75 mL) in anhydrous DCM (1.5 mL) was reacted 
as described in the procedure for 2.25a. The TFA salt 
of the crude product 2.25c (21 mg) was used in the 
next reaction without further purification. Some crude 
TFA salt 2.25c (approx. 3 mg) was purified for biological testing by semi-preparative 
RP-HPLC, yielding 2.25c (1.0 mg) as a white solid.  
HRMS-ESI calculated for C24H25NNaO6 [M+Na]
+ 446.1574, found m/z 446.1561.  
Analytical RP-HPLC Rt = 18.10.  
Fmoc-Ala-Ala-1,2-diaminoethane trityl resin (2.26) 
1,2-Diaminoethane trityl resin (300 mg, 1.8 
mmol/g, 200-400 mesh) was swelled 
overnight in DMF. Fmoc-Ala-OH (504 mg, 
1.6 mmol), HBTU (614 mg, 1.6 mmol) and 
DIPEA (0.56 mL, 3.2 mmol) were dissolved in DMF (3.2 mL), swirled for 1 min, then 
added to the drained, swelled resin in a SPPS vessel. This mixture was swirled and left 
standing for 1 h, after which the resin was drained and washed with DMF. The Fmoc-
Ala-OH coupling procedure was repeated to double-couple, then the resin washed with 
DMF. The resin was capped by double treatment with acetic anhydride (500 µL) and 
DIPEA (500 µL) in DMF (1 mL) for 20 min, after which the resin was drained and 
washed with DMF and DCM and then dried under vacuum for 2 h. An Fmoc loading 
test was performed on the resin (6.9 mg), by adding a solution of piperidine in DMF (1 
mL, 20% v/v). After 60 mins, 100 µL of this solution was diluted to 10 mL with DMF. 
The absorbance was measured at 301 nm and the substitution was calculated to be 0.68 
mmol/g, using the formula:  
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𝑆𝑢𝑏𝑠𝑡𝑖𝑡𝑢𝑡𝑖𝑜𝑛 (𝑚𝑚𝑜𝑙/𝑔) =  
100 ×  𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒
7.8 × 𝑟𝑒𝑠𝑖𝑛 𝑚𝑎𝑠𝑠 (𝑚𝑔)
 
The resin was swelled in DMF for 1-2 h and the Fmoc was cleaved by treatment with 
20% v/v piperidine/DMF (3 mL) for 20 min with occasional stirring, then the resin 
drained and the piperidine treatment repeated for another 20 min, then the resin was 
drained and washed thoroughly with DMF. A solution of Fmoc-Ala-OH (224 mg, 0.72 
mmol), HBTU (273 mg, 0.72 mmol) and DIPEA (0.25 mL, 1.4 mmol) was dissolved in 
DMF (1.4 mL), swirled for 1 min, then added to the resin, swirled to mix and then left 
for 1 h. The resin was drained, washed with DMF, then DCM and left under vacuum 
for 2 h to dry to yield 2.26 (440 mg). Another Fmoc loading test was performed on the 
resin and the substitution was calculated to be 0.72 mmol/g, using the aforementioned 
formula.  
tert-Butyl N-(8-aminooctyl)carbamate (2.28a) 
To a vigorously stirred solution of 1,8-diaminooctane 
2.27a (2 g, 13.9 mmol) in dioxane (60 mL) at 0°C 
was added dropwise over 2 h a solution of Boc2O (0.64 mL, 2.8 mmol) in dioxane (60 
mL). The mixture was then stirred for 16 h, filtered, washed with dioxane and 
evaporated under reduced pressure. The residue was dissolved in DCM (90 mL), 
washed with warm H2O (15 x 90 mL) and sat. aq. NaCl (1 x 90 mL), dried over 
MgSO4, filtered and evaporated under reduced pressure, to yield the desired product 
2.28a (470 mg, 1.9 mmol, 69%) as a colourless oil.  
1H NMR (400 MHz, CDCl3) δ 4.56 (br s, 1H, NH), 3.07 (q, J = 6.8 Hz, 2H, NH-CH2), 
2.65 (t, J = 7.0 Hz, 2H, NH2-CH2), 1.66 – 1.52 (m, 2H, NH2), 1.47 – 1.37 (m, 13H, CH2 
& CH3 t Bu), 1.34 – 1.23 (m, 8H, CH2). This matched literature data.  
HRMS-ESI calculated for C13H29N2O2 [M+H]
+ 245.2224, found m/z 245.2224.  
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tert‐Butyl N‐{2‐[2‐(2‐aminoethoxy)ethoxy]ethyl}carbamate (2.28b) 
To a vigorously stirred solution of 2-2’-
(ethylenedioxy)bis(ethylamine) 2.27b (2.0 mL, 13.5 
mmol) in anhydrous DCM (30 mL) at 0°C was added dropwise over 2 h a solution of 
Boc2O (0.43 mL, 1.89 mmol) in anhydrous DCM (60 mL). The mixture was stirred for 
3 h, then washed with NaHCO3 (20 mL), H2O (2 x 20 mL) and sat. aq. NaCl (20 mL), 
dried over MgSO4, filtered and evaporated under reduced pressure, to yield the desired 
product 2.28b (322 mg, 1.3 mmol, 69%) as a colourless oil.  
1H NMR (400 MHz, CDCl3) δ 5.18 (br s, 1H, NH), 3.68-3.56 (m, 4H, O-CH2CH2-O), 
3.51 (dt, J = 9.0, 5.2 Hz, 4H, O-CH2), 3.28 (q, J = 5.3 Hz, 2H, NH-CH2), 2.95-2.77 (br 
m, 2H, NH2-CH2), 1.82 (br s, 2H, NH2), 1.41 (s, 9H, CH3 t Bu).  
13C NMR (101 MHz, CDCl3) δ 156.11, 79.25, 73.31, 70.30, 70.27, 41.73, 40.43, 28.51. 
1H and 13C NMR matched literature data.321  
HRMS-ESI calculated for C11H25N2O4 [M+H]
+ 249.1809, found m/z 249.1812.  
tert-Butyl N-[8-(2-{[3-(4-methoxybenzoyl)-1-[2-(morpholin-4-yl)ethyl]-1H-indol-5-
yl]oxy}acetamido)octyl]carbamate (2.29a) 
To a solution of the TFA salt 
of 2.25a (27 mg, 41.2 μmol) 
in anhydrous DMF (2 mL) 
were added DIPEA (21.5 µL, 
0.12 mmol) and HATU (16 
mg, 41.2 μmol). After 
stirring for 5 min, a solution of 2.28a (33 mg, 0.14 mmol) and DIPEA (21.5 µL, 0.12 
mmol) in DMF (1.5 mL) was added. The reaction mixture was stirred for 14 h and then 
the solvent evaporated under reduced pressure. The crude product was purified by flash 
silica gel column chromatography (99:1 DCM/MeOH with 0.3% of 25% aq. ammonia 
solution to load silica) to yield 2.29a (19 mg, 28.6 mmol, 69%) as a brown oil (Rf 0.28, 
9:1 DCM/MeOH).  
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1H NMR (500 MHz, CDCl3) δ 7.98 (d, J = 2.5 Hz, 1H, ArH indole), 7.88 – 7.81 (m, 
2H, ArH MeOPh), 7.70 (br s, 1H, ArH indole), 7.33 (br s, 1H, ArH indole), 7.02 – 6.97 
(m, 2H, ArH MeOPh), 6.70 (t, J = 5.8 Hz, 1H, ArH indole), 4.56 (s, 2H, O-CH2), 4.52 
(br s, 1H, NH), 4.31 - 4.15 (br m, 2H, N1-CH2), 3.90 (s, 3H, O-CH3), 3.79 – 3.56 (br m, 
4H, O-CH2 morpholino), 3.41 – 3.31 (m, 2H, CH2 octyl), 3.14 – 3.01 (m, 2H, CH2 
octyl), 2.86 – 2.69 (br m, 2H, N1-CH2CH2), 2.63 – 2.31 (br m, 4H, N-CH2 
morpholino), 1.60 – 1.51 (m, 2H, CH2 octyl), 1.50 – 1.39 (m, 11H, CH2 octyl & CH3 t 
Bu), 1.37 – 1.23 (m, 8H, CH2 octyl).  
HRMS-ESI calculated for C37H52N4NaO7 [M+Na]
+ 687.3728, found m/z 687.3717.  
tert-Butyl N-(2-{2-[2-(2-{[3-(4-methoxybenzoyl)-1-[2-(morpholin-4-yl)ethyl]-1H-
indol-5-yl]oxy}acetamido)ethoxy]ethoxy}ethyl)carbamate (2.29b) 
The TFA salt of 2.25a (23 
mg, 34.4 μmol), 2.28b (26 
mg, 0.11 mmol) DIPEA (36 
µL, 0.21 mmol) and HATU 
(13 mg, 34.4 μmol) in DMF 
(3 mL) were reacted as 
described in the procedure for 2.29a. The crude product was purified by flash silica gel 
column chromatography (99:1 DCM/MeOH with 0.3% of 25% aq. ammonia solution to 
load silica) to yield 2.29b (22 mg, 32.9 µmol, 94%) as a brown oil (Rf 0.38, 9:1 
DCM/MeOH).  
1H NMR (500 MHz, CDCl3) δ 7.97 (d, J = 2.5 Hz, 1H, ArH indole), 7.88 – 7.82 (m, 
2H, ArH MeOPh), 7.69 (br s, 1H, ArH indole), 7.33 (br s, 1H, ArH indole), 7.18 – 7.10 
(br m, 1H, ArH indole), 7.06 – 6.97 (m, 3H, ArH MeOPh & NH), 5.08 (br s, 1H, NH), 
4.59 (s, 2H, indole-O-CH2), 4.31 – 4.15 (br m, 2H, N1-CH2), 3.90 (s, 3H, O-CH3), 3.75 
– 3.51 (m, 14H, ([CH2]2O)2(CH2)2 & O-CH2 morpholino), 3.32 – 3.25 (br m, 2H, 
([CH2]2O)2(CH2)2), 2.82 – 2.71 (br m, 2H, N1-CH2CH2), 2.61 – 2.38 (br m, 4H, N-CH2 
morpholino), 1.42 (s, 9H, CH3 t Bu).  
13C NMR (126 MHz, CDCl3) δ 162.37, 156.57, 137.17, 136.76, 133.55, 131.98, 131.04, 
131.00, 128.45, 114.67, 114.38, 113.80, 113.73, 110.81, 105.54, 103.99, 74.21, 67.44, 
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67.42, 65.72, 55.97, 55.62, 55.60, 53.37, 43.78, 36.08, 30.87, 30.85.  
HRMS-ESI calculated for C35H48N4NaO9 [M+Na]
+ 691.3313, found m/z 691.3320. 
tert-Butyl N-{8-[2-({1-[2-(morpholin-4-yl)ethyl]-3-(naphthalene-1-carbonyl)-1H-
indol-5-yl}oxy)acetamido]octyl}carbamate (2.29c) 
The TFA salt of 2.25b (12 mg, 
18.1 μmol), 2.28a (16 mg, 67.1 
μmol), DIPEA (19 µL, 0.11 
mmol) and HATU (6.8 mg, 18.1 
μmol) in DMF (1.8 mL) were 
reacted as described in the 
procedure for 2.29a. The crude 
product was purified by flash silica gel column chromatography (97:3 DCM/MeOH 
with 0.3% of 25% aq. ammonia solution to load silica) to yield 2.29c (8.3 mg, 12.1 
µmol, 67%) as a brown oil (Rf 0.48, 9:1 DCM/MeOH).  
1H NMR (500 MHz, CDCl3) δ 8.14 (d, J = 8.4 Hz, 1H, ArH naphthalene), 8.08 (br s, 
1H, ArH indole), 7.97 (dt, J = 8.3, 1.0 Hz, 1H, ArH naphthalene), 7.94 – 7.87 (m, 1H, 
ArH naphthalene), 7.63 (dd, J = 7.0, 1.2 Hz, 1H, ArH naphthalene), 7.57 – 7.50 (m, 2H, 
ArH naphthalene), 7.47 (ddd, J = 8.3, 6.8, 1.5 Hz, 1H, ArH naphthalene), 7.44 (s, 1H, 
ArH indole), 7.32 (d, J = 13.2 Hz, 1H, ArH indole), 7.03 (d, J = 8.8 Hz, 1H, ArH 
indole), 6.79 – 6.67 (m, 1H, NH), 4.58 (s, 2H, indole-O-CH2), 4.51 (s, 1H, NH), 4.21-
4.05 (br m, 2H, N1-CH2), 3.71 – 3.42 (br m, 4H, O-CH2 morpholino), 3.41 – 3.32 (m, 
2H, CH2 octyl), 3.08 (q, J = 6.8 Hz, 2H, CH2 octyl), 2.78 – 2.60 (br m, 2H, N1-
CH2CH2), 2.56 – 2.22 (br m, 4H, N-CH2 morpholino), 1.78 – 1.52 (m, 4H, CH2 octyl), 
1.43 (s, 9H, CH3 t Bu), 1.38 – 1.16 (m, 8H, CH2 octyl).  
13C NMR (126 MHz, CDCl3) δ 192.05, 168.33, 156.12, 154.48, 139.48, 133.89, 130.80, 
130.29, 128.43, 127.95, 127.01, 126.53, 125.89, 124.63, 113.09, 110.90, 107.55, 79.12, 
68.48, 66.92, 57.63, 53.66, 44.53, 40.74, 39.19, 30.17, 29.71, 29.32, 29.30, 28.58, 
26.96, 26.86 (four quaternary carbons were not observed).  
HRMS-ESI calculated for C40H53N4O6 [M+H]





The TFA salt of 2.25b (27 mg, 
39.1 μmol), 2.28b (33 mg, 0.13 
mmol), DIPEA (41 µL, 0.23 
mmol) and HATU (15 mg, 39.1 
μmol) in DMF (3.5 mL) were 
reacted as described in the 
procedure for 2.29a. The crude 
product was purified by flash silica gel column chromatography (98:2 DCM/MeOH 
with 0.3% of 25% aq. ammonia solution to load silica) to yield 2.29d (13 mg, 18.9 
µmol, 50%) as a brown oil (Rf 0.36, 9:1 DCM/MeOH).  
1H NMR (400 MHz, CDCl3) δ 8.19 – 8.12 (m, 1H, ArH naphthalene), 8.09 (d, J = 2.6 
Hz, 1H, ArH indole), 7.96 (d, J = 8.0 Hz, 1H, ArH naphthalene), 7.91 (dd, J = 7.8, 1.5 
Hz, 1H, ArH naphthalene), 7.64 (dd, J = 7.0, 1.3 Hz, 1H, ArH naphthalene), 7.57 – 
7.44 (m, 3H, ArH naphthalene), 7.42 (s, 1H, ArH indole), 7.33 (d, J = 9.1 Hz, 1H, ArH 
indole), 7.17 (br s, 1H, NH), 7.03 (dd, J = 8.9, 2.6 Hz, 1H, ArH indole), 5.08 (br s, 1H, 
NH), 4.62 (s, 2H, indole-O-CH2), 4.29 – 4.03 (br m, 2H, N1-CH2), 3.68 – 3.50 (m, 
14H, ([CH2]2O)2(CH2)2 & O-CH2 morpholino), 3.36 – 3.24 (m, 2H, ([CH2]2O)2(CH2)2), 
2.75 – 2.61 (br m, 2H, N1-CH2CH2), 2.52 – 2.25 (br m, 4H, N-CH2 morpholino), 1.41 
(s, 9H, CH3 t Bu).  
13C NMR (126 MHz, CDCl3) δ 192.04, 168.56, 156.11, 154.50, 139.38, 138.88, 133.86, 
132.70, 130.78, 130.24, 128.39, 127.86, 126.97, 126.49, 125.87, 125.83, 124.61, 
117.72, 113.69, 110.96, 107.14, 79.33, 70.44, 70.36, 70.34, 69.93, 68.47, 66.84, 57.47, 
53.52, 44.44, 40.48, 38.94, 28.53.  
HRMS-ESI calculated for C38H49N4O8 [M+H]





2.29a (7.3 mg, 10.9 µmol) was 
dissolved in DCM (1.6 mL) and 
TFA (1.6 mL) was added. After 1 
h stirring, the reaction mixture was 
evaporated under N2 stream, 
followed by reduced pressure. The 
crude was purified by semi-preparative RP-HPLC to yield the TFA salt of 2.30a (5.2 
mg, 5.7 μmol, 52%) as a white solid.  
HRMS-ESI calculated for C32H45N4O5 [M+H]
+ 565.3384, found m/z 565.3338.  
Analytical RP-HPLC Rt = 13.43 min.  
N-{2-[2-(2-Aminoethoxy)ethoxy]ethyl}2-{[3-(4-methoxybenzoyl)-1-[2-(morpholin-
4-yl)ethyl]-1H-indol-5-yl]oxy}acetamide (2.30b) 
A solution of 2.29b (8.4 mg, 12.6 
µmol) and TFA (1.6 mL) in DCM 
(1.6 mL) was reacted as described 
in the procedure for 2.30a. The 
crude was purified by semi-
preparative RP-HPLC to yield the 
TFA salt of 2.30b (8.8 mg, 9.7 μmol, 77%) as a white solid.  
HRMS-ESI calculated for C30H41N4O7 [M+H]
+ 569.2970, found m/z 569.2926.  





A solution of 2.29c (7 mg, 10.2 μmol) 
and TFA (1 mL) in DCM (1 mL) was 
reacted as described in the procedure 
for 2.30a. The crude was purified by 
semi-preparative RP-HPLC to yield 
the TFA salt of 2.30c (5.3 mg, 5.7 
μmol, 56%) as a white solid.  
HRMS-ESI calculated for C35H45N4O4 [M+H]
+ 585.3435, found m/z 585.3384.  
Analytical RP-HPLC Rt = 14.32 min. 
N-{2-[2-(2-Aminoethoxy)ethoxy]ethyl}-2-({1-[2-(morpholin-4-yl)ethyl]-3-
(naphthalene-1-carbonyl)-1H-indol-5-yl}oxy)acetamide (2.30d) 
A solution of 2.29d (12 mg, 17.4 
μmol) and TFA (1 mL) in DCM (1 
mL) was reacted as described in the 
procedure for 2.30a. The crude was 
purified by semi-preparative RP-HPLC 
to yield the TFA salt of 2.30d (4.3 mg, 
4.6 μmol, 27%) as a white solid.  
HRMS-ESI calculated for C33H41N4O6 [M+H]
+ 589.3021, found m/z 589.2984.  





2.26 (58 mg, 41.4 μmol) was 
swelled in DMF, Fmoc-
deprotected using 20% v/v 
piperidine/DMF and then washed 
thoroughly with DMF. A solution 
of the TFA salt of 2.25a (23 mg, 
34.3 μmol), HATU (16 mg, 41.4 μmol) and DIPEA (29 µL, 0.17 mmol) in DMF (83 
µL) was swirled for 1 min and then added to the drained resin and left for 2 h. The resin 
was drained, washed with DMF and DCM and dried under vacuum. The resin was 
transferred to a round bottom flask and cleaved using a solution of TFA in DCM (5 mL, 
5% v/v), stirring for 1 h. The mixture was filtered, washed with DCM and the filtrate 
dried under reduced pressure. The crude residue was purified using semi-preparative 
RP-HPLC, to yield the TFA salt of 2.30e (9.9 mg, 10.2 μmol, 30%) as a white solid.  
HRMS-ESI calculated for C32H43N6O7 [M+H]
+ 623.3188, found m/z 623.3133.  
Analytical RP-HPLC Rt = 11.83 min.  
(2S)‐N‐[(1S)‐1‐[(2‐aminoethyl)carbamoyl]ethyl]‐2‐[2‐({1‐[2‐(morpholin‐4‐yl)ethyl]‐
3‐(naphthalene‐1‐carbonyl)‐1H‐indol‐5‐yl}oxy)acetamido]propanamide (2.30f) 
2.26 (38 mg, 27.3 μmol), piperidine in 
DMF (20% v/v), 2.25b (16 mg, 22.7 
μmol), HATU (10 mg, 27.3 μmol), 
DIPEA (19 µL, 0.11 mmol), TFA in 
DCM (5 mL 5% v/v) were used as in 
the procedure for 2.30e. The crude was 
purified using semi-preparative RP-
HPLC, to yield the TFA salt of 2.30f (5.14 mg, 6.2 μmol, 27%) as a white solid.  
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HRMS-ESI calculated for C35H43N6O6 [M+H]
+ 643.3239, found m/z 643.3194.  
Analytical RP-HPLC Rt = 13.21 min.  
(2S)‐N‐[(1S)‐1‐[(2‐aminoethyl)carbamoyl]ethyl]‐2‐(2‐{[3‐(4‐methoxybenzoyl)‐1‐
[(oxan‐4‐yl)methyl]‐1H‐indol‐5‐yl]oxy}acetamido)propanamide (2.30g) 
2.26 (44 mg, 31.7 μmol), 
piperidine in DMF (20% v/v), the 
TFA salt of 2.25c (17 mg, 31.7 
μmol), HATU (12 mg, 31.7 μmol), 
DIPEA (22 µL, 0.13 mmol), TFA 
in DCM (5 mL 5% v/v) were used as described in the procedure for 2.30e. The crude 
was purified using semi-preparative RP-HPLC, to yield the TFA salt of 2.30g (7.45 mg, 
8.9 μmol, 28%) as a white solid.  
HRMS-ESI calculated for C32H42N5O7 [M+H]
+ 608.3079, found m/z 608.3031.  
Analytical RP-HPLC Rt = 15.63 min.  
N-{2-[2-(2-Acetamidoethoxy)ethoxy]ethyl}-2-{[3-(4-methoxybenzoyl)-1-[2-
(morpholin-4-yl)ethyl]-1H-indol-5-yl]oxy}acetamide (2.31) 
To a solution of the TFA salt of 
2.30b (2.6 mg, 2.9 µmol) and 
DIPEA (1.71 µL, 9.8 µmol, 
added as a 1:10 solution in 
DCM) was added acetic 
anhydride (0.34 µL 3.6 µmol, 
added as a 1:10 solution in DCM) and the mixture was stirred at rt for 1 h. The reaction 
solvent was evaporated under N2 stream. The product was purified by semi-preparative 
RP-HPLC and passed through an Amberlyst A21 ion exchange resin to remove TFA, 
yielding 2.31 (1.69 mg, 2.8 μmol, 97%) as a white solid.  
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HRMS-ESI calculated for C32H43N4O8 [M+H]
+ 611.3075, found m/z 611.3068.  






To a solution of the TFA salt of 2.30a (2.82 mg, 3.11 µmol) in anhydrous DMF (500 
µL), was added a solution of DIPEA (1.91 µL, 11.0 µmol) in anhydrous DMF (30.59 
µL), followed by a solution of BODIPY 630/650-X-OSu 2.15 (1.25 mg, 1.89 µmol) in 
anhydrous DMF (300 µL). The mixture was swirled, left standing for 12 h, then 
evaporated under reduced pressure. The crude product was purified by semi-preparative 
RP-HPLC and passed through an Amberlyst A21 ion exchange resin to remove TFA, 
yielding 2.32a (1.56 mg, 1.41 μmol, 74%) as a bright blue solid.  
HRMS-ESI calculated for C61H70BF2N7NaO8S [M+Na]
+ 1132.4970, found m/z 
1132.5064.  









The TFA salt of 2.30b (3.59 mg, 3.94 µmol), DIPEA (2.24 µL, 12.9 µmol), BODIPY 
630/650-X-OSu 2.15 (1.25 mg, 1.89 µmol) and DMF (836 µL) were reacted as 
described in the procedure for 2.32a. The crude product was purified by semi-
preparative RP-HPLC and passed through an Amberlyst A21 ion exchange resin to 
remove TFA, yielding 2.32b (1.26 mg,1.13 μmol, 60%) as a bright blue solid.  
HRMS-ESI calculated for C59H66BF2N7NaO10S [M+Na]
+ 1136.4555, found m/z 
1136.4618.  








The TFA salt of 2.30c (3.22 mg, 3.47 µmol), DIPEA (2.04 µL, 11.7 µmol), BODIPY 
630/650-X-OSu 2.15 (1.25 mg, 1.89 µmol) and DMF (832 µL) were reacted as 
described in the procedure for 2.32a. The crude product was purified by semi-
preparative RP-HPLC and passed through an Amberlyst A21 ion exchange resin to 
remove TFA, yielding 2.32c (1.88 mg, 1.66 μmol, 88%) as a bright blue solid.  
HRMS-ESI calculated for C64H70BF2N7NaO7S [M+Na]
+ 1152.5021, found m/z 
1152.5090.  









The TFA salt of 2.30d (2.41 mg, 2.59 µmol), DIPEA (1.71 µL, 9.8 µmol), BODIPY 
630/650-X-OSu 2.15 (1.25 mg, 1.89 µmol) and DMF (827 µL) were reacted as 
described in the procedure for 2.32a. The crude product was purified by semi-
preparative RP-HPLC and passed through an Amberlyst A21 ion exchange resin to 
remove TFA, yielding 2.32d (1.75 mg, 1.54 μmol, 82%) as a bright blue solid.  
HRMS-ESI calculated for C62H66BF2N7NaO9S [M+Na]
+ 1156.4606, found m/z 
1156.4661.  









The TFA salt of 2.30e (3.67 mg, 3.80 µmol), DIPEA (2.37 µL, 13.6 µmol), BODIPY 
630/650-X-OSu 2.15 (1.67 mg, 2.52 µmol) and DMF (840 µL) were reacted as 
described in the procedure for 2.32a. The crude product was purified by semi-
preparative RP-HPLC and passed through an Amberlyst A21 ion exchange resin to 
remove TFA, yielding 2.32e (1.56 mg, 1.34 μmol, 53%) as a bright blue solid.  
HRMS-ESI calculated for C61H68BF2N9NaO10S [M+Na]
+ 1190.4773, found m/z 
1190.4840.  









The TFA salt of 2.30f (3.32 mg, 3.37 µmol), DIPEA (2.19 µL, 12.6 µmol), BODIPY 
630/650-X-OSu 2.15 (1.67 mg, 2.52 µmol) and DMF (837 µL) were reacted as 
described in the procedure for 2.32a. The crude product was purified by semi-
preparative RP-HPLC and passed through an Amberlyst A21 ion exchange resin to 
remove TFA, yielding 2.32f (2.08 mg, 1.75 μmol, 70%) as a bright blue solid.  
HRMS-ESI calculated for C64H69BF2N9O9S [M+H]
+ 1188.5005, found m/z 1188.5012.  









The TFA salt of 2.30g (3.89 mg, 4.65 µmol), DIPEA (2.46 µL, 14.1 µmol), BODIPY 
630/650-X-OSu 2.15 (1.67 mg, 2.52 µmol) and DMF (842 µL) were reacted as 
described in the procedure for 2.32a. The crude product was purified by semi-
preparative RP-HPLC and passed through an Amberlyst A21 ion exchange resin to 
remove TFA, yielding 2.32g (1.06 mg, 0.92 μmol, 36%) as a bright blue solid.  
HRMS-ESI calculated for C61H67BF2N8NaO10S [M+Na]
+ 1175.4664, found m/z 
1175.4655.  
Analytical RP-HPLC Rt = 23.14 min. 
7-(Benzyloxy)-1-[(oxan-4-yl) methyl]-1H-indole (3.2) 
7-Benzyloxyindole 3.1 (335 mg, 1.5 mmol), NaH (268 mg, 6.7 
mmol) and 2.17b (582 mg, 3.0 mmol) in DMF (14 mL) were 
reacted as described in the procedure for 2.19a. The crude product 
was purified using flash silica column chromatography (4:1 
hexane/EA) to yield the desired 3.2 (418 mg, 1.3 mmol, 87%), as a 
pale violet wax (Rf 0.63, 2:1 PE/EA).  
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1H NMR (400 MHz, CDCl3) δ 7.51 – 7.44 (m, 2H, ArH Bn), 7.44 – 7.33 (m, 3H, ArH 
Bn), 7.24 (dt, J = 8.0, 0.7 Hz, 1H, ArH indole), 7.00 (t, J = 7.8 Hz, 1H, ArH indole), 
6.91 (d, J = 2.9 Hz, 1H, ArH indole), 6.73 (dd, J = 7.8, 0.8 Hz, 1H, ArH indole), 6.40 
(d, J = 3.0 Hz, 1H, ArH indole), 5.14 (s, 2H, CH2 Bn), 4.08 (d, J = 7.2 Hz, 2H, N-CH2), 
3.87 – 3.76 (m, 2H, O-CH2 THP), 3.13 (td, J = 11.6, 2.5 Hz, 2H, O-CH2 THP), 2.11 – 
1.92 (m, 1H, CH THP), 1.26 – 1.03 (m, 4H, O-CH2CH2 THP).  
13C NMR (101 MHz, CDCl3) δ 146.85, 136.98, 131.35, 130.02, 128.71, 128.56, 128.41, 
125.57, 119.87, 114.12, 103.02, 100.83, 70.60, 67.70, 55.41, 37.68, 30.43.  
HRMS-ESI calculated for C21H23NNaO2 [M+Na]
+ 344.1621, found m/z 344.1591.  
7-(Benzyloxy)-3-(4-methoxybenzoyl)-1-[(oxan-4-yl)methyl]-1H-indole (3.3) 
A solution of 3.2 (104 mg, 0.32 mmol), 4-methoxybenzonitrile 
(129 mg, 0.97 mmol) and 2.21 (13 mg, 32.0 μmol) in H2O 
(0.12 mL), glacial AcOH (0.18 mL) and 1,4-dioxane (0.6 mL) 
was reacted as described in the procedure for 2.22a. The crude 
residue was purified by flash silica column chromatography 
(2:1 hexane/EA) to yield 3.3 (85 mg, 0.19 mmol, 58%) as a 
pale pinkish-white solid (Rf 0.44, 1:1 hexane/EA).  
1H NMR (400 MHz, CDCl3) δ 8.01 (dd, J = 8.1, 0.9 Hz, 1H, ArH indole), 7.85 – 7.78 
(m, 2H, ArH MeOPh), 7.51 – 7.46 (m, 2H, ArH Bn), 7.45 – 7.37 (m, 3H, ArH Bn), 
7.37 (s, 1H, ArH indole), 7.23 (t, J = 8.0 Hz, 1H, ArH indole), 7.02 – 6.95 (m, 2H, ArH 
MeOPh), 6.87 (dd, J = 7.9, 0.9 Hz, 1H, ArH indole), 5.15 (s, 2H, CH2 Bn), 4.10 (d, J = 
7.2 Hz, 2H, N-CH2), 3.89 (s, 3H, O-CH3), 3.86 – 3.77 (m, 2H, O-CH2 THP), 3.12 (td, J 
= 11.6, 2.4 Hz, 2H, O-CH2 THP), 2.14 – 1.93 (m, 1H, CH THP), 1.22 – 0.99 (m, 4H, 
O-CH2CH2 THP).  
13C NMR (101 MHz, CDCl3) δ 189.81, 162.33, 146.60, 137.85, 136.49, 133.54, 131.04, 
130.25, 128.82, 128.74, 128.66, 126.27, 123.20, 115.56, 115.32, 113.64, 105.14, 70.84, 
67.54, 56.29, 55.55, 37.10, 30.22.  
HRMS-ESI calculated for C29H30NO4 [M+H]




A mixture of 3.3 (723 mg, 1.6 mmol), EtOH (12 mL), CHCl3 (32 
mL) and Pd/C (72 mg) was reacted as described in the procedure 
for 2.23a. The crude residue was purified by flash silica gel 
column chromatography (2:1 hexane/EA) to yield the desired 
product 3.4 (322 mg, 0.88 mmol, 55%) as a brown oil, (Rf 0.47, 
1:1 PE/EA).  
1H NMR (400 MHz, CDCl3) δ 7.96 – 7.89 (m, 1H, ArH indole), 7.87 – 7.79 (m, 2H, 
ArH MeOPh), 7.44 (s, 1H, ArH indole), 7.07 (t, J = 7.9 Hz, 1H, ArH indole), 7.02 – 
6.95 (m, 2H, ArH MeOPh), 6.69 (dt, J = 7.6, 1.1 Hz, 1H, ArH indole), 4.31 (d, J = 7.2 
Hz, 2H, N-CH2), 4.02 – 3.91 (m, 2H, O-CH2 THP), 3.89 (s, 3H, O-CH3), 3.31 (td, J = 
11.7, 2.3 Hz, 2H, O-CH2 THP), 2.31 – 2.07 (m, 1H, CH THP), 1.58 – 1.27 (m, 4H, O-
CH2CH2 THP).  
13C NMR (101 MHz, CDCl3) δ 190.53, 162.47, 143.72, 138.20, 133.38, 131.19, 130.33, 
126.12, 123.47, 115.56, 114.63, 113.71, 109.48, 67.65, 55.72, 55.59, 37.41, 30.45.  
HRMS-ESI calculated for C22H23NNaO4 [M+Na]
+ 388.1519, found m/z 388.1553.  
Analytical RP-HPLC Rt = 18.19 min.  
tert‐Butyl 2‐{[3‐(4‐methoxybenzoyl)‐1‐[(oxan‐4‐yl)methyl]‐1H‐indol‐7‐
yl]oxy}acetate (3.5) 
A solution of 3.4 (11 mg, 30.1 µmol), NaH (2.4 mg, 60.2 
µmol) and tert-butylbromoacetate (5.8 µL, 39.1 µmol) in 
DMF (1.8 mL) was reacted as described in the procedure for 
2.24a. The crude product was purified by flash silica gel 
column chromatography (1:1 hexane/EA) to yield 3.5 (4.7 
mg, 9.8 µmol, 33%) as a yellow oil (Rf 0.6, 1:2 hexane/EA).  
1H NMR (400 MHz, CDCl3) δ 8.02 (dd, J = 8.1, 0.8 Hz, 1H, ArH indole), 7.87 – 7.79 
(m, 2H, ArH MeOPh), 7.43 (s, 1H, ArH indole), 7.17 (t, J = 8.0 Hz, 1H, ArH indole), 
7.03 – 6.95 (m, 2H, ArH MeOPh), 6.64 (dd, J = 8.0, 0.8 Hz, 1H, ArH indole), 4.64 (s, 
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2H, O-CH2), 4.39 (d, J = 7.2 Hz, 2H, N-CH2), 3.94 (dd, J = 11.5, 4.0 Hz, 2H, O-CH2 
THP), 3.90 (s, 3H, O-CH3), 3.30 (td, J = 11.8, 2.1 Hz, 2H, O-CH2 THP), 2.28 – 2.11 
(m, 1H, CH THP), 1.57 – 1.31 (m, 13H, O-CH2CH2 THP & CH3 t Bu).  
13C NMR (101 MHz, CDCl3) δ 189.86, 167.36, 162.39, 145.50, 138.02, 133.53, 131.11, 
130.38, 126.44, 123.03, 116.18, 115.46, 113.69, 105.22, 82.60, 67.68, 65.99, 56.19, 
55.60, 37.29, 30.53, 28.25.  
HRMS -ESI calculated for C28H34NO6 [M+H]
+ 480.2381, found m/z 480.2346. 
2‐{[3‐(4‐Methoxybenzoyl)‐1‐[(oxan‐4‐yl)methyl]‐1H‐indol‐7‐yl]oxy}acetic acid 
(3.6) 
A solution of 3.5 (3.1 mg, 6.46 µmol) and TFA (0.4 mL) in 
DCM (0.8 mL) was reacted as described in the procedure for 
2.25a. The crude was purified by semi-preparative RP-HPLC 
and passed through an Amberlyst A21 ion exchange resin to 
remove TFA, yielding 3.6 (1.45 mg, 3.4 µmol, 53%), a white 
solid.  
HRMS -ESI calculated for C24H24NO6 [M-H]
- 422.1609, found m/z 422.1598.  
Analytical RP-HPLC Rt = 17.17 min.  
3-(4-Methoxybenzoyl)-1-[(oxan-4-yl)methyl]-5-propoxy-1H-indole (3.7a) 
To a solution of 2.23e (50 mg, 0.14 mmol) in anhydrous 
DMF (3 mL) was added NaH (60% by mass dispersion 
in mineral oil) (20 mg, 0.50 mmol), followed by 
dropwise addition of 1-bromopropane (18.6 µL, 0.21 
mmol) in anhydrous DMF (2 mL). After stirring for 20 
h, the reaction was quenched with sat. aq. NH4Cl (2 mL) and H2O (3 mL) and extracted 
with EA (4 × 5 mL). The combined organics were washed with H2O (4 × 20 mL), dried 
over MgSO4, filtered and evaporated under reduced pressure.  The crude product was 
purified using flash silica column chromatography (99:1 DCM/MeOH) to yield the 
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desired 3.7a (46 mg, 0.11 mmol, 83%), as a white-opaque solid (Rf 0.57, 99:1 
DCM/MeOH).  
1H NMR (400 MHz, CDCl3) δ 7.93 (d, J = 2.5 Hz, 1H, ArH indole), 7.86 – 7.79 (m, 
2H, ArH MeOPh), 7.48 (s, 1H, ArH indole), 7.25 (dd, J = 8.9, 0.5 Hz, 1H, ArH indole), 
7.03 – 6.95 (m, 3H, ArH indole & ArH MeOPh), 4.07 – 3.92 (m, 6H, O-CH2 propyl, N-
CH2 & O-CH2 THP), 3.89 (s, 3H, O-CH3), 3.31 (td, J = 11.8, 2.2 Hz, 2H, O-CH2 THP), 
2.19 – 2.03 (m, 1H, CH THP), 1.93 – 1.76 (m, 2H, O-CH2-CH2 propyl), 1.55 – 1.30 (m, 
4H, O-CH2CH2 THP), 1.05 (t, J = 7.4 Hz, 3H, CH3 propyl).  
13C NMR (101 MHz, CDCl3) δ 189.83, 162.29, 156.02, 136.66, 133.58, 131.88, 130.93, 
128.43, 115.32, 114.72, 113.67, 110.71, 104.90, 70.25, 67.41, 55.55, 53.29, 36.03, 
30.84, 22.80, 10.71.  
HRMS-ESI calculated for C25H29NNaO4 [M+Na]
+ 430.1989, found m/z 430.1954.  
Analytical RP-HPLC Rt = 22.17 min. 
3-(4-Methoxybenzoyl)-1-[(oxan-4-yl)methyl]-7-propoxy-1H-indole (3.7b) 
A solution of 3.4 (9.5 mg, 25.9 μmol), NaH (3.1 mg, 77.7 
μmol), and 1-bromopropane (3.5 µL, 38.9 μmol) in DMF (0.95 
mL) was reacted as described in the procedure for 3.7a. The 
crude product was purified using flash silica column 
chromatography (2:1 hexane/EA) to yield the desired 3.7b (6.1 
mg, 15.0 µmol, 57%), as a colourless oil (Rf 0.56, 1:1 hexane/EA).  
1H NMR (400 MHz, CDCl3) δ 7.96 (dd, J = 8.1, 0.9 Hz, 1H, ArH indole), 7.86 – 7.77 
(m, 2H, ArH MeOPh), 7.40 (s, 1H, ArH indole), 7.18 (t, J = 7.9 Hz, 1H, ArH indole), 
7.03 – 6.95 (m, 2H, ArH MeOPh), 6.74 (dd, J = 7.9, 0.9 Hz, 1H, ArH indole), 4.29 (d, J 
= 7.3 Hz, 2H, N-CH2), 4.10 (t, J = 6.5 Hz, 2H, O-CH2 propyl), 4.01 – 3.92 (m, 2H, O-
CH2 THP), 3.89 (s, 3H, O-CH3), 3.30 (td, J = 11.7, 2.3 Hz, 2H, O-CH2 THP), 2.26 – 
2.11 (m, 1H, CH THP), 1.99 – 1.82 (m, 2H, O-CH2-CH2 propyl), 1.52 – 1.28 (m, 4H, 
O-CH2CH2 THP), 1.12 (t, J = 7.4 Hz, 3H, CH3 propyl).  
13C NMR (101 MHz, CDCl3) δ 189.88, 162.34, 146.87, 137.66, 133.65, 131.09, 130.10, 
126.36, 123.25, 115.50, 115.13, 113.67, 105.03, 69.83, 67.63, 56.21, 55.59, 37.29, 
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30.58, 22.97, 11.04.  
HRMS-ESI calculated for C25H29NNaO4 [M+Na]
+ 430.1989, found m/z 430.1994.  
Analytical RP-HPLC Rt = 22.55 min.  
tert-Butyl N-(2-{2-[2-(2-hydroxyethoxy)ethoxy]ethoxy}ethyl)carbamate (3.9) 
To a stirred solution of 2-(2-(2-(2-
aminoethoxy)ethoxy)ethoxy)ethanol 3.8 (100 
µL, 0.55 mmol) in dioxane (1 mL) was added Boc2O (152 µL, 0.66 mmol). The 
mixture was stirred for 18 h at rt and then evaporated under reduced pressure. The 
crude was taken up in DCM (6 mL), washed with H2O (2 x 6 mL) and sat. aq. NaCl (1 
x 5 mL), dried over MgSO4, filtered and evaporated under reduced pressure. The crude 
product was purified using flash silica column chromatography (99:1 DCM/MeOH) to 
yield the desired 3.9 (24 mg, 81.8 µmol, 15%), as a pale yellow oil (Rf 0.52, 9:1 
DCM/MeOH).  
1H NMR (400 MHz, CDCl3) δ 3.75 – 3.67 (m, 4H, O-CH2), 3.66 – 3.57 (m, 8H, O-
CH2CH2-O), 3.52 (t, J = 5.2 Hz, 2H, O-CH2), 3.29 (t, J = 5.2 Hz, 2H, NH-CH2), 1.43 
(s, 9H, CH3 t Bu).  
13C NMR (101 MHz, CDCl3) δ 156.31, 79.19, 72.77, 70.72, 70.67, 70.55, 70.36, 70.20, 
61.76, 40.67, 28.56.  
HRMS-ESI calculated for C13H27NNaO6 [M+Na]
+ 316.1731, found m/z 316.1738.  
tert-Butyl N-(2-{2-[2-(2-bromoethoxy)ethoxy]ethoxy}ethyl)carbamate (3.10) 
A solution of bromine (7.3 µL, 0.14 mmol) in 
anhydrous DCM (0.2 mL) at 0°C was added to a 
solution of triphenylphosphine (37 mg, 0.14 mmol) and Et3N (20 µL, 0.14 mmol) in 
anhydrous DCM (0.2 mL) at 0°C. Following stirring at 0°C for 30 min, a solution of 
3.9 (42 mg, 0.14 mmol) in anhydrous DCM (0.2 mL) was added dropwise. After 
stirring at 0°C for 2 h, the mixture was evaporated under reduced pressure. The crude 
product was purified using flash silica column chromatography (5:1 hexane/EA) to 
yield the desired 3.10 (13 mg, 36.5 µmol, 26%) as a colourless oil.  
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1H NMR (400 MHz, CDCl3) δ 5.03 (br s, 1H, NH), 3.81 (t, J = 6.3 Hz, 2H, O-CH2), 
3.73 – 3.58 (m, 8H, O-CH2CH2-O), 3.54 (t, J = 5.1 Hz, 2H, O-CH2), 3.47 (t J = 6.3, 1.2 
Hz, 2H, CH2Br), 3.31 (q, J = 5.6 Hz, 2H, NH-CH2), 1.44 (s, 9H, CH3 t Bu).  
HRMS-ESI calculated for C13H26BrNNaO5 [M+Na]
+ 378.0887, found m/z 378.0894.  
tert-Butyl N-(2-{2-[2-(2-{[3-(4-methoxybenzoyl)-1-[(oxan-4-yl)methyl]-1H-indol-5-
yl]oxy}ethoxy)ethoxy]ethoxy}ethyl)carbamate (3.11) 
To a solution of 2.23e (13 
mg, 35.1 μmol) in anhydrous 
DMF (0.7 mL) was added 
NaH (60% by mass 
dispersion in mineral oil) 
(5.5 mg, 0.14 mmol). After stirring for 30 min, a solution of 3.10 (12.5 mg, 35.1 μmol) 
in anhydrous DMF (0.6 mL) was added. The reaction mixture was stirred for 18 h, then 
quenched with H2O (1.5 mL), extracted with EA (4 × 2 mL), washed with H2O (2 × 7 
mL), dried over MgSO4, filtered and evaporated under reduced pressure. The crude 
product was purified using flash silica column chromatography (99:1 DCM/MeOH) 
and semi-preparative RP-HPLC to yield the desired 3.11 (6.88 mg, 10.7 µmol, 31%), as 
a white solid.  
1H NMR (400 MHz, DMSO-d6) δ 7.97 (s, 1H, ArH indole), 7.81 – 7.75 (m, 3H, ArH 
indole and MeOPh), 7.58 (d, J = 9.0 Hz, 1H, ArH indole), 7.12 – 7.05 (m, 2H, ArH 
MeOPh), 6.95 (dd, J = 8.9, 2.5 Hz, 1H, ArH indole), 6.74 (br s, 1H, NH), 4.21 – 4.07 
(m, 4H, N1-CH2 & indole-O-CH2), 3.86 (s, 3H, O-CH3), 3.85 – 3.75 (m, 4H, O-CH2 & 
O-CH2 THP), 3.65 – 3.45 (m, 8H, O-CH2CH2-O), 3.37 (t, J = 6.1 Hz, 2H, O-CH2), 3.19 
(td, J = 11.7, 2.0 Hz, 2H, O-CH2 THP), 3.05 (q, J = 6.0 Hz, 2H, NH-CH2), 2.13 – 2.02 
(m, 1H, CH THP), 1.41 – 1.21 (m, 13H, O-CH2CH2 THP, CH3 t Bu).  
HRMS-ESI calculated for C35H48N2NaO9 [M+Na]
+ 663.3252, found m/z 663.3247.  





To a solution of 3.11 (1.81 mg, 
2.8 µmol) in DCM (0.45 mL) 
was added TFA (0.45 mL). The 
reaction mixture was swirled, 
left to stand for 1 h and then 
evaporated under reduced pressure. The residue was then dissolved in a solution of 
DCM (0.4 mL) and a solution of DIPEA (1.48 µL, 8.5 µmol, added as a 1:50 solution 
in DCM) added, followed by a solution of acetic anhydride (0.29 µL, 3.1 µmol, added 
as a 1:50 solution in DCM). The reaction mixture was swirled and then left to stand for 
1.5 h, after which the reaction solvent was evaporated under air. The product was 
purified by semi-preparative RP-HPLC and passed through an Amberlyst A21 ion 
exchange resin to remove TFA, yielding 3.12 (1.17 mg, 2.0 μmol, 71%), as a white 
solid.  
HRMS-ESI calculated for C32H42N2NaO8 [M+Na]
+ 605.2833, found m/z 605.2828.  
Analytical RP-HPLC Rt = 18.12 min.  
Methyl 5‐{[3‐(4‐methoxybenzoyl)‐1‐[(oxan‐4‐yl)methyl]‐1H‐indol‐7‐
yl]oxy}pentanoate (3.13) 
A solution of 3.4 (261 mg, 0.71 mmol), NaH (86 
mg, 2.1 mmol) and methyl 5-bromovalerate (153 
µL, 1.1 mmol) in DMF (20 mL) was reacted as 
described in the procedure for 3.7a. The crude 
product was purified using flash silica column 
chromatography (4:1 hexane/EA) to yield the desired 3.13 (103 mg, 0.28 mmol, 30%), 
as a white solid (Rf 0.32, 1:1 hexane/EA).  
1H NMR (400 MHz, CDCl3) δ 7.97 (dd, J = 8.1, 0.8 Hz, 1H, ArH indole), 7.84 – 7.80 
(m, 2H, ArH MeOPh), 7.40 (s, 1H, ArH indole), 7.18 (t, J = 8.0 Hz, 1H, ArH indole), 
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7.01 – 6.96 (m, 2H, ArH MeOPh), 6.73 (dd, J = 7.9, 0.9 Hz, 1H, ArH indole), 4.28 (d, J 
= 7.3 Hz, 2H, N-CH2), 4.15 (t, J = 5.8 Hz, 2H, O-CH2 butyl), 3.98 – 3.92 (m, 2H, O-
CH2 THP), 3.89 (s, 3H, Ph-O-CH3), 3.69 (s, 3H, COOCH3), 3.29 (td, J = 11.6, 2.4 Hz, 
2H, O-CH2 THP), 2.43 (t, J = 6.9 Hz, 2H, CH2COO), 2.22 – 2.08 (m, 1H, CH THP), 
1.96 – 1.83 (m, 4H, CH2CH2), 1.48 – 1.30 (m, 4H, O-CH2CH2 THP).  
13C NMR (101 MHz, CDCl3) δ 189.89, 173.66, 162.36, 146.64, 137.77, 133.52, 131.10, 
130.14, 126.27, 123.24, 115.45, 115.30, 113.66, 105.06, 67.63, 67.57, 56.20, 55.58, 
51.79, 37.28, 33.71, 30.56, 29.06, 21.94.  
HRMS-ESI calculated for C28H34NO6 [M+H]
+ 480.2381, found m/z 480.2366.  
Analytical RP-HPLC Rt = 20.92 min. 
5‐{[3‐(4‐Methoxybenzoyl)‐1‐[(oxan‐4‐yl)methyl]‐1H‐indol‐7‐yl]oxy}pentanoic acid 
(3.14) 
To a stirred solution of 3.13 (91 mg, 0.19 mmol) in 
THF (1.6 mL) at 0°C was added dropwise 0.2 M 
aq. lithium hydroxide monohydrate solution (2.4 
mL). The mixture was stirred at 0°C for 18 h, then 
quenched with biphase of 0.2 M aq. HCl/EA (1:1 
v/v) until pH 4. The aqueous layer was extracted with EA (4 × 4 mL), dried over 
MgSO4, filtered and evaporated under reduced pressure to yield the hydrochloride salt 
of 3.14 (84 mg, 0.17 mmol, 88%) as a brown solid.  
1H NMR (400 MHz, CDCl3) δ 7.97 (dd, J = 8.1, 0.8 Hz, 1H, ArH indole), 7.85 – 7.79 
(m, 2H, ArH MeOPh), 7.40 (s, 1H, Ar indole), 7.18 (t, J = 8.0 Hz, 1H, ArH indole), 
7.02 – 6.95 (m, 2H, ArH MeOPh), 6.74 (dd, J = 8.2, 0.7 Hz, 1H, ArH indole), 4.29 (d, J 
= 7.3 Hz, 2H, N-CH2), 4.16 (t, J = 5.6 Hz, 2H, O-CH2 butyl), 3.99 – 3.92 (m, 2H, O-
CH2 THP), 3.89 (s, 3H, O-CH3), 3.30 (td, J = 11.6, 2.5 Hz, 2H, O-CH2 THP), 2.48 (t, J 
= 6.9 Hz, 2H, CH2COOH), 2.21 – 2.11 (m, 1H, CH THP), 2.00 – 1.84 (m, 4H, 
CH2CH2), 1.48 – 1.31 (m, 4H, O-CH2CH2 THP).  
HRMS-ESI calculated for C27H31NNaO6 [M+Na]
+ 488.2044, found m/z 488.2007.  





The hydrochloride salt of 
3.14 (38 mg, 74.9 μmol), 
DIPEA (85 µL, 0.49 
mmol), HATU (31 mg, 
80.8 μmol) and 2.28b (60 
mg, 0.24 mmol) in DMF (5.8 mL) were reacted as described in the procedure for 2.29a. 
The crude product was purified by flash silica gel column chromatography (99:1 
DCM/MeOH) to yield 3.15 (46 mg, 66.1 µmol, 88%) as a brown solid (Rf 0.56, 9:1 
DCM/MeOH).  
1H NMR (400 MHz, CDCl3) δ 7.97 (dd, J = 8.1, 0.8 Hz, 1H, ArH indole), 7.86 – 7.78 
(m, 2H, ArH MeOPh), 7.39 (s, 1H, ArH indole), 7.18 (t, J = 8.0 Hz, 1H, ArH indole), 
7.03 – 6.95 (m, 2H, ArH MeOPh), 6.73 (dd, J = 7.9, 1.0 Hz, 1H, ArH indole), 6.10 (br 
s, 1H, NH), 5.02 (br s, 1H, NH), 4.28 (d, J = 7.3 Hz, 2H, N1-CH2), 4.20 – 4.11 (m, 2H, 
O-CH2 butyl), 3.95 (dd, J = 11.6, 3.9 Hz, 2H, O-CH2 THP), 3.89 (s, 3H, O-CH3), 3.65 – 
3.52 (m, 8H, CH2-O-(CH2)2-O-CH2), 3.47 (d, J = 4.8 Hz, 2H, CH2CONH), 3.35 – 3.23 
(m, 4H, O-CH2 THP & CH2NHCOO), 2.30 (t, J = 6.9 Hz, 2H, CH2NHCO), 2.22 – 2.09 
(m, 1H, CH THP), 1.90 (q, J = 4.2, 3.5 Hz, 4H, O-CH2(CH2)2), 1.48 – 1.30 (m, 13H, O-
CH2CH2 THP, CH3 t Bu).  
13C NMR (101 MHz, CDCl3) δ 189.84, 172.62, 162.28, 156.07, 146.63, 137.72, 133.48, 
131.00, 130.03, 126.24, 123.16, 115.34, 115.12, 113.60, 105.02, 79.55, 70.38, 70.32, 
70.25, 70.20, 67.69, 67.51, 56.11, 55.51, 40.48, 39.36, 37.20, 35.86, 30.48, 29.09, 
28.48, 22.45.  
HRMS-ESI calculated for C38H53N3NaO9 [M+Na]





 A solution of 3.15 (15 mg, 
21.9 μmol) and TFA (1.1 mL) 
in DCM (1.1 mL) was reacted 
as described in the procedure 
for 2.30a. The crude product 
was purified by semi-preparative RP-HPLC to yield the TFA salt of 3.16 (17 mg, 20.7 
μmol, 95%) as a white solid.  
HRMS-ESI calculated for C33H46N3O7 [M+H]
+ 596.3330, found m/z 596.3286.  
Analytical RP-HPLC Rt = 16.28 min. 
N‐{2‐[2‐(2‐Acetamidoethoxy)ethoxy]ethyl}‐5‐{[3‐(4‐methoxybenzoyl)‐1‐[(oxan‐4‐
yl)methyl]‐1H‐indol‐7‐yl]oxy}pentanamide (3.17) 
The TFA salt of 3.16 (3.4 mg, 
4.3 µmol), DIPEA (2.3 µL, 
13.0 µmol), acetic anhydride 
(0.45 µL, 4.8 µmol) and 
DCM (0.27 mL) were reacted 
as described in the procedure for 2.31. The product was purified by semi-preparative 
RP-HPLC and passed through an Amberlyst A21 ion exchange resin to remove TFA, 
yielding 3.17 (2.67 mg, 4.2 μmol, 96%) as a white solid.  
HRMS-ESI calculated for C35H47N3NaO8 [M+Na]
+ 660.3255, found m/z 660.3193.  









The TFA salt of 3.16 (5.88 mg, 7.1 µmol), DIPEA (3.26 µL, 18.7 µmol), BODIPY 
630/650-X-OSu 2.15 (1.25 mg, 1.89 µmol) and DMF (852 µL) were reacted as 
described in the procedure for 2.32a. The crude product was purified by semi-
preparative RP-HPLC and passed through an Amberlyst A21 ion exchange resin to 
remove TFA, yielding 3.18 (2.01 mg, 1.76 μmol, 93%) as a bright blue solid.  
HRMS-ESI calculated for C62H71BF2N6NaO10S [M+Na]
+ 1163.4916, found m/z 
1163.4991.  
Analytical RP-HPLC Rt = 23.50 min.  
tert‐Butyl N‐(6‐hydroxyhexyl)carbamate (3.20) 
To a solution of 6-amino-1-hexanol 3.19 (96 mg, 0.82 
mmol) in dioxane (1.4 mL), was added Boc2O (226 µL, 
0.99 mmol). The mixture was stirred for 18 h at rt, then evaporated under reduced 
pressure. The crude was taken up in EA (8 mL), washed with H2O (2 x 8 mL) and sat. 
aq. NaCl (1 x 6 mL), dried over MgSO4, filtered and evaporated under reduced 
pressure. The crude product was purified by flash silica gel column chromatography 
(2:1 EA/hexane) to yield 3.20 (141 mg, 0.65 mmol, 79%) as a colourless oil, (Rf 0.58, 
3:1 EA/hexane).  
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1H NMR (400 MHz, CDCl3) δ 4.50 (br s, 1H, NH), 3.64 (t, J = 6.5 Hz, 2H, CH2OH), 
3.11 (t, J = 7.0 Hz, 2H, NHCH2), 1.62 – 1.27 (m, 18H, CH2, OH, CH3 t Bu).  
13C NMR (101 MHz, CDCl3) δ 156.25, 79.37, 62.79, 40.66, 32.69, 30.19, 28.55, 26.50, 
25.40.  
HRMS-ESI calculated for C11H24NO3 [M+H]
+ 218.1751, found m/z 218.1730. 
tert‐Butyl N‐(6‐bromohexyl)carbamate (3.21) 
A solution of 3.20 (139 mg, 0.64 mmol), bromine (33 µL, 
0.64 mmol), triphenylphosphine (168 mg, 0.64 mmol) and 
triethylamine (89 µL, 0.64 mmol) in DCM (1.8 mL) was reacted as described in the 
procedure for 3.10. The crude product was purified using flash silica column 
chromatography (4:1 hexane/EA) to yield the desired 3.21 (103 mg, 0.37 mmol, 57%), 
as a yellow oil (Rf 0.37, 4:1 hexane/EA).  
1H NMR (400 MHz, CDCl3) δ 4.50 (br s, 1H, NH), 3.40 (t, J = 6.8 Hz, 2H, CH2Br), 
3.11 (q, J = 6.7 Hz, 2H, NHCH2), 1.86 (p, J = 7.0 Hz, 2H, CH2CH2Br), 1.54 – 1.40 (m, 
13H, CH2, CH3 t Bu), 1.39 – 1.27 (m, 2H, CH2).  
13C NMR (101 MHz, CDCl3) δ 156.12, 79.28, 40.66, 33.91, 32.79, 30.08, 28.56, 27.96, 
26.08. The 1H and 13C NMR matched literature reports.322  
HRMS-ESI calculated for C11H22BrNNaO2 [M+Na]
+ 302.0726, found m/z 302.0708.  
tert‐Butyl N‐(6‐{[3‐(4‐methoxybenzoyl)‐1‐[(oxan‐4‐yl)methyl]‐1H‐indol‐7‐
yl]oxy}hexyl)carbamate (3.22) 
A solution of 3.4 (22 mg, 61.4 μmol), NaH 
(7.4 mg, 0.18 mmol) and 3.21 (26 mg, 
92.1 μmol) in DMF (2.7 mL) was reacted 
as described in the procedure for 3.7a. The 
crude product was purified using flash 
silica column chromatography (1:1 hexane/EA) to yield the desired 3.22 (27 mg, 47.8 
µmol, 79%), as a brown solid (Rf 0.31, 1:1 hexane/EA).  
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1H NMR (400 MHz, CDCl3) δ 7.96 (dd, J = 8.1, 0.8 Hz, 1H, ArH indole), 7.86 – 7.78 
(m, 2H, ArH MeOPh), 7.40 (s, 1H, ArH indole), 7.18 (t, J = 8.0 Hz, 1H, ArH indole), 
7.02 – 6.95 (m, 2H, ArH MeOPh), 6.73 (dd, J = 7.9, 0.9 Hz, 1H, ArH indole), 4.56 (br 
s, 1H, NH), 4.28 (d, J = 7.3 Hz, 2H, N1-CH2), 4.12 (t, J = 6.5 Hz, 2H, O-CH2 hexyl), 
4.02 – 3.91 (m, 2H, O-CH2 THP), 3.89 (s, 3H, O-CH3), 3.29 (td, J = 11.7, 2.5 Hz, 2H, 
O-CH2 THP), 3.13 (t, J = 7.0 Hz, 2H, NHCH2), 2.23 – 2.09 (m, 1H, CH THP), 1.94 – 
1.81 (m, 2H, O-CH2CH2 hexyl), 1.61 – 1.23 (m, 19H, (CH2)3, O-CH2CH2 THP & t Bu 
CH3).  
13C NMR (101 MHz, CDCl3) δ 189.86, 162.32, 156.15, 146.76, 137.66, 133.55, 131.07, 
130.06, 126.31, 123.22, 115.46, 115.14, 113.64, 105.05, 79.32, 68.03, 67.57, 56.12, 
55.56, 40.71, 37.27, 30.54, 30.28, 29.56, 28.55, 26.72, 26.19.  
HRMS-ESI calculated for C33H44N2NaO6 [M+Na]
+ 587.3092, found m/z 587.3057. 
6‐{[3‐(4‐Methoxybenzoyl)‐1‐[(oxan‐4‐yl)methyl]‐1H‐indol‐7‐yl]oxy}hexan‐1‐amine 
(3.23) 
A solution of 3.22 (14 mg, 25.7 μmol) and TFA 
(1 mL) in DCM (1 mL) was reacted as described 
in the procedure for 2.30a. The crude product 
was purified by semi-preparative RP-HPLC to 
yield the TFA salt of 3.23 (16 mg, 23.7 μmol, 
92%) as a white solid.  
HRMS-ESI calculated for C28H37N2O4 [M+H]
+ 465.2748, found m/z 465.2710.  





The TFA salt of 3.23 (3.2 mg, 4.6 µmol), 
DIPEA (2.5 µL, 14.4 µmol), and acetic 
anhydride (0.5 µL, 5.3 µmol) in DCM (297 
µL) were treated as in the procedure for 2.31. 
The product was purified by semi-preparative 
RP-HPLC and passed through an Amberlyst A21 ion exchange resin to remove TFA, 
yielding 3.24 (2.3 mg, 4.6 μmol, 98%) as a white solid.  
HRMS-ESI calculated for C30H38N2NaO5 [M+Na]
+ 529.2673, found m/z 529.2661.  






The TFA salt of 3.23 (6.05 mg, 8.73 µmol), DIPEA (3.90 µL, 22.4 µmol), BODIPY 
630/650-X-OSu 2.15 (1.25 mg, 1.89 µmol) and DMF (862 µL) were reacted as 
described in the procedure for 2.32a. The crude product was purified by semi-
preparative RP-HPLC and passed through an Amberlyst A21 ion exchange resin to 
remove TFA, yielding 3.25 (1.46 mg, 1.45 μmol, 77%) as a bright blue solid.  
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HRMS-ESI calculated for C57H62BF2N5NaO7S [M+Na]
+ 1032.4333, found m/z 
1032.4411.  
Analytical RP-HPLC Rt = 24.73 min.  
2-Amino-5-bromopyridine-3-carbaldehyde (4.13)  
To a solution of 2-amino-3-pyridinecarboxaldehyde 4.12 (3.66 g, 30.0 
mmol) in glacial acetic acid (70 mL) was added a solution of bromine 
(1.54 mL, 30.0 mmol) in acetic acid (20 mL) dropwise. The reaction 
mixture was stirred for 24 h and the precipitate formed was filtered and washed with 
diethyl ether. The precipitate was then added to water and treated with solid NaOH 
until pH 7-8, then extracted with DCM, dried over MgSO4 and evaporated under 
reduced pressure. The crude was purified by recrystallisation in ACN, to yield 4.13 
(3.68 g, 18.3 mmol, 61%), as a canary yellow solid.  
1H NMR (400 MHz, DMSO-d6) δ 9.83 (s, 1H, CHO), 8.31 (d, J = 2.6 Hz, 1H, ArH), 
8.24 (d, J = 2.6 Hz, 1H, ArH), 7.69 (br s, 2H, NH2). 
13C NMR (101 MHz, DMSO-d6) δ 192.91, 156.79, 155.01, 145.72, 114.17, 104.29. 
HRMS-ESI calculated for C6H6BrN2O [M+H]
+ 200.9658, found m/z 200.9661. 
Ethyl 6-bromo-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxylate (4.14) 
To a stirred solution of 4.13 (4.49 g, 22.33 mmol) in EtOH (55 
mL) were added diethyl malonate (5.1 mL, 33.6 mmol) and 
piperidine (0.63 mL, 6.4 mmol). The mixture was stirred under 
reflux for 18 h and the resulting solid filtered, washed with EtOH and dried, to yield 
4.14 (6.22 g, 20.9 mmol, 94%), as a yellow solid, which was used without further 
purification.  
1H NMR (400 MHz, DMSO-d6) δ 12.63 (br s, 1H, NH), 8.70 (d, J = 2.4 Hz, 1H, ArH), 
8.55 (d, J = 2.4 Hz, 1H, ArH), 8.44 (s, 1H, ArH), 4.28 (q, J = 7.1 Hz, 2H, CH2), 1.30 (t, 
J = 7.1 Hz, 3H, CH3). This matches the literature reference.
145  
13C NMR (101 MHz, DMSO-d6) δ 163.78, 159.11, 152.78, 149.10, 141.27, 139.55, 
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125.69, 114.50, 112.43, 61.07, 14.09. 
HRMS-ESI calculated for C11H9BrN2NaO3 [M+Na]
+ 318.9689, found m/z 318.9665.  
6-Bromo-N-(4-methylcyclohexyl)-2-oxo-1,2-dihydro-1,8-naphthyridine-3-
carboxamide (4.15) 
In a sealed tube, 4.14 (424 mg, 1.4 mmol) and 4-
methylcyclohexylamine (equal mixture of cis and trans 
isomers) (0.94 mL, 7.1 mmol) were heated to 150°C for 24 
h. Upon cooling, diethyl ether was added to the reaction mixture and the solid residue 
was collected by filtration. The crude product was purified by precipitation in EA, to 
give 4.15 (376 mg, 1.0 mmol, 72%) as a white solid.  
HRMS-ESI calculated for C16H18BrN3NaO2 [M+Na]
+ 386.0475, found m/z 386.0450.  
6-Bromo-N-(4-methylcyclohexyl)-1-[2-(morpholin-4-yl)ethyl]-2-oxo-1,2-dihydro-
1,8-naphthyridine-3-carboxamide (4.8) 
To a stirred solution of 4.15 (22 mg, 59.9 µmol) in DMF (1 
mL) was added caesium carbonate (55 mg, 0.17 mmol). 
After stirring for 1 h, 4-(2-chloroethyl)morpholin 
hydrochloride (22 mg, 0.12 mmol) was added. The mixture 
was stirred at 50°C for 12 h and upon cooling was 
evaporated under reduced pressure. Saturated aq. NaHCO3 
was added until pH 10-11 and then extracted with DCM (3 x 20 mL). The combined 
organics were washed with H2O (1 x 60 mL), dried over MgSO4 and evaporated under 
reduced pressure. The crude product was purified by recrystallisation in ACN to yield 
4.8 (10.5 mg, 22.0 µmol, 37%), as a yellow solid.  
1H NMR (400 MHz, CDCl3) δ 9.80 (m, 1H, NH isomer A), 9.41 (m, 1H, NH isomer B) 
8.80 (s, 1H, ArH), 8.69 (d, J = 2.3 Hz, 1H, ArH), 8.19 (t, J = 2.1 Hz, 1H, ArH), 5.04 – 
4.58 (m, 2H, N1-CH2), 4.32 – 3.91 (m, 1H, NHCH isomer A and NHCH isomer B), 
3.92 – 3.55 (m, 4H, N-CH2 morpholino), 3.40 – 2.22 (m, 6H, N1-CH2CH2 & O-CH2 
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morpholino), 2.12 – 0.88 (m, 12H, CH & CH2 cyclohexyl, CH3). Isomers A and B 
represent cis/trans (in no defined order) isomers. This matches the literature 
reference.145 
13C NMR (101 MHz, CDCl3) δ 162.50, 162.36, 161.26, 152.67, 152.61, 148.21, 141.02, 
140.10, 124.54, 116.46, 55.51, 53.40, 49.06, 45.76, 33.99, 33.07, 32.11, 31.24, 30.25, 
29.84, 29.74, 22.36, 21.80. Isomers A and B resolved as separate peaks in some 
instances, but are not assigned.  
HRMS-ESI calculated for C22H30BrN4O3 [M+H]
+ 477.1496, found m/z 477.1462.  
Analytical RP-HPLC Rt = 15.57 min (57%) and 15.84 min (43%).  
Methyl 5‐{6‐bromo‐3‐[(4‐methylcyclohexyl)carbamoyl]‐2‐oxo‐1,2‐dihydro‐1,8‐
naphthyridin‐1‐yl}pentanoate (4.9) 
To a stirred solution of 4.15 (319 mg, 0.88 mmol) in DMF 
(4 mL), was added caesium carbonate (799 mg, 2.5 mmol). 
After stirring for 1 h, methyl 5-bromovalerate (0.25 mL, 
1.8 mmol) was added. The mixture was stirred at 50°C for 
12 h and upon cooling was evaporated under reduced 
pressure. The solid was taken up in ACN and filtered. The 
filtrate was evaporated and then purified by recrystallisation in ACN to yield 4.9 (94 
mg, 0.20 mmol, 22%), as a white solid.  
1H NMR (400 MHz, CDCl3) δ 9.93 (d, J = 7.8 Hz, 1H, NH isomer A), 9.55 (d, J = 8.1 
Hz, 1H, NH isomer B), 8.79 (s, 1H, ArH), 8.70 (d, J = 2.4 Hz, 1H, ArH), 8.17 (dd, J = 
3.5, 2.4 Hz, 1H, ArH), 4.65 – 4.46 (m, 2H, N-CH2), 4.25 (m, 1H, NHCH isomer A), 3.9 
(m, 1H, NHCH isomer B), 3.67 (s, 3H, O-CH3), 2.47 – 2.34 (m, 2H, CH2COOMe), 
2.11 – 0.87 (m, 16H, N-CH2(CH2)2, CH & CH2 cyclohexyl & CH3). Isomers A and B 
represent cis/trans (in no defined order) isomers. 
13C NMR (101 MHz, CDCl3) δ 173.92, 173.87, 162.34, 162.29, 161.55, 161.53, 152.77, 
152.72, 148.34, 148.28, 140.76, 140.58, 139.83, 139.79, 124.47, 124.38, 116.25, 
116.24, 114.27, 114.21, 51.71, 51.70, 49.03, 45.83, 41.80, 41.72, 34.01, 33.83, 33.82, 
33.07, 32.12, 31.21, 30.30, 29.72, 27.48, 27.47, 22.47, 22.45, 22.36, 21.67. Isomers A 
and B resolved as separate peaks in some instances, but are not assigned. 
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HRMS-ESI calculated for C22H28BrN3NaO4 [M+Na]
+ 500.1155, found m/z 500.1117.  
Analytical RP-HPLC Rt = 23.16 min (50%) and 24.15 min (50%).  
Methyl 4‐({6‐bromo‐3‐[(4‐methylcyclohexyl)carbamoyl]‐2‐oxo‐1,2‐dihydro‐1,8‐
naphthyridin‐1‐yl}methyl)benzoate (4.10) 
A solution of 4.15 (75 mg, 0.23 mmol), caesium carbonate 
(206 mg, 0.63 mmol) and methyl 4-bromomethylbenzoate 
(104 mg, 0.45 mmol) in DMF (1.1 mL) was reacted as 
described in the procedure for 4.9. The crude residue was 
purified by flash silica gel column chromatography (99:1 
DCM/MeOH) and a portion (6 mg) of the solid obtained 
(20 mg) was further purified by semi-preparative RP-HPLC to yield 4.10 (3.54 mg, 
6.93 µmol), as a white solid.  
1H NMR (400 MHz, CDCl3) δ 9.92 – 9.75 (m, 1H, NH isomer A), 9.49 – 9.38 (m, 1H, 
NH isomer B), 8.84 (s, 1H, ArH), 8.73 – 8.65 (m, 1H, ArH), 8.22 – 8.16 (m, 1H, ArH), 
8.00 – 7.89 (m, 2H, ArH Ph), 7.48 – 7.38 (m, 2H, ArH Ph), 5.81 (d, J = 8.6 Hz, 2H, N1-
CH2), 4.37 – 4.16 (m, 1H, NHCH), 2.11 – 0.89 (m, 15H, CH & CH2 cyclohexyl, CH3). 
Isomers A and B represent cis/trans (in no defined order) isomers.  
HRMS-ESI calculated for C25H26BrN3NaO4 [M+Na]
+ 534.0999, found m/z 534.1008.  
Analytical RP-HPLC Rt = 24.16 min (50%) and 24.44 min (50%).  
Methyl 5‐[6‐(4‐methoxyphenyl)‐3‐[(4‐methylcyclohexyl)carbamoyl]‐2‐oxo‐1,2‐
dihydro‐1,8‐naphthyridin‐1‐yl]pentanoate (4.11) 
4.9 (16 mg, 32.8 µmol), 4-methoxyphenylboronic 
acid (6.5 mg, 42.7 µmol) and Na2CO3 (9.1 mg, 85.4 
µmol) were dissolved in a 1:4 v:v mixture of H2O 
and DMF (1.5 mL). Pd(OAc)2 (0.08 mg, 0.33 µmol) 
was added and the reaction mixture heated to 110°C 
and stirred for 3 h, then cooled to rt and diluted with 
H2O (1.5 mL). The aqueous phase was extracted with EA (4 x 1.5 mL) and the 
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combined organics washed with H2O (3 x 6 mL) and sat. aq. NaCl (1 x 6 mL), dried 
over MgSO4 and evaporated under reduced pressure. The crude product was purified by 
flash silica gel column chromatography (2:1 hexane/EA) to yield the desired 4.11 (9.2 
mg, 18.1 µmol, 55%), as a yellow solid (Rf 0.5, 1:1 hexane/EA).  
1H NMR (400 MHz, CDCl3) δ 10.04 (d, J = 7.8 Hz, 1H, NH isomer A), 9.67 (d, J = 8.0 
Hz, 1H, NH, isomer B), 8.91 (s, 1H, ArH), 8.89 (d, J = 2.4 Hz, 1H, ArH), 8.19 – 8.12 
(m, 1H, ArH), 7.63 – 7.50 (m, 2H, ArH MeOPh), 7.11 – 6.99 (m, 2H, ArH MeOPh), 
4.73 – 4.54 (m, 2H, N-CH2), 4.26 (m, 1H, NHCH isomer A), 3.93 (m, 1H, NHCH 
isomer B), 3.88 (s, 3H, PhO-CH3), 3.67 (s, 3H, COOCH3), 2.52 – 2.40 (m, 2H, 
CH2COOMe), 2.36 (m, 1H, CHCH3 isomer A), 2.09 (m, 1H, CHCH3 isomer B), 1.90 – 
0.87 (m, 15H, N-CH2(CH2)2, CH2 cyclohexyl, CH3). Isomers A and B represent 
cis/trans (in no defined order) isomers. 
13C NMR (101 MHz, CDCl3) δ 174.04, 173.99, 162.56, 162.52, 162.10, 160.07, 160.06, 
150.63, 150.58, 148.57, 148.51, 142.07, 141.89, 135.46, 135.43, 132.28, 132.22, 
128.96, 128.92, 128.27, 123.56, 123.47, 114.93, 114.83, 55.58, 51.73, 51.70, 48.94, 
45.80, 41.66, 41.57, 34.21, 34.05, 33.93, 33.91, 33.61, 33.11, 32.14, 31.20, 30.34, 
29.75, 28.21, 27.61, 22.56, 22.53, 22.39, 21.65, 21.36. Isomers A and B resolved as 
separate peaks in some instances, but are not assigned. 
HRMS-ESI calculated for C29H35N3NaO5 [M+Na]
+ 528.2469, found m/z 528.2475.  
Analytical RP-HPLC Rt = 24.33 min (50%) and 25.08 min (50%).  
5‐{6‐Bromo‐3‐[(4‐methylcyclohexyl)carbamoyl]‐2‐oxo‐1,2‐dihydro‐1,8‐
naphthyridin‐1‐yl}pentanoic acid (4.16) 
A solution of 4.9 (60 mg, 0.13 mmol) and 10% NaOH (10 
mL) was heated to 110°C for 5 h. The mixture was cooled 
and conc. HCl added until pH 2-3. The precipitate was 
filtered and treated with diethyl ether to yield 4.16 (25 mg, 




1H NMR (400 MHz, CDCl3) δ 9.95 (d, J = 7.7 Hz, 1H, NH isomer A), 9.57 (d, J = 7.9 
Hz, 1H, NH isomer B), 8.81 (s, 1H, ArH), 8.70 (d, J = 2.1 Hz, 1H, ArH), 8.18 (t, J = 
2.7 Hz, 1H, ArH), 4.64 – 4.46 (m, 2H, N-CH2), 4.25 (m, 1H, NHCH isomer A), 3.89 
(m, 1H, NHCH isomer B), 2.56 – 2.35 (m, 2H, CH2COOH), 2.15 – 0.87 (m, 16H, N-
CH2(CH2)2, CH & CH2 cyclohexyl & CH3). Isomers A and B represent cis/trans (in no 
defined order) isomers.  
13C NMR (101 MHz, CDCl3) δ 178.34, 178.28, 162.35, 162.30, 161.70, 161.69, 152.84, 
152.80, 148.31, 148.26, 140.98, 140.81, 139.92, 139.88, 124.30, 124.21, 116.26, 
116.25, 114.34, 114.28, 49.11, 45.91, 41.75, 41.67, 33.99, 33.65, 33.64, 33.04, 32.10, 
31.20, 30.28, 29.84, 29.71, 27.40, 22.36, 22.21, 22.19, 21.68. Isomers A and B resolved 
as separate peaks in some instances, but are not assigned. 
HRMS-ESI calculated for C21H26BrN3NaO4 [M+Na]
+ 486.0999, found m/z 486.1007.  
tert‐Butyl N‐[8‐(5‐{6‐bromo‐3‐[(4‐methylcyclohexyl)carbamoyl]‐2‐oxo‐1,2‐
dihydro‐1,8‐naphthyridin‐1‐yl}pentanamido)octyl]carbamate (4.17a) 
4.16 (13 mg, 27.8 µmol), 2.28a (22 mg, 88.8 µmol), 
DIPEA (29 µL, 0.17 mmol) and HATU (11 mg, 27.8 
µmol) in DMF (3.5 mL) were used as described in 
the procedure for 2.29a. The crude residue was 
purified by flash silica gel column chromatography 
(1:1 hexane/EA) to yield 4.17a (14 mg, 19.6 µmol, 
71%) as a grey solid (Rf 0.484 1:2 hexane/EA).  
1H NMR (400 MHz, MeOD-d4) δ 10.33 (d, J = 7.9 
Hz, 1H, NH isomer A), 9.89 (d, J = 7.9 Hz, 1H, NH 
isomer B), 8.83 – 8.75 (m, 2H, ArH), 8.52 (dd, J = 
4.2, 2.4 Hz, 1H, ArH), 4.65 – 4.51 (m, 2H, N1-CH2), 4.21 (m, 1H, NHCH isomer A), 
3.81 (m, 1H, NHCH isomer B), 3.14 (t, J = 7.0 Hz, 2H, CH2), 3.04 – 2.86 (m, 2H, 
CH2), 2.32 – 2.20 (m, 2H, CH2), 2.10 – 0.90 (m, 37H, CH, CH2, CH3). Isomers A and B 
represent cis/trans (in no defined order) isomers.  
13C NMR (101 MHz, MeOD-d4) δ 175.66, 163.62, 163.41, 154.11, 149.57, 142.26, 
141.71, 124.66, 117.54, 117.51, 115.28, 115.24, 79.74, 50.33, 49.64, 49.43, 49.21, 
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49.00, 48.79, 48.57, 48.36, 46.69, 42.76, 42.66, 41.35, 40.76, 40.34, 40.23, 36.71, 
36.67, 34.96, 33.82, 33.16, 32.69, 31.08, 30.95, 30.74, 30.35, 30.32, 30.09, 30.02, 
28.80, 28.53, 28.39, 28.36, 27.91, 27.81, 27.77, 27.34, 24.43, 24.40, 22.56. Isomers A 
and B resolved as separate peaks in some instances, but are not assigned. 
HRMS-ESI calculated for C34H52BrN5NaO5 [M+Na]




4.16 (8.9 mg, 19.2 µmol), DIPEA (20.1 µL, 0.12 
mmol), HATU (7.3 mg, 19.2 µmol) and 2.28b (15 
mg, 62.0 µmol) in DMF (1.8 mL) were used as 
described in the procedure for 2.29a. The crude 
product was purified by flash silica gel column 
chromatography (1:7 hexane/EA) to yield 4.17b (10 
mg, 14.7 µmol, 77%) as a grey solid (Rf 0.19 1:2 
hexane/EA). 
1H NMR (400 MHz, CDCl3) δ 9.95 (d, J = 7.7 Hz, 
1H, NH isomer A), 9.57 (d, J = 8.0 Hz, 1H, NH 
isomer B), 8.76 (s, 1H, ArH), 8.69 (d, J = 2.1 Hz, 1H, ArH), 8.20 – 8.12 (m, 1H, ArH), 
6.16 (s, 1H, NH), 4.98 (s, 1H, NH), 4.62 – 4.43 (m, 2H, N1-CH2), 4.22 (m, 1H, NHCH 
isomer A), 3.87 (m, 1H, NHCH isomer B), 3.74 – 3.38 (m, 10H, CH2), 3.36 – 3.20 (br 
m, 2H, CH2), 2.36 – 2.21 (br m, 2H, CH2), 2.10 – 0.85 (m, 25H, CH, CH2, CH3). 
Isomers A and B represent cis/trans (in no defined order) isomers.  
13C NMR (101 MHz, CDCl3) δ 162.31, 162.27, 161.65, 152.89, 152.86, 148.27, 140.83, 
140.66, 139.86, 139.82, 124.33, 124.24, 116.24, 114.31, 114.25, 70.47, 70.36, 70.25, 
70.10, 49.07, 45.88, 41.87, 39.60, 36.14, 33.99, 33.07, 32.11, 30.29, 29.71, 28.55, 
27.53, 23.33, 22.36, 21.69. Isomers A and B resolved as separate peaks in some 
instances, but are not assigned. 
HRMS-ESI calculated for C32H49BrN5O7 [M+H]





A solution of 4.17a (11 mg, 16.1 μmol) and TFA (0.9 
mL) in DCM (0.9 mL) was reacted as described in the 
procedure for 2.30a. The crude was purified by semi-
preparative RP-HPLC to yield the TFA salt of 4.18a 
(11.9 mg, 14.6 μmol, 91%) as a white solid.  
HRMS-ESI calculated for C29H45BrN5O3 [M+H]
+ 
590.2700, found m/z 590.2703.  
Analytical RP-HPLC Rt = 18.12 min (40%) and 18.27 
min (60%).  
1‐[4‐({2‐[2‐(2‐Aminoethoxy)ethoxy]ethyl}carbamoyl)butyl]‐6‐bromo‐N‐(4‐
methylcyclohexyl)‐2‐oxo‐1,2‐dihydro‐1,8‐naphthyridine‐3‐carboxamide (4.18b) 
A solution of 4.17b (8.0 mg, 11.5 μmol) and TFA (1.2 
mL) in DCM (1.2 mL) was reacted as described in the 
procedure for 2.30a. The crude was purified by semi-
preparative RP-HPLC to yield the TFA salt of 4.18b 
(8.1 mg, 9.8 μmol, 86%) as a white solid.  
HRMS-ESI calculated for C27H41BrN5O5 [M+H]
+ 
594.2286, found m/z 594.2294. 






The TFA salt of 4.18a (2.4 mg, 2.9 µmol), DIPEA 
(1.9 µL, 10.9 µmol), and acetic anhydride (0.28 µL, 
3.0 µmol) in DCM (516 µL) were treated as in the 
procedure for 2.31. The product was purified by semi-
preparative RP-HPLC and passed through an 
Amberlyst A21 ion exchange resin to remove TFA, 
yielding 4.19a (1.76 mg, 2.8 μmol, 95%) as a white 
solid.  
HRMS-ESI calculated for C31H46BrN5NaO4 [M+Na]
+ 
654.2625, found m/z 654.2612.  
Analytical RP-HPLC Rt = 21.04 min (40%) and 21.20 min (60%). 
6‐Bromo‐1‐[4‐({2‐[2‐(2‐acetamidoethoxy)ethoxy]ethyl}carbamoyl)butyl]‐N‐(4‐
methylcyclohexyl)‐2‐oxo‐1,2‐dihydro‐1,8‐naphthyridine‐3‐carboxamide (4.19b) 
The TFA salt of 4.18b (1.53 mg, 1.9 µmol), DIPEA 
(1.2 µL, 6.9 µmol), and acetic anhydride (0.18 µL, 1.9 
µmol) in DCM (437 µL) were treated as in the 
procedure for 2.31. The product was purified by semi-
preparative RP-HPLC and passed through an 
Amberlyst A21 ion exchange resin to remove TFA, 
yielding 4.19b (1.14 mg, 1.8 μmol, 96%) as a white 
solid.  
HRMS-ESI calculated for C29H42BrN5NaO6 [M+Na]
+ 
658.2211, found m/z 658.2191.  








The TFA salt of 4.18a (4.9 mg, 6.0 µmol), DIPEA (2.6 µL, 14.9 µmol), BODIPY 
630/650-X-OSu 2.15 (1.25 mg, 1.89 µmol) and DMF (842 µL) were reacted as 
described in the procedure for 2.32a. The crude product was purified by semi-
preparative RP-HPLC and passed through an Amberlyst A21 ion exchange resin to 
remove TFA, yielding 4.20a (1.98 mg, 1.7 μmol, 92%) as a bright blue solid.  
HRMS-ESI calculated for C58H70BBrF2N8NaO6S [M+Na]
+ 1157.4285, found m/z 
1157.4175.  
Analytical RP-HPLC Rt = 25.44 min (cis trans isomers resolved as one peak in 









The TFA salt of 4.18b (5.32 mg, 6.5 µmol), DIPEA (2.8 µL, 15.9 µmol), BODIPY 
630/650-X-OSu 2.15 (1.25 mg, 1.89 µmol) and DMF (844 µL) were reacted as 
described in the procedure for 2.32a. The crude product was purified by semi-
preparative RP-HPLC and passed through an Amberlyst A21 ion exchange resin to 
remove TFA, yielding 4.20b (1.9 mg, 1.7 μmol, 88%) as a bright blue solid.  
HRMS-ESI calculated for C56H66BBrF2N8NaO8S [M+Na]
+ 1161.3870, found m/z 
1161.3780.  
Analytical RP-HPLC Rt = 24.39 min (55%) and 24.50 min (45%). 
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Mixture of Ethyl 6‐bromo‐1‐[2‐(morpholin‐4‐yl)ethyl]‐2‐oxo‐1,2‐dihydro‐1,8‐
naphthyridine‐3‐carboxylate (5.10a) and 6‐bromo‐1‐[2‐(morpholin‐4‐yl)ethyl]‐2‐
oxo‐1,2‐dihydro‐1,8‐naphthyridine‐3‐carboxylic acid (5.10b) 
To a stirred solution of 4.14 (6.08 g, 20.5 mmol) in anhydrous 
DMF (150 mL) was added caesium carbonate (18.67 g, 57.3 
mmol). The reaction mixture was stirred for 1 h at rt, then 4-
(2-chloroethyl)morpholinhydrochloride (7.62 g, 40.1 mmol) 
was added and the mixture was heated to 50°C and stirred for 
12 h. The DMF was evaporated under reduced pressure and 
then saturated aq. NaHCO3 (80 mL) was added to the residue 
which was then extracted with DCM (3 x 80 mL). The 
combined organics were washed with H2O (2 x 80 mL), dried 
over MgSO4, filtered and evaporated under reduced pressure. 
The crude was purified by precipitation in ACN, yielding a 
1:3 mixture (5.17 g) of the ethyl formate 5.10a and carboxylic 
acid 5.10b, as a yellow solid.  
Characterisation of the ethyl formate 5.10a (yielded at 41% in smaller scale reaction): 
1H NMR (400 MHz, CDCl3) δ 8.66 (d, J = 2.4 Hz, 1H, ArH), 8.24 (s, 1H, ArH), 8.07 
(d, J = 2.4 Hz, 1H, ArH), 4.66 (t, 2H, N1-CH2), 4.42 (q, J = 7.1 Hz, 2H, O-CH2), 3.66 
(t, J = 4.6 Hz, 4H, O-CH2 morpholino), 2.70 (t, J = 7.2 Hz, 2H, N1-CH2CH2), 2.60 (t, J 
= 4.8 Hz, 4H, N-CH2 morpholino), 1.40 (t, J = 7.1 Hz, 3H, CH3).  
13C NMR (101 MHz, CDCl3) δ 164.17, 158.99, 152.77, 149.16, 140.38, 139.45, 125.56, 
115.37, 113.58, 67.02, 62.08, 55.80, 53.94, 38.89, 14.38.  
MS-ESI calculated for C17H21BrN3O4 [M+H]
+ 410.0715, found 410.1.  
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Mixture of Ethyl 6‐(4‐methoxyphenyl)‐1‐[2‐(morpholin‐4‐yl)ethyl]‐2‐oxo‐1,2‐
dihydro‐1,8‐naphthyridine‐3‐carboxylate (5.11a) and 6‐(4‐Methoxyphenyl)‐1‐[2‐
(morpholin‐4‐yl)ethyl]‐2‐oxo‐1,2‐dihydro‐1,8‐naphthyridine‐3‐carboxylic acid 
(5.11b) 
A 1:3 mixture (4.07 g) of the ethyl formate 5.10a and 
carboxylic acid 5.10b, 4-methoxyphenylboronic acid 
(2.03 g, 13.3 mmol), Na2CO3 (2.83 g, 26.7 mmol) and 
Pd(OAc)2 (23 mg, 0.10 mmol) in H2O (25 mL) and 
DMF (100 mL) were reacted as described in the 
procedure for 4.11. Upon completion of the reaction, aq. 
HCl was added until the reaction mixture was pH 1-2, 
then diluted with H2O (100 mL) and extracted with 
DCM (3 x 100 mL). The combined organics were 
washed with H2O (2 x 150 mL) and sat. aq. NaCl (1 x 
150 mL), dried over MgSO4, filtered and rotary 
evaporated. The crude residue was washed with EtOH 
and filtered and the solid dried under reduced pressure 
yielding a 1:15 mixture (1.99 g) of the ethyl formate 
5.11a and carboxylic acid 5.11b, as a yellow solid.  
6‐(4‐Methoxyphenyl)‐1‐[2‐(morpholin‐4‐yl)ethyl]‐2‐oxo‐1,2‐dihydro‐1,8‐
naphthyridine‐3‐carboxylic (5.11b) 
A stirred solution of the 1:15 mixture of 5.11a and 5.11b 
(1.9 g) in THF (30 mL) was cooled to 0°C and 0.2 M 
lithium hydroxide monohydrate solution (49 mL) added 
dropwise. The reaction mixture was stirred at 0°C for 1 h 
and then quenched with a biphase of 0.2 M aq. HCl/EA (1:1 
v:v, 200 mL) was added. The aqueous layer was extracted 
with DCM (10 x 100 mL), dried over MgSO4, filtered and 
evaporated under reduced pressure to yield 5.11b (1.66 g) as a yellow solid.  
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1H NMR (400 MHz, CDCl3) δ 8.97 (d, J = 2.4 Hz, 1H, ArH), 8.93 (s, 1H, ArH), 8.22 
(d, J = 2.4 Hz, 1H, ArH), 7.58 – 7.51 (m, 2H, ArH MeOPh), 7.08 – 7.01 (m, 2H, ArH 
MeOPh), 4.86 (t, J = 6.8 Hz, 2H, N1-CH2), 3.87 (s, 3H, O-CH3), 3.77 – 3.64 (m, 4H, O-
CH2 morpholino), 2.93 – 2.83 (m, 2H, N1-CH2CH2), 2.82 – 2.56 (m, 4H, N-CH2 
morpholino).  
13C NMR (101 MHz, CDCl3) δ 164.63, 164.56, 160.41, 152.08, 148.49, 144.86, 135.94, 
133.49, 128.33, 128.14, 119.28, 115.08, 115.07, 66.93, 56.00, 55.59, 53.96, 39.37.  
HRMS-ESI calculated for C22H24N3O5 [M+H]
+ 410.1710, found m/z 410.1701.  
trans-N‐(4‐Hydroxycyclohexyl)‐6‐(4‐methoxyphenyl)‐1‐[2‐(morpholin‐4‐yl)ethyl]‐
2‐oxo‐1,2‐dihydro‐1,8‐naphthyridine‐3‐carboxamide (5.1a) 
To a stirred solution of 5.11b (800 mg, 2.0 mmol) 
in anhydrous DMF (40 mL) was added DIPEA (1 
mL, 5.9 mmol) and HATU (743 mg, 2.0 mmol). 
The reaction mixture was stirred for 5 min, then 
trans-4-aminocyclohexanol (675 mg, 5.9 mmol) 
and DIPEA (1 mL, 5.9 mmol) was added and the 
mixture stirred for 42 h. The DMF was evaporated under reduced pressure and the 
residue taken up in H2O (50 mL) and extracted with DCM (3 x 50 mL). The combined 
organics were washed with H2O (2 x 60 mL), dried over MgSO4, filtered and 
evaporated under reduced pressure. The crude was purified by precipitation in ACN, 
yielding 5.1a (815 mg, 1.6 mmol, 82%) as a yellow solid.  
1H NMR (400 MHz, CDCl3) δ 9.72 (d, J = 7.9 Hz, 1H, NH), 8.91 (s, 1H, ArH), 8.89 (d, 
J = 2.4 Hz, 1H, ArH), 8.17 (d, J = 2.4 Hz, 1H, ArH), 7.60 – 7.51 (m, 2H, ArH MeOPh), 
7.10 – 7.00 (m, 2H, ArH MeOPh), 4.83 – 4.71 (m, 2H, N-CH2), 4.07 – 3.93 (m, 1H, 
CH), 3.87 (s, 3H, O-CH3), 3.75 – 3.64 (m, 5H, CH & O-CH2 morpholino), 2.78 – 2.69 
(m, 2H, N-CH2), 2.68 – 2.57 (m, 4H, N-CH2 morpholino), 2.18 – 2.09 (m, 2H, CH2), 
2.09 – 1.99 (m, 2H, CH2), 1.54 – 1.36 (m, 4H, CH2).  
13C NMR (101 MHz, CDCl3) δ 162.57, 162.30, 160.11, 150.64, 148.65, 142.24, 135.44, 
132.36, 128.85, 128.26, 123.24, 114.95, 114.78, 69.93, 67.15, 56.04, 55.58, 54.05, 
47.94, 39.13, 34.04, 30.67.  
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HRMS-ESI calculated for C28H35N4O5 [M+H]
+ 507.2602, found m/z 507.2571.  
Analytical RP-HPLC Rt = 13.85 min.  
cis-N‐(4‐Hydroxycyclohexyl)‐6‐(4‐methoxyphenyl)‐1‐[2‐(morpholin‐4‐yl)ethyl]‐2‐
oxo‐1,2‐dihydro‐1,8‐naphthyridine‐3‐carboxamide (5.1b) 
A stirred solution of 5.11b (800 mg, 2.0 mmol), 
DIPEA (2 mL, 11.8 mmol), HATU (743 mg, 2.0 
mmol), and cis-4-aminocyclohexanol 
hydrochloride (889 mg, 5.9 mmol) in DMF (40 
mL) was reacted as described in the procedure for 
5.1a. Upon completion, the reaction mixture was 
diluted with NaHCO3 (50 mL) and the aqueous phase extracted with DCM (4 x 50 mL). 
The combined organics were washed with H2O (2 x 60 mL), dried over MgSO4, filtered 
and evaporated under reduced pressure. The crude was purified by precipitation in 
ACN, yielding 5.1b (784 mg, 1.5 mmol, 79%) as a yellow solid.  
1H NMR (400 MHz, CDCl3) δ 9.95 (d, J = 7.8 Hz, 1H, NH), 8.91 (s, 1H, ArH), 8.88 (d, 
J = 2.4 Hz, 1H, ArH), 8.16 (d, J = 2.4 Hz, 1H, ArH), 7.55 (d, J = 8.5 Hz, 2H, ArH 
MeOPh), 7.04 (d, J = 8.5 Hz, 2H, ArH MeOPh), 4.78 (t, J = 7.1 Hz, 2H, N-CH2), 4.18 
– 4.08 (m, 1H, CH), 3.96 – 3.88 (m, 1H, CH), 3.87 (s, 3H, O-CH3), 3.69 (t, J = 4.6 Hz, 
4H, O-CH2 morpholino), 2.74 (t, J = 7.1 Hz, 2H, N-CH2), 2.63 (t, J = 4.5 Hz, 4H, N-
CH2 morpholino), 1.94 – 1.68 (m, 8H, CH2).  
13C NMR (101 MHz, CDCl3) δ 162.56, 162.15, 160.08, 150.57, 148.68, 142.09, 135.40, 
132.27, 128.89, 128.24, 123.35, 114.93, 114.77, 67.23, 67.16, 56.04, 55.57, 54.04, 
46.58, 39.09, 31.50, 27.64.  
HRMS-ESI calculated for C28H35N4O5 [M+H]
+ 507.2602, found m/z 507.2552.  
Analytical RP-HPLC Rt = 14.13 min.  
7‐{[(tert‐Butoxy)carbonyl]amino}heptanoic acid (5.19) 
A stirred solution of 7-aminoheptanoic acid 5.18 (100 
mg, 0.69 mmol) and NaOH (28 mg, 0.69 mmol) in 
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dioxane and H2O (2:1, 3 mL) was cooled to 0°C and a solution of Boc2O (165 mg, 0.76 
mmol) in dioxane (1.5 mL) was slowly added. The mixture was stirred for 15 h at rt, 
then evaporated under reduced pressure. The resulting residue was taken up in H2O (3 
mL) and extracted with EA (2 x 2 mL). The aqueous phase was acidified to pH 4-5 
with aqueous 1 M HCl and extracted with EA (3 x 3 mL). The combined organics were 
dried over MgSO4, filtered and evaporated under reduced pressure to yield 5.19 (102 
mg, 0.42 mmol, 60%) as a colourless oil.  
1H NMR (400 MHz, CDCl3) δ 10.69 (s, 1H, COOH), 4.55 (s, 1H, NH), 3.16 – 2.98 (m, 
2H, CH2NH), 2.33 (t, J = 7.5 Hz, 2H, CH2COOH), 1.62 (quint, J = 7.4 Hz, 2H, CH2), 
1.52 – 1.25 (m, 15H, CH2 and CH3).  
13C NMR (101 MHz, CDCl3) δ 179.35, 156.17, 79.29, 40.62, 34.09, 29.97, 28.83, 
28.55, 26.54, 24.74.  
HRMS-ESI calculated for C12H23NNaO4 [M+Na]
+ 268.1519, found m/z 268.1500.  
trans-4‐[6‐(4‐Methoxyphenyl)‐1‐[2‐(morpholin‐4‐yl)ethyl]‐2‐oxo‐1,2‐dihydro‐1,8‐
naphthyridine‐3‐amido]cyclohexyl 2‐{[(tert‐butoxy)carbonyl]amino}acetate (5.20a) 
A stirred solution of Boc-glycine 
(10 mg, 59 µmol) and TFFH (16 
mg, 59 µmol) in anhydrous DCM 
(1.6 mL) was cooled to 0°C and 
Et3N (41 µL, 0.30 mmol) was 
added. The mixture was warmed to 
rt and stirred for 30 min and then 
5.1a (30 mg, 59 µmol) and DMAP (0.7 mg, 5.9 µmol) were added. The mixture was 
stirred for 48 h at rt and then evaporated under reduced pressure. The residue was taken 
up in EA (3 mL) and washed with H2O (3 x 3 mL) and sat. aq. NaCl (1 x 3 mL), dried 
over MgSO4, filtered and evaporated under reduced pressure. The crude residue was 
purified by flash silica column chromatography (100% EA) to yield 5.20a (8.5 mg, 12.8 
µmol, 22%) as a yellow solid.  
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1H NMR (400 MHz, CDCl3) δ 9.71 (d, J = 7.9 Hz, 1H, NH), 8.97 – 8.86 (m, 2H, ArH), 
8.17 (d, J = 2.4, 1H, ArH), 7.61 – 7.52 (m, 2H, ArH MeOPh), 7.11 – 7.00 (m, 2H, ArH 
MeOPh), 5.05 – 4.98 (m, 1H, NH), 4.78 (t, J = 7.1 Hz, 2H, N1-CH2), 4.51 – 4.33 (m, 
1H, CH), 4.07 – 3.91 (m, 2H, CH2), 3.87 (s, 3H, O-CH3), 3.74 – 3.64 (m, 5H, CH, N-
CH2 morpholino), 2.76 (t, J = 7.2 Hz, 2H, N1-CH2CH2), 2.66 (t, J = 4.5 Hz, 4H, O-CH2 
morpholino), 2.19 – 1.99 (m, 4H, CH2), 1.70 – 1.06 (m, 13H, CH2, tBu CH3). 
13C NMR (101 MHz, CDCl3) δ 171.12, 162.56, 162.31, 160.13, 150.68, 148.61, 142.31, 
135.48, 132.41, 128.84, 128.27, 123.22, 114.96, 114.80, 84.41, 69.94, 66.98, 55.91, 
55.58, 53.90, 47.95, 47.47, 38.91, 34.03, 30.66, 28.47 (one quaternary carbon was not 
observed). 
HRMS-ESI calculated for C35H46N5O8 [M+H]




A solution of 5.1b (50 mg, 99 µmol), 
Boc-glycine (17 mg, 99 µmol), TFFH 
(26 mg, 99 µmol), Et3N (69 µL, 0.49 
mmol) and DMAP (1.2 mg, 9.9 µmol) 
in DCM (3 mL) was reacted as 
described in the procedure for 5.20a. 
The crude residue was purified by flash silica column chromatography (100% EA) to 
yield 5.20b (4.8 mg, 7.23 mmol, 9%) as a yellow solid.  
1H NMR (400 MHz, CDCl3) δ 9.89 (d, J = 7.7 Hz, 1H, NH), 8.95 – 8.86 (m, 2H, ArH), 
8.17 (d, J = 2.4 Hz, 1H, ArH), 7.62 – 7.47 (m, 2H, ArH MeOPh), 7.10 – 6.99 (m, 2H, 
ArH MeOPh), 5.07 – 4.99 (m, 2H, NH, CH), 4.80 (t, J = 7.1 Hz, 2H, N1-CH2), 4.20 – 
4.07 (m, 1H, CH), 3.93 (d, J = 5.7 Hz, 2H, CH2), 3.88 (s, 3H, O-CH3), 3.76 – 3.63 (m, 
4H, N-CH2 morpholino), 2.76 (t, J = 7.1 Hz, 2H, N1-CH2CH2), 2.70 – 2.58 (m, 4H, O-
CH2 morpholino), 1.98 – 1.71 (m, 8H, CH2), 1.47 (s, 9H, tBu CH3).  
13C NMR (101 MHz, CDCl3) δ 169.94, 162.61, 162.24, 160.13, 150.68, 148.69, 142.25, 
135.45, 132.38, 128.87, 128.27, 123.24, 114.97, 114.79, 80.11, 70.85, 67.18, 56.06, 
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55.59, 54.07, 46.82, 42.82, 39.17, 28.53, 28.49, 27.74 (one quaternary carbon was not 
observed). 
HRMS-ESI calculated for C35H46N5O8 [M+H]





A solution of 5.1a (28 mg, 55 µmol), 5.19 (27 mg, 0.11 mmol), TFFH (27 mg, 0.11 
mmol), Et3N (77 µL, 0.55 mmol) and DMAP (0.7 mg, 5.5 µmol) in DCM (1 mL) was 
reacted as described in the procedure for 5.20a. The crude residue was purified by flash 
silica column chromatography (100% EA) to yield 5.20c (32 mg, 44 µmol, 80%) as a 
yellow brown oil.  
1H NMR (400 MHz, CDCl3) δ 9.77 (d, J = 7.9 Hz, 1H, NH), 8.93 – 8.86 (m, 2H, ArH), 
8.17 (d, J = 2.4 Hz, 1H, ArH), 7.61 – 7.50 (m, 2H, ArH MeOPh), 7.08 – 7.00 (m, 2H, 
ArH MeOPh), 4.84 – 4.71 (m, 3H, NH and N1-CH2), 4.58 – 4.46 (m, 1H, CH), 4.12 – 
3.97 (m, 1H, CH), 3.88 (s, 3H, O-CH3), 3.69 (t, J = 4.6 Hz, 4H, N-CH2 morpholino), 
3.11 (q, J = 6.7 Hz, 2H, CH2), 2.74 (t, J = 7.2 Hz, 2H, N1-CH2CH2), 2.69 – 2.58 (m, 
4H, O-CH2 morpholino), 2.29 (t, J = 7.5 Hz, 2H, CH2), 2.20 – 1.96 (m, 4H, CH2), 1.66 
– 1.47 (m, 8H, CH2), 1.44 (s, 9H, tBu CH3), 1.37 – 1.30 (m, 4H, CH2).
  
13C NMR (101 MHz, CDCl3) δ 173.38, 162.58, 162.37, 160.14, 156.11, 150.69, 148.69, 
142.26, 135.46, 132.39, 128.87, 128.28, 123.22, 114.97, 114.78, 71.78, 67.16, 56.05, 
55.59, 54.07, 47.63, 40.66, 39.15, 34.67, 30.27, 30.07, 30.04, 28.92, 28.59, 26.60, 
25.07 (one quaternary carbon was not observed).  
HRMS-ESI calculated for C40H55N5O8 [M+H]







A solution of 5.1b (50 mg, 99 µmol), 5.19 (48 mg, 0.20 mmol), TFFH (49 mg, 0.20 
mmol), Et3N (137 µL, 0.99 mmol) and DMAP (1.2 mg, 9.9 µmol) in DCM (4 mL) was 
reacted as described in the procedure for 5.20a. The crude residue was purified by flash 
silica column chromatography (1:2 hexane/EA) to yield 5.20d (48 mg, 66 µmol, 66%) 
as a yellow brown oil.  
1H NMR (400 MHz, CDCl3) δ 9.85 (d, J = 7.8 Hz, 1H, NH), 8.97 – 8.88 (m, 2H, ArH), 
8.17 (d, J = 2.4 Hz, 1H, ArH), 7.60 – 7.52 (m, 2H, ArH MeOPh), 7.09 – 7.01 (m, 2H, 
ArH MeOPh), 4.98 (s, 1H, NH), 4.80 (t, J = 7.1 Hz, 2H, N1-CH2), 4.68 – 4.49 (m, 1H, 
CH), 4.17 – 4.05 (m, 1H, CH), 3.88 (s, 3H, O-CH3), 3.69 (t, J = 4.6 Hz, 4H, N-CH2 
morpholino), 3.11 (q, J = 6.7 Hz, 2H, CH2), 2.76 (t, J = 7.1 Hz, 2H, N1-CH2CH2), 2.70 
– 2.52 (m, 4H, O-CH2 morpholino), 2.33 (t, J = 7.5 Hz, 2H, CH2), 1.93 – 1.60 (m, 10H, 
CH2), 1.51 – 1.32 (m, 15H, CH2 and tBu CH3).  
13C NMR (101 MHz, CDCl3) δ 173.28, 162.66, 162.18, 160.14, 156.12, 150.67, 148.66, 
142.30, 135.45, 132.41, 128.85, 128.27, 123.29, 114.97, 114.81, 69.19, 67.13, 56.06, 
55.59, 54.06, 47.05, 40.68, 39.16, 34.74, 30.11, 29.84, 28.98, 28.66, 28.58, 27.84, 
26.63, 25.14. 
HRMS-ESI calculated for C40H56N5O8 [M+H]




naphthyridine‐3‐amido]cyclohexyl 2‐aminoacetate (5.21a) 
A solution of 5.20a (4.1 mg, 6.2 μmol) and 
TFA (0.2 mL) in DCM (0.8 mL) was reacted 
as described in the procedure for 2.30a. The 
crude was purified by semi-preparative RP-
HPLC to yield the TFA salt of 5.21a (3.1 
mg, 3.42 μmol, 55%) as a yellow solid.  
Analytical RP-HPLC Rt = 12.83 min. 
cis-4‐[6‐(4‐Methoxyphenyl)‐1‐[2‐(morpholin‐4‐yl)ethyl]‐2‐oxo‐1,2‐dihydro‐1,8‐
naphthyridine‐3‐amido]cyclohexyl 2‐aminoacetate (5.21b) 
A solution of 5.20b (7.0 mg, 10.4 μmol) and 
TFA (0.2 mL) in DCM (0.8 mL) was reacted 
as described in the procedure for 2.30a. The 
crude was purified by semi-preparative RP-
HPLC to yield the TFA salt of 5.21b (4.3 
mg, 4.75 μmol, 45%) as a yellow solid.  
Analytical RP-HPLC Rt = 12.83 min. 
trans-4‐[6‐(4‐Methoxyphenyl)‐1‐[2‐(morpholin‐4‐yl)ethyl]‐2‐oxo‐1,2‐dihydro‐1,8‐
naphthyridine‐3‐amido]cyclohexyl 7‐aminoheptanoate (5.21c) 
A solution of 5.20c (15 mg, 20.8 
μmol) and TFA (0.25 mL) in 
DCM (1 mL) was reacted as 
described in the procedure for 
2.30a. The crude was purified by 
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semi-preparative RP-HPLC to yield the TFA salt of 5.21c (11.1 mg, 11.4 μmol, 55%) 
as a yellow solid.  
HRMS-ESI calculated for C35H48N5O6 [M+H]
+ 634.3599, found m/z 634.3583.  
Analytical RP-HPLC Rt = 14.42 min.  
cis-4‐[6‐(4‐Methoxyphenyl)‐1‐[2‐(morpholin‐4‐yl)ethyl]‐2‐oxo‐1,2‐dihydro‐1,8‐
naphthyridine‐3‐amido]cyclohexyl 7‐aminoheptanoate (5.21d) 
A solution of 5.20d (22 mg, 29.6 
μmol) and TFA (0.25 mL) in 
DCM (1 mL) was reacted as 
described in the procedure for 
2.30a. The crude was purified by 
semi-preparative RP-HPLC to 
yield the TFA salt of 5.21d (13 mg, 13.3 μmol, 45%) as a yellow solid.  
HRMS-ESI calculated for C35H48N5O6 [M+H]
+ 634.3599, found m/z 634.3595.  
Analytical RP-HPLC Rt = 14.41 min. 
trans-4‐[6‐(4‐Methoxyphenyl)‐1‐[2‐(morpholin‐4‐yl)ethyl]‐2‐oxo‐1,2‐dihydro‐1,8‐
naphthyridine‐3‐amido]cyclohexyl 2‐acetamidoacetate (5.22a) 
The TFA salt of 5.21a (1.4 mg, 1.5 µmol), 
DIPEA (0.81 µL, 4.6 µmol), and acetic 
anhydride (0.16 µL, 1.7 µmol) in DCM 
(496 µL) were treated as in the procedure 
for 2.31. The product was purified by 
semi-preparative RP-HPLC and passed 
through an Amberlyst A21 ion exchange 
resin to remove TFA, yielding 5.22a (0.9 
mg, 1.49 μmol, 96%) as a yellow solid.  
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MS-ESI calculated for C32H40N5O7 [M+H]
+ 606.2922, found 606.2.  
Analytical RP-HPLC Rt = 14.70 min. 
cis-4‐[6‐(4‐Methoxyphenyl)‐1‐[2‐(morpholin‐4‐yl)ethyl]‐2‐oxo‐1,2‐dihydro‐1,8‐
naphthyridine‐3‐amido]cyclohexyl 2‐acetamidoacetate (5.22b) 
The TFA salt of 5.21b (1.5 mg, 1.7 µmol), 
DIPEA (0.87 µL, 5.0 µmol), and acetic 
anhydride (0.17 µL, 1.8 µmol) in DCM 
(503 µL) were treated as in the procedure 
for 2.31. The product was purified by 
semi-preparative RP-HPLC and passed 
through an Amberlyst A21 ion exchange 
resin to remove TFA, yielding 5.22b (0.97 
mg, 1.6 μmol, 96%) as a yellow solid.  
HRMS-ESI calculated for C32H40N5O7 [M+H]
+ 606.2922, found m/z 606.2933. 
Analytical RP-HPLC Rt = 14.73 min. 
trans-4‐[6‐(4‐Methoxyphenyl)‐1‐[2‐(morpholin‐4‐yl)ethyl]‐2‐oxo‐1,2‐dihydro‐1,8‐
naphthyridine‐3‐amido]cyclohexyl 7‐acetamidoheptanoate (5.22c) 
The TFA salt of 5.21c (3.5 mg, 
3.6 µmol), DIPEA (1.87 µL, 
10.8 µmol), and acetic 
anhydride (0.7 µL, 4.0 µmol) in 
DCM (622 µL) were treated as 
in the procedure for 2.31. The 
product was purified by semi-
preparative RP-HPLC and passed through an Amberlyst A21 ion exchange resin to 
remove TFA, yielding 5.22c (2.36 mg, 3.5 μmol, 97%) as a yellow solid.  
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HRMS-ESI calculated for C37H50N5O7 [M+H]
+ 676.3705, found m/z 676.3737.  
Analytical RP-HPLC Rt = 16.81 min. 
cis-4‐[6‐(4‐Methoxyphenyl)‐1‐[2‐(morpholin‐4‐yl)ethyl]‐2‐oxo‐1,2‐dihydro‐1,8‐
naphthyridine‐3‐amido]cyclohexyl 7‐acetamidoheptanoate (5.22d) 
The TFA salt of 5.21d (3.3 mg, 
3.4 µmol), DIPEA (1.77 µL, 
10.2 µmol), and acetic 
anhydride (0.35 µL, 3.7 µmol) 
in DCM (610 µL) were treated 
as in the procedure for 2.31. 
The product was purified by semi-preparative RP-HPLC and passed through an 
Amberlyst A21 ion exchange resin to remove TFA, yielding 5.22d (2.23 mg, 3.3 μmol, 
98%) as a yellow solid.  
HRMS-ESI calculated for C37H50N5O7 [M+H]
+ 676.3705, found m/z 676.3710.  








The TFA salt of 5.21a (1.7 mg, 1.9 µmol), DIPEA (1.3 µL, 7.6 µmol), BODIPY 
630/650-X-OSu 2.15 (1.25 mg, 1.89 µmol) and DMF (721 µL) were reacted as 
described in the procedure for 2.32a. The crude product was purified by semi-
preparative RP-HPLC and passed through an Amberlyst A21 ion exchange resin to 
remove TFA, yielding 5.9a (1.51 mg, 1.36 μmol, 72%) as a bright blue solid.  
HRMS-ESI calculated for C59H64BF2N8O9S [M+H]
+ 1109.4582, found m/z 1109.4580.  




yl]ethenyl]phenoxy}acetamido)hexanamido]acetate (5.9b)  
 
The TFA salt of 5.21b (2.8 mg, 3.1 µmol), DIPEA (1.7 µL, 10.0 µmol), BODIPY 
630/650-X-OSu 2.15 (1.25 mg, 1.89 µmol) and DMF (728 µL) were reacted as 
described in the procedure for 2.32a. The crude product was purified by semi-
preparative RP-HPLC and passed through an Amberlyst A21 ion exchange resin to 
remove TFA, yielding 5.9b (2.03 mg, 1.83 μmol, 97%) as a bright blue solid.  
HRMS-ESI calculated for C59H64BF2N8O9S [M+H]
+ 1109.4582, found m/z 1109.4556.  








The TFA salt of 5.21c (4.2 mg, 4.3 µmol), DIPEA (2.2 µL, 12.5 µmol), BODIPY 
630/650-X-OSu 2.15 (1.25 mg, 1.89 µmol) and DMF (735 µL) were reacted as 
described in the procedure for 2.32a. The crude product was purified by semi-
preparative RP-HPLC and passed through an Amberlyst A21 ion exchange resin to 
remove TFA, yielding 5.9c (2.16 mg, 1.83 μmol, 97%) as a bright blue solid.  
HRMS-ESI calculated for C64H74BF2N8O9S [M+H]
+ 1179.5366, found m/z 1179.5275.  








The TFA salt of 5.21d (3.7 mg, 3.8 µmol), DIPEA (2.0 µL, 11.4 µmol), BODIPY 
630/650-X-OSu 2.15 (1.25 mg, 1.89 µmol) and DMF (732 µL) were reacted as 
described in the procedure for 2.32a. The crude product was purified by semi-
preparative RP-HPLC and passed through an Amberlyst A21 ion exchange resin to 
remove TFA, yielding 5.9d (1.74 mg, 1.48 μmol, 78%) as a bright blue solid.  
HRMS-ESI calculated for C64H74BF2N8O9S [M+H]
+ 1179.5366, found m/z 1179.5276.  
Analytical RP-HPLC Rt = 21.39 min. 
tert‐Butyl N‐[(1s,4s)‐4‐[6‐(4‐methoxyphenyl)‐1‐[2‐(morpholin‐4‐yl)ethyl]‐2‐oxo‐1,2‐
dihydro‐1,8‐naphthyridine‐3‐amido]cyclohexyl]carbamate (5.23) 
5.11b (50 mg, 0.12 mmol), DIPEA (128 µL, 
0.73 mmol), HATU (46 mg, 0.12 mmol) and 
1-N-Boc-cis-1,4-cyclohexyldiamine (79 mg, 
0.37 mmol) in DMF (2.5 mL) were used as 
described in the procedure for 2.29a. The 
reaction mixture was evaporated under 
reduced pressure and the residue taken up in EA (5 mL), washed with H2O (3 x 5 mL), 
dried over MgSO4, filtered and evaporated under reduced pressure. The crude product 
was purified by flash silica gel column chromatography (4:1 EA/hexane) to yield 5.23 
(53 mg, 87.2 µmol, 71%) as a yellow solid (Rf 0.34, 100% EA).  
1H NMR (400 MHz, CDCl3) δ 10.00 (d, J = 7.8 Hz, 1H, NH), 9.01 – 8.81 (m, 2H, 
ArH), 8.25 – 8.11 (m, 1H, ArH), 7.62 – 7.44 (m, 2H, ArH MeOPh), 7.09 – 6.95 (m, 2H, 
ArH MeOPh), 4.77 (t, J = 7.2 Hz, 2H, N1-CH2), 4.72 – 4.59 (m, 1H, NH), 4.28 – 4.14 
(m, 1H, CH), 3.86 (s, 3H, O-CH3), 3.68 (t, J = 4.5 Hz, 5H, CH, N-CH2 morpholino), 
2.74 (t, J = 7.2 Hz, 2H, N1-CH2CH2), 2.64 (t, J = 4.4 Hz, 4H, O-CH2 morpholino), 1.82 
(d, J = 14.6 Hz, 6H, CH2), 1.68 – 1.54 (m, 2H, CH2), 1.45 (d, J = 1.4 Hz, 9H, tBu CH3).  
13C NMR (101 MHz, CDCl3) δ 162.61, 162.11, 160.09, 155.28, 150.60, 148.63, 142.13, 
135.39, 132.33, 128.81, 128.23, 123.26, 114.93, 114.76, 79.33, 67.12, 56.00, 55.55, 
54.02, 47.41, 45.60, 39.09, 28.91, 28.64, 28.57.  
HRMS calculated for C33H44N5O6 [M+H]





A solution of 5.23 (43 mg, 71.3 μmol) and TFA 
(0.3 mL) in DCM (3 mL) was reacted as described 
in the procedure for 2.30a, to yield the TFA salt of 
5.24 (60 mg) as a yellow solid, which was used in 
the next step without further purification.  
HRMS calculated for C28H36N5O4 [M+H]




The TFA salt of 5.24 (55 mg, 65.3 
µmol), DIPEA (68 µL, 0.39 mmol), 
HATU (25 mg, 65.3 µmol) and Boc-
glycine (34 mg, 0.20 mmol) in DMF 
(2 mL) were used as described in the 
procedure for 2.29a. The reaction 
mixture was evaporated under 
reduced pressure and the residue taken up in EA (5 mL), washed with H2O (3 x 5 mL), 
sat. aq. NaCl (3 mL) and sat. NaHCO3 (1 mL), dried over MgSO4, filtered and 
evaporated under reduced pressure. The crude product was purified by flash silica gel 
column chromatography (95:5 EA/MeOH) to yield 5.25 (13.4 mg, 20.3 µmol, 31%) as 
a yellow solid (Rf 0.10, 100% EA).  
1H NMR (400 MHz, CDCl3) δ 10.01 (d, J = 7.5 Hz, 1H, NH), 8.94 – 8.87 (m, 2H, 
ArH), 8.17 (d, J = 2.4 Hz, 1H, ArH), 7.59 – 7.51 (m, 2H, ArH MeOPh), 7.08 – 7.01 (m, 
2H, ArH MeOPh), 6.24 (d, J = 7.7 Hz, 1H, NH), 5.31 – 5.16 (m, 1H, NH), 4.79 (t, J = 
6.8 Hz, 2H, N1-CH2), 4.29 – 4.16 (m, 1H, CH), 4.03 – 3.90 (m, 1H, CH), 3.88 (s, 3H, 
O-CH3), 3.78 (d, J = 5.8 Hz, 2H, COCH2NH), 3.69 (t, J = 4.6 Hz, 4H, N-CH2 
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morpholino), 2.82 – 2.72 (m, 2H, N1-CH2CH2), 2.71 – 2.57 (m, 4H, O-CH2 
morpholino), 1.90 – 1.75 (m, 6H, CH2), 1.68 – 1.56 (m, 2H, CH2), 1.47 (s, 9H, tBu 
CH3).  
13C NMR (101 MHz, CDCl3) δ 168.81, 162.67, 162.22, 160.14, 156.30, 150.68, 148.65, 
142.23, 135.46, 132.42, 128.82, 128.27, 123.24, 114.97, 114.80, 80.47, 67.14, 56.05, 
55.58, 53.98, 46.50, 45.56, 44.85, 39.07, 29.83, 28.65, 28.49.  
HRMS calculated for C35H47N6O7 [M+H]
+ 663.3501, found m/z 663.3508. 
6‐(4‐Methoxyphenyl)‐1‐[2‐(morpholin‐4‐yl)ethyl]‐2‐oxo‐N‐[(1s,4s)‐4‐(2‐
aminoacetamido)cyclohexyl]‐1,2‐dihydro‐1,8‐naphthyridine‐3‐carboxamide (5.26) 
A solution of 5.25 (12 mg, 18.1 μmol) and 
TFA (0.4 mL) in DCM (1.6 mL) was reacted 
as described in the procedure for 2.30a. The 
crude was purified by semi-preparative RP-
HPLC to yield the TFA salt of 5.26 (9.27 
mg, 10.3 μmol, 57%) as a yellow solid.  
HRMS calculated for C30H39N6O5 [M+H]
+ 563.2904, found m/z 563.2943.  









The TFA salt of 5.26 (3.39 mg, 3.8 µmol), DIPEA (1.85 µL, 10.6 µmol), BODIPY 
630/650-X-OSu 2.15 (1 mg, 1.51 µmol) and DMF (731 µL) were reacted as described 
in the procedure for 2.32a. The crude product was purified by semi-preparative RP-
HPLC and passed through an Amberlyst A21 ion exchange resin to remove TFA, 
yielding 5.27 (2.29 mg, 2.07 μmol, quantitative yield)****** as a bright blue solid.  
HRMS calculated for C59H65BF2N9O8S [M+H]
+ 1108.4742, found m/z 1108.4777.  
Analytical RP-HPLC Rt = 20.12 min. 
  
                                                 
****** The greater than 100% calculated yield for 5.27 (137%) was likely due to the commercially 
supplied container of BODIPY 630/650-X-OSu 2.15 containing more than the stated 1 mg. Previous 
synthesis of dye compounds have used a larger container of BODIPY 630/650-X-OSu 2.15 (e.g. 5 mg) 
split between three or four reactions, and therefore any excess in BODIPY 630/650-X-OSu 2.15 would 




Pharmacological evaluation of compounds was carried out in the laboratory of 
Professor Michelle Glass at the University of Auckland. All pharmacological 
experiments were carried out by myself, except:  
- Preparation of membranes for radioligand binding assays was carried out by 
various members of the Glass lab.  
- The 10 µM BRET screen of 2.23a, 2.23c, 2.23d, 2.23e, 2.23f and 2.25c in the 
presence and absence of CP55,940 1.10 at hCB2 receptor (n = 1) was carried out by 
Christa Macdonald.  
- Radioligand binding assays of 3.7a, 3.7b, 3.4 and 3.12 at hCB2 and hCB1 receptor 
(n = 4 or 5) were carried out by Christa Macdonald.  
- Concentration response radioligand binding assays for 4.8, 4.9 and 4.11 at hCB2 
receptor (n = 4) were carried out by Jamie Manning.  
7.2.1 Radioligand binding assays 
Competition binding assays were carried out on membranes prepared from HEK293 
cells and protein concentrations were quantified using the DC Protein Assay Kit (Bio-
Rad, Hercules, CA) by other members of the Glass lab as previously described.224 
These cells were stably transfected with either hCB1 or hCB2 receptors as previously 
described,81, 231 which was also carried out by researchers in the Glass lab. The 
following pharmacology experimental describes the work I carried out myself, after 
training by Christa Macdonald.  
Membranes were resuspended in binding buffer (50 mM HEPES, 1 mM MgCl2, 1 mM 
CaCl2, 0.2% [w/v] fatty acid free bovine serum albumin [FAF BSA; MP Biomedicals, 
Auckland, New Zealand], pH 7.4) to give a final assay concentration of 10 μg/well 
(Chapters 2-4) or 7.5 µg/well (Chapter 5) for hCB2 or 7.5 μg/well (Chapters 2-4) or 5 
µg/well (Chapter 5) for hCB1. Test compounds (10 mM in DMSO) were diluted with 
binding buffer containing EtOH to match CP55,940 1.10 (5-(1,1-dimethylheptyl)-2-[5-
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hydroxy-2-(3-hydroxypropyl)cyclohexyl]phenol) (Cayman Chemical, Michigan, USA) 
vehicle and serial dilutions were prepared using binding buffer containing the requisite 
amount of EtOH and DMSO to maintain vehicle levels throughout the dilution series. 
For CP55,940 1.10 control points, a stock aliquot in EtOH was diluted with binding 
buffer containing DMSO to match compound vehicle. All compounds were prepared at 
4 × the required assay concentration and 50 μL added to a v-bottom 96-well plate and 
made up to a total volume of 200 μL with [3H]CP55,940 1.17 (PerkinElmer) and 
membrane. Similarly, [3H]CP55,940 1.17 was prepared at 10 nM or 4 nM, with 50 μL 
added to each well to give a final concentration of 2.5 nM or 1 nM. For vehicle control 
points, binding buffer containing matched concentrations of EtOH and DMSO was 
used in place of ligand or CP55,940 1.10. The v-bottom plates containing hCB2 or 
hCB1 membranes, [
3H]CP55,940 1.17 and ligand (or CP55,940 1.10 or vehicle) were 
incubated at 30°C for 1 h.  
GF/C 96-well harvest plates (PerkinElmer) were soaked in 50 μL/well of 0.1% 
polyethylenimine for 1 h, then washed with 200 μL/well of ice-cold wash buffer (50 
mM HEPES pH 7.4, 500 mM NaCl, 0.1% FAF BSA). The contents of the v-bottom 
plates were filtered through the harvest plates, followed by a 200 μL/well wash of the 
v-bottom plates with ice-cold wash buffer. The harvest plates were promptly washed 
three times with 200 μL/well of ice-cold wash buffer and dried overnight at 24°C. 
Scintillation fluid (50 μL/well) (IRGASAFE PLUS, PerkinElmer) was added to the 
harvest plates and incubated for 30 mins in darkness, after which the harvest plates 
were read for 2 min/well in a MicroBeta TriLux (PerkinElmer). Binding experiments 
were performed a minimum of three times in triplicate.  
Data was analysed with GraphPad Prism 7 (GraphPad Software, Inc., San Diego, CA, 
USA) and competition binding curves fit by nonlinear regression using one site 
competition binding. Dissociation constants (Ki) of compounds were determined using 
[3H]CP55,940 1.17 Kd = 2 nM (hCB1) or 3 nM (hCB2). Ki values are expressed as mean 
± SEM. In cases where less than 50% displacement of [3H]CP55,940 1.17 was 
observed with 10 μM compound, affinity of the compound was deemed too low to be 
able to generate an accurate competition binding curve. Therefore, a one sample t-test 
(P <0.05) was used to determine if there was significant difference between 
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displacement in the absence (vehicle normalised to 0%) and presence of compound 
(with CP55,940 1.10 normalised to 100%), in which case the ligand was determined to 
have a Ki >10 μM, otherwise it was determined to show no significant binding. 
7.2.2 cAMP assays 
Function of compounds at hCB2 and hCB1 receptor was determined using a BRET 
assay measuring forskolin-stimulated cellular cAMP in the appropriate HEK293 cells 
transfected with a plasmid that encodes for the cAMP sensor YFP-Epac-RLuc 
(CAMYEL) as previously described.231 One or two days prior to transfection, HEK 
3HA-hCB1 pEF4A, HEK 3HA-hCB2 S4 low, HEK S4 low WT, HEK-Flp 
pcDNA5/FRT HA-3TCS-hCB2 63Q or HEK-Flp WT cells, generated as previously 
described81, 231 were seeded in 10 cm sterile tissue culture dishes. Cells were transfected 
with 5 μg of pcDNA3L-His-CAMYEL plasmid (ATCC, Manassas, VA, USA) using 30 
μg of linear polyethylenimine (PEI) (molecular weight 25 kDa; Polysciences, 
Warrington, PA, USA) in 150 mM NaCl. After 24 h, transfected cells were plated in 
poly-ᴅ-lysine (PDL) (0.05 mg mL-1 in phosphate buffered saline (PBS); Sigma-Aldrich, 
St Louis, MO, USA) treated 96-Well Solid White Flat Bottom Polystyrene TC-Treated 
Microplates (Corning) at a density of 60-80,000 cells/well in Dulbecco’s Modified 
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS). After 16 
h, cells were serum-starved in Hank’s balanced salt solution (HBSS) containing 1 mg 
mL-1 FAF BSA, pH 7.4 for 30 mins. Cells were then treated with 5 or 7.5 μM 
coelenterazine-h (Nanolight Technology) for 5 mins, followed by addition of ligand or 
matched vehicle in HBSS plus 1mg mL-1 FAF BSA and 5 μM forskolin (Tocris, 
Bristol, UK). A LUMIstar plate reader (BMG) was used to immediately measure 
emission signals at 37 °C following ligand addition, which were simultaneously 
detected at 460/25 nM (RLuc) and 535/25 nM (YFP). The inverse BRET ratio of 
emission at 460/535 nm is presented in the raw data, and hence an increase in ratio 
correlates to an increase in cAMP production. Assays were carried out a minimum of 
three times (except where stated) in duplicate.  
Data analysis was performed using GraphPad Prism 7, with dose response curves fit by 
nonlinear regression. AUC analysis was achieved using values normalised to the 
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vehicle (0%) or forskolin (100%) values for individual experiments and Emax was 
determined as a percentage of the normalised forskolin values. A t-test (P <0.05) was 
used to determine if there was a significant difference in response for compounds at 10 
µM in HEK-hCB2 or -hCB1 cells in the presence or absence of CP55,940 1.10 and in 




All receptor sequences used were downloaded from UniProt.323 All CB2 receptor 
homology models were generated using MODELLER 9.19324. Model A was generated 
using the structure of the inverse agonist-bound human β2-adrenoceptor (PDB ID: 
2RH1)325 as a template, based on the modified sequence alignment between hCB2 
receptor (P34972), human β2-adrenoceptor (P07550), bovine rhodopsin (P02699), 
human D3 receptor (P35462-3) and human β1-adrenoceptor (P08588) from the T-Coffee 
server.291 Models B, C and D were generated using either the structure of the 
antagonist-bound hCB1 receptor (PDB ID: 5U09),
67 the inverse-agonist bound hCB1 
receptor (PDB ID: 5TGZ)66 or the agonist bound hCB1 receptor (PDB ID: 5XRA)
65 as 
templates, respectively, based on a modified sequence alignment between hCB2 
(P34972) and hCB1 (P21554) receptors from the T-coffee server.  
Three dimensional models of ligands were generated using Avogadro 1.2315 and 
minimised using the universal force field (UFF). Ligand docking was performed using 
GOLD v5.5 (CCDC Software)326 centred on S285 extending for a distance of up to 10 
or 15 Å and visualised in PyMOL (The PyMOL Molecular Graphics System, Version 
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